Search by Journal
- HOME
- > Search by Journal
- > Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences
Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences
Volume , Issue suppl.1 / 2024
English Article
Japanese Article- Please note that metadata of J-type articlesare generated by machine-translation and the original texts are written in Japanese.
|
|
[YPL]. Viewpoint of a pharmacy, the pharmacist designing future medical care 本間真人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 248-248, 2024. |
|---|
|
|
[PL]. Efforts and problem of the Japanese cure association 山本康次郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 249-249, 2024. |
|---|
|
|
[SL1]. The medical care that digitization, AI is effective by security filled with consideration in becoming it! 中村祐輔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 250-250, 2024. |
|---|
|
|
[SL2]. Digital nature and medical care: Possibility of new nature and pharmacy 落合陽一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 251-251, 2024. |
|---|
|
|
[SL3]. We challenge a mystery of the sleep: From the pursuit of the principle to social implementation 柳沢正史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 252-252, 2024. |
|---|
|
|
[EL1]. Introduction and problem of the new Alzheimer's dementia therapeutic drug 新井哲明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 253-253, 2024. |
|---|
|
|
[EL2]. Drug discovery project creation by an innovative antibody technology and the application 倉持太一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 254-254, 2024. |
|---|
|
|
[AW-1]. Indoxyl sulfate-producing responsibility enzyme, drug discovery development that assumed toxic pharmacologic role investigation of transferase SULT1A1 sulfate an axis in the kidney condition of a patient formation 齋藤秀之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 255-255, 2024. |
|---|
|
|
[AW-2]. The basics, clinical studies aiming at individual optimization of the antiinfection medicine 松元一明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 255-256, 2024. |
|---|
|
|
[AW-3]. Practice of the multi-organization collaborative investigation that pointed to individualization of the antiemesis therapy 辻大樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 256-257, 2024. |
|---|
|
|
[AW-4]. Evidence creation about the proper use support of a base and the antimicrobial medicine by the integration analysis with clinical studies 加藤秀雄1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 257-258, 2024. |
|---|
|
|
[AW-5]. Evidence creation - by the hospital pharmacist concerned with clinical pharmacy study on medical therapy optimization - community medical care in elderly people 薗田晃弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 258-259, 2024. |
|---|
|
|
[AW-6]. Clinical pharmacy, human pharmacology study aiming at optimization of the medical therapy in the special population 田中遼大 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 259-260, 2024. |
|---|
|
|
[AW-7]. Construction of adverse event measures aiming at improvement of the effect of treatment of the cancer medical therapy 藤井宏典 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 260-260, 2024. |
|---|
|
|
[PA-1]. Construction of the in vivo pharmacokinetics/pharmacodynamics evaluation method in the combination therapy of beta-lactam medicine/β - lactamase inhibitor 五十嵐裕貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 261-261, 2024. |
|---|
|
|
[PA-2]. Study on medical therapy for the central nerve disease in consideration of a drug central transitional change 石川雅之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 261-262, 2024. |
|---|
|
|
[PA-3]. Study on risk factor to affect the medical treatment using the true clinical data in patients with malignant tumor 梅原健吾 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 262-263, 2024. |
|---|
|
|
[PA-4]. Individualization of the ampicillin - sulbactam combination drug administration method based on pharmacokinetic/pharmacodynamic model analysis in the action target part 大仁田哲修 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 263-263, 2024. |
|---|
|
|
[PA-5]. Study on becoming severe prediction of the dermatopathy due to antiepidermal growth factor receptor antibody medicine 高橋宏彰1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 263-264, 2024. |
|---|
|
|
[PA-6]. Suggestion of opioid criteria for selection for the intractable cancer pain and the safe direction for uses 竹村美穂 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 264-265, 2024. |
|---|
|
|
[PA-7]. The development of the nanoeye drops which assumed the wet process beads mil method a nucleus and development to the drug delivery system through the eyes tissue 出口粧央里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 265-266, 2024. |
|---|
|
|
[PA-8]. Examination of SCCmec type II in the second emergency hospital and the factor associated with clinical features and the infection of the type IV methicillin-resistant staphylococcus aureus 中野祐樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 266-267, 2024. |
|---|
|
|
[PA-9]. Study on proper use of antiTNF - α antibody pharmaceutical products based on the real world data analysis 増井翔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 267-267, 2024. |
|---|
|
|
[PA-10]. Development of the new combination therapy that assumed the beta-lactam derivative antimicrobial for the pulmonary Mycobacterium abscessus complex symptom a base 三澤可奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 268-268, 2024. |
|---|
|
|
[YPS1]. Fill-in 石井伊都子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 269-269, 2024. |
|---|
|
|
[YPS1-1]. To raise health literacy 佐藤淳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 269-269, 2024. |
|---|
|
|
[YPS1-2]. With the role that background, essence of "medical institution DX" which rapidly advances and we should take? 石見陽 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 269-270, 2024. |
|---|
|
|
[YPS1-3]. Alliesthesia with VR and the robot 田中文英 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 270-270, 2024. |
|---|
|
|
[YPS1-4]. Disseminating information and health literacy about the social security 亀井美和子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 270-270, 2024. |
|---|
|
|
[YPS2-1]. Drug absorption process to read from drug information 大谷壽一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 271-271, 2024. |
|---|
|
|
[YPS2-2]. Attempt ... of the absorption prediction using differentiation small intestine cells derived from quantitative evaluation - humans crypt of the factor controlling the gastrointestinal absorption of the drug 前田和哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 271-271, 2024. |
|---|
|
|
[YPS2-3]. A drug absorption change and the change factor judging from an advanced imaging technology 白坂善之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 272-272, 2024. |
|---|
|
|
[YPS2-4]. Function change of the drug transportation bearer to take drug gastrointestinal absorption on 秋好健志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 272-273, 2024. |
|---|
|
|
[YPS3-1]. Importance of the regular Tolly science study in the drug interactions evaluation 永井尚美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 274-274, 2024. |
|---|
|
|
[YPS3-2]. Approach of the drug interactions evaluation in the development of new pharmaceutical products 水野克彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 274-275, 2024. |
|---|
|
|
[YPS3-3]. The prospects of the domestic implementation and pharmaceutical products examination of ICH M12 "drug interactions study" guidelines 星野心広 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 275-275, 2024. |
|---|
|
|
[YPS3-4]. For the appropriate drug interactions management in the healthcare setting 大野能之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 275-276, 2024. |
|---|
|
|
[YPS4-1]. Near future of the time medical therapy with RNA editing as a key 小柳悟 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 277-277, 2024. |
|---|
|
|
[YPS4-2]. Sex differences pharmacy and medical care of the near future 黒川洵子, 坂本多穗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 277-277, 2024. |
|---|
|
|
[YPS4-3]. Nutrigenomics and medical care of the near future 矢作直也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 277-278, 2024. |
|---|
|
|
[YPS4-4]. The dementia prevention, diagnosis, treatment of the near future 富田泰輔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 278-278, 2024. |
|---|
|
|
[YPS5-1]. The construction of the temporary transfer system of the hospital pharmacist and the effect 崔吉道 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 279-279, 2024. |
|---|
|
|
[YPS5-2]. Preparations and expectation of the acceptance of the temporary transfer pharmacist 中山晃次 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 279-280, 2024. |
|---|
|
|
[YPS5-3]. From the situation of the temporary transfer pharmacist acceptance hospital 村上由恵 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 280-280, 2024. |
|---|
|
|
[YPS5-4]. About securing of pharmacist measures business in Ishikawa 福井優子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 280-281, 2024. |
|---|
|
|
[YPS5-5]. New process of the improvement in drug duties addition 内田裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 281-281, 2024. |
|---|
|
|
[YPS6-1]. Economic usefulness of the Chinese medicine in the medical service under health insurance 赤瀬朋秀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 282-282, 2024. |
|---|
|
|
[YPS6-2]. Chinese medicine necessary for improvement in quality of life of patients with cancer 江頭伸昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 282-282, 2024. |
|---|
|
|
[YPS6-3]. Usefulness of the Chinese medicine for the frailty to investigate from fundamental researches 渡辺拓也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 282-283, 2024. |
|---|
|
|
[YPS6-4]. New application development of the Chinese medicine which assumed new application development aquaporin of the Chinese medicine which assumed aquaporin a target a target 礒濱洋一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 283-283, 2024. |
|---|
|
|
[YPS7-1]. The present location of the examination for PGx: Overview of the basics and the clinical background 平塚真弘1,2,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 284-284, 2024. |
|---|
|
|
[YPS7-2]. An examination for PGx utilization example in the clinical practice: Mainly on transplant medical care 梅村圭祐, 片田佳希, 寺田智祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 284-285, 2024. |
|---|
|
|
[YPS7-3]. An examination for PGx utilization example in the clinical practice: Mainly on the side effect management 野田哲史1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 285-285, 2024. |
|---|
|
|
[YPS7-4]. The present problem and approach for the insurance publication 中村克徳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 285-285, 2024. |
|---|
|
|
[YPIS-1]. Identifying evidence gaps and clinical research in Japan's Super-Aged Society: A pharmacists' perspective Ichimura Takenori Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 286-286, 2024. |
|---|
|
|
[YPIS-2]. Planning and implementation of a specified clinical trial by a pharmacist aiming to generate high-quality evidence Mohri Junichi Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 286-287, 2024. |
|---|
|
|
[YPIS-3]. Dose individualization of oral molecular-targeted anticancer drugs: Towards maximizing efficacy and safety Noda Satoshi Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 287-287, 2024. |
|---|
|
|
[YPIS-4]. Ten things I have learned from my interdisciplinary research Alexandre Chan Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 287-288, 2024. |
|---|
|
|
[IS-1]. Introduction and Activities of The KSHP Patient Safety & Drug Risk Management Center Eun-Sun Son Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 289-289, 2024. |
|---|
|
|
[IS-2]. Machine Learning Application in Optimizing the Outcomes of Pharmacotherapy Shawn Hsiang-Yin Chen Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 289-290, 2024. |
|---|
|
|
[IS-3]. Value-Based Pharmaceutical Care - Creating an ecosystem in pharmacy for a better future Kathleen Tao Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 290-291, 2024. |
|---|
|
|
[IS-4]. Generative AI in Pharmacy Practice: Revolution or Troublesome Technology? Hisakazu Ohtani Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 291-291, 2024. |
|---|
|
|
[2-02-S01-1]. Use and application of J-SIPHE in inside the hospital of the large hospital 片田佳希 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 292-292, 2024. |
|---|
|
|
[2-02-S01-2]. Use and application of J-SIPHE in inside the hospital of the small and medium size hospital 五十川達哉1,2, 村木優一3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 292-292, 2024. |
|---|
|
|
[2-02-S01-3]. Use and application of J-SIPHE, OASCIS in regional alliances 小泉龍士 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 293-293, 2024. |
|---|
|
|
[2-02-S01-4]. Clinical studies utilizing RWD (own institution, large-scale insurance claim information) 青戸和宏1,2, 村木優一2, 小阪直史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 293-294, 2024. |
|---|
|
|
[2-02-S01-5]. For the promotion of the infection study utilizing RWD 岡田直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 294-294, 2024. |
|---|
|
|
[2-02-S02-1]. We will think about the treatment of the kidney transplantation X infection 辻本高志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 295-295, 2024. |
|---|
|
|
[2-02-S02-4]. We will think about a case of the breast cancer X CKD X Multimorbidity X primary care 橋口宏司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 296-297, 2024. |
|---|
|
|
[2-02-S03-1]. Search of the therapeutic range of vancomycin in the Corynebacterium genus bloodstream infection 佐藤一真 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 298-298, 2024. |
|---|
|
|
[2-02-S03-2]. Update of the blood drug levels assay using the LC-MS/MS 佐藤裕, 前川正充, 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 298-299, 2024. |
|---|
|
|
[2-02-S03-3]. Importance of the TDM as the laboratory study in the psychiatric care 赤嶺由美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 299-299, 2024. |
|---|
|
|
[2-02-S03-4]. Association between quantitative evaluation and condition of a patient of the pharmacokinetics-related biomarker by the mass spectrography 鈴木陽介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 299-300, 2024. |
|---|
|
|
[2-02-S03-5]. Construction of the treatment with new cancer molecules target medicine centering on new effect prediction marker CYLD 城野博史1,2, 齋藤秀之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 300-300, 2024. |
|---|
|
|
[2-03-S04-1]. Perioperative drug duties and the outcome that aimed at the high quality perioperative medical care 柴田みづほ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 301-301, 2024. |
|---|
|
|
[2-03-S04-2]. We were able to see it from distance ... swing return marks of perioperative drug duties 長谷川和恵 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 301-302, 2024. |
|---|
|
|
[2-03-S04-3]. From art - past experience to begin perioperative drug control - 浅香倫子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 302-302, 2024. |
|---|
|
|
[2-03-S04-4]. Approach until perioperative drug control addition calculation in our hospital 鈴木聡子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 302-303, 2024. |
|---|
|
|
[2-03-S04-5]. The current situation and problem of the perioperative drug control, postoperative pain team in the small hospital 八本久仁子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 303-303, 2024. |
|---|
|
|
[2-03-S05-1]. ... which thinks about an optimal renal function evaluation method from administration plan of adequacy - vancomycin of the infection medical treatment in first aid, the intensive care domain 伊部裕太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 304-304, 2024. |
|---|
|
|
[2-03-S05-2]. Shu, Ha, Ri : Creating evidence to support the appropriate use of antibiotics, starting from a community hospital 篠田康孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 304-305, 2024. |
|---|
|
|
[2-03-S05-3]. May you choose third generation cephalosporin for intestinal bacteria eyes bacteria with chromosomal ampC? 小林和博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 305-305, 2024. |
|---|
|
|
[2-03-S05-4]. Approach ... to practice evidence creation - effect-like AS activity about the antimicrobial proper use support (AS) activity by the pharmacist 山口諒 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 305-306, 2024. |
|---|
|
|
[2-03-S05-5]. Construction of the optimal administration method based on basics by the university teacher and TDM which we connected clinical studies with and PK/PD analysis 横山雄太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 306-307, 2024. |
|---|
|
|
[2-03-S06-1]. Clinical needs to be born from the healthcare setting and preparation study from the healthcare setting 内田淳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 308-308, 2024. |
|---|
|
|
[2-03-S06-2]. How to catch clinical needs judging from academia and solution 中島孝則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 308-309, 2024. |
|---|
|
|
[2-03-S06-3]. Manufacturing for the medical needs solution in Takeda Pharmaceutical 丹羽雅裕 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 309-309, 2024. |
|---|
|
|
[2-03-S06-4]. The thing which the "needs of the healthcare setting" X "clinical preparation" brings 花輪剛久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 309-310, 2024. |
|---|
|
|
[2-04-S07-1]. Four Tips in the clinical pharmacy system data analysis 濃沼政美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 311-311, 2024. |
|---|
|
|
[2-04-S07-2]. Tips at article making 山本武人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 311-312, 2024. |
|---|
|
|
[2-04-S07-3]. Tips at contribution 小林正紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 312-312, 2024. |
|---|
|
|
[2-04-S07-4]. Tips for review 矢野良一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 312-313, 2024. |
|---|
|
|
[2-04-S07-5]. Tips as the person of review 百賢二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 313-313, 2024. |
|---|
|
|
[2-04-S08-1]. Effective online training education - activity report - for pharmacists 舘知也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 314-314, 2024. |
|---|
|
|
[2-04-S08-2]. Design of the online training that is not a simple substitute of the meeting training 平岡斉士 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 314-315, 2024. |
|---|
|
|
[2-04-S08-3]. To hold the effective training even if we meet under the online environmental limit 西村由弥子1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 315-315, 2024. |
|---|
|
|
[2-04-S08-4]. Precaution as the lecturer conducting the online training seminar 金井紀仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 315-316, 2024. |
|---|
|
|
[2-04-S08-5]. We regard improvement in quality as the fact of the online training workshop 安川乃里子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 316-316, 2024. |
|---|
|
|
[2-04-S09-1]. The choice method of the patients who are optimal for trough or trough/peak drawing blood 鈴木絢子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 317-317, 2024. |
|---|
|
|
[2-04-S09-2]. Optimal AUC rating system in first aid, the ICU 石郷友之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 317-317, 2024. |
|---|
|
|
[2-04-S09-3]. AUC evaluation in elderly people, leptosome patients, the obese patients 佐村優1,2, 高田啓介2, 冨澤淳3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 317-318, 2024. |
|---|
|
|
[2-04-S09-4]. Reconsideration of vancomycin appropriateness doses by the kidney capacity and the kidney head 枦秀樹1, 並木孝哉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 318-318, 2024. |
|---|
|
|
[2-04-S09-5]. PK/PD in enterococcus/MRCNS infection, a serious case, the complexity infection 花井雄貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 319-319, 2024. |
|---|
|
|
[2-05-S10-1]. Of the Shinshu University faculty of medicine hospital "outpatient department of the perinatal heart", actually 村上寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 320-320, 2024. |
|---|
|
|
[2-05-S10-2]. Relation of the pharmacist in the perinatal mental health 赤阪未来 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 320-320, 2024. |
|---|
|
|
[2-05-S10-3]. Relation utilized the specialty for the perinatal psychiatry medical therapy 重面雄紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 321-321, 2024. |
|---|
|
|
[2-05-S10-4]. About the enforcement of clinical studies aiming at improvement in perinatal mental health 小澤秀介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 321-322, 2024. |
|---|
|
|
[2-05-S11-1]. Reading how to solve pharmaceutical products package inserts 西順也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 323-323, 2024. |
|---|
|
|
[2-05-S11-2]. Reading solution of an adverse event report, the pregnancy registry 西村あや子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 323-324, 2024. |
|---|
|
|
[2-05-S11-3]. Critical examination of the study using the information of The Teratology Information Service (TIS) 兒嶋眞子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 324-324, 2024. |
|---|
|
|
[2-05-S11-4]. Critical examination of the study using national registry, prescription data 三浦寄子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 324-325, 2024. |
|---|
|
|
[2-06-S12-1]. Side effect of chemo informatics and machine learning predictive model 榎屋友幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 326-326, 2024. |
|---|
|
|
[2-06-S12-2]. Example introduction - of the study that we combined with study - other database analysis using the database analysis of the field of bioinformatics 中馬真幸1, 合田光寛2,3, 座間味義人4,5, 濱野裕章4,5, 武智研志6, 新村貴博2,7, 石澤有紀2,8, 石澤啓介2,3,7, 田崎嘉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 326-326, 2024. |
|---|
|
|
[2-06-S12-3]. The drug repositioning method by the multi-omics analysis using the public database 雨宮崇之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 327-327, 2024. |
|---|
|
|
[2-06-S12-4]. The construction of real world data about the TDM and the usefulness 尾田一貴 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 327-328, 2024. |
|---|
|
|
[2-06-S13-1]. The practice guidelines on patients, and the like with children, AYA generation cancer 2024 version about the fecundity preservation: Contribution of the pharmacist concerned with revision 日置三紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 329-329, 2024. |
|---|
|
|
[2-06-S13-2]. Commentary of the risk classification list about the nature glandular toxicity to be able to put according to a drug and regimens 歌野智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 329-330, 2024. |
|---|
|
|
[2-06-S13-3]. Usage by the risk assessment of the alkylating agent using CED and the true clinical practice 佐々木実緒 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 330-330, 2024. |
|---|
|
|
[2-06-S13-4]. The nature glandular toxic actual situation and problem with the molecular target medicine 小室雅人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 330-331, 2024. |
|---|
|
|
[2-06-S14-1]. Efforts of university in the before graduation education of a summary and the pharmacist of the new core Cali revision 矢野良一1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 332-332, 2024. |
|---|
|
|
[2-06-S14-2]. From - resident education to think about case conference as the postgraduate education of the physician to lifelong learning - 矢吹拓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 332-333, 2024. |
|---|
|
|
[2-06-S14-3]. Practice of "the problem solving type case conference solving "the current problem" of patients between pharmacists" 伊勢崎竜也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 333-333, 2024. |
|---|
|
|
[2-06-S14-4]. Example of the case conference using the case summary of authorization, the specialized pharmacist 板井進悟 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 333-334, 2024. |
|---|
|
|
[2-06-S14-5]. Hospital, drugstore combination conference in polypharmacy measures 神保美紗子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 334-335, 2024. |
|---|
|
|
[2-06-S14-6]. Let's think from results of the questionary survey; is an art of the high case conference of satisfaction and the learning effect 長谷川裕矢 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 335-335, 2024. |
|---|
|
|
[2-12-S15-1]. Characteristic of the oral preparation which a pharmacist should know 片岡誠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 336-336, 2024. |
|---|
|
|
[2-12-S15-2]. Role of the pharmacist carrying it out for the solution to oral trouble 花輪剛久, 廣瀬香織 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 336-337, 2024. |
|---|
|
|
[2-12-S15-3]. Characteristic of the instillation preparation which a pharmacist should know 増田柊也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 337-337, 2024. |
|---|
|
|
[2-12-S15-4]. Characteristic of the instillation of nose drop preparation which a pharmacist should know 古林呂之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 337-338, 2024. |
|---|
|
|
[2-12-S15-5]. Characteristic of the gene therapeutic drug which a pharmacist should know 櫻井文教 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 338-338, 2024. |
|---|
|
|
[2-12-S15-6]. Characteristic of the self-injection device which a pharmacist should know 水野智博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 338-339, 2024. |
|---|
|
|
[2-12-S16-1]. Purpose explanation & "problems - of the deglutition that we saw from tablet dysphagia - medicine" 倉田なおみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 340-340, 2024. |
|---|
|
|
[2-12-S16-2]. Problems of the medication in the community medical care 白鳥千穂 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 340-340, 2024. |
|---|
|
|
[2-12-S16-3]. Early detection (fact-finding using PILL-5) of tablet dysphagia 大坪博子1, 倉田なおみ1, 大城真理奈2, 高橋伸幸2, 山口天士2, 田中広紀2, 楠裕美子2, 詫間章俊2, 三井奈緒2, 島本一志2, 伊藤綾花2, 越塚宏美2, 古屋宏章2, 大音師澄子3, 飯田純一4, 輿石徹5, 上田章人6, 萩田均司7, 坪内理恵子8, 宇都宮励子9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 341-341, 2024. |
|---|
|
|
[2-12-S16-4]. Drug - to affect role - eating deglutition of the pharmacist in the eating deglutition support team 金原寛子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 341-342, 2024. |
|---|
|
|
[2-12-S16-5]. Is the tablet crushed in your institution? ! Efforts to have you work as a medication assistance person in peace 鈴木慶介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 342-342, 2024. |
|---|
|
|
[2-12-S17-1]. Guidelines on antiemesis therapy revision: Art of a point and the practice of the revision 林稔展 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 343-343, 2024. |
|---|
|
|
[2-12-S17-2]. New antiemesis therapy: The latest evidence after the guidelines revision 前田章光 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 343-343, 2024. |
|---|
|
|
[2-12-S17-3]. The challenge to an unsolved problem: Clinical studies from the viewpoint of the pharmacist 山本扇里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 344-344, 2024. |
|---|
|
|
[2-12-S17-4]. An evaluation of the antiemesis therapy in the cancer domain: The inflection of the patient reported outcome and importance of the patients viewpoint 川口崇1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 344-345, 2024. |
|---|
|
|
[2-13-S18-1]. Priority of the antihypertensive medications which fixed their eyes on comorbidities and prognosis 西田祥啓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 346-346, 2024. |
|---|
|
|
[2-13-S18-2]. Medical therapy and problem of anemia for the seriously ill patients 吉廣尚大 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 346-346, 2024. |
|---|
|
|
[2-13-S18-3]. Problems and measures of the sedative sedative delirium management in the times to coexist with new coronavirus 西村知晃, 柴田啓智, 田上治美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 347-347, 2024. |
|---|
|
|
[2-13-S18-4]. Problems and measures of the prophylactic medical therapy to be given to the seriously ill patients who entered the intensive care unit 若杉和美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 347-347, 2024. |
|---|
|
|
[2-13-S19-1]. Can do it by the multi-type of job cooperation by the daily life; is polypharmacy measures 武藤浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 348-348, 2024. |
|---|
|
|
[2-13-S19-2]. Medication simplification of the elderly people institution 丸岡弘治1, 浜田将太2, 糀屋絵理子3, 篠永浩4, 東原和美5, 新井克明6, 黄倉崇7, 倉田なおみ8, 早乙女彩子9, 竹屋泰3, 大河内二郎10, 溝神文博11, 秋下雅弘12 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 348-348, 2024. |
|---|
|
|
[2-13-S19-3]. Development of the anticholinergic drug risk scale for Japan 溝神文博1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 349-349, 2024. |
|---|
|
|
[2-13-S19-4]. Trend of the medical therapy guidelines on elderly people 小島太郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 349-349, 2024. |
|---|
|
|
[2-13-S20-1]. Cancer chemotherapy of the elderly people non-Hodgkin's lymphoma 中川潤一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 350-350, 2024. |
|---|
|
|
[2-13-S20-2]. It is ... mainly on antimicrobial prophylactic for individualization administration plan - perioperative period of the antimicrobial in elderly people 小松敏彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 350-351, 2024. |
|---|
|
|
[2-13-S20-3]. Individualization administration plan of the tolvaptan in patients with old heart failure 見野靖晃 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 351-351, 2024. |
|---|
|
|
[2-13-S20-4]. For the individualization administration plan of the mental nervous disease therapeutic drug in elderly people 猿渡淳二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 351-352, 2024. |
|---|
|
|
[2-14-S21-1]. Career up support of the fact and the student of the department education in the national university 川田敬1,2,3, 山本高成1, 佐藤智恵美1, 小川敦3, 相澤風花2,3, 八木健太3,4, 石澤有紀2,5, 新村貴博2,4, 阿部真治1, 合田光寛2,3, 石澤啓介2,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 353-353, 2024. |
|---|
|
|
[2-14-S21-2]. Career up support of the fact and the student of the department education at the private university 林稔展 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 353-353, 2024. |
|---|
|
|
[2-14-S21-3]. Resident education and career up support 溝口博之1, 渡邉美菜子1, 千崎康司1,2, 山田清文1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 354-354, 2024. |
|---|
|
|
[2-14-S21-4]. Career up support to fix the eyes on future medical care, and to raise a specialized pharmacist authorization 蔵田靖子, 座間味義人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 354-355, 2024. |
|---|
|
|
[2-14-S21-5]. Significance of the doctorate acquisition in the carrier pass of the pharmacist 石澤啓介1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 355-355, 2024. |
|---|
|
|
[2-14-S22-1]. Think in the clinic of the pharmacist from the situation of the multi-type of job, the medical education 木内祐二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 356-356, 2024. |
|---|
|
|
[2-14-S22-2]. The current situation and problem of postgraduate training and the carrier formation of the pharmacist 山田清文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 356-356, 2024. |
|---|
|
|
[2-14-S22-3]. After graduation clinical practice model business: The report and prospects for 3 years 石井伊都子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 357-357, 2024. |
|---|
|
|
[2-14-S22-4]. F clinical pharmacy, new business training guidelines and pharmacist education 角山香織 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 357-357, 2024. |
|---|
|
|
[2-14-S22-5]. You experience clinical settings and university, both viewpoints, and think in a clinic 橋田亨 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 358-358, 2024. |
|---|
|
|
[2-14-S23-1]. About the current situation and a problem of the before graduation education in university 山谷明正 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 359-359, 2024. |
|---|
|
|
[2-14-S23-2]. Efforts of the before graduation postgraduate education about childhood medical therapy in the university hospital 小川隆弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 359-360, 2024. |
|---|
|
|
[2-14-S23-3]. Sense of values - attitude ... which we want to succeed to from the position of the drugstore pharmacist to look at patients, the dweller generally 川名三知代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 360-360, 2024. |
|---|
|
|
[2-14-S23-4]. Seamless education ... from needs ... university of the side receiving education 加藤美和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 360-361, 2024. |
|---|
|
|
[2-14-S23-5]. The approach in the pediatric medical therapy workshop and the future prospects 冨家俊弥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 361-361, 2024. |
|---|
|
|
[3-02-S24-1]. It is ... mainly on pharmacy study - antimicrobial association nephropathy that is narrative to protect kidney 石郷友之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 362-362, 2024. |
|---|
|
|
[3-02-S24-2]. Focus on essence and utilization - cystatin C of the renal function evaluation; and ... 津下遥香, 田中遼大, 龍田涼佑, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 362-363, 2024. |
|---|
|
|
[3-02-S24-3]. It is ... mainly on problems - tacrolimus change of the condition of a patient X drug which is manifested simply because it is kidney transplantation 辻本高志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 363-363, 2024. |
|---|
|
|
[3-02-S24-4]. It is ... around pharmacy study - anemia in renal disease, CKD-MBD contributing to deepening of complications treatment of the dialysis domain 吉田拓弥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 363-364, 2024. |
|---|
|
|
[3-02-S25-1]. Future for the pharmacy education of electronic drug remedy history data to be able to see from the study of the quality indicator on medication counseling 工藤知也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 365-365, 2024. |
|---|
|
|
[3-02-S25-2]. Result and problem to feel through pharmacist education using medical specialization type EdTech 木村郁哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 365-365, 2024. |
|---|
|
|
[3-02-S25-3]. Directionality and problem point of the pharmacy education using DX 鮎川洋, 今任拓也, 牛尾聡一郎, 右田啓介, 江川孝, 三島健一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 366-366, 2024. |
|---|
|
|
[3-02-S25-4]. New development of a pharmacy student, the pharmacist education that made full use of big data, DX 座間味義人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 366-367, 2024. |
|---|
|
|
[3-02-S25-5]. Development to a future pharmacy education study utilizing DX 村木優一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 367-367, 2024. |
|---|
|
|
[3-02-S26-1]. Purpose explanation and the authorized situation of 2023 池田龍二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 368-368, 2024. |
|---|
|
|
[3-02-S26-2]. How to write case to make use of the valuable experience that we learned from patients in 佐野元彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 368-368, 2024. |
|---|
|
|
[3-02-S26-3]. Case ... which discontinued the concomitant drug which became early detection and the risk factor of lung cancer - irAE renal failure 松金良祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 369-369, 2024. |
|---|
|
|
[3-02-S26-4]. Correspondence ... to side effect measures and a risk factor of recurrent DLBCL ... anticancer medicine 上瀧喬仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 369-370, 2024. |
|---|
|
|
[3-02-S26-5]. Intervention ... to decreased visual acuity and the supportive care after pancreatic cancer - chemotherapy start 宇野彩香 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 370-370, 2024. |
|---|
|
|
[3-02-S26-6]. Specialized intervention and ability of the pharmacist in the cancer team approach in medical care for management 河原昌美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 370-370, 2024. |
|---|
|
|
[3-03-S27-1]. About algorithm of the medical therapy of type 2 diabetes from the viewpoint of - pharmacist - 井上岳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 371-371, 2024. |
|---|
|
|
[3-03-S27-2]. We think about algorithm from the viewpoint of the CKD domain 杉本悠花 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 371-371, 2024. |
|---|
|
|
[3-03-S27-3]. We think about algorithm from the viewpoint of the circulatory organ domain 中島美知穂 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 372-372, 2024. |
|---|
|
|
[3-03-S27-4]. We think about algorithm of the medical therapy from patients viewpoint 坂倉圭一1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 372-373, 2024. |
|---|
|
|
[3-03-S28-1]. The basics of bioactive prediction based on the chemical structure information 植沢芳広 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 374-374, 2024. |
|---|
|
|
[3-03-S28-2]. Pharmaceutical examination about the cancer medical therapy using the large-scale side effect database 奥中真白1,2, 植沢芳広2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 374-374, 2024. |
|---|
|
|
[3-03-S28-3]. Drug information to read from a structural formula, and to solve 高橋秀依 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 375-375, 2024. |
|---|
|
|
[3-03-S28-4]. The prospects to hypothesis generation and the drug discovery study using the adverse event report database based on the chemical idea 清水忠1, 中尾周平2, 山岡健太1,3, 藤原正規1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 375-375, 2024. |
|---|
|
|
[3-03-S28-5]. Prediction of an effect, the side effect of pharmaceutical products utilizing machine learning, the simulation 山西芳裕 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 376-376, 2024. |
|---|
|
|
[3-04-S29-1]. As for the pharmaceutical products, and the like, it is regulation harmony, evaluation study business: The evaluation study about study requirements of the Serrano Styx-adaptive radioactive medicines: To steady supply and use promotion 斎藤嘉朗, 三澤隆史, 出水庸介, 蜂須賀暁子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 377-377, 2024. |
|---|
|
|
[3-04-S29-2]. As for the pharmaceutical products, and the like, it is regulation harmony, evaluation study business: Research and development about the noninvasive intrapulmonary delivery estimate for the effectiveness, safety, equivalency evaluations of the inhalant 平大樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 377-378, 2024. |
|---|
|
|
[3-04-S29-3]. Life sciences, drug discovery study support base business (BINDS): Advancement and support of the metabolic loam analysis base 菱沼英史1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 378-378, 2024. |
|---|
|
|
[3-04-S29-4]. Genome drug discovery base promotion study business: Base study to realize effective efficiency-like individualization medical therapy by the PGx study utilizing the biobank 平塚真弘1,2,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 378-379, 2024. |
|---|
|
|
[3-04-S30-1]. The clinical studies development that assumed an electronic medical chart a base 小泉祐一1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 380-380, 2024. |
|---|
|
|
[3-04-S30-2]. Medicine, the pharmacy crossing study that hospital pharmacist conducts 重面雄紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 380-380, 2024. |
|---|
|
|
[3-04-S30-3]. Possibility of the clinical studies that assumed fundamental researches technology a nucleus 森田真也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 381-381, 2024. |
|---|
|
|
[3-04-S30-4]. Inspection using the medical big data for the hypothesis obtained from fundamental researches 豕瀬諒, 村木優一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 381-382, 2024. |
|---|
|
|
[3-04-S30-5]. Practice of clinical studies based on the knowledge of fundamental researches 宮本朋佳1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 382-382, 2024. |
|---|
|
|
[3-04-S30-6]. Clinical basic interactive translational research strategy 川畑篤史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 382-383, 2024. |
|---|
|
|
[3-04-S31-1]. Is real-world data a good idea? Is it better to have it than not? The curse and bias of data sources 漆原尚巳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 384-384, 2024. |
|---|
|
|
[3-04-S31-2]. Thing necessary for the appropriate enforcement of the individual case safety report database study and the report 野口義紘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 384-385, 2024. |
|---|
|
|
[3-04-S31-3]. Data drive type drug repositioning study for the side effect with the cancer chemotherapy 石澤啓介1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 385-385, 2024. |
|---|
|
|
[3-04-S31-4]. Can the data in the search engine become the data saying that they are clear with the actual situation of the drug abuse? 牛尾聡一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 385-386, 2024. |
|---|
|
|
[3-05-S32-1]. How should you utilize pharmaceutical products risk management plan (RMP) for patients? 若林進 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 387-387, 2024. |
|---|
|
|
[3-05-S32-2]. The RMP general remarks (include the latest information such as medical service fees revisions, and the like) 竹本信也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 387-388, 2024. |
|---|
|
|
[3-05-S32-3]. Examination of RMP in the new medicine examination of PMDA 平松彩佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 388-388, 2024. |
|---|
|
|
[3-05-S32-4]. How do make the RMP material; from the situation of ... pharmaceutical company - 長濱敬樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 388-389, 2024. |
|---|
|
|
[3-05-S32-5]. It is ... from position of utilization - hospital pharmacist of RMP in the hospital 大庭理寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 389-389, 2024. |
|---|
|
|
[3-05-S32-6]. It is ... from the position of utilization - drugstore pharmacist of RMP in the drugstore 鈴木すみれ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 389-390, 2024. |
|---|
|
|
[3-05-S33-1]. It is efforts to the current situation and the problem solution to investigation after the production and sales that we saw from the regulator 福田祐介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 391-391, 2024. |
|---|
|
|
[3-05-S33-2]. It is efforts to investigation improvement after the production and sales in the investigation client 北郷次郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 391-392, 2024. |
|---|
|
|
[3-05-S33-3]. It is the problem of the investigation after the production and sales 成川衛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 392-392, 2024. |
|---|
|
|
[3-05-S33-4]. It is ... mainly on an investigation and study ethic ... use results investigation after the production and sales 渡邉達也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 392-392, 2024. |
|---|
|
|
[3-06-S34-1]. Improving the quality of pre-avoidance reports : effective descriptions and approaches for data utilization 平島由香 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 393-393, 2024. |
|---|
|
|
[3-06-S34-2]. Priority issue for collecting pre-avoidance reports : "Physical Assessment" : Issues derived from the analysis of reported cases and development of solutions 横山威一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 393-394, 2024. |
|---|
|
|
[3-06-S34-3]. Analysis of Pre-Avoid Mode 3 "Improvement of Drug Treatment Efficacy" and Future Challenges 山口諒 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 394-394, 2024. |
|---|
|
|
[3-06-S34-4]. Efforts of our hospital and the future prospects 前勇太郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 394-395, 2024. |
|---|
|
|
[3-06-S35-1]. ... DEX-1 study to consider the possibility of the dexamethasone weight loss by the olanzapine combination and SPARED study ... 飯原大稔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 396-396, 2024. |
|---|
|
|
[3-06-S35-2]. It is (CDDP) - PATROL-I study ... for dexamethasone perfection abbreviation 辻大樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 396-397, 2024. |
|---|
|
|
[3-06-S35-3]. It is (AC/EC therapy) - PATROL-II study ... for dexamethasone perfection abbreviation 鈴木賢一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 397-397, 2024. |
|---|
|
|
[3-06-S35-4]. Second analysis results - J-FORCE study ... of the four-drug antiemesis therapy containing olanzapine for the cisplatin regimen 安部正和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 397-398, 2024. |
|---|
|
|
[3-06-S35-5]. Accompaniment study ... of the identification - PATROL test of the retching vomiting risk factor aiming at individualization of the antiemesis therapy 横川貴志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 398-398, 2024. |
|---|
|
|
[3-06-S36-1]. Rehabilitation drug based on clinical evidence to practice it on the site 小瀬英司1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 399-399, 2024. |
|---|
|
|
[3-06-S36-2]. The rehabilitation drug management in the acute phase hospital 牧宏樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 399-399, 2024. |
|---|
|
|
[3-06-S36-3]. Rehabilitation drug in the convalescent rehabilitation ward 田中絵里子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 399-400, 2024. |
|---|
|
|
[3-06-S36-4]. Rehabilitation drug in the local inclusion care ward 篠永浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 400-400, 2024. |
|---|
|
|
[3-07-S37-1]. The current situation of the radioactive medicines in the Nuclear medicine practice 久下裕司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 401-401, 2024. |
|---|
|
|
[3-07-S37-2]. Inflection (from the situation of the physician) of the radioactive medicines as Radiotheranostics 石守崇好 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 401-402, 2024. |
|---|
|
|
[3-07-S37-3]. It inflects as a companion diagnostic agent of the radioactive medicines 間賀田泰寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 402-402, 2024. |
|---|
|
|
[3-07-S37-4]. Efforts to the spread of RI private business therapy that a pharmacist pulls and safe use 加納大輔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 402-403, 2024. |
|---|
|
|
[3-07-S37-5]. Expectation and symposium summaries from the Japanese Society of Nuclear Medicine to a pharmacist 間賀田泰寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 403-403, 2024. |
|---|
|
|
[3-07-S38-1]. It is ... from care - birth of PLWH cooperating in multidomain to end-of-life care 村松崇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 404-404, 2024. |
|---|
|
|
[3-07-S38-2]. Relation of the pharmacist by the perinatal HIV fetomaternal infection prevention 山崎香織 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 404-404, 2024. |
|---|
|
|
[3-07-S38-3]. PLWH and cardiovascular disease care 石井聡一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 405-405, 2024. |
|---|
|
|
[3-07-S38-4]. Health care and treatment support - that PLWH (People Living With HIV) and malignant tumor - pharmacist think 平野淳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 405-405, 2024. |
|---|
|
|
[3-07-S38-5]. Caring at home (example, problem of the caring at home of PLWH) of PLWH 島田淳史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 406-406, 2024. |
|---|
|
|
[3-07-S39-1]. Role of the drugstore pharmacist for the pharmaceutical products misuser 鈴木弘道 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 407-407, 2024. |
|---|
|
|
[3-07-S39-2]. Role of the pharmacist in the emergency visit 小岩井祥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 407-407, 2024. |
|---|
|
|
[3-07-S39-3]. Systemic management after the hospitalization 加藤隆寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 408-408, 2024. |
|---|
|
|
[3-07-S39-4]. Role of the pharmacist in treatment and the recovery support of commercial drug abuse, the addict 北侑未 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 408-408, 2024. |
|---|
|
|
[3-07-S39-5]. Pharmacist - as overDors and casual "unnecessary interference" - gatekeeper of the commercial drug 嶋根卓也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 409-409, 2024. |
|---|
|
|
[3-12-S40-1]. For cancer supportive care, mild medical science 中川貴之1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 410-410, 2024. |
|---|
|
|
[3-12-S40-2]. The reverse translational research which aimed at the prevention, the treatment of the taste disturbance in the cancer chemotherapy 宗可奈子1, 津田真弘1,2, 山下富義1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 410-411, 2024. |
|---|
|
|
[3-12-S40-3]. The basics, clinical mediation study for the evasion of peripheral neuropathy with the cancer chemotherapy 川尻雄大, 峯圭佑, 森皓平, 藤田隼輔, 小林大介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 411-411, 2024. |
|---|
|
|
[3-12-S40-4]. Proteinuria, hypertensive ... with "basic question" that a pharmacist working on the site pursues - VEGF inhibitor 二瓶哲 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 411-412, 2024. |
|---|
|
|
[3-12-S40-5]. The support that cancer supportive care, a skill, the leader whom a young person learns from to push forward mild medical clinical studies perform 佐藤淳也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 412-412, 2024. |
|---|
|
|
[3-12-S41-1]. How do you regard cancer cachexia, medical therapy as palliative care? 間宮敬子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 413-413, 2024. |
|---|
|
|
[3-12-S41-2]. Individual differences of the clinical response of antibody pharmaceutical products at the condition of a patient of the cancer cachexia 柴田海斗 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 413-413, 2024. |
|---|
|
|
[3-12-S41-3]. Cancer cachexia and individual differences of fentanyl blood level and the clinical response 須野学, 伊藤雄大, 松原和夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 413-414, 2024. |
|---|
|
|
[3-12-S41-4]. We utilize the pharmacokinetic change of antimicrobial and the antiepileptic drug under the condition of a patient of the cancer cachexia to medical therapy 中山裕一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 414-414, 2024. |
|---|
|
|
[3-12-S42-1]. Why is the pharmacokinetic prediction of patients with liver damage difficult? 大野能之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 415-415, 2024. |
|---|
|
|
[3-12-S42-2]. Is it How to use Gram stain? First hand ... of the antibiotic exposure that a color and the form of ... bacteria tell 村田龍宣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 415-416, 2024. |
|---|
|
|
[3-12-S42-3]. We evaluate the effectiveness, safety of the medical therapy from an examination of examination for image, menstruation 門村将太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 416-416, 2024. |
|---|
|
|
[3-12-S42-4]. The problems are not one! - Intervention - to patients with cancer of the pharmacist specialized in medical therapy 山崎美保 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 416-417, 2024. |
|---|
|
|
[3-13-S43-1]. Contribute to improvement in quality of the emergency care; about the participation in planning to the emergency visit of the pharmacist and utilization of "the process of pharmacist duties in the emergency visit!" 今井徹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 418-418, 2024. |
|---|
|
|
[3-13-S43-2]. Design original bill of the pharmacist image 太田浩平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 418-418, 2024. |
|---|
|
|
[3-13-S43-3]. From the position of the nurse 浅香えみ子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 419-419, 2024. |
|---|
|
|
[3-13-S43-4]. Acceptance preparations before the patients conveyance in the emergency visit and role of the pharmacist 川島裕明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 419-420, 2024. |
|---|
|
|
[3-13-S43-5]. Role of the pharmacist in the patients intelligence in the emergency visit 齋藤靖弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 420-420, 2024. |
|---|
|
|
[3-13-S43-6]. We regard subsequent cooperation as a relation by the primary care 宮田祐一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 420-420, 2024. |
|---|
|
|
[3-13-S44-1]. Message ... from the specialist toward the pharmacist who do not stop the heart failure prevention, and is the leading role of ... heart failure prevention in heart failure 齋藤秀輝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 421-421, 2024. |
|---|
|
|
[3-13-S44-2]. Cut off; a negative chain! The heart failure pandemic that diabetes medical treatment instruction person & heart failure medical treatment instruction person confronts 林太祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 421-421, 2024. |
|---|
|
|
[3-13-S44-3]. Attack the relation to a heart failure primary prophylaxis judging from the position of the kidney disease medical treatment instruction person 松下智侑 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 422-422, 2024. |
|---|
|
|
[3-13-S44-4]. The advice of "the heart rehabilitation" toward the heart failure primary prophylaxis 櫻下弘志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 422-422, 2024. |
|---|
|
|
[3-13-S44-5]. Heart failure primary prophylaxis to further spread in heart failure medical treatment instruction person & cardiovascular disease adviser system 西垣賢1,5, 磯崎弘恵2,5, 土岐真路3,5, 斎藤能彦4,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 423-423, 2024. |
|---|
|
|
[3-13-S45-1]. From the position of importance - clinical studies coordinator (CRC)/trial, clinical studies medicine manager of the drug control in a trial, clinical studies - 森山菜緒 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 424-424, 2024. |
|---|
|
|
[3-13-S45-2]. Management of the medicine for the clinical studies in the health insurance pharmacy 亀之園学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 424-425, 2024. |
|---|
|
|
[3-13-S45-3]. Have a pharmacist for subjects protection 黒田智 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 425-425, 2024. |
|---|
|
|
[3-13-S45-4]. Possibility of the pharmacist in the pharmaceutical products development 久保田有香 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 425-426, 2024. |
|---|
|
|
[3-13-S45-5]. With the on the site prospective pharmacist of the pharmaceutical products examination: We learn from experience in PMDA 細野浩之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 426-426, 2024. |
|---|
|
|
[3-13-S45-6]. A role and expectation of the pharmacist to a trial, clinical studies 近藤直樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 426-427, 2024. |
|---|
|
|
[3-14-S46-1]. Past background over a psychotropic drug and the driving 吉村玲児 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 428-428, 2024. |
|---|
|
|
[3-14-S46-2]. The process that is necessary for structure and the revision of the package insert 木村駿 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 428-428, 2024. |
|---|
|
|
[3-14-S46-3]. Driving test guidelines and new driving pro-evaluation development for efficacy evaluations of the psychotropic drug 岩本邦弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 428-429, 2024. |
|---|
|
|
[3-14-S46-4]. About criteria to evaluate the effect that a psychotropic drug gives to driving 中林哲夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 429-430, 2024. |
|---|
|
|
[3-14-S46-5]. Point to keep in mind of the medication counseling about the driving 肥田裕丈1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 430-430, 2024. |
|---|
|
|
[3-14-S47-1]. Evidence update of the benzodiazepine 桑原秀徳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 431-431, 2024. |
|---|
|
|
[3-14-S47-2]. It is ... from the position of efforts - pharmacist of the proper use of the benzodiazepine receptor agonist 高橋結花 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 431-432, 2024. |
|---|
|
|
[3-14-S47-3]. Should you not use the benzodiazepine? We reconsider problems and significance 松崎朝樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 432-432, 2024. |
|---|
|
|
[3-14-S47-4]. What is the essence in matters relating to the inappropriate use of benzodiazepine drugs? 青島周一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 432-433, 2024. |
|---|
|
|
[4-02-S48-1]. Expectation - medical care information DX and Ikuyaku - to a pharmacist in medical DX 中井清人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 434-434, 2024. |
|---|
|
|
[4-02-S48-2]. We think about drug information DX causing medical DX 若林進 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 434-434, 2024. |
|---|
|
|
[4-02-S48-3]. Use and application of the drug information in the medical DX era and medical information sharing 小川充恵 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 435-435, 2024. |
|---|
|
|
[4-02-S48-4]. Drug information DX which approaches all pharmacists 佐藤弘康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 435-436, 2024. |
|---|
|
|
[4-02-S49-1]. Of a supplement and pharmaceutical products make drink, and give customer-adaptive service with the construction of the database 生田智樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 437-437, 2024. |
|---|
|
|
[4-02-S49-2]. ... which reads an interaction example reported by menthol and analysis - clinical practice of the interaction with pharmaceutical products from fundamental researches 五十嵐信智 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 437-438, 2024. |
|---|
|
|
[4-02-S49-3]. Interaction ... a variety of mechanism and individual differences ... of citrus fruit fruit juice and pharmaceutical products 秋好健志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 438-438, 2024. |
|---|
|
|
[4-02-S49-4]. Interaction of lipid, fat-solubility vitamin and the drug 山梨義英, 伊藤紗代, 鈴木洋史, 高田龍平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 438-439, 2024. |
|---|
|
|
[4-03-S50-1]. Side effect management of the digestive organ cancer domain 千阪智美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 440-440, 2024. |
|---|
|
|
[4-03-S50-2]. Side effect management of the urologic domain that a pharmacist outpatient connects 高田慎也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 440-441, 2024. |
|---|
|
|
[4-03-S50-3]. In the case of patients with point - breast cancer of the intervention before medical examination in response to patients needs - 組橋由記, 福島ゆかり, 萩歩美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 441-441, 2024. |
|---|
|
|
[4-03-S50-4]. Side effect management of the immune-mediated adverse event 四十物由香 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 441-442, 2024. |
|---|
|
|
[4-04-S51-1]. Expectation ... to multi-type of job cooperation - pharmacist in the Parkinson's disease practice 関守信1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 443-443, 2024. |
|---|
|
|
[4-04-S51-2]. It is daily life ... of ... cranial nerve medical service from the position of the cranial nerve medical service pharmacist 恩川彩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 443-444, 2024. |
|---|
|
|
[4-04-S51-3]. We will be concerned with the Parkinson's disease patients of ... outpatient department from the position of the pharmacist of the general hospital 山本恭平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 444-444, 2024. |
|---|
|
|
[4-04-S51-4]. It is ... to the collaborative investigation with the physician for ... clinical question from the position of the pharmacy clinical system teacher 安高勇気1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 444-445, 2024. |
|---|
|
|
[4-05-S52-1]. The latest information of cigarette epidemiologic studies 原梓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 446-446, 2024. |
|---|
|
|
[4-05-S52-2]. Risk of the heating-type cigarette 田淵貴大 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 446-446, 2024. |
|---|
|
|
[4-05-S52-3]. We know the pharmacokinetics of nicotine and make use in smoking cessation support 相澤政明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 446-446, 2024. |
|---|
|
|
[4-05-S52-4]. Smoking cessation support education in the pharmacy school 伊東育己 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 446-447, 2024. |
|---|
|
|
[4-05-S52-5]. Smoking cessation support of the new age in connection with an area and the multi-type of job 加藤淳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 447-447, 2024. |
|---|
|
|
[4-05-S53-1]. Possibility of the pharmaceutical management of the decreased renal function patients by the serum creatinine self simplified measurement 竹内裕紀1,2, 松本有右2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 448-448, 2024. |
|---|
|
|
[4-05-S53-2]. A doctor at medical office expect it for the foreign TDM duties at the health insurance pharmacy 前田稔彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 448-449, 2024. |
|---|
|
|
[4-05-S53-3]. Current situation and problem ... "drugstore TDM" of the TDM duties of the pharmacist in the drugstore are ... for the future to support community medical care 藤田あゆみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 449-449, 2024. |
|---|
|
|
[4-05-S53-4]. Cooperation - with the efforts - University pharmacy school for the intervention to the TDM duties by the health insurance pharmacy pharmacist 松元加奈1, 和田晶子1, 浦嶋庸子2, 加藤隆児3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 449-450, 2024. |
|---|
|
|
[4-06-S54-1]. ... which connects the front line ... world living in good health of contraindicated setting/cancellation of the pharmaceutical products package insert together to tomorrow 難波友香莉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 451-451, 2024. |
|---|
|
|
[4-06-S54-2]. Use restrictions and medical needs for the patients ensuring safety that we saw from the healthcare setting 川上純一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 451-451, 2024. |
|---|
|
|
[4-06-S54-3]. We regard the contraindications of pharmaceutical products as pediatrics from a viewpoint of the developmental pharmacology 中村秀文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 452-452, 2024. |
|---|
|
|
[4-06-S54-4]. It is ... from the situation of ... company thinking about the contraindications of pharmaceutical products 松井理恵 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 452-453, 2024. |
|---|
|
|
[4-06-S55-1]. Progress report on regional formularies in Japan and new functions of hospital pharmacists 今井博久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 454-454, 2024. |
|---|
|
|
[4-06-S55-2]. Progress report on regional formularies in Japan and new functions of hospital pharmacists 小池博文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 454-455, 2024. |
|---|
|
|
[4-06-S55-3]. The professional role of hospital pharmacists in the regional formulary in the Tsukuba area 糸賀守 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 455-455, 2024. |
|---|
|
|
[4-06-S55-4]. Useful local formulary practice in emergency clinics on holidays 菅野浩1,2, 西悠吾1,2, 阿部正隆2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 455-456, 2024. |
|---|
|
|
[4-12-S56-1]. Efforts of the clinical studies support in Yamagata hospital pharmacist society arts and sciences Committee 小倉次郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 457-457, 2024. |
|---|
|
|
[4-12-S56-2]. The clinical studies activity that received support of Yamagata hospital pharmacist society arts and sciences Committee 小林聖子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 457-457, 2024. |
|---|
|
|
[4-12-S56-3]. Study promotion of the pharmacist by the Kyoto Pharmaceutical University study proof (Lehmann) program 村木優一, 辻本雅之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 457-458, 2024. |
|---|
|
|
[4-12-S56-4]. Taking Lehmann program, and having obtained it subsequently 山根孝太1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 458-459, 2024. |
|---|
|
|
[4-12-S56-5]. Practice and problem of the member of society graduate school study instruction of the health insurance pharmacy pharmacist 大津史子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 459-459, 2024. |
|---|
|
|
[4-12-S56-6]. Research activities in the member of society graduate school of the drugstore pharmacist 渡邉慶剛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 459-460, 2024. |
|---|
|
|
[4-12-S57-1]. About pharmaceutical products and bar code (from an administrative viewpoint) 福田悠平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 461-461, 2024. |
|---|
|
|
[4-12-S57-2]. About the use inflection of the GS1 bar code in our hospital pharmacy 森健太郎1,2, 舟越亮寛1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 461-462, 2024. |
|---|
|
|
[4-12-S57-3]. Use and application and problem of the pharmaceutical products GS1 bar code in a hospital, the pharmacy 千原里美1, 上田宏2, 中田精三3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 462-462, 2024. |
|---|
|
|
[4-12-S57-4]. Where will the bar code face from now on? 植村康一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 462-463, 2024. |
|---|
|
|
[4-13-S58-1]. Disaster pharmaceutical affair coordinates - hospital pharmacist society in the Ishikawa health medical care welfare adjustment headquarters, real ... of the liaison activity with the DMAT, administration 中出順也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 464-464, 2024. |
|---|
|
|
[4-13-S58-2]. Coordinates of the pharmacist disaster dispatch that Japanese Society of Hospital Pharmacists conducted 安藝敬生 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 464-465, 2024. |
|---|
|
|
[4-13-S58-3]. We work on the support by the disaster registration dispatch pharmacist of the hospital pharmacist society in the district in northern Noto 中島彰子1, 柴田啓智2, 中筋美穂1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 465-465, 2024. |
|---|
|
|
[4-13-S58-4]. Experience of the municipal Wajima hospital pharmacy in the 2024 Noto Peninsula earthquake 村田航一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 465-466, 2024. |
|---|
|
|
[4-13-S58-5]. About the reopening of the pharmacy business training at the damaged hospital soon after the disaster 端谷大輝1, 村田航一2, 内手昇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 466-466, 2024. |
|---|
|
|
[4-13-S59-1]. Did you come in such a thing? Efforts of the pharmaceutical products-related error decrease utilizing the electronic medical chart function 三村享1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 467-467, 2024. |
|---|
|
|
[4-13-S59-2]. Efforts about the pediatric medicine maximal doses check 吉田直樹1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 467-468, 2024. |
|---|
|
|
[4-13-S59-3]. Inflection of the medical information system in the communication of a pharmacist and the multi-type of job 嶋田沙織1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 468-468, 2024. |
|---|
|
|
[4-13-S59-4]. Fact-finding about the alert with the prescription check system 小林武志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 468-469, 2024. |
|---|
|
|
[4-13-S59-5]. Realizing improvement of the medical security in medical DX 高田敦史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 469-469, 2024. |
|---|
|
|
[4-13-S59-6]. Allergy to analysis - pharmaceutical products alert for the standard specifications construction of the electronic medical chart function, inflection ... of the clinical test value 横山威一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 470-470, 2024. |
|---|
|
|
[4-14-S60-1]. The present situation and the approach situation of the electronic prescription 長嶋賢太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 471-471, 2024. |
|---|
|
|
[4-14-S60-2]. The introduction of the electronic prescription and the problem 植竹宣江1, 古谷智裕1, 北本真一1, 宮森伸一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 471-472, 2024. |
|---|
|
|
[4-14-S60-3]. Having been able to see it than an investigation about the operational situation of the electronic prescription 鶴田洋平1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 472-472, 2024. |
|---|
|
|
[4-14-S60-4]. Directionality of drugstore DX including the electronic prescription 原口亨 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 472-473, 2024. |
|---|
|
|
[4-14-S61-1]. For a pressure sore regional alliances from a viewpoint of the modularization! 秋山和宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 474-474, 2024. |
|---|
|
|
[4-14-S61-2]. The Furuta Method : Pressure Ulcer Treatment in Practice, Possible for Collaboration at Home and in Facilities 古田勝経 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 474-475, 2024. |
|---|
|
|
[4-14-S61-3]. What pharmacists can do for pressure ulcers during limited hospital stays - Collaboration and cooperation in acute care hospitals 土屋博子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 475-475, 2024. |
|---|
|
|
[4-14-S61-4]. Even if there is a pressure sore; good acceptance; until it is in ... 坪井憲江 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 475-476, 2024. |
|---|
|
|
[4-14-S61-5]. The current situation and problem of pressure sore treatment in being at home 冨沢道俊 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 476-476, 2024. |
|---|
|
|
[Shimin]. The future medical care that a medical person collaborates with patients 山口育子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 477-477, 2024. |
|---|
|
|
[2-7-O01-1]. It is developed the collaboration monitoring system using the patients with cancer support application between a hospital and local pharmacists 藤堂真紀1, 一瀬友希2, 島田浩子2, 松浦一生2, 貫井麻未2, 藤本章博2, 大崎昭彦2, 佐伯俊昭2, 立澤明4, 加藤美奈子5, 高山智成6, 関洋介3, 牧野好倫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 478-478, 2024. |
|---|
|
|
[2-7-O01-2]. Effect by the introduction of the multidirectional pain relief in spinal operations 起塚美沙1, 豕瀬諒2, 槇尾智3, 村木優一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 478-479, 2024. |
|---|
|
|
[2-7-O01-3]. Relative examination of the inhalational maneuver acquisition in elderly people and the cognitive function test 横山敏紀1,2, 水谷怜子2, 小山愛彩和2, 高田健司3, 澤田格4, 櫻井秀彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 479-479, 2024. |
|---|
|
|
[2-7-O01-4]. The introduction of the digital teaching materials for the purpose of reinforcement, the improvement of preparation training and the evaluation 原伸輔, 米村俊哉, 樋口渓一郎, 松井浩子, 前田真一郎, 奥田真弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 479-480, 2024. |
|---|
|
|
[2-7-O01-5]. Attempt of the "medical treatment adherence standard of the children by the protector of the preschooler" to evaluate an administration, the medication environment in the home, and to be improved development 柳奈津代1, 佐藤宏樹1,2, 澤田康文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 480-480, 2024. |
|---|
|
|
[2-7-O02-1]. Basic study on adsorption ability of the pharmaceutical products with the oral hyperkalemic therapeutic drug 植松勇伍, 水野友理, 緒方文彦, 川崎直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 481-481, 2024. |
|---|
|
|
[2-7-O02-2]. Nasal cavity absorption promotion effect of the mometasone furan carboxylate nanocrystal dispersion liquid 岩井誓冶, 門脇玲太, 中村早桜里, 増田柊也, 大竹裕子, 長井紀章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 481-482, 2024. |
|---|
|
|
[2-7-O02-3]. The analysis of the change factor between the individual of blood isolation form Perampanel concentrations and construction of the prediction method 山口れな1, 八木達也1, 見野靖晃1, 小泉慎一郎2, 鈴木光路1, 内藤隆文3, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 482-482, 2024. |
|---|
|
|
[2-7-O02-4]. 1 case that we conducted the blood level measurement of ganciclovir in the lung transplantation patients during the extracorporeal membrane oxygenation enforcement 小島悠輔1,2, 片田佳希1,2, 中川俊作1, 梅村圭祐1, 勝部友理恵1, 石村裕樹1, 松村勝之1, 平井真智子1,2, 田中里奈3, 伊達洋至3, 長尾美紀2,4, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 482-483, 2024. |
|---|
|
|
[2-7-O02-5]. Association between plasma trough level and Albumin-bilirubin grade of regorafenib and the main metabolite 藤田一馬1, 田口大樹2, 福田耕二2, 吉田泰一2, 島津和弘2, 篠崎英恵2, 柴田浩行2, 三浦昌朋1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 483-483, 2024. |
|---|
|
|
[2-7-O03-1]. Relative analysis with multiple immune-mediated adverse events and the effect of treatment of the immune checkpoint inhibitor 山口敦史1,2, 齋藤佳敬3, 岡本敬介2, 古堅彩子2, 鳴海克哉2,4, 武隈洋1, 榊原純5, 清水康6, 木下一郎6, 菅原満1,2, 小林正紀2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 484-484, 2024. |
|---|
|
|
[2-7-O03-2]. Inspection of magnesium sulfate doses in the cisplatin origin-related nephropathic prevention 岡本敬介1, 齋藤佳敬2, 山口敦史1,3, 坂田浩太郎4, 鳴海克哉1, 小林正紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 484-485, 2024. |
|---|
|
|
[2-7-O03-3]. Association with peripheral neuropathy of the elderly people general usability test G8 score in patients with old colon cancer and the oxaliplatin-containing regimen and the effect of treatment 原亘輝1, 藤井宏典1, 山田友奈美1, 飯原大稔1, 渡辺大地1, 大畑紘一1, 廣瀬智恵美1, 近石和花菜2, 田島ジェシー2, 牧山明資3, 松橋延壽2, 鈴木昭夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 485-485, 2024. |
|---|
|
|
[2-7-O03-4]. Comparison of the rituximab-induced infusion-related reaction inhibitory effect with the administration in front of the bepotastine or diphenhydramine 中川智章1, 堀智貴1,2, 山本和宏2,3, 武知理菜子1, 岡山雅美1, 須藤多実香1, 濱咲萌1, 安田真依1, 小林真也4, 中村文彦5, 八木秀男4, 北廣優実2, 矢野育子2, 生島繁樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 485-486, 2024. |
|---|
|
|
[2-7-O03-5]. Inspection of the protective efficacy of the AT2 receptor blocker for pyrimidine system anticancer medicine-induced stomatitis utilizing the chart fluoride 井上真理1, 土屋雅美1, 嶋本公徳2, 河添悦昌2, 篠原恵美子2, 矢田竣太郎3, 若宮翔子3, 今井俊吾1, 木崎速人1, 堀里子1, 荒牧英治3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 486-486, 2024. |
|---|
|
|
[2-7-O04-1]. The ribonucleotide reductase becomes the target of the resistant conquest in the Gemcitabine-resistant pancreatic cancer cells 南謙太朗1, 山本雅達2, 河原康一2, 古川龍彦3, 池田龍二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 487-487, 2024. |
|---|
|
|
[2-7-O04-2]. Search of the risk factor of the drug-related leukoencephalopathy in the central nervous system (origin) malignant lymphoma 森彩里穂1, 奈良克彦1, 増田康隆2, 山本武人1, 志村有香2, 田岡和城3, 森田剣2, 黒川峰夫2,4, 高田龍平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 487-488, 2024. |
|---|
|
|
[2-7-O04-3]. The mechanism of action elucidation of the SGLT2 inhibitor as the cisplatin-induced renal failure preventive preparation 神田将哉1,2, 合田光寛1,2, 石田朋奈1, 石田俊介1,2, 櫻田巧1,2, 坂東貴司1,2, 川田敬1,4, 相澤風花1,2, 新村貴博1,3, 八木健太1,3, 石澤有紀1,5, 桐野靖1,2, 石澤啓介1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 488-488, 2024. |
|---|
|
|
[2-7-O04-4]. Observational, prospective study (JASCC-CINV 2002) about the emetic risk classification evaluation of the PARP inhibitor in patients with ovarian cancer 堀恭子1, 山本扇里2, 飯原大稔2, 土屋雅美3, 早崎容4, 熊倉康郎5, 渡邊大地2, 境秀樹6, 中川慧7, 工藤明子8, 大石元9, 角暢浩10, 郷真貴子11, 真島宏太12, 内田敬3, 安江萌夏2, 前田章光1, 西野公博13, 松本光史6, 佐藤慎也8, 上田豊7, 冨尾賢介9, 林克剛3, 坊本佳優4, 安部正和14 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 488-489, 2024. |
|---|
|
|
[2-7-O04-5]. Examination of the exacerbation inhibitory effect of the incretin analogous drug for the onset of bevacizumab-induced proteinuria of patients with diabetes concurrence cancer: Look at the multi-organization rear; a mark cohort study 高田麻季1, 山本和宏1,2, 堀智貴3, 生島繁樹3, 真野優利花1, 丹田雅明1, 大村友博1, 矢野育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 489-489, 2024. |
|---|
|
|
[2-7-O05-1]. Effect of various factors giving it to the fall risk of the chemotherapy enforcement patients 小田真司1, 武智研志2, 津久井千之1, 平井覚3, 高取真吾2, 大塚尚1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 490-490, 2024. |
|---|
|
|
[2-7-O05-2]. Exploratory examination of the drug factor associated with the urination independence difficulty after the stroke 隅屋暦1, 正源寺美穂2, 池永康規3, 小川依3, 平子紘平4, 藤田有美5, 嶋田努1,5, 橋本昌子6, 増田晃伯7, 長基健人7, 玉井郁巳8, 小倉央行1, 遠山直志9, 和田隆志10, 崔吉道1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 490-490, 2024. |
|---|
|
|
[2-7-O05-3]. Chinese medicine aperient, Characteristic as role analysis and the therapeutic drug of the combination crude drug in the Mashiningan 今理紗子1, 原田由美2, 藤塚直樹2, 最上祥子2, 五十嵐信智1, 酒井寛泰1, 細江智夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 491-491, 2024. |
|---|
|
|
[2-7-O05-4]. Adequacy of the choice and the renal function evaluation of the sarcopenia patients who assumed the Cr/CysC ratio an index 神矢莉那, 津下遥香, 田中遼大, 龍田涼佑, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 491-492, 2024. |
|---|
|
|
[2-7-O05-5]. Interference (the second report) of the Eltrombopag in the serum bilirubin measurement: Effect of blood Eltrombopag concentrations 小田峻1, 土岐浩介1,2, 鈴木嘉治1, 小原直3, 千葉滋3,4,5, 本間真人1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 492-492, 2024. |
|---|
|
|
[2-7-O06-1]. Consciousness about knowledge and the remedy continuation of the drug which may cause the thirst in patients with elderly health insurance pharmacy next situation: Descriptive crossing study 井阪千晟, 松木史, 半田京子, 木村涼子, 松井優子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 493-493, 2024. |
|---|
|
|
[2-7-O06-2]. Effective evaluation of the standard therapeutic drug two drugs combination for Clostridioides difficile 池上眞太郎, 田代渉, 榎木裕紀, 田口和明, 松元一明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 493-494, 2024. |
|---|
|
|
[2-7-O06-3]. The pregnancy in the early pregnancy use of the gastric mucosa protective and fetal risk assessment: Multicenter case series study using the integration database 小澤秀介1, 山折大1,2, 後藤美賀子3, 八鍬奈穂3, 山根律子4, 村島温子3, 内藤隆文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 494-494, 2024. |
|---|
|
|
[2-7-O06-4]. Prospective cohort study - for patients with making - decompensated heart failure of the medication adherence evaluation score in patients with heart failure 石田智滉1, 佐川喬也1, 岡崎萌水1, 川田敬2, 浜田知幸3, 久保亨3, 兵頭勇己4, 常風興平1, 北岡裕章3, 浜田幸宏4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 494-495, 2024. |
|---|
|
|
[2-7-O06-5]. Effect of sacubitril valsartan and human natriuretic peptide combination on urine output in patients with heart failure : a multicenter retrospective cohort study 簗川樹1, 朝居祐貴1,2, 座光寺伸幸3, 細江慎吾4, 近藤芳皓5, 大月慎之助6, 加藤瑛一7, 青木まりあ8, 山本吉章9, 山本高範10, 高橋昌明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 495-495, 2024. |
|---|
|
|
[2-9-O07-1]. Examination of the effective and effective education for patients method based on the expression situation of the immune-mediated adverse event and the exhaustive analysis of the discovery opportunity 南晴奈, 松金良祐, 松田圭祐, 中尾智史, 島内あかり, 末次王卓, 廣田豪 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 496-496, 2024. |
|---|
|
|
[2-9-O07-2]. A case which caused cancer treatment-related myocardial disorder after the use of bevacizumab for ovarian cancer 田中美玲, 佐々木涼子, 西垣哲太, 松本真琴, 吉友葵, 鈴木智代, 井出和男, 佐橋幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 496-497, 2024. |
|---|
|
|
[2-9-O07-3]. A case of hypocalcemia after administration of Akalux 門萌子1, 坂本達彦1, 武隈洋1, 齋藤佳敬2, 鈴木崇祥3, 菅原満1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 497-497, 2024. |
|---|
|
|
[2-9-O07-4]. Search of the risk factor to contribute to the onset of Serious Adverse Event in the docetaxel + ramucirumab therapy 玉木慎也1, 平手大輔2, 高田慎也3, 高橋健太4, 菅原満5, 齋藤佳敬5,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 497-498, 2024. |
|---|
|
|
[2-9-O07-5]. Evaluation of the protective efficacy by the combination of minocycline and steroid drug for external use for the antiEGFR antibody medicine-induced dermatopathy 内山数貴1, 齋藤佳敬2, 武隈洋1, 小松嘉人3, 菅原満1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 498-498, 2024. |
|---|
|
|
[2-9-O08-1]. Protective efficacy of vinorelbine origin characteristics periphery phlebitis by the hot compress 谷口理1, 齋藤佳敬2, 坂本達彦1, 内山数貴1, 菅野亮太1, 渡辺拓也1, 武隈洋1, 榊原純3, 菅原満1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 499-499, 2024. |
|---|
|
|
[2-9-O08-2]. Examination of the prophylactic minocycline dosing period for the dermatopathy with the antiEGFR antibody medicine in patients with progress recurrence colon cancer 梁川稔規1, 片岡幸三2, 山下典子1, 板東純子1, 宮崎美貴子1, 福田知子1, 緒方文洪1, 田中亜里菜1, 平田真由美3, 出町友子3, 中村豪志1, 田中邦佳1, 柳井美奈1, 伊藤一真2, 池田正孝2, 木村健1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 499-500, 2024. |
|---|
|
|
[2-9-O08-3]. Examination of the cisplatin origin-related nephropathic onset risk in patients with diabetes 平手大輔1, 齋藤佳敬2,3, 玉木慎也4, 中村勝之5, 高橋健太6, 菅原満3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 500-500, 2024. |
|---|
|
|
[2-9-O08-4]. Inspection of the dose-dependent protective efficacy of the dexamethasone for docetaxel-induced peripheral neuropathy 菅野亮太1, 齋藤佳敬2, 武隈洋1, 高橋將人3, 菅原満1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 500-501, 2024. |
|---|
|
|
[2-9-O08-5]. Examination of risk factor analysis of the adverse event expression by the Abemaciclib and the effect to give for a survival period: Look at the multi-organization combination rear; a mark observational study 田中怜1,2, 辻大樹3, 伊藤夕3, 中村和代4, 山本圭祐5, 中尾將彦6, 石川寛2, 嘉屋道裕4, 中垣繁4, 澤昇平7, 奈良修平6, 伊藤邦彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 501-501, 2024. |
|---|
|
|
[2-9-O09-1]. Improvement in nature of the health insurance pharmacy pharmacist utilizing the specialized medical institution cooperation drugstore 近藤元三1, 天方奉子1, 稲葉一郎1, 松坂大輔2, 池田一之3, 中村繁良4, 田中由起子5, 山室蕗子5, 小園亜希6, 合澤啓二7, 大山高廣8, 中村和美8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 502-502, 2024. |
|---|
|
|
[2-9-O09-2]. Creation and implementation of a flowchart for CRS prevention using epcolitamab 木村雄太1, 西原夢乃1, 野口唯香1, 佐東慶一2, 明庭圭吾3, 森瀬修平3, 阿部結哉1, 高田慎也1, 山岸佳代1, 高橋承吾4, 江端浩4, 坂井俊哉4, 藤本勝也4, 橋下浩紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 502-503, 2024. |
|---|
|
|
[2-9-O09-3]. Compliance investigation utilizing the patients participation type medical care cooperation support system in the treatment with oral breast cancer hormone 高山慎司1, 田中裕子2, 笠原里紗3, 尹玲花4, 土田寧恵5, 山内英子6, 吉田敦3, 中村清吾3,5, 後藤一美1, 林直輝3,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 503-503, 2024. |
|---|
|
|
[2-9-O09-4]. Reduction of the duties burden in the introduction of the pertuzumab trastuzumab combination subcutaneous injection preparation 原敬1, 村田梨香1, 長谷潤子1, 松方絢美2, 酒井啓子3, 藤村まどか3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 503-504, 2024. |
|---|
|
|
[2-9-O09-5]. One case that type I diabetes mellitus, dysfunction thyroid, adrenal insufficiency, irAE of encephalitis developed by compound immune therapy, and came by treatment maintenance by the multi-type of job intervention 上ノ段友里1,3, 福山康朗2, 辛島高志2, 富田珠美1, 林秀樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 504-504, 2024. |
|---|
|
|
[2-9-O10-1]. Study on effect that DVO using the anticancer agent preparation robot gives for abacterial security 後藤佳奈1, 青山聖2,5, 近藤周平3, 朝岡みなみ1,5, 堀田祐志1,5, 井上貴子4, 近藤勝弘5,6, 日比陽子1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 505-505, 2024. |
|---|
|
|
[2-9-O10-2]. Fact-finding about the anticancer agent exposure to pharmacist, nurse in the national cancer research center center Hospital 佐藤正和1, 西垣玲奈1, 宇田川涼子1, 寺田公介1, 伊藤暖子2, 伊藤知亜紀2, 浅野智央1, 渡部大介1, 齋藤義正1, 橋本浩伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 505-506, 2024. |
|---|
|
|
[2-9-O10-3]. Comparison of the environmental pollution situation before and after the preparation of the anticancer agent and the Closed system drug transfer device introduction in the administration 宇田川涼子1, 西垣玲奈1, 松村千麻2, 山本酉子2, 藤井健太郎2, 渡部大介1, 浅野智央1, 齋藤義正1, 橋本浩伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 506-506, 2024. |
|---|
|
|
[2-9-O10-4]. Evaluation about the preparation performance of the anticancer agent preparation robot by long-term operation data and the duties efficiency to result 外海友規1,2, 近藤勝弘2,3, 堀田康弘1,2, 堀田祐志1,2, 日比陽子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 506-507, 2024. |
|---|
|
|
[2-9-O10-5]. It is effectively utilized the anticancer agent preparation robot 福井嵩浩, 鈴木日向子, 伊藤和佳奈, 山本晃平, 柴田みづほ, 横山威一郎, 内田雅士, 山崎伸吾, 石井伊都子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 507-507, 2024. |
|---|
|
|
[2-9-O11-1]. Verification of adverse events associated with the concomitant use of venetoclax and antifungal drugs with CYP3A inhibitors 國澤敦史, 滝沢大吾, 櫻下弘志, 佐伯康之, 松尾裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 508-508, 2024. |
|---|
|
|
[2-9-O11-2]. Examination about chemotherapy-induced peripheral neuropathy with the Pola-R-CHP therapy in the true clinical practice 岡崎一真1, 高田慎也2, 梅原健吾2, 木村雄太2, 橋下浩紀2, 加藤遥平1, 和泉早智子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 508-509, 2024. |
|---|
|
|
[2-9-O11-3]. An observational, prospective study of the anamorelin in the pancreatic cancer cachexia: Search of hyperglycemia expression and the risk factor 平井聡1,2, 松金良祐1, 南晴奈1, 末次王卓1, 藤森尚2, 小川佳宏2, 家入一郎1, 廣田豪1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 509-509, 2024. |
|---|
|
|
[2-9-O11-4]. We look at the serum creatinine level after the Abemaciclib administration and the rear about effect of treatment and the side effect and examine a mark 大橋邦央1, 筒井佑紀1, 樋口文子2, 橋本雅司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 509-510, 2024. |
|---|
|
|
[2-9-O11-5]. The effect that a gastric-acid secretion antagonist gives in the effectiveness and the safety of the CDK4/6 inhibitor: Tendency score matching analysis 岩部翠1, 高橋佳織2, 魚住龍史3, 向原徹4, 林田哲5, 飯原大稔6, 楠原佳那子7, 土屋雅美8, 北洞美佳6, 永山愛子5, 小坂真吉9, 丹羽好美10, 関朋子5, 大貫幸二11, 鈴木昭夫6, 二村学10, 河添仁2, 中村智徳2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 510-510, 2024. |
|---|
|
|
[2-9-O12-1]. The effectiveness by the difference in trifluridine/Tipiracil administration regimen of patients with stomach cancer and safe examination 板橋皓海1, 金子裕美1, 鈴木貴明2, 早野康一3, 藏田能裕3, 石井伊都子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 511-511, 2024. |
|---|
|
|
[2-9-O12-2]. Examination of the operational usefulness of the anticancer drug audit support system "Chemosuke" 岩川悟, 戸田純司, 高橋信也, 野津祐貴, 細野貴成, 大谷拓也, 室岡邦彦, 高瀬久光 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 511-511, 2024. |
|---|
|
|
[2-9-O12-3]. About a dosage of the Carboplatin by the 24 hours urine collection law in our hospital gynecology 加賀真樹, 石川大介, 茂木佳子, 阿部桂子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 512-512, 2024. |
|---|
|
|
[2-9-O12-4]. It is tested the use results and behavior flexibility, the safety of the infusor pump in continuously administering it for 5-FU five days 田嶋大輝, 高木昭佳, 江守勇紀, 高橋則正, 石川雄大, 加藤敦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 512-513, 2024. |
|---|
|
|
[2-9-O12-5]. Inspection of the pre-rear predictor before the colon cancer FTD/TPI therapy administration 氏木里依子1, 壁谷めぐみ2, 足立茂樹3, 片山広美4, 牛膓沙織5, 鈴木善貴6, 中根茂喜7, 永松秀紹8, 間瀬広樹9, 和田康弘10, 井上裕貴11, 宮崎雅之12, 通木淳史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 513-513, 2024. |
|---|
|
|
[2-10-O13-1]. Effect of the training that the physical assessment after hypodermic injection, the intravascular injection enforcement for pharmacy students assumed 薄井健介1,2, 大内竜介1,2, 渡邊卓嗣1,2, 工藤香澄2,3, 岡田浩司1,2, 鈴木裕之2,4, 金野太亮2,4, 西川陽介2,5, 村井ユリ子4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 514-514, 2024. |
|---|
|
|
[2-10-O13-2]. About results of the satisfaction investigation of the pharmacy business training in the University of Yamanashi faculty of medicine hospital and the future prospects 一瀬彩, 寺田芳弘, 莊司智和, 寺田知世, 輿石泰良, 白井和輝, 松村大樹, 小林みわ子, 橘田文彦, 鈴木貴明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 514-515, 2024. |
|---|
|
|
[2-10-O13-3]. Self-assessment investigation of the pharmacy school business trainee in the hospital pharmacy attached to University of Toyama 植竹龍一, 龍伸和, 中川洋子, 小笠原明美, 窪田佳代子, 丸山千春, 高木昭佳, 加藤敦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 515-515, 2024. |
|---|
|
|
[2-10-O13-4]. Efforts of the training in the drugstore using the tracing report (cancer, non-cancer case) and the inspection 浅野恭平1, 高木昭佳2, 月岡良太3, 加藤敦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 515-516, 2024. |
|---|
|
|
[2-10-O13-5]. The training systems architectural attempt from the health insurance pharmacy to a care mix hospital 狭間研至1,2, 杉田康1, 安里芳人1, 高橋沙紀1, 中村吏志1, 山本千尋2, 永井洋子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 516-516, 2024. |
|---|
|
|
[2-10-O14-1]. Inspection of the training method mainly on the case correction in the pharmacist training specialized in local pharmacy care 高木昭佳, 加藤敦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 517-517, 2024. |
|---|
|
|
[2-10-O14-2]. Efforts in "Cancer & Medical learning society" which supports self-study in the cancer medical care 藤本亜弓, 石井寿佳, 影山寛人, 高木裕介, 宮木理子, 小中千広, 古波津美紗, 小嶋葵, 前原悠, 森宏幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 517-518, 2024. |
|---|
|
|
[2-10-O14-3]. Change of the consciousness for the ward duties of the new hiring pharmacist by the excellent City University Hospital group institution cross-sectional educational program 木村理恵1, 三村佳久1,2, 和知野春2,3, 野田雅人3, 長水正也4, 諸角一成4, 大久保奈美5, 恒川有里6, 堀田祐志1,2, 橋本功5, 中村康夫6, 森下修行4, 近藤勝弘2,3, 日比陽子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 518-518, 2024. |
|---|
|
|
[2-10-O14-4]. Evaluation of the resident training in our hospital 野口周作, 宮内秀典, 田原温, 松岡順子, 笠原英城 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 518-519, 2024. |
|---|
|
|
[2-10-O14-5]. Investigation about the validity of the target in the ward training of the pharmacist resident and the effect 山本幸二郎, 畠山成寛, 小森智也, 成田由紀, 長谷川拓也, 重村明香, 渡邉直優, 小池博文, 佐橋幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 519-519, 2024. |
|---|
|
|
[2-10-O15-1]. The case that we suspected metronidazole encephalopathy and suggested drug cancellation, a drug change, and a symptom improved 花房喜子1,2, 鈴木ゆきえ1,2, 若松弘行1,2, 小森亮子1,2, 草野元1, 高木賢司2, 飯高祐子2, 田山英樹2, 神山隆道2, 高橋成一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 520-520, 2024. |
|---|
|
|
[2-10-O15-2]. The effect of dose adjustment according to renal function on the incidence of adverse reactions to nilmatrervir/ritonavir 西山晃1, 沢田佳祐1,2, 中谷丈之1, 河野修治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 520-520, 2024. |
|---|
|
|
[2-10-O15-3]. Effect by having changed the prophylactic antimicrobial of the prostate biopsy clinical path from levofloxacin to sulfamethoxazole trimethoprim 勝谷和馬, 長田一晃, 安原昌宏, 横山匠太, 森川記道, 滝雪歩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 521-521, 2024. |
|---|
|
|
[2-10-O15-4]. Immunodepression mouse lungs part S. PK/PD analysis of cefditoren pivoxil using the pneumoniae infection model and clinical dose evaluation 五十嵐裕貴1,2, 小島菜奈2, 高田啓介1,2, 榎木裕紀2, 田口和明2, 谷川浩司1, 松元一明2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 521-522, 2024. |
|---|
|
|
[2-10-O15-5]. Inspection of the all cases intervention effect of the antimicrobial proper use support team on patients with substrate specific expansion type β - lactamase-producing Escherichia coli bacteremia 山田楊太1, 平田ひとみ1, 宮崎元康1,2, 串間尚子3, 小川新1, 萩原知佳1, 中島章雄1,2, 石井寛3, 今給黎修1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 522-522, 2024. |
|---|
|
|
[2-10-O16-1]. The effect that an in-hospital carbapenem alert gave for blood culture-positive patients treatment 岡冨大輔1, 小野早百合1, 梶山真一1, 宅江良隼1, 山西紀子1, 布村拓也2, 高木慎太郎3, 樫本考司1, 前田貴司4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 523-523, 2024. |
|---|
|
|
[2-10-O16-2]. Examination about effect of treatment and the adverse event of low-dose TMP/SMX for non-HIV-PCP 相楽勇人1, 佐々木勇人2, 三船大樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 523-524, 2024. |
|---|
|
|
[2-10-O16-3]. Effect inspection and problem by the clinical record mention contents change of the antimicrobial proper use support team aiming at antimicrobial proper use 楠美克紀1, 久米央子1, 奥ヶ谷教1, 松岡佳吾1, 加藤由美子2, 野澤祐輔3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 524-524, 2024. |
|---|
|
|
[2-10-O16-4]. Efforts and evaluation aiming at hand hygiene and the improvement of the pharmacist in consciousness for infection measures 前田和彦1, 古川涼香1, 新田由美子2, 岡井由美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 524-525, 2024. |
|---|
|
|
[2-10-O16-5]. Efforts and evaluation to preventive measures against HBV reactivation 谷口潤1, 梅本啓史1, 大重彰彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 525-525, 2024. |
|---|
|
|
[2-10-O17-1]. Usefulness evaluation about the drug control summary at hospital transfer 菅原隆文, 柿原聡美, 阿部圭輔, 石田翔, 渡邊篤 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 526-526, 2024. |
|---|
|
|
[2-10-O17-2]. Effect of the outpatient home follow promotion by the health insurance pharmacy using "an internal use chemotherapy follow request book, results report" 吉田弘樹, 高原悠子, 鈴木雅人, 牧原明秀, 三屋良太, 近藤舞子, 木全司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 526-527, 2024. |
|---|
|
|
[2-10-O17-3]. Efforts for the multi-type of job cooperation and the regional alliances for the nintedanib remedy patients 和田宜久1, 的場美香1, 木村貴1, 友井理恵子1, 木澤成美1, 川口翔子2, 竹川幸恵2, 平田聡子2, 村上由美子2, 森下裕3, 金銅葉子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 527-527, 2024. |
|---|
|
|
[2-10-O17-4]. Evaluation after the tracing report operation for exclusive use of the polypharmacy 千葉崇久, 高崎修一, 大音師澄子, 須田範行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 527-528, 2024. |
|---|
|
|
[2-10-O17-5]. Inflection of a tracing report and the doubt inquiry simplification protocol in 300 beds of public hospitals 磯貝一成1, 三國貴子1, 栗太隆2, 有賀友基2, 伊藤威2, 柴崎俊明2, 中野弘子2, 川村千鶴1, 西脇優1, 林綾子1, 井上宗信3, 神保雄一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 528-528, 2024. |
|---|
|
|
[2-10-O18-1]. Usefulness evaluation of the discharge follow-up request handwriting in the medication support of children 成宮彩加, 菅原隆文, 木下瑛莉子, 前田美桜, 阿部圭輔, 石田翔, 田中和行, 渡邊篤 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 529-529, 2024. |
|---|
|
|
[2-10-O18-2]. Investigation about the actual situation of electronic medical chart mention at outside Parliament prescription doubt inquiry contents and the change of prescription 小田典子, 岡本知子, 岡井由美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 529-530, 2024. |
|---|
|
|
[2-10-O18-3]. Utilization of the tracing report in the public Nanto center Hospital to perform the inquiry simplification protocol in the outside Parliament prescription 讓原千広, 荒木遼太, 小川紗知, 波多晶子, 中澤美樹子, 橋爪和恵, 窪田真弓, 鶴居勝也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 530-530, 2024. |
|---|
|
|
[2-10-O18-4]. The task which we saw from an attitude survey questionnaire to the Kaizuka-shi pharmacist society about the electronic prescription introduction 長谷川豊1, 中谷健一1, 村上佳愛1, 伊藤優子1, 磯山翔太2, 茨木透3, 兒玉真也4, 西村卓也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 530-531, 2024. |
|---|
|
|
[2-10-O18-5]. Operation and medicine medicine cooperation of the electronic prescription 金原寛子1, 高本美由喜1, 西村麻友子1, 加嶋あかね2, 福岡幹夫3, 野花幸哉3, 西川裕規3, 加藤正美3, 吉田誠4, 横山邦彦5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 531-531, 2024. |
|---|
|
|
[2-11-O19-1]. Significance of the pharmacist intervention in the emergency visit in spinal operations 檜山洋子1, 吉川博1, 佐藤智人1, 大饗和憲2, 松尾裕彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 532-532, 2024. |
|---|
|
|
[2-11-O19-2]. One case that showed improvement by apixaban interruption for a post-operative haematoma case of the infection after the around the right thighbone implant bone fracture technique 片山稔1, 島田隆行1, 佐野雅昭1, 杉本裕宣2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 532-533, 2024. |
|---|
|
|
[2-11-O19-3]. Role of the ward pharmacist for the proximal thighbone bone fracture case in the acute phase ward 川柳大翔, 鈴木俊敬, 秋月崇行, 安部成人, 浅井和浩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 533-533, 2024. |
|---|
|
|
[2-11-O19-4]. The construction of the postoperative pain management team and investigation about the operational situation 鈴木彩貴1, 竹本雄一1, 上葛義浩1, 戸田健太郎1, 鈴木万三2, 柴田純平2, 小川慧2, 岩田裕里2, 増田雅也1, 山田成樹1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 533-534, 2024. |
|---|
|
|
[2-11-O19-5]. Change of the postoperative pain by the postoperative pain management team intervention in the Mazda Motor Corporation Mazda Hospital 吉川昌子, 勝谷和馬, 横山匠太, 森川記道, 安原昌宏, 原田靖子, 滝雪歩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 534-535, 2024. |
|---|
|
|
[2-11-O20-1]. The current situation and problem point about the refill prescription in the Urayasu Hospital attached to the Juntendo University faculty of medicine 高瀬久光, 荘山咲智子, 鬼原亜紀, 後藤なつみ, 大谷拓也, 戸田純司, 成田久美, 室岡邦彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 536-536, 2024. |
|---|
|
|
[2-11-O20-2]. Attitude survey about the support asked for at drugstore DX promotion 佐藤七香1, 佐藤宏樹1,2,3, 柳奈津代1, 古賀友一郎3,4, 長谷川佳孝3,5, 森和明3,6, 澤田康文1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 536-537, 2024. |
|---|
|
|
[2-11-O20-3]. About the simplification of doubt inquiry by the PBPM inflection of our hospital (the first report) 村地康, 金原千明, 高垣佳史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 537-537, 2024. |
|---|
|
|
[2-11-O20-4]. The current situation and problem of the periodical prescription input support by the pharmacist 大塚紗季, 永島久義, 渡辺研弥, 菅野奈緒美, 須藤孝浩, 黒田純子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 537-538, 2024. |
|---|
|
|
[2-11-O20-5]. Examination of safety and the effect by the discharge prescription representation by the pharmacist 永倉史子1,2, 高橋依世理2, 関降実2, 塩地園代1, 小坂鎮太郎2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 538-538, 2024. |
|---|
|
|
[2-11-O21-1]. Examination of the development of the assay using the LC-MS/MS of the new antiphlogistic redie fen relative and the internal change in the rat 和田時奈1, 後藤ひかり2, 蒲地未来2, 前田絢子1,2, 鈴木悠己3, 小向杏佳3, 村田絵理3, 佐藤芙美3, 村田貴嗣3, 椎名勇3, 真野泰成1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 539-539, 2024. |
|---|
|
|
[2-11-O21-2]. Examination of the rat internal change about new heart disease therapeutic drug SNPiP and the metabolite 松井瑠李1, 鶴窪和果2, 前田絢子1,2, 中村成夫3, 柿沼由彦4, 真野泰成1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 539-540, 2024. |
|---|
|
|
[2-11-O21-3]. Analysis of the design of the rebamipide-containing drug controlled release characteristics contact device and the drug behavior out of tears 田所朋久1, 矢野詩歩1, 梅田一輝1, 小早川信一郎2, 檜野栞3, 松永透3, 長井紀章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 540-540, 2024. |
|---|
|
|
[2-11-O21-4]. Effect of the extracorporeal membrane oxygenation to give it to pharmacokinetics of Dexmedetomidine 佐藤雄己1, 元石恵里奈1, 角場里菜1, 永塚由佳1, 阿部拓也2, 藤井豊2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 540-541, 2024. |
|---|
|
|
[2-11-O21-5]. Effect and in vitro-in vivo quantitative predictive analysis of osmotic pressure to give to the interaction between drug - drink and the membrane permeability 日野太崇, 竹村美由記, 丸谷明香音, 玉井郁巳, 白坂善之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 541-541, 2024. |
|---|
|
|
[2-11-O22-1]. Association between expected free form blood level and impaired renal function onset of the Teicoplanin 杉山恭平1,2, 平井啓太3,4, 須山由佳子2, 古谷賢人5, 伊藤健太5, 伊藤邦彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 542-542, 2024. |
|---|
|
|
[2-11-O22-2]. Association of free blood trough level and thrombocytopenia of TEIC 小澤拓, 吉岡睦展, 石津智司, 饒平名長武 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 542-542, 2024. |
|---|
|
|
[2-11-O22-3]. Evaluation of the enforcement pulse-taking of the loading dose of the Teicoplanin using the insurance claim information and the factor associated with safety and the effectiveness 後藤良太1, 豕瀬諒1, 沢田佳祐1,2, 水野香菜子1, 村木優一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 543-543, 2024. |
|---|
|
|
[2-11-O22-4]. Factor examination of the initial trough level low level in the initial administration plan of the Teicoplanin using the in-hospital manual 橋本理沙1, 今中翔一1, 足立匠1, 山元孝俊1, 柴田裕介1, 宮本将誉1, 義那有彩1, 長瀬幸恵1,2, 渡部多真紀1,2, 光永義治1, 安野伸浩1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 543-544, 2024. |
|---|
|
|
[2-11-O22-5]. Search of the risk of developing acute renal failure factor in the TDM based on the AUC index by one point of drawing blood of vancomycin 浜田祐成1, 大磯茂2, 本田憲一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 544-544, 2024. |
|---|
|
|
[2-11-O23-1]. Intervention effect of the pharmacist on blood level measurement of the Clozapine to an outpatient 加藤真也1,2, 見野靖晃2, 鈴木祐介2, 加藤彩2, 和久田智靖3, 川上純一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 545-545, 2024. |
|---|
|
|
[2-11-O23-2]. Look at blood level of the Perampanel in patients with brain tumor and the rear about the side effect; mark investigation 石原慎, 吉年正宏, 岩崎浩子, 藤原季美子, 竹上学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 545-546, 2024. |
|---|
|
|
[2-11-O23-3]. Is "the effect of the Tokishakuyakusan described in a package insert on stain" true? 五十嵐信智, 齋藤凜佳, 篠崎優衣, 西中ゆい, 田端慶斗, 横山公紀, 今理紗子, 酒井寛泰, 細江智夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 546-546, 2024. |
|---|
|
|
[2-11-O23-4]. Prescription fact-finding (the fifth report) of the Ninjin'yoeito: Comparison of patients with mental disorder, dementia and patients with cancer 長崎茜1, 嶋田沙織1, 田村昌士2, 新井哲明2, 本間真人1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 546-547, 2024. |
|---|
|
|
[2-11-O23-5]. Effect on effect of treatment by the steroid combination during checkpoint inhibitor administration of immunity 榊間絢子, 矢澤優衣奈, 五味裕大, 横山征史, 水谷妙子, 登内盛治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 547-547, 2024. |
|---|
|
|
[2-11-O24-1]. Examination of the effect that the folate use in patients with rheumatoid arthritis gives to safety of the methotrexate and the effectiveness 中川千拓1,2, 横山聡1, 宇野貴哉1, 太田涼介2, 平田敦士2, 細見光一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 548-548, 2024. |
|---|
|
|
[2-11-O24-2]. Development of the troxipide nanosuspension and evaluation of the dry eye effect of treatment 板橋瑞稀1, 小坂太陽1, 伊藤奈希1, 岡本紀夫2, 大竹裕子1, 長井紀章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 548-549, 2024. |
|---|
|
|
[2-11-O24-3]. A preparation of the rebamipide nanocrystal-containing polyvinyl alcohol gel and application to stomatitis treatment 和久田耀, 小松美莉, 谷口雅弥, 大竹裕子, 長井紀章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 549-549, 2024. |
|---|
|
|
[2-11-O24-4]. About an evaluation and usefulness of the inhalational instruction using the two-dimensional bar code 近藤貴子1, 盛麻美1, 永田祐子2, 川村萌人1, 大坪輝行1, 小迫晶寛1, 大久保博史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 549-550, 2024. |
|---|
|
|
[2-11-O24-5]. Search of the factor influencing the treatment continuation days of the biopreparation in the psoriasis vulgaris 前田留那, 白岩健, 田中遼大, 龍田涼佑, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 550-550, 2024. |
|---|
|
|
[3-8-O25-1]. Operational flow making and practice ... for mobile pharmacy introduction in activity report - 2024 Noto Peninsula earthquake of Wajima insurance medical care adjustment headquarters DMAT 小林義政, 水谷麻希子, 高木裕介, 鵜飼一歩, 三屋良太, 小田幸弘, 木全司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 551-551, 2024. |
|---|
|
|
[3-8-O25-2]. About the activity of the disaster dispatch pharmacist of the Japanese Society of Hospital Pharmacists in the 2024 Noto Peninsula earthquake 田浦稔基 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 551-552, 2024. |
|---|
|
|
[3-8-O25-3]. Collection of damage situation in the hospital pharmacy gate at disaster: Questionary survey and intelligence training by the Osaka hospital pharmacist society 吉田紗理1, 藤江直輝2, 中川貴弘3, 吉田宏二4, 小林政彦5, 竹上学4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 552-552, 2024. |
|---|
|
|
[3-8-O25-4]. Construction of the disaster good use of disaster relief vehicle in the health insurance pharmacy and battery procedure 植村由香, 田中李奈, 鈴木智之, 桶野友恵, 比嘉耕基, 石尾有司, 染谷光洋, 林貴宏, 谷口亮央, 中島史雄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 552-553, 2024. |
|---|
|
|
[3-8-O25-5]. Exploratory investigation of the factor having an influence on the self-efficacy of the behavior after the disaster for members of pharmacy 相松伸哉1, 松田浩明2, 濱田浩彰1, 前田玲於奈1, 浅野菜緒美1, 南川文哉1, 宮崎寛隆1, 秦光平1, 脇由香里1, 渡邉明日香1, 江原亜沙子1, 野田晋司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 553-553, 2024. |
|---|
|
|
[3-8-O26-1]. Long-term efficacy after having changed it to the gong biline for the patients that virologic inhibition was obtained and safe investigation 山口泰弘1, 平田亮介1, 高武嘉道1, 菊地憂衣1, 大石博史1, 大橋邦央1, 橋本雅司1, 中嶋恵理子2,3, 高濱宗一郎2,3, 南留美2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 554-554, 2024. |
|---|
|
|
[3-8-O26-2]. Efforts by the multi-type of job cooperation for multidrug-resistant HIV-positive patients 高林学1, 田上直美1, 中田浩智2, 松下修三3, 高木雅敏4, 上村裕子5, 緒方釈2, 城野博史1, 齋藤秀之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 554-555, 2024. |
|---|
|
|
[3-8-O26-3]. Pharmacists are the key players in managing cabotegravir/rilpivirine administration. - Case study at Chiba Medical Center - 田中裕子1,2, 早川史織1, 井上真紀3, 市田泰彦1, 金田暁4, 新藤学2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 555-555, 2024. |
|---|
|
|
[3-8-O26-4]. Questionary survey about the medication support of the health insurance pharmacy for patients with HIV infection to have meeting a demand at a health insurance pharmacy 櫛田宏幸1, 山本順也2, 迫田直樹3, 稲葉雅英4, 長谷部茂5, 庄野裕志1, 佐光留美1, 吉野宗宏6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 555-556, 2024. |
|---|
|
|
[3-8-O26-5]. Maintenance of the patients support by efforts and the medicine medicine cooperation to the blood products outside Parliament prescription in the Kyushu medical center 合原嘉寿1, 藤瀬陽子2, 大橋邦央2, 橋本雅司2, 東島幸道1, 鈴田浩孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 556-556, 2024. |
|---|
|
|
[3-8-O27-2]. Case study of the use of pre-avoidance reports in our hospital 辻井佳代, 瀬名波暢子, 小林政彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 557-557, 2024. |
|---|
|
|
[3-8-O27-3]. On every 1st about pharmaceutical products blunder prevention effect by the formulations withdrawal 坂上逸孝1, 横溝綾子2, 前田幹広1, 有木宏宗3, 濱野公俊1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 557-557, 2024. |
|---|
|
|
[3-8-O27-4]. About the way of the effective manual in our hospital (followup) 田村曉識, 松井俊典, 谷田彩, 池田和之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 557-558, 2024. |
|---|
|
|
[3-8-O27-5]. Consciousness change of the nurse for alerting it of the high-risk medicine 鈴木寛人1,2, 平田亮介3, 津曲恭一4, 山形真一5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 558-559, 2024. |
|---|
|
|
[3-8-O28-1]. The effect that incident analysis using P-mSHELL gives for breeding of the medical safe culture of the pharmacy 田場愛子, 高武嘉道, 藤瀬陽子, 大橋邦央, 橋本雅司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 560-560, 2024. |
|---|
|
|
[3-8-O28-2]. Construction and evaluation of the pharmaceutical products proper use monitoring system by the administrative data analysis 永田健一郎1, 石田茂1, 村岡香代子1, 月野木祥子1, 中島貴史1, 中村尚司1, グリム理恵子1, 金谷朗子1, 末次王卓1, 廣田豪1, 家入一郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 560-561, 2024. |
|---|
|
|
[3-8-O28-3]. About the change of the dialysis drug conference suggestion contents by the ward resident start 福永圭佑1,2, 島田美輝1, 橋本貴史1, 坂本有里恵1, 寺崎展幸1, 井上智恵1, 西窪奈津子1, 藤井直彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 561-561, 2024. |
|---|
|
|
[3-8-O28-4]. The prescription trend of the sleeping drug by the standardization of the ward drug for household delivery and change of a fall, the fall incidence of the inpatient 岩本有紀1, 三村享1,2, 土屋広行1, 寺澤美穂1, 熊崎康介2,3, 江津篤3, 牧田ゆかり2,3, 増田雄一2, 関島良樹2, 内藤隆文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 561-562, 2024. |
|---|
|
|
[3-8-O28-5]. What can the hospital pharmacist speak toward fall recurrent prevention? 中田淳也1, 望月愛子1, 鈴木美佳2, 染谷大2, 大石真史3, 原田晴司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 562-562, 2024. |
|---|
|
|
[3-8-O29-1]. Use fact-finding of the Gee raster subcutaneous injection 3.6 mg body pod in the Kurashiki center Hospital 菊池恭, 樋口純一, 宮下佳大, 小林宏太朗, 西村健二, 門野愛美, 益本周治, 有澤礼子, 徳田衡紀, 高柳和伸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 563-563, 2024. |
|---|
|
|
[3-8-O29-2]. Survey of gefapixant citrate tablet use in patients with chronic cough 日高八重1, 小林宏太朗1, 西田麻以2, 西村健二1, 益本周治1, 有澤礼子1, 徳田衡紀1, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 563-564, 2024. |
|---|
|
|
[3-8-O29-3]. Patient preference survey for switching from intravenous pertuzumab + trastuzumab to subcutaneous therapy (Phesgo) in patients with HER2-positive breast cancer 深井雄太1, 梅原健吾1, 高田慎也1, 木村雄太1, 田中晃佑1, 庄崎駿1, 熊本みな子1, 高瀬たまき3, 渡邊健一2, 橋下浩紀3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 564-564, 2024. |
|---|
|
|
[3-8-O29-4]. It is instruction manual ... of the internal use pain-killer in efforts - orthopedics special hospital of the prescription situation investigation and the pharmacist of the oral medicine after the operation in our hospital 篠田健一, 川原由紀子, 後藤益生, 久保智子, 上坂真依子, 藤井佳奈枝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 564-565, 2024. |
|---|
|
|
[3-8-O30-1]. Management of the off-label use of the existing approval medicine in the small and medium size hospital 森光恵1, 中川貴史1, 小坂建夫2, 仲井培雄2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 566-566, 2024. |
|---|
|
|
[3-8-O30-3]. About a concept of the pharmaceutical products management that we introduced into the field in the humanitarian crisis relief business in Ukraine and the system 仲里泰太郎1,2, 光森健二1, 小林政彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 566-567, 2024. |
|---|
|
|
[3-8-O30-4]. Efforts of the pharmaceutical products inventory control which we saw from "the guidelines that the distribution person concerned should observe for distribution improvement on ethical drug" 守谷顕人, 井本陽子, 渡邊裕之, 宅和真由美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 567-567, 2024. |
|---|
|
|
[3-8-O30-5]. Pharmaceutical products traceability system (effect of the pharmaceutical products management using CUBIXX(R), NOVUMN(R) 森泰毅, 原澤仁美, 龍恵美, 岸川礼子, 大塚早紀, 太田千代枝, 兒玉幸修, 大山要 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 567-568, 2024. |
|---|
|
|
[3-9-O31-1]. 3 cases that developed adrenal cortical insufficiency after the checkpoint inhibitor administration of immunity 安島亜矢子1,2, 宮内秀典1, 川嵜椋太1, 勝俣範之2, 野口周作1, 笠原英城1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 569-569, 2024. |
|---|
|
|
[3-9-O31-3]. The search of the infusion reaction onset at the Obinutuzumab initial administration in the true clinical practice and the contributing factor: Single institution case-control study 伊藤佳織1,2,3, 大坪達弥4, 土手賢史5, 守作美咲6, 山田成樹2,6, 冨田章裕3, 早川伸樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 569-570, 2024. |
|---|
|
|
[3-9-O31-4]. The use actual situation of the pain-killer for oral mucositis in patients with cancer catching the radiation exposure 仁尾祐太1,2, 内倉健2, 嶋根俊和3,4, 百賢二2,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 570-570, 2024. |
|---|
|
|
[3-9-O31-5]. The pharmacist outpatient inhibits Apalutamide-induced dermatopathy 梅原健吾1, 高田慎也1, 齋藤佳敬2, 山岸佳代1, 高田徳容3, 丸山覚3, 原林透3, 橋下浩紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 570-571, 2024. |
|---|
|
|
[3-9-O32-1]. Single institution fact-finding of the immune-mediated adverse event that needed admission after the checkpoint inhibitor administration of immunity 宮下佳大1, 石原泰子1, 樋口純一1, 小林宏太朗1, 古谷祥子1, 西村健二1, 仁科慎一2, 森脇俊和3, 有澤礼子1, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 572-572, 2024. |
|---|
|
|
[3-9-O32-2]. Factor analysis of oral mucositis with the FEC therapy using the order logistic-regression analysis or the taste disturbance: Retrospective study in the single institution 神林祐子1,2,3, 田口哲也4, 石川剛2,5, 高山浩一2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 572-573, 2024. |
|---|
|
|
[3-9-O32-3]. Usefulness of the pharmacist-led intervention for the hypomagnesemia at the panitumumab administration in progress, recurrent colon cancer 伊藤大輔, 浅野裕紀, 木村美智男, 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 573-573, 2024. |
|---|
|
|
[3-9-O32-4]. An evaluation of safety and the tolerability of the treatment with immune checkpoint inhibitor in elderly people: We look at the multicenter rear and study a mark 松金良祐1,7, 大山高廣2,7, 龍田涼佑3,7, 木村早希子4,7, 秦晃二郎5,7, 浦田修平6,7, 渡邊裕之5,7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 573-574, 2024. |
|---|
|
|
[3-9-O32-5]. Usefulness of examination input support PBPM for immune-mediated adverse event early detection and evaluation of the time required 森本麻友1, 原田和明1, 増田義雄1, 吉田早希1, 吉野新太郎1, 池末裕明1, 平畠正樹2, 橋田亨1, 室井延之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 574-574, 2024. |
|---|
|
|
[3-9-O33-1]. The effect that the difference in dexamethasone doses of the first day in patients receiving oxaliplatin gives to retching, vomiting frequencies and blood sugar control 島田浩和1, 大神正宏1, 立原茂樹1, 天貝賢二2, 小島寛3, 鈴木美加1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 575-575, 2024. |
|---|
|
|
[3-9-O33-2]. An effect of the aprepitant combination antiemesis therapy in the biliary cancer gemcitabine + cisplatin therapy and inspection of the risk factor 小岡亜矢1, 梅原健吾2, 藤林遼3, 高崎修一4, 下口谷貴5, 日下部鮎子6, 畠山智明7, 長谷川由季8, 清水敦也9, 太田明秀10, 前田健太11, 渡邊大毅12, 高田慎也2, 山岸佳代2, 永島裕之13, 平手大輔1, 橋下浩紀2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 575-576, 2024. |
|---|
|
|
[3-9-O33-3]. The effectiveness evaluation of an olanzapine combination antiemesis therapy and the dexamethasone administration abbreviation in patients with lung cancer that received Carboplatin-based chemotherapy 三瓶祐貴, 奥田泰考, 品田誠, 齋藤賢宏, 小林直人, 山下尊子, 中田雅人, 荒井大地, 大平実佳, 田村依珠美, 今井靖 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 576-576, 2024. |
|---|
|
|
[3-9-O33-4]. Case-control study about the actual situation and the risk factor of the antiemesis therapy for oral anticancer medicine for moderate emetic risk Trifluridine/Tipiracil 中谷祐介, 朝居祐貴, 平松駿一, 岡本明大, 加藤秀雄, 岩本卓也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 576-577, 2024. |
|---|
|
|
[3-9-O33-5]. Examination about the antiemesis effect of the fosnetupitant on chemotherapy-induced retching, vomiting after the late start period in the cisplatin-containing chemotherapy 鈴木聖也1,2, 陳美樹1, 有馬崇充1, 浅野智央1, 渡部大介1, 齋藤義正1, 赤木徹1, 橋本浩伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 577-577, 2024. |
|---|
|
|
[3-9-O34-1]. We look at the single institution rear in the fosnetupitant and weigh a mark against Fosaprepitant 實川東洋, 片山皓希, 敦賀剛気, 伊藤匠, 葛西美彩 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 578-578, 2024. |
|---|
|
|
[3-9-O34-2]. Case accumulation study on actual situation of antiemesis therapy and retching, the vomiting expression for the Cabozantinib 稲垣早織, 中谷祐介, 朝居祐貴, 岩本卓也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 578-578, 2024. |
|---|
|
|
[3-9-O34-3]. Cost effectiveness simulation to determine appropriate costs of the prophylactic antiemesis therapy in chemotherapy-induced retching, vomiting 小嶋亮太, 近藤有, 志賀有雅, 酒井幹康, 小田切由梨, 間瀬悟 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 579-579, 2024. |
|---|
|
|
[3-9-O34-4]. Examination of the effectiveness of the NK1 receptor blocker combination antiemesis therapy for retching vomiting of patients with HER2-positive breast cancer, gastric cancer received T-DXd 齋藤賢宏1,2, 奥田泰考1, 三瓶祐貴1, 品田誠1, 佐藤梨絵1, 荒井大地1, 大野翼1, 金井栄里香1, 中澤寛仁1, 大澤英之2, 今井靖1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 579-579, 2024. |
|---|
|
|
[3-9-O34-5]. Efforts about unifying it of the antiemesis therapy of the chemotherapy regimen in the Osaka City 13 municipal hospital 石坂崚, 横川琴枝, 大江保奈美, 吉田徹也, 市田裕之, 土井克彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 580-580, 2024. |
|---|
|
|
[3-9-O35-1]. What did the student get from the story of effect - pharmacist of the relation of the pharmacist in the cancer education? ... 網野一真1, 青木祐子2, 登内盛治1, 進士明宏3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 581-581, 2024. |
|---|
|
|
[3-9-O35-2]. Effect of modified Glasgow Prognostic Score giving it to a treatment result after the chemotherapy enforcement in patients with unresectable biliary cancer 福司弥生1, 藤田一馬1, 五十嵐遥1, 赤嶺由美子1, 佐々木克也1, 福田耕二2, 柴田浩行2, 菊地正史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 581-582, 2024. |
|---|
|
|
[3-9-O35-3]. A case which intervened pharmaceutical for the patients whom chemical coping is suspected in 柴田亜実子1, 高取俊和1, 岡本知久1, 沖田健太郎1, 藤本伸一2, 太田萌子3, 船越幸代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 582-582, 2024. |
|---|
|
|
[3-9-O35-4]. It is a case using the erythromycin for bowel control after the enteroparalysis by the peritoneal dissemination 伊藤美結, 谷口結基, 太田達也, 田中章郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 582-583, 2024. |
|---|
|
|
[3-9-O35-5]. Biomarker search of cancer-related fatigue using the plasma of the model mouse not to carry on the shoulder 吉澤一巳1, 黒野日花里1, 山口彩夏1, 井倉渚1, 諸井春菜1, 笠井智香1, 熊王俊男1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 583-583, 2024. |
|---|
|
|
[3-9-O36-1]. Somnolence at pregabalin in the use of strong opioid patients and mirogabalin combination, competitive review of the dizziness expression situation 岩崎仁志1, 古関竹直1, 加藤博史2, 近藤征史2,3, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 584-584, 2024. |
|---|
|
|
[3-9-O36-2]. Investigation about the psychological wall to opioid analgesic for the medical care in Japanese pharmacists and nurses using JBQ-II 地嵜悠吾, 大元美佳, 桜野結衣香, 今西孝至 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 584-585, 2024. |
|---|
|
|
[3-9-O36-3]. Fact-finding of the use of methadone situation in our hospital 末松菜月1, 櫛原秀之1, 成瀬徳彦1, 河合奈津子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 585-585, 2024. |
|---|
|
|
[3-9-O36-4]. The effect that the C-reactive protein level in the patients gives for naldemedine administration continuation for cancer terminal phase 蟹江孝樹1, 水野智博1, 覚前有希子1, 古関竹直1, 花本彩2, 富田雅子3, 林高弘1,3, 松岡宏4, 臼井正信5, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 585-586, 2024. |
|---|
|
|
[3-9-O36-5]. Investigation about the diarrhea of the naldemedine in patients with opioid-induced constipation 戸井ひとみ, 桂英之, 太田浩士, 高田直子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 586-586, 2024. |
|---|
|
|
[3-10-O37-1]. The pharmaceutical intervention of the health insurance pharmacy through the tracing report in the foreign cancer medical therapy and the effect 津田瑞季1, 丹田雅明1, 伊藤雄大1,2, 飯田真之1, 大本暢子1, 山本和宏1,3, 大村友博1, 矢野育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 587-587, 2024. |
|---|
|
|
[3-10-O37-2]. Patients questionary survey about the efforts of the illness medicine cooperation in the foreign cancer chemotherapy 齋藤一樹1, 二瓶哲1,2, 後藤慎平1, 朝賀純一1,2, 工藤賢三1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 587-588, 2024. |
|---|
|
|
[3-10-O37-3]. Efforts to the tracing report spread for medicine medicine cooperation promotion in the cancer domain 後藤敏也, 鈴木直哉, 廣瀬和昭, 太田敦代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 588-588, 2024. |
|---|
|
|
[3-10-O37-4]. Effect of the telephone follow-up system of the foreign Lenvatinib therapy by the medical cooperation 森岡朝美1, 山本和宏1,2, 榎本大智1,3, 小松昇平4, 大村友博1, 矢野育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 588-589, 2024. |
|---|
|
|
[3-10-O37-5]. Usefulness of the illness medicine for patients with colon cancer cooperation using the reporting document between institutions in the CapeOX therapy supporting after the operation: Look at the rear; a mark cohort study 寺谷祐亮, 板村亮, 櫻下弘志, 佐伯康之, 松尾裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 589-589, 2024. |
|---|
|
|
[3-10-O38-1]. Efforts - from medicine pharmacy cooperation to way (medical care and prophylactic coexistence) - appropriate and effective reporting and improvement of the local pharmacist whom we saw in health conscious 石坂敏彦1,2,3, 面谷幸子1,3, 藤井一美1,2, 鹿嶋隆行2, 宮川道英2, 和田憲周2, 是川美里2, 名徳倫明3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 590-590, 2024. |
|---|
|
|
[3-10-O38-2]. For the treatment at home that is the same as a hospital 富岡節子1, 齋藤充生2, 上松清子3, 小澤美和4, 古屋秀和5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 590-591, 2024. |
|---|
|
|
[3-10-O38-3]. To be effective, and to continue safe medical treatment ... about usefulness of the pharmacist placement to a care health center for the elderly; ... 大荒政志, 増田博也, 久岡清子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 591-591, 2024. |
|---|
|
|
[3-10-O38-4]. Intervention of the pharmacist for the home health care support inpatient in the local inclusion care ward 上野綾海, 揚張真利子, 日下豊史, 瀧祐介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 591-592, 2024. |
|---|
|
|
[3-10-O38-5]. The effectiveness in an effect and the duties that a chronic kidney disease (CKD) seal gives for the patients disease grasp of the pharmacist 中川裕介1,2, 忰田亮平2, 鈴木優也2, 成田一衛2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 592-592, 2024. |
|---|
|
|
[3-10-O39-1]. Comparison of the Everolimus measurements by the ACMIA method, the ECLIA method and the LC-MS/MS method 甲斐真己都1, 松永典子1,2, 潮崎孝則2, 里加代1,2, 兒玉幸修1,2, 大山要1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 593-593, 2024. |
|---|
|
|
[3-10-O39-2]. Relations of time (TTR) in the therapeutic range of blood tacrolimus levels in the allogeneic hematopoietic stem cell transplantation patients and the acute GVHD protective efficacy 江原幸菜, 吉川直樹, 松崎裕紀, 山田侑世, 池田龍二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 593-594, 2024. |
|---|
|
|
[3-10-O39-3]. Basic examination about the inhalational pattern optimization that pointed to the local side effect reduction of the inhalational powdered drug 畠添咲希子1,2, 平大樹1, 近藤哲理3, 重面雄紀1, 今吉菜月1, 勝部友理恵1, 幾田慧子1, 國津侑貴1, 上島智4, 中川俊作1, 津田真弘1,2, 岡野友信4, 角本幹夫4, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 594-594, 2024. |
|---|
|
|
[3-10-O39-4]. Examination of the renal function evaluation of patients with obesity that is less than less than 152.4cm tall and eGFR60mL/min/1.73m2 平井さやか1, 細沼花穂里1, 清水優貴1, 松井浩志1, 門田佳子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 594-595, 2024. |
|---|
|
|
[3-10-O39-5]. Inspection of the thrombocytopenia risk reduction by the individualization administration plan of the linezolid: Systematic review & meta analysis 鶴田健流1, 尾田一貴2, 山田智之3, 花井雄貴4, 小松敏彰5, 近藤昭志2, 城野博史2, 齋藤秀之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 595-596, 2024. |
|---|
|
|
[3-10-O40-1]. One case that extension of significant PT-INR was suspected by combination of warfarin potassium and duloxetine and it was led by a pharmacist and monitored PT-INR and improved 山下悟史, 曽我弘道, 渡邊慶子, 内村充志, 都野川真優, 富田敏章, 町田聖治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 597-597, 2024. |
|---|
|
|
[3-10-O40-2]. As for the combination of the immune checkpoint inhibitor in the warfarin remedy patients, PT-INR may be extended 上ノ山和弥1, 槙原克也2, 山本浩史3, 高木麻里4, 尾本和彦5, 尾上雅英1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 597-598, 2024. |
|---|
|
|
[3-10-O40-3]. Investigation second report about the serum selenium concentration in the severeness people experiencing disability taking an antiepileptic drug 桶本幸1, 関本裕美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 598-598, 2024. |
|---|
|
|
[3-10-O40-4]. Search of the drug influencing a dermatopathy onset risk by the lamotrigine which assumed medical big data analysis a base 坂東寛1,2, 合田光寛1,2, 小川敦1,2, 川田敬1,3, 新田侑生4, 櫻田巧1,2, 桐野靖1,2, 平井啓太5,6, 中瀧理仁7, 中馬真幸4, 内藤隆文5,6, 沼田周助7, 田崎嘉一4, 石澤啓介1,2,8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 598-599, 2024. |
|---|
|
|
[3-10-O40-5]. The effect that clopidogrel combination gives in HbA1c of patients receiving repaglinide 高橋勇己1, 中澤祐介1, 元日田阿子1, 西村理明2, 川久保孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 599-599, 2024. |
|---|
|
|
[3-10-O41-1]. Association of fasting administration and side effect of the distigmine and the serum cholinesterase 竹内祐介1, 多胡友絵1, 星育子1, 小泉祐一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 600-600, 2024. |
|---|
|
|
[3-10-O41-2]. One case that discovered poor medication adherence of the Cabozantinib by blood drug levels monitoring 丸山真一1,2, 百賢二3, 案納忠譜4, 石田勝4, 菅野浩1, 加藤大2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 600-601, 2024. |
|---|
|
|
[3-10-O41-3]. Effect of the heart cachexia to give it to pharmacokinetics and a bleeding risk of the edoxaban 鈴木利昌1, 八木達也1, 柴田海斗2, 内藤隆文2, 前川裕一郎3, 川上純一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 601-601, 2024. |
|---|
|
|
[3-10-O41-4]. Does it have the significance to practice Modeling & Simulation by clinical practice? - - to think through a challenge to population pharmacokinetics analysis 森田和弥, 阿部裕子, 小場佐仁美, 宮崎賢三, 牧坂夏実, 高橋英範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 601-602, 2024. |
|---|
|
|
[3-10-O41-5]. Application development and anticipatory inspection to enable PT-INR prediction after the warfarin administration by the population kinetic-pharmacodynamic model 青山隆彦1, 北川雅憲1, 関悟史1, 平井利典2, 辻泰弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 602-602, 2024. |
|---|
|
|
[3-10-O42-1]. Factor analysis including the genetic polymorphism influencing blood level of posaconazole in patients with blood disorder 安井友佳子1,5, 岡山裕介2, 久野雅智3, 康秀男4, 柴多渉5, 掛屋弘5, 安井裕之6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 603-603, 2024. |
|---|
|
|
[3-10-O42-2]. The effect of the genetic factor on OATP1B activity in patients with chronic kidney disease that assumed an endogenous substrate an index and elucidation of the relationship with CMPF levels 小野寛之1, 田中遼大1, 鈴木陽介2, 佐藤春輝2, 小田絢子2, 安藤忠助3, 秦聡孝3, 大野恵子2, 伊東弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 603-604, 2024. |
|---|
|
|
[3-10-O42-3]. The effect that recovery from febrile neutropenia gives for a pediatric pharmacokinetic intraindividual variability of vancomycin 内匠幸恵, 田中遼大, 岩男元志, 龍田涼佑, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 604-604, 2024. |
|---|
|
|
[3-10-O42-4]. The effect that perioperative inflammatory response gives to a change of the CYP2C19 activity 中川潤一1, 石戸圭之輔2, 木村憲央2, 長瀬勇人2, 若狭悠介2, 相内尚也1, 東野優花1, 上野桂代1, 袴田健一2, 新岡丈典1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 604-605, 2024. |
|---|
|
|
[3-10-O42-5]. Effect of interleukin-6 giving it to PK/PD of the Osimertinib in patients with non-small cell lung cancer 横田隼人1, 赤嶺由美子1, 佐藤一洋2, 坂本祥2, 奥田佑道2, 竹田正秀2, 中山勝敏2, 三浦昌朋1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 605-605, 2024. |
|---|
|
|
[3-11-O43-1]. Safety and the effectiveness of the oral beclomethasone propionate ester (BDP) therapy for late onset acute GVHD after the allogeneic hematopoietic stem cell transplantation 畠中友理子1,2, 山本久史2, 島野玲菜1, 小倉真由美1, 藤井博之1, 内田直之2, 伊藤忠明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 606-606, 2024. |
|---|
|
|
[3-11-O43-2]. Superoxide is partially responsible for the renal tubular toxicity of the BRAF inhibitor vemurafenib 真川明将1, 堀田祐志1, 高瀬弘嗣2, 家田直弥3, 川口充康4, 前田康博5, 中川秀彦4, 日比陽子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 606-607, 2024. |
|---|
|
|
[3-11-O43-3]. Consideration about the drug-induced lymphocyte stimulation test-positive molecular mechanism with valsartan 大久保正1,2, 田中真理子2, 大久保七枝3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 607-607, 2024. |
|---|
|
|
[3-11-O43-4]. Relative evaluation with the adverse event by the organic anionic transportation polypeptide inhibitor and paclitaxel 赤城友章, 橋詰淳哉, 黄智剛, 河内佑樹, 小林瑞希, 谷尾莉佳, 兒玉幸修, 大山要 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 607-608, 2024. |
|---|
|
|
[3-11-O43-5]. Elucidation of the digestive organ toxicity expression of metformin mechanism due to homeostatic rupture of serotonin change/gut flora 番場琴音1, 鮒井悠汰1, 関裕太1, 浅地英1, 樋田純1, 大島浩子2, 大島正伸2, 玉井郁巳1, 白坂善之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 608-608, 2024. |
|---|
|
|
[3-11-O44-1]. A case which developed repeated diverticula of colon bleeding by an esflurbiprofen Mentha Oil patch 延藤勇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 609-609, 2024. |
|---|
|
|
[3-11-O44-2]. A case of the iatrogenic adrenal insufficiency that it was thought that it was caused by triamcinoloneacetonide intraarticular administration 池上孝明1, 牛島智子1, 大柿滋1, 西田健朗2, 浜田英明2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 609-610, 2024. |
|---|
|
|
[3-11-O44-3]. 2 cases that developed irAE after administration in the Tremelimumab + Durvalumab therapy first time 柏木怜, 渡辺浩明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 610-610, 2024. |
|---|
|
|
[3-11-O44-4]. Comparison of the frequency of the digestive organ symptom with the crush administration of aspirin Enteric tablet in patients who received percutaneous coronary intervention 岸本拓也1, 沢田佳祐1,2, 熊谷春佳1, 西山晃1, 河野修治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 610-611, 2024. |
|---|
|
|
[3-11-O44-5]. The effect that the combination of benzodiazepine receptor agonist and orexin receptor blocker or melatonin receptor agent gives in a fall fall risk 石川雄也1, 荒木拓也1,2, 樋口裕哉1, 八島秀明1,2, 山本康次郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 611-611, 2024. |
|---|
|
|
[3-11-O45-1]. The current situation investigation about the pharmacist initial interview situation in patients undergoing surgery in the daily service zone on weekdays 齋藤靖弘1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 612-612, 2024. |
|---|
|
|
[3-11-O45-2]. About usefulness of the last confirmation before administration by the foreign chemotherapy center permanent residence pharmacist 松由幸司, 山口雄士, 曽根章貴, 高澤圭輔, 安田翔, 近藤章吾, 生駒辰夫, 日江井和英, 宮部芳之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 612-612, 2024. |
|---|
|
|
[3-11-O45-3]. The actual situation of medication adherence in the bringing medicine of the university hospital inpatient and the prescription complexity 宮崎元康1, 高木聡子1, 山田楊太1, 三崎桃子1, 森由夏子1, 戸倉歌緒子1, 平田ひとみ1, 福山安里彩1, 中島章雄1,2, 今給黎修1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 613-613, 2024. |
|---|
|
|
[3-11-O45-4]. Participation in planning of the pharmacist to the medical therapy for patients with acute coronary syndrome 畑中章吾1, 吉村光弘1, 片岡聡1, 村岡淳二1, 若菜紀之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 613-614, 2024. |
|---|
|
|
[3-11-O45-5]. Analysis of the bleeding event of patients who underwent percutaneous transluminal coronary angioplasty using blood vessel elasticity index CAVI 川上聡士1, 佐藤修司2, 佐藤直子1, 清水一寛2, 土井啓員1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 614-614, 2024. |
|---|
|
|
[3-11-O46-1]. Characteristic of the person of Edinburgh after giving birth depression self-assessment vote high score of the nursing mother who received the counseling by a pregnant woman, a nursing mother specialty, the authorized pharmacist 伊藤有美1, 鳥居綾2, 増森なつ紀2, 尾関聖里花2, 佐藤寛子1, 鳥居昌太1, 鈴木秀明1, 林高弘2, 吉川昌江2, 滝本典夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 615-615, 2024. |
|---|
|
|
[3-11-O46-2]. Using medication improvement evaluation - PILL-5 assessment tool with fact-finding and the medication adjuvant product of tablet dysphagia - 大坪博子1, 倉田なおみ1, 大城真理奈2, 高橋伸幸2, 山口天士2, 田中広紀2, 楠裕美子2, 詫間章俊2, 三井奈緒2, 島本一志2, 伊藤綾花2, 越塚宏美2, 古屋宏章2, 大音師澄子3, 飯田純一4, 輿石徹5, 上田章人6, 萩田均司7, 坪内理恵子8, 宇都宮励子9, 森田俊博10 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 615-616, 2024. |
|---|
|
|
[3-11-O46-3]. Study on evaluation and adherence evaluation of the consensual communication technology of the drugstore pharmacist 安田颯志1, 金田仁孝2, 林良紀3, 三田康子4, 上田幹子5, 池田賢二5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 616-616, 2024. |
|---|
|
|
[3-11-O46-4]. Study cafe held effect investigation aiming at the clinical studies promotion by the pharmacist 吉友葵1, 清水絢子1, 坂本靖宜1, 川邊一寛2, 小森智也1, 後藤洋仁1,3, 小池博文1, 佐橋幸子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 616-617, 2024. |
|---|
|
|
[3-11-O46-5]. Questionary survey about the education of the nurse conducting heart failure medical treatment instruction 木原慶子1, 陣山由紀2, 磯野慈2, 山本尚博2, 山中美穂2, 川上こず恵2, 森妙子2, 藤堂朱香1, 富田敏章1, 町田聖治1, 森永崇3, 磯谷彰宏4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 617-618, 2024. |
|---|
|
|
[3-11-O47-1]. Search of the appropriate mode of transportation for pharmaceutical products delivery to the patients's house 川端大千1, 海地夏月1, 小池紫1, 山下修司1, 伊野陽子2, 松丸直樹3, 鈴木昭夫4, 山本佳久5, 林秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 619-619, 2024. |
|---|
|
|
[3-11-O47-2]. The actual situation of the operation in a drugstore and the distribution supplier about the pharmaceutical products delivery to the patients's house 海地夏月1, 川端大千1, 小池紫1, 山下修司1, 伊野陽子2, 松丸直樹3, 鈴木昭夫4, 山本佳久5, 林秀樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 619-620, 2024. |
|---|
|
|
[3-11-O47-3]. We regard a policy as a problem to maintain generic drug industry of our country, and to promote: Proposal for the user side 渡辺善照1, 横濱重晴1, 太田進1, 石川康成1, 戸島洋一1, 花岡一雄1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 620-620, 2024. |
|---|
|
|
[3-11-O47-4]. Correlative analysis of a property and the pushing out power of the container for various hyaluronic acid eye drops 酒井琢朗1, 松本夏奈1, 神尾あすか1, 大竹裕子1, 稲葉一訓2, 小畑友紀雄3, 中田雄一郎3, 長井紀章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 620-621, 2024. |
|---|
|
|
[3-11-O47-5]. The examination of the aerosol properties rating system of the instillation of nose drop preparation and comparison between a point, the generic medicine 森田時生, 吉田寛幸, 佐藤陽治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 621-621, 2024. |
|---|
|
|
[3-11-O48-1]. Usefulness of the DI inquiry database utilizing the bulletin board function (IRIS portal) of prescription check system IRIS 櫻田穣, 丸山あゆみ, 神佳祐, 村永諒, 山本いずみ, 中嶋紘文, 坂田幸雄, 長浜谷耕司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 622-622, 2024. |
|---|
|
|
[3-11-O48-2]. It is ... mainly on an attention column in current situation investigation - benefit of health insurance of the electronic recommendation which is not based on the mention point 山中理1, 山村篤史2, 早川太朗2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 622-623, 2024. |
|---|
|
|
[3-11-O48-3]. The effect that the deletion of pharmaceutical products registered with a generic name prescription master gives to master management 齊藤安昌, 島田雅彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 623-623, 2024. |
|---|
|
|
[3-11-O48-4]. Examination of the effect that the pediatric antimicrobial proper use addition gives in an antimicrobial prescription trend 河野祐輝1,6, 新村貴博1,2, 合田光寛1,3, 川田敬4, 八木健太1,2, 相澤風花1,3, 石澤有紀1,5, 石澤啓介1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 623-624, 2024. |
|---|
|
|
[3-11-O48-5]. Unequal analysis study - using melatonin receptor agonist and arrhythmia - fur Mako bidiLance database in patients with insomnia 増田陸人, 野口義紘, 吉村知哲 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 624-624, 2024. |
|---|
|
|
[4-7-O49-1]. Efforts for the HBV reactivation prevention with the cancer chemotherapy 柿本秀樹1, 福江悠香1, 吹上勇真1, 萩原知佳1, 中島章雄1,2, 眞崎晃3, 加治杏奈4, 宮崎元康1,2, 今給黎修1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 625-625, 2024. |
|---|
|
|
[4-7-O49-2]. Examination of the optimal administration timing and medication method of the filgrastim in the regimen to be administered daily 竹下充哉1, 山本孝枝1, 川崎貴蔵1, 成瀬徳彦2, 櫛原秀之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 625-625, 2024. |
|---|
|
|
[4-7-O49-3]. Search of the risk factor of the taste disturbance onset in patients who received dose-dense MVAC therapy 木村沙織1, 田中雄大1, 折山豊仁1, 山本武人1, 森彩里穂1, 田内梨理1, 田口慧2, 川合剛人3, 久米春喜2, 高田龍平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 626-626, 2024. |
|---|
|
|
[4-7-O49-4]. Look at the rear with examination ... single institution of the appropriate cardiac activity monitoring period in the antiHER2 monoclonal antibody medicine administration; mark observational study ... 槙原克也, 金剛圭佑, 基村佳世, 福井梨乃, 木本大樹, 山本友佳子, 谷畑美里, 松村友和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 626-627, 2024. |
|---|
|
|
[4-7-O49-5]. The clinical role of the vascular endothelium function for the high blood pressure in bevacizumab treated patients and proteinuria: Pilot study 二瓶哲1, 朝賀純一1, 及川隆喜2, 旭浩一3, 工藤賢三1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 627-627, 2024. |
|---|
|
|
[4-7-O50-1]. Examination of the effectiveness of patient education using instruction sheets aimed at improving self-care awareness for stomatitis caused by fluorouracil repeated administration regimens 川崎梓, 東郁子, 新藤実香, 宇田川涼子, 中村恵子, 北爪賀子, 陳美樹, 浅野智央, 渡部大介, 齋藤義正, 橋本浩伸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 628-628, 2024. |
|---|
|
|
[4-7-O50-2]. Inspection of the protective efficacy of the angiotensin II receptor antagonist for high-dose methotrexate-induced hepatic dysfunction 宮田有優, 今井俊吾, 木崎速人, 土屋雅美, 堀里子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 628-629, 2024. |
|---|
|
|
[4-7-O50-3]. 1 case that showed pigmentation to a tongue and oral mucosa after the FOLFIRI+ cetuximab therapy introduction 杉山弘樹1, 中田淳也1, 志田優璃1, 高田真子1, 杉山祐子2, 岩科麻見2, 山崎將典3, 八代聖4, 高森康次5, 原田晴司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 629-629, 2024. |
|---|
|
|
[4-7-O50-4]. One case that was able to accomplish chemotherapy as the adrenal insufficiency concurrence DLBCL patients received intervention of the adrenal crisis prevention 滝沢大吾, 櫻下弘志, 佐伯康之, 松尾裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 629-630, 2024. |
|---|
|
|
[4-7-O50-5]. Examination about the kidney protection effect of the anamorelin for the cachexia patients 佐登礼佳, 炭本隆宏, 田中遼大, 龍田涼佑, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 630-630, 2024. |
|---|
|
|
[4-7-O51-1]. Intervention analysis of the medical treatment management based on by medical examination front and the protocol in the pharmacist outpatient department 郷真貴子1, 木村美智男1, 山田志緒里1, 西村充礼1, 松山卓矢1, 吉村知哲2, 宇佐美英績1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 631-631, 2024. |
|---|
|
|
[4-7-O51-2]. A case which we took medicine and supported which continued about Adverse Drug Event with the foreign chemotherapy 山口慧, 浅見友一, 宮崎賢太郎, 小鷹篤, 飯塚敏美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 631-632, 2024. |
|---|
|
|
[4-7-O51-3]. Making of the adrenal cortical insufficiency early detection tool in patients receiving immune checkpoint inhibitor 塩谷衣津子1,2, 八木達也2, 室伏琢磨2, 佐藤聖2, 今井志乃ぶ3, 飯山教好1, 伊藤譲1, 川上純一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 632-632, 2024. |
|---|
|
|
[4-7-O51-4]. Questionary survey about the needs to hospital pharmacist, the health insurance pharmacy pharmacist of patients with cancer 原田哲彦1,13, 坂野博紀1,13, 佐々木俊則2,13, 山口智江3,13, 中村敏史4,13, 鈴木善貴5,13, 松下直樹6,13, 小柳津瞳7,13, 藤村浩司8,13, 石川未奈子9,13, 佐藤由美子10,13, 堀田和男11,13, 宮崎雅之12,13 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 632-633, 2024. |
|---|
|
|
[4-7-O51-5]. Recognition investigation of patients about the effect that chemotherapy-induced peripheral neuropathy gives to driving 片原帆奈美, 川澄賢司, 岩本義弘, 鈴木秀隆 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 633-633, 2024. |
|---|
|
|
[4-7-O52-1]. The effect that a quantity of extraction air of the plastic bottle gives in spontaneous dribbling at use of CSTD 杉野善彦, 大島有美子, 桜田宏明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 634-634, 2024. |
|---|
|
|
[4-7-O52-2]. Tolerability assessment of niraparib in elderly patients with ovarian cancer 松山里奈1, 松山卓矢1, 村瀬寛美1, 西村充礼1, 山田志緒里1, 郷真貴子1, 木村美智男1, 吉村知哲2, 宇佐美英績1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 634-634, 2024. |
|---|
|
|
[4-7-O52-3]. The use results of the CAR-T cellular therapy in our hospital 清水彬弘, 渡邉貴子, 成田航基, 前川めぐみ, 山村康比古 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 635-635, 2024. |
|---|
|
|
[4-7-O52-4]. Safe examination in the decreased renal function patients in the cisplatin combination chemoradiotherapy for cervical cancer 花井誠, 杉山里奈, 土田愛子, 安部智哉, 中山季昭 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 635-636, 2024. |
|---|
|
|
[4-7-O52-5]. About a relationship of Pembrolizumab therapy and the dermatopathy 濱武清範1,2, 松田ちひろ1, 奥村有香1, 野間敏也1, 橋本仁美1, 奥村優介1, 兼行佑奈1, 松本弘誠1, 仲忠士1, 美和孝之1, 小島一晃1, 北英夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 636-636, 2024. |
|---|
|
|
[4-8-O53-2]. The effect that sarcopenia, cachexia gives for treatment with nivolumab outcome of craniocervical part cancer 西山由紀子1, 中川祐紀子1, 志村裕介1, 山本奈歩1, 菅幸生1,2, 嶋田努1,2, 崔吉道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 637-637, 2024. |
|---|
|
|
[4-8-O53-3]. Outcome of the bismuth subgallate mixture zinc oxide ointment for the pressure sore of patients with stroke 轟幸泰1, 杉村勇輔1, 影下雄一2, 吉田麻里1, 宇野晴菜1, 山川和宏1, 宮森悠綺1, 丸山賢士1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 637-638, 2024. |
|---|
|
|
[4-8-O53-4]. A case which came to remarkably have difficulty in some weight decrease, administration continuation by Dulaglutide, a digestive organ symptom by the metformin combination in the institution home care patient 米田武司, 山崎由香子, 狭間研至 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 638-638, 2024. |
|---|
|
|
[4-8-O53-5]. Vancomycin-induced renal failure inhibitory effect of antioxidant material coenzyme Q10 武内咲知枝1, 佐藤夕紀2, 梨本俊亮2, 柏木仁2, 武隈洋3, 菅原満2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 638-639, 2024. |
|---|
|
|
[4-8-O54-1]. The long-term support of the person of HIV infection hemophilia medical treatment that we examined while fixing the eyes on Long Term Treatment Success (LTTS) and intervention of the pharmacist 田上直美1, 高林学1, 中田浩智2, 内場光浩3, 松下修三4, 齋藤秀之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 640-640, 2024. |
|---|
|
|
[4-8-O54-2]. A setup and result of the insomnia pharmacist outpatient for staff 奥村知香1,2,3, 柏原道志1, 内山剛2, 大野友久3, 矢部勝茂1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 640-641, 2024. |
|---|
|
|
[4-8-O54-3]. About an approach of the cooperation full addition 山田剛1, 大塚英一1, 須藤エミ2, 田村賢一2, 伊藤由華2, 高橋千晶2, 加藤博和2, 伊東達也2, 嶋崎みゆき2, 岸本和義2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 641-641, 2024. |
|---|
|
|
[4-8-O54-4]. How all can confirmation of common use medicine at the time of the outpatient department in front of the art cover results of confirmation of common use medicine in the on admission? 田村真由子, 野々内裕紀, 仲宗根千佳, 塚本泰彦, 眞継賢一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 641-642, 2024. |
|---|
|
|
[4-8-O54-5]. It is stopping instruction during the preoperation by the use fact-finding and the pharmacist of the health food having an influence on the perioperative period 安達真紀子, 八島有彌, 涌嶋伴之助, 藤吉正哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 642-642, 2024. |
|---|
|
|
[4-8-O55-1]. The observance situation investigation of the advice about the proper use of the SGLT2 inhibitor 嶺豊春, 中川博雄, 橋詰淳哉, 大山要 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 643-643, 2024. |
|---|
|
|
[4-8-O55-2]. In silico analysis for predictions of the drug-related necrosis of the jaw bone using side effect database FAERS 鳥海真也1, 大場麻帆1, 関美羽1, 鶴岡治朗1, 長山めぐみ1, 酒井侑季1, 山口裕子1, 岡田美晴1, 三森竜司1, 下川亨明1, 植沢芳広2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 643-643, 2024. |
|---|
|
|
[4-8-O55-3]. Analysis about the parasomnias risk accompanied with the use of sleeping drug using adverse drug reaction database (JADER) 小林正太郎1,2, 篠崎浩司1, 永野浩之2,3, 宮森彩香2,4, 小岩まの2,5, 村松泰地2, 櫛山暁史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 644-644, 2024. |
|---|
|
|
[4-8-O55-4]. Change factor analysis of efficacy, the side effect in the hepatectomy patients for the tramadol individualization administration plan 神谷貴樹1, 飯田洋也2, 上島智1,3, 北川優香3, 山田日向美3, 平大樹1,4, 池田義人1, 谷眞至2, 寺田智祐1,4, 森田真也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 644-645, 2024. |
|---|
|
|
[4-8-O55-5]. Inspection of the adverse event of nal-IRI+5-FU/l-LV in the UGT1A1 hetero mutation (*6, *28) case 二日市昂太1, 高木昭佳2, 伊東岳1, 山本将孝1, 岡田明美1, 向井妙子1, 加藤敦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 645-645, 2024. |
|---|
|
|
[4-8-O56-1]. Trend of the fatal dose intake case with the nonprescription drug (OTC) 廣瀬正幸1, 平川昭彦2, 植西憲達3, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 646-646, 2024. |
|---|
|
|
[4-8-O56-2]. It is ... based on the emergency visit pharmacist duties guideline of efforts - Tokushukai group of the working full time pharmacist placement in the emergency visit 坂口結斗1, 立石裕樹2, 齋藤靖弘3, 宮田祐一4, 白木萌1, 安里衣真1, 小林夕莉1, 重松舞1, 平野光希1, 正田千明1, 町田修1, 渡邉理生1, 喜多洋嗣1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 646-647, 2024. |
|---|
|
|
[4-8-O56-3]. The case that patients with burn were given vancomycin and tobramycin, and tested the effectiveness and safety 赤羽理也1, 福井里佳1, 松田雅史1, 岡本陽香1, 炭昌樹1, 池田義人1,2, 塩見直人3, 森田真也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 647-647, 2024. |
|---|
|
|
[4-8-O56-4]. One case of the normoglycemia ketoacidosis that occurred by having introduced SGLT2 inhibitor during treatment for acute phase of acute myocardial infarction 大久保綾香1, 中薗健一1, 吉田英樹2, 松崎貴志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 647-648, 2024. |
|---|
|
|
[4-8-O56-5]. Effect of the fentanyl concentrations change in the postoperative autoregulation pain relief poor at general anesthesia 村井陽一1, 天野杏南1, 渕上翔太1, 伊藤優2, 水谷早希2, 棚橋順治2, 木全司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 648-648, 2024. |
|---|
|
|
[4-9-O57-1]. Efforts to the task shift of the outpatient department charge pharmacist 川崎美紀, 高井杏弥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 649-649, 2024. |
|---|
|
|
[4-9-O57-2]. Acting utilization, prescription input protocol ... of Mr. efforts - formulations of task shift/share aiming at further professional ability display of the hospital pharmacist 才野壽子, 平健太郎, 崎代英樹, 東裕子, 高谷奏子, 山口幸恵, 多賀由美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 649-649, 2024. |
|---|
|
|
[4-9-O57-3]. Effect to the dispensary duties by task shift/share that permanent residence of SPD brings 小山晃紀1, 高山慎司1, 阿部猛1, 菅原真希2, 唄野愛己2, 重元瑞香2, 島津崇2, 後藤一美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 650-650, 2024. |
|---|
|
|
[4-9-O57-4]. Inspection after the task shift start of drug set duties 長谷部千夏1, 大瀬江美子1, 山口大貴1, 佐野彩女1, 兼松友紀1, 若尾真弓2, 杉本晴美2, 宮部芳之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 650-651, 2024. |
|---|
|
|
[4-9-O57-5]. A key and the prospects to task shift/share extension to hospital pharmacist: Than interview investigation of the both pharmacist, physicians 幾田慧子1, 長縄華子1, 米澤淳1,2, 岡田浩3,4, 眞中章弘5, 西郷雅美子1, 杉本充弘1, 池見泰明1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 651-651, 2024. |
|---|
|
|
[4-9-O58-1]. Efforts of the warfarin potassium representation prescription for the purpose of task shift/share 町田聖治, 曽我弘道, 山下悟史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 652-652, 2024. |
|---|
|
|
[4-9-O58-2]. Construction of the task sharing for the insulin secession of patients with elderly people diabetes in the convalescent ward 梶原洋文1, 濱口和之2, 生山祥一郎2, 山田雅也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 652-653, 2024. |
|---|
|
|
[4-9-O58-3]. It is managed the discontinuation reopening protocol after the antithrombotic drug, the operation in the digestive organ surgery 山崎茉由, 野口周作, 田原温, 前岡理利子, 奥平菜美, 松岡順子, 宮内秀典, 笠原英城 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 653-653, 2024. |
|---|
|
|
[4-9-O58-4]. Efforts of the hospital pharmacist in the treatment system maintenance of the antinuclear antibody of Alzheimer's disease 中井聖子1, 荻原好章1, 後藤美紀2, 藤田和久3, 佐藤恒太3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 653-654, 2024. |
|---|
|
|
[4-9-O58-5]. Efforts of delirium measures in our hospital 岡田圭央1,2,3,4, 三吉祐太1, 荻原好章1, 飯守淳喜2, 村上祐介3, 佐藤恒太4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 654-654, 2024. |
|---|
|
|
[4-9-O59-1]. Change of disease structure before and after Covid-19 Pandemic of our country and the prescription drug constitution 植松卓也1,4, 西崎祐史2,4, 野尻宗子3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 655-655, 2024. |
|---|
|
|
[4-9-O59-2]. Examination of the effect that concomitant drug and estimated Teicoplanin isolation form blood level gives to renal failure by the Teicoplanin 清水優貴1, 花田和彦2, 渡邉武明1, 佐々木祐香1, 中村朋花1, 駒坂英実1, 門田佳子1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 655-656, 2024. |
|---|
|
|
[4-9-O59-3]. One case that vancomycin clearance greatly fluctuated before and after a dermatoplasty right move in patients with extensive burns 須山由佳子1, 成田知大2, 神戸宏憲1, 三浦基靖3, 内田信也3, 櫻井和子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 656-656, 2024. |
|---|
|
|
[4-9-O59-4]. Staphylococcus aureus bacteremia treatment by the AST pharmacist leadership 石津智司, 小澤拓, 饒平名長武, 杉生雅和, 若松雄太, 小林由美子, 近藤万友美, 森田聡子, 西山祐実, 正置耕一, 吉岡睦展 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 656-657, 2024. |
|---|
|
|
[4-9-O59-5]. Use fact-finding of the infection prophylaxis antimicrobial at tooth extraction in the infective endocarditis risk case 磯邉浩和1, 吉田謙介2, 和田実優1, 齋藤千愛3, 古賀雅良3,4, 冨原圭3,4, 金丸博子5, 黒川亮5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 657-657, 2024. |
|---|
|
|
[4-9-O60-1]. Factor analysis of the hand hygiene observance drop accompanied with the pharmacy duties system change 小林遼平, 檜山洋子, 吉田由佳, 冨田隆志, 鴫田江理嘉, 松尾裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 658-658, 2024. |
|---|
|
|
[4-9-O60-2]. Treatment, the prognosis of patients with Staphylococcus lugdunensis bacteremia in patients with cardiovascular disease and investigation about the patients background 中蔵伊知郎1, 坂倉広大1,2, 若林智仁1,2, 今西嘉生里1, 永田理香子1, 大西由華1, 廣瀬優冴1, 坂本麻衣1, 中野一也1, 山西香織1, 高橋彩子2, 佐田誠2, 畝佳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 658-659, 2024. |
|---|
|
|
[4-9-O60-3]. A prescription trend of the oral antimicrobial using the AWaRe classification and investigation of the use reason 森田眞由, 村田龍宣, 小野勝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 659-659, 2024. |
|---|
|
|
[4-9-O60-4]. Investigation of the environmental surface pollution in the drug section and the bacteriological environmental pollution 小原美保1, 橋本麻衣子1,2, 吉川結美1, 名取達矢3, 河西彩香3, 塩原真弓2, 金井信一郎2, 松本剛3, 内藤隆文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 659-660, 2024. |
|---|
|
|
[4-9-O60-5]. The antimicrobial proper use situation investigation using DASC (Days of Antibiotic Spectrum Coverage) 鈴木朋克1, 齊藤景子1, 片山歳也2, 鈴木達宙1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 660-660, 2024. |
|---|
|
|
[4-10-O61-1]. One case of patients with acute myeloid leukemia that adrenal insufficiency was suspected by posaconazole, and was improved by a drug change and hydrocortisone administration 保ヶ辺美月1, 石岡美樹1, 桝田浩司2, 田中茜3, 中世古知昭3, 篠崎浩司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 661-661, 2024. |
|---|
|
|
[4-10-O61-2]. Examination of the onset of hepatic dysfunction risk factor with latent tuberculosis infection treatment 上田真也1,2, 成田和希2, 植松若那3, 奥隅拓朗2, 薄雅人4, 小川千晶1, 軍司剛宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 661-662, 2024. |
|---|
|
|
[4-10-O61-3]. Examination about the hearing situation and the antimicrobial choice of allergy to cephem 遠山泰崇, 山尾卓也, 井上真 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 662-662, 2024. |
|---|
|
|
[4-10-O61-4]. The effect that Albumin-bilirubin score gives to the onset of ampicillin/sulbactam-induced liver damage risk 大井勇秀1, 朝居祐貴2, 郡山恵樹3, 高橋昌明1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 662-663, 2024. |
|---|
|
|
[4-10-O61-5]. Decreased body temperature of the new quinolone antibacterial at at non-fever or fever 原量平, 榎木裕紀, 田口和明, 松元一明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 663-663, 2024. |
|---|
|
|
[4-10-O62-1]. Study on non-appropriate dose in the case that treatment with anticoagulant was given in for cardioembolic 平野龍一, 井須恭平, 菅基次, 曽我和子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 664-664, 2024. |
|---|
|
|
[4-10-O62-2]. The effectiveness of the antimicrobial after the valve replacement in the infective endocarditis of the self-valve and safe examination 伊東愛理1,2, 門口直仁1, 濱田一成1, 大上賢祐2, 公文登代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 664-665, 2024. |
|---|
|
|
[4-10-O62-3]. Clinical background and outcome of patients with chronic cardiac insufficiency that discontinued a mineralocorticoid receptor blocker 岩出佳樹1, 久保田芳明2, 林太祐1, 西野拓哉3, 橘貴大2, 渡邉将央2, 松田淳也2, 加藤活人4, 太良修平2, 宮地秀樹2, 時田祐吉2, 伊勢雄也1, 岩崎雄樹2, 浅井邦也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 665-665, 2024. |
|---|
|
|
[4-10-O62-4]. The perioperative drug control utilizing the check sheet that we can edit on an electronic medical chart jointly and the evaluation 佐藤史織, 橋本晴香, 陸丸幹男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 665-666, 2024. |
|---|
|
|
[4-10-O62-5]. Effectively utilizing it and the management of the bringing medicine 坪井憲江1, 恵美宣彦2, 小野寅雄3, 後藤紗彩1, 飯島尚子1, 松平尚希1, 吉澤明子1, 藤田政弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 666-666, 2024. |
|---|
|
|
[4-10-O63-1]. It is ... from the setup of ... south Kaga district medicine medicine cooperation promotion team to the making of the list of drug doses according to the renal function for drug proper use in the outside Parliament prescription 安藤友貴1, 北出紘規2, 示野哲也2, 西野正義2, 高田直子3, 若林広樹3, 西尾千草4, 石田美由紀5, 中村美紀5, 森光恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 667-667, 2024. |
|---|
|
|
[4-10-O63-2]. Understanding degree investigation after the joint workshop of the renal function evaluation in Asahi-ku, Yokohama-shi, Seya-ku 多田純平1, 東垂水裕和2, 櫻井彩1, 小串興平2, 西崎百合絵3, 今渕瞳3, 櫻井学3, 日向彰4, 近藤一成5, 久保田充明5, 平本千佳子6, 熊谷仁7, 泉和孝8, 松崎貴志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 667-668, 2024. |
|---|
|
|
[4-10-O63-3]. Cooperation - heart failure disease medicine cooperation ... with the ethical pharmacy for patients with heart failure in Nagoya Memorial Hospital 近藤奈央子1, 伊藤紳人1, 壁谷めぐみ1, 明野愛1, 椎野憲二2, 湯浅周1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 668-668, 2024. |
|---|
|
|
[4-10-O63-4]. Medicine medicine cooperation using the telephone follow-up for patients with heart failure 根上朋子1, 田村知子2, 杉生雅和1, 高子優子1, 正置耕一1, 吉岡睦展1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 668-669, 2024. |
|---|
|
|
[4-10-O64-1]. Case ... which was treated effectively with Shimbuto for the effusion of suggestion - cancer terminal patient of the Chinese medicine prescribed medicine for the patients that enough effect of treatment was not obtained with Western medicine 狭間紀代, 山日祐平, 大橋淑起, 狭間研至 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 670-670, 2024. |
|---|
|
|
[4-10-O64-2]. Development of question promotion list (QPLP) from a drugstore user to a pharmacist: Focus group interview targeted for patients and examination by the modified Delphi method 早川雅代1, 木崎速人1, 柳澤友希1, 鈴木信行2, 香川由美3, 佐山杏子1, 今井俊吾1, 堀里子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 670-671, 2024. |
|---|
|
|
[4-10-O64-3]. Qualitative study - using process - M-GTA to want to collaborate with a person concerned with school which school pharmacist thinks about, and to promote pickpocket education 山本健, 森元能仁, 神林弾, 廣澤伊織, 渡部一宏, 廣原正宜 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 671-671, 2024. |
|---|
|
|
[4-10-O64-4]. Investigation of the accessibility from the public transport of the healthcare-related institution using the geographical information system 山崎智文1, 前澤美佳1, 宮坂香海1, 広藤咲子1, 山下萌1, 市原奈々加1, 野倉優華1, 杉下香菜1, 松井健祐1, 中尾智史1,2, 外山和弥3, 玉木啓文3, 北村真由美4, 堀部めぐみ5, 井口和弘3, 中村光浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 671-672, 2024. |
|---|
|
|
[4-10-O64-5]. Making of guideline "medicine compasses" for promotion of the pharmaceutical products proper use in the old age assistance institution 佐藤宏樹1,2, 柳奈津代1, 佐久間美穂3, 武久信子3, 櫻田美奈3, 雫石英里3, 松岡順治3,4, 澤田康文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 672-672, 2024. |
|---|
|
|
[4-11-O65-1]. The facilitation of compounding of medicines duties by the choice of pharmaceutical products and cost cut 奥野真澄, 陣野大輔, 菅野奈緒美, 須藤孝浩, 黒田純子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 673-673, 2024. |
|---|
|
|
[4-11-O65-2]. Troubleshooting of the disk type powders divided powder plane to think about from the viewpoint of the pharmacist 山本一輝, 浜田茂明, 森本真仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 673-673, 2024. |
|---|
|
|
[4-11-O65-3]. Evaluation of the formulations support system by the bar code certification 相羽優樹, 加藤隆寛, 手塚剛彦, 竹内正幸, 大西正文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 674-674, 2024. |
|---|
|
|
[4-11-O65-4]. Evaluation of the operational situation of the prior agreement protocol to depend on change formulations for the hospitalization prescription 木下智絵, 木下徳康, 山本智也, 奥田真弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 674-674, 2024. |
|---|
|
|
[4-11-O65-5]. About contribution to dose adequacy by the registration to the section system of the dose according to indication of the test value to an in-hospital prescription and the renal function 島田美輝, 西窪奈津子, 井上智恵, 寺崎展幸, 坂本有里恵, 福永圭佑 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 675-675, 2024. |
|---|
|
|
[4-11-O66-1]. Development of the furosemide nanocrystal enclosure silverberry and the properties of matter evaluation 板東彩香, 大迫華乃, 吉村彩菜, 大竹裕子, 長井紀章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 676-676, 2024. |
|---|
|
|
[4-11-O66-2]. Suggestion of the oral multilayered seat type rebamipide preparation using the 3D printer and the properties of matter evaluation 畑見理奈, 辻極瑞希, 川端壮基, 大竹裕子, 長井紀章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 676-676, 2024. |
|---|
|
|
[4-11-O66-3]. Making of the transdermal applicable preparation with ketoprofen nanocrystal seal using the 3D printing technique 森玲奈, 大明沙季, 井上ゆり果, 大竹裕子, 長井紀章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 677-677, 2024. |
|---|
|
|
[4-11-O66-4]. Prescription examination of the minoxidil emulsion using the wet process atomization device and the usefulness evaluation 城山空翔, 久保田ちか, 岡本奈々, 長井紀章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 677-677, 2024. |
|---|
|
|
[4-11-O66-5]. Introduction effect of the thermogram data output robot aiming at efficiency of the clinical experimental medicine administrative work 吉川結美, 竹澤崇, 小池彩花, 平井啓太, 内藤隆文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 678-678, 2024. |
|---|
|
|
[IO-01]. Fructose-induced oxidative stress causes protein aggregation with S-nitrosylation of PDI Jiro Ogura, Hiroaki Yamaguchi Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 679-679, 2024. |
|---|
|
|
[IO-02]. The antiplatelet effect of mirtazapine by co-blocking of the 5-HT2A and α2-adrenergic receptors on platelets : A rodent plasma-based study Yohei Kawano1, Maho Katsuyama1, Masashi Nagata2, Maki Obana1, Satoshi Nakamatsu1, Ayano Mori1, Namiki Sakamoto1, Yasunari Mano1, Kenichi Negishi3, Shuji Shimada1, Takao Aoyama1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 679-680, 2024. |
|---|
|
|
[IO-03]. Novel therapies targeting NF-κ B signal for triple-negative breast cancer patients with poor prognosis caused by loss of CYLD expression Hitomi Arakaki1, Akari Kuwano1, Chika Hirai1, Chica Saigo2, Ayumi Kanemaru1, Mitsuhiro Hayashi3, Hideyuki Saito1,2, Yuki Narita1,2, Hirofumi Jono1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 680-681, 2024. |
|---|
|
|
[IO-04]. Extraction of diseases and symptoms from patients' complaints using natural language processing system. Yukiko Ohno1, Tohru Aomori2, Riri Kato3, Yuma Hikita3, Reina Fujiki4, Haruki Ishikawa4, Keisuke Kiyomiya3, Minae Isawa3, Mayumi Mochizuki3, Tomohiro Nishiyama5, Eiji Aramaki5, Hisakazu Ohtani1,3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 681-682, 2024. |
|---|
|
|
[IO-05]. Drug-drug interaction of Letermovir and Tacrolimus in Japanese renal transplant recipients simulated using a physiologically-based pharmacokinetic model Takumi Maruyama1, Yukihiro Hamada2, Hidefumi Kasai3, Yutaka Fukaya1, Mitsuru Shiokawa1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 682-683, 2024. |
|---|
|
|
[IO-06]. Pharmacokinetics of brexpiprazole, quetiapine, risperidone, and its active metabolite paliperidone in perinatal period : A case study Yumi Kitahiro1, Toru Konishi1, Naoko Fujiwara1, Kazuhiro Yamamoto1,2, Mari Hashimoto1, Takahiro Ito1, Kotaro Itohara1, Kazumichi Fujioka3, Hitomi Imafuku4, Ikuo Otsuka5, Tomohiro Omura1, Ikuko Yano1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 684-684, 2024. |
|---|
|
|
[IO-07]. Efficacy of antiemetic therapy with olanzapine in multiple myeloma patients treated with high-dose melphalan with autologous peripheral blood stem cell transplantation Junpei Kato1, Masashi Uchida2, Masayuki Ishikawa2,3, Shinya Tatsuta1, Takeshi Yoshimi1, Kota Ishida1, Osamu Hosoya1, Nobuhiro Tsukada4, Tadao Ishida4, Shingo Yamazaki2,3, Itsuko Ishii2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 685-685, 2024. |
|---|
|
|
[IO-08]. Antidepressant Use and the Risk of Diabetes Mellitus in Patients with Depression : A Nested Case-Control Study Io Hasebe1, Keiko Ikuta1, Shunsaku Nakagawa1, Kenji Momo2, Yuki Shigetsura1, Daiki Hira1, Tomohiro Terada1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 685-686, 2024. |
|---|
|
|
[IO-09]. Preventive effects of proton pump inhibitors for oxaliplatin-induced peripheral neuropathy : Analyses of two clinical databases and model mice Akihide Kobayashi1,2, Kenji Ikemura1,2, Eri Wakai3, Manami Ueno4, Masayoshi Kondo4, Masahiro Okuda1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 686-687, 2024. |
|---|
|
|
[IO-10]. Impact of the protocol-based pharmacotherapy management for preventing postoperative delirium following cardiovascular surgery on the incidence of delirium and prescription trend of benzodiazepines Yuki Asai1, Yuki Nakano2, Tatsuki Yanagawa3, Masaaki Takahasi3, Takuya Iwamoto1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 687-688, 2024. |
|---|
|
|
[P0001-2-PM]. Effect examination after the formulations robot introduction 近藤広人, 水谷恵美生, 田島浩佑, 通木淳史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 689-689, 2024. |
|---|
|
|
[P0002-3-PM1]. Examination of the usefulness of the automatic drug withdrawal system 溝口優, 高山恵太, 小澤翼, 石井都萌花, 佐々木英久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 689-689, 2024. |
|---|
|
|
[P0003-2-PM]. It is operational stocktaking of tablet sortation equipment TABSORT+ one package in our hospital 片倉萌花, 川上聡士, 西澤広介, 小峰彩, 佐藤直子, 土井啓員 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 689-690, 2024. |
|---|
|
|
[P0004-3-PM1]. Review of the deployment pharmaceutical products in the injection automatic withdrawal machine 志岐優花, 徳永晃己, 谷口慶彦, 田中忠宏, 田上治美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 690-691, 2024. |
|---|
|
|
[P0005-2-PM]. About the excessive quantity filling formulations which we gave priority to a sampling maneuver of the triclofos sodium syrup over 小杉洸平, 渡邊未来, 奥村俊一, 大平沙里, 今成甫, 高見真理子, 石井紀子, 廣井順子, 内藤梨奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 691-691, 2024. |
|---|
|
|
[P0006-3-PM1]. The design development of the desk type made-to-order tablet production device and the formulation proof 田辺和也1,2, 松井航1, 田原耕平2, 林勇佑3, 杉山弘和3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 691-692, 2024. |
|---|
|
|
[P0007-2-PM]. Pre-; a study on storage of the produced ambroxol hydrochloride dry syrup preparation 島崎学, 高橋詩音 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 692-692, 2024. |
|---|
|
|
[P0008-3-PM1]. The in-hospital doubt inquiry simplification protocol making and use situation 祖父江伸匡, 森田華奈子, 田中智子, 酒井要, 堀敦雄, 坂井恭子, 岡田智子, 杉江善樹, 吉田紀子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 692-693, 2024. |
|---|
|
|
[P0009-2-PM]. Promotion of the proper use by the operational flowchart making for the Andexanet alpha IV infusion 鈴木桃佳, 近藤匡慶, 渡辺圭, 源平麻衣, 長野槙彦, 菅谷量俊, 林太祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 693-693, 2024. |
|---|
|
|
[P0010-3-PM1]. Utilization to the attitude survey of the pharmacist by the renal function, liver function inspection sheet making and the local support system addition 松本直美1,2,3,4,5, 井上裕2, 佐々木睦1, 内野雄太3, 森田克洋4, 宮崎知範5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 693-694, 2024. |
|---|
|
|
[P0011-2-PM]. Examination of the effect that the withdrawal method change of the injection drug gives at injection duties time 藤村亜未, 小島庸子, 桂川健司, 遠山幸男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 694-694, 2024. |
|---|
|
|
[P0012-3-PM1]. The task shift in pre-, producing it of the petrolatum album by the ointment mixer introduction and effect contracted at duties time 三輪龍哉, 小島庸子, 桂川健司, 遠山幸男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 694-695, 2024. |
|---|
|
|
[P0013-2-PM]. About the human change of compounding of medicines duties by all automatic PTP sheet withdrawal device introduction 千崎宏樹, 佐々木健将, 水津智樹, 河合実 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 695-695, 2024. |
|---|
|
|
[P0014-3-PM1]. Search of the effect that storage environment gives to incompatibility of heparinoid from animal organ oil-related cream and the betamethasone ointment 大澤隆志1,2, 京恭弘2, 吉岡憲吾3, 松村卓4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 695-696, 2024. |
|---|
|
|
[P0015-2-PM]. The evaluation of the identification rate of tablet automatic assortment return device (Genie(TM)) and future problem 森田聡子, 新康憲, 高橋直浩, 長尾彰太, 近藤万友美, 西山祐美, 高子優子, 正置耕一, 吉岡睦展 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 696-696, 2024. |
|---|
|
|
[P0016-3-PM1]. A merit and the demerit that the cool place pharmaceutical products inventory control system "cubic" introduction depends on 中村和彦, 中村嘉孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 697-697, 2024. |
|---|
|
|
[P0017-2-PM]. The storage condition of magnesium oxide tablets and relations with the effect to collapse time 山本佳久1, 山下修司2, 伊野陽子2, 松丸直樹2, 鈴木昭夫3, 深水啓朗4, 小出達夫5, 林秀樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 697-697, 2024. |
|---|
|
|
[P0018-3-PM1]. Introduction effect prediction of NOVUMN to tumor center satellite pharmacy 千葉菜摘1, 木村まゆみ1, 佐藤奈緒美1, 磯上一成1, 津田壮一郎1, 村松博1, 大谷壽一1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 698-698, 2024. |
|---|
|
|
[P0019-2-PM]. Relation of a flow in the operation to TEMCELL HS note administration in this museum and the multi-type of job 佐野雅彦1, 仲真美恵1, 徳永晃1, 宮原強1, 草葉一友1, 倉谷実希2, 吉本五一3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 698-698, 2024. |
|---|
|
|
[P0020-3-PM1]. Effect of the tablet automatic assortment change device (Genie) introduction 竹内悟士, 大谷仁美, 高木彰子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 699-699, 2024. |
|---|
|
|
[P0021-2-PM]. Contribution to appropriate request by a confirmation of the use drug during the operation of the pharmacist 齋藤雄大, 相原瞳, 高橋友佳, 菅原浩介, 茂野健司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 699-699, 2024. |
|---|
|
|
[P0022-3-PM1]. Construction and evaluation of the drug management system which enabled the interlocking movement with the surgery section system by the good use of two-dimensional cord 山本香緒里1,2, 山本譲1, 飯田慎也1, 菅谷香緒里1,2, 山下恭範1, 小野尚志1, 黒澤温3, 小野寺美子2,3, 谷祐児4, 中馬真幸1, 田崎嘉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 699-700, 2024. |
|---|
|
|
[P0023-2-PM]. The current situation investigation of the effect that pharmaceutical products understock gives to pharmacist duties 高橋奈々子, 武藤虎甫, 藤野玲子, 藤岡貴光, 柴田壮一, 平山武司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 700-700, 2024. |
|---|
|
|
[P0024-3-PM1]. Efforts for the acquisition of the use of generic medicine system addition in the pharmaceutical products understock and the maintenance 吉田裕生, 佐澤卓哉, 上之将明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 701-701, 2024. |
|---|
|
|
[P0026-3-PM1]. Examination about the trituration concentrations by the Larixin tablets crush 渡邉未来, 今成甫, 小杉洸平, 大平紗里, 高見真理子, 西前麻央, 奥村俊一, 金塚明子, 内藤梨奈, 石井紀子, 廣井順子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 701-702, 2024. |
|---|
|
|
[P0027-2-PM]. Examination about the stability of hospital preparation mitomycin C eye drops 八島秀明1,2, 荒木拓也1,2, 中村浩規1, 山本康次郎1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 702-702, 2024. |
|---|
|
|
[P0028-3-PM1]. Use evaluation of the 5% scopolamine ointment in our hospital 山本紳一郎1, 小出彰文2, 田原みどり2, 保母薫里2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 702-702, 2024. |
|---|
|
|
[P0029-2-PM]. Correspondence with the hospital preparation accompanied with the examination for taste fixed-quantity reagent supply stop by the filter paper disc test 北爪教貴1, 仲鉢英夫1, 小山健一2, 樋口雄將3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 703-703, 2024. |
|---|
|
|
[P0030-3-PM1]. The new agent type development of the indometacin-containing oral mucositis therapeutic drug and preparation properties evaluation 湯川朱夏1, 松川駿介2, 肥田典子2, 山崎太義2, 滝伊織2, 藤田吉明2, 三邉武彦3, 中村明弘2, 原田努2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 703-704, 2024. |
|---|
|
|
[P0031-2-PM]. Understock time of the heparin sodium physiological salt solution syringe and germfree report for preparation 松本芳樹1, 岡千恵1, 高取秀人1, 後藤卓也1, 山本聖子1, 黒田真莉2, 萱野勇一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 704-704, 2024. |
|---|
|
|
[P0032-3-PM1]. A release test of the drug for external use: Relationship with release behavior and bioequivalence and preparation properties 朴剛, 仲尾英史, 野々上喜一, 波々伯部真希 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 704-705, 2024. |
|---|
|
|
[P0033-2-PM]. Propriety of the transluminal administration by the simple suspension method of cell Beck's capsule 石田志朗1, 中山ひなた2, 高橋亜実1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 705-705, 2024. |
|---|
|
|
[P0034-3-PM1]. Exploratory examination for the blue light cut film utilization in the pharmaceutical products storage under the LED light 山下修司, 林秀樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 705-706, 2024. |
|---|
|
|
[P0035-2-PM]. Change of the skin permeability of stability and the principal ingredient of the skin drug for external use by the artificial sun lighting exposure 湯谷玲子, 中瀬朋夏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 706-706, 2024. |
|---|
|
|
[P0036-3-PM1]. Effect on difference and taking taste, fragrance of the roasting liquid prepared by the roasting method and the Immersing Powdered Crude Drugs method that it was the way Kikyoto and the Daiokanzoto goes 成橋和正, 瓜生津智穂, 白須彩香 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 706-707, 2024. |
|---|
|
|
[P0037-2-PM]. Inspection after the intelligent cabinet introduction for the efficiency of improvement of the pharmaceutical products management in security and perioperative drug control duties 岡崎雅史, 加賀屋陽子, 甲斐俊介, 富好真沙也, 田村尚久, 白石久, 門田亜紀, 常風興平, 浜田幸宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 707-707, 2024. |
|---|
|
|
[P0038-3-PM1]. Trend of the secondary bone fracture prophylactic efforts and osteoporosis therapeutic drug in our hospital 戸上博昭1, 青木まりあ1, 渡邊剛2, 松井寛樹2, 西原恵司3, 高橋智子4, 前田篤史5, 木村沙織6, 市野貴信1, 酒井義人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 707-708, 2024. |
|---|
|
|
[P0039-2-PM]. Efforts and effect inspection of the osteoporosis therapeutic drug prescription suggestion of the secondary bone fracture prevention team pharmacist in our hospital 丸山あゆみ, 櫻田穣, 山本いずみ, 中嶋紘文, 坂田幸雄, 長浜谷耕司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 708-708, 2024. |
|---|
|
|
[P0040-3-PM1]. The effect that ward team system introduction gives to drug control instruction duties 薗部有沙, 田沼道也, 兼平暖, 田中昌代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 708-709, 2024. |
|---|
|
|
[P0041-2-PM]. The use drug operational change during the operation that a pharmacist was made up mainly of and the effect 石田智之, 福永晟也, 福永晃右, 鶴永大貴, 中村有莉恵, 堀内智裕, 赤星真広, 森岡友美, 池増鮎美, 佐多照正 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 709-709, 2024. |
|---|
|
|
[P0042-3-PM1]. Efforts and evaluation for the information sharing of a ward exclusive duty pharmacist and the nurse 田中優, 松浦知博, 馬島務, 龍神博之, 山下剛史郎, 満田正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 709-710, 2024. |
|---|
|
|
[P0043-2-PM]. Efforts of the pharmacist in the osteoporotic liaison service 米須文香, 新垣千夏, 浜元善仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 710-710, 2024. |
|---|
|
|
[P0044-3-PM1]. For the making of system of the physician-led sleeping drug adequacy 石谷理紗1, 長谷川啓1, 細田未紀1, 大澤万智子1, 山根正也1, 千原里美1, 上田宏1, 三好崇文2, 伊東範尚3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 710-711, 2024. |
|---|
|
|
[P0045-2-PM]. Analysis examination of efforts and the intervention case to polypharmacy improvement in the Wakayama Hospital 仙石歩夢, 廣瀬沙紀, 山内真治, 中西陽一, 清水宏太郎, 渡辺雄太, 井上敦介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 711-712, 2024. |
|---|
|
|
[P0046-3-PM1]. Template making for ward drug duties standardization and future problem 原田嵩大1, 中野友寛2, 末廣拓1, 十亀將輝1, 新居田能章1, 村井望1, 越智啓介1, 古田光平1, 松岡葉子1, 大下幸子1, 西畑友尋1, 玉井宏一1, 烏谷政和1, 倉田知久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 712-712, 2024. |
|---|
|
|
[P0047-2-PM]. Report - about research - patients attribute about the usefulness by the pharmacist intervention in the convalescent ward 藤原久登1,2,3, 岸本真1,4, 小瀬英司1,5, 篠永浩1,6, 田中絵里子1,7, 中道真理子1,8, 溝神文博1,9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 712-713, 2024. |
|---|
|
|
[P0048-3-PM1]. To prevent the rehospitalization of patients with heart failure; usefulness ... of ... initial interview sheet 山本紗世, 岩村貴紗, 渡辺朱里, 大石美沙子, 田中実奈, 田所美和, 市吉真貴子, 八木亜紀子, 小松めぐみ, 田中照夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 713-713, 2024. |
|---|
|
|
[P0049-2-PM]. About the use situation of the perioperative antirheumatic drug in the orthopedics surgery patients and the development of surgical-site infections situation 伊藤美羽1, 坪井秀規2, 赤坂寛子1, 馬島務1, 龍神博之1, 山下剛史郎1, 満田正樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 713-714, 2024. |
|---|
|
|
[P0050-3-PM1]. About the intervention effect of the pharmacist in the lipid management accomplishment of patients with acute coronary syndrome 渡嘉敷俊介1, 鈴木志歩1, 片桐麻未1, 福川怜那1, 篠原美紀1, 長江美帆1, 宮島佳祐2, 若林康2, 中道秀徳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 714-714, 2024. |
|---|
|
|
[P0051-2-PM]. Pharmaceutical intervention to patients with cerebral infarction that antiplatelet dual therapy was continued without aim 黒木彩加 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 714-715, 2024. |
|---|
|
|
[P0052-3-PM1]. New efforts of the drug instruction in the hospitalization and release medicine window 那須結衣, 佐藤智也, 本田貴朗, 板垣有紀, 羽太光範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 715-715, 2024. |
|---|
|
|
[P0053-2-PM]. Current status survey of pre-avoidance reports at our hospital 上村美結1, 上田和明1, 薮内由里香2, 東島幸道3, 近藤譲1, 山脇一浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 715-716, 2024. |
|---|
|
|
[P0054-3-PM1]. The need of the education for the calculation increase of the drug global assessment adjustment addition 細田未紀1, 長谷川啓1, 石谷理紗1, 千原里美1, 上田宏1, 三好崇文2, 伊東範尚3, 中村好男3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 716-716, 2024. |
|---|
|
|
[P0055-2-PM]. The discontinuation situation investigation of the SGLT2 inhibitor in the perioperative period 松浦知博, 馬島務, 龍神博之, 山下剛史郎, 満田正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 716-717, 2024. |
|---|
|
|
[P0056-3-PM1]. Examination of the expression situation and the ward drug duties of the liver damage in all laparoscopic panhysterectomy cases for uterine myoma treatment in the Nippon Life Insurance Co. Hospital 森岡浩子1, 池田久雄1, 古久保有希子1, 千原亜紀子1, 宮原阿友美1, 神原弘和1, 足立充司1, 橋本奈美子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 717-718, 2024. |
|---|
|
|
[P0057-2-PM]. Approach of the pharmacist to treatment-resistant hypokalemia 栗原弘充 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 718-718, 2024. |
|---|
|
|
[P0058-3-PM1]. One case that we suspected drug fever with the antimicrobial during subdural abscess treatment, and a ward pharmacist intervened in early 刀根理香子1, 佐々木暢琢1, 小森千優1, 近藤健太1, 市川尚己2, 木村匡男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 718-718, 2024. |
|---|
|
|
[P0059-2-PM]. 1 example that caused solidification ability abnormality by use of cefazolin under the non-fast 今津智子1,2, 水口真利江1, 松田翔平1, 福原伸治1, 中村護1, 山崎美保2, 西園寺真二1, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 719-719, 2024. |
|---|
|
|
[P0060-3-PM1]. Case of primary bilious cholangitis that PT-INR, APTT extended to for the perioperative period 伊東充1, 四方公亮2, 佐藤香織1, 加藤潤一郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 719-720, 2024. |
|---|
|
|
[P0061-2-PM]. Qualitative study on psychology and behavior of the pharmacist in charge of the delirium assessment of the inpatient 篠崎聡1, 新田茜1, 永田実沙2, 森安里彩2, 矢原恵美2, 木下淳2, 本多秀俊1,3, 林由紀子1, 並木路広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 720-720, 2024. |
|---|
|
|
[P0062-3-PM1]. Investigation of the number of the drugs situation after the drug global assessment adjustment addition, the drug adjustment addition calculation 原田泉希, 小竹慶子, 友野一美, 大野史子, 犬塚さやか, 桑平汐莉, 内田里紗, 窪谷昌子, 垣内智子, 松田縁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 720-721, 2024. |
|---|
|
|
[P0063-2-PM]. Than the current situation investigation of examination - Japanese Society of Hospital Pharmacists 2022 hospital pharmacy gate about the current situation of the drug duties in the ward in the small and medium size hospital ... 瀧祐介, 横山敏紀, 八代佳子, 西塚亨, 吉田明弘, 上野山周雄, 北田さくら, 三森陽介, 宮川哲也, 濱浦睦雄, 筒井由佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 721-721, 2024. |
|---|
|
|
[P0064-3-PM1]. It is reported the attitude survey to floor nurse after the activity evaluation and the operation of the postoperative pain management team 小杉卓大1, 金城勝大1, 宮良遥奈1, 姫野智子1, 藤田翔1, 吾津千秋1, 梶原理恵2, 宜保さと子2, 新里泰一3, 國分千代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 721-722, 2024. |
|---|
|
|
[P0065-2-PM]. Comparison of fasudil hydrochloride and clazosentan for preventing cerebral vasospasm in aneurysmal subarachnoid hemorrhage at our hospital 細野真吾1, 細野亜由美1, 見尾谷昇1, 堀浩子1, 林克彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 722-722, 2024. |
|---|
|
|
[P0066-3-PM1]. Efforts to improvement in self-PUSH understanding of the patients in postoperative pain management team autoregulation pain relief by the activity 濱浦弘光1, 金子沙織2, 佐藤伊織2, 奥田しのぶ2, 山田祐樹2, 鬼頭宗誠2, 鈴木慎治2, 鷲見智子2, 大矢真3, 大谷寧次郎1, 三浦毅1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 722-723, 2024. |
|---|
|
|
[P0067-2-PM]. Survey on the use of clazosentan sodium at Okayama City Hospital 杉山直也, 古谷晃紀, 渡邉桃子, 鍛治園誠, 松山哲史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 723-723, 2024. |
|---|
|
|
[P0068-3-PM1]. A tendency and acceptance rate of the suggestion of the pharmacist in the Tokushima Red Cross hospital critical care center 宮守佑次, 組橋由記 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 723-724, 2024. |
|---|
|
|
[P0069-2-PM]. We vomit and are taken measures nausea after the operation in the postoperative pain management team 伊藤真美1, 石川みき2, 保富佐穂里3, 松元美香1, 大谷道輝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 724-724, 2024. |
|---|
|
|
[P0070-3-PM1]. It is ICU/HCU management ... after the emergency surgery, the operation from filler position - ER of the seamless emergency care that an operating room charge pharmacist takes 藤田翔1, 金城勝大1, 宮良遥奈1, 吾津千秋1, 小杉卓大1, 梶原理恵2, 山内素直3, 新里泰一4, 國分千代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 724-725, 2024. |
|---|
|
|
[P0071-2-PM]. The current situation investigation of the second emergency visit working full time pharmacist duties in the Fukuoka Tokushukai Hospital 立石裕樹, 矢野洋平, 後藤貴央, 川前隆一, 高橋菜生, 松浦徹, 宮津大輔, 渡邊裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 725-725, 2024. |
|---|
|
|
[P0072-3-PM1]. Participation of the second emergency visit working full time pharmacist in the Fukuoka Tokushukai Hospital which focused on a drug information offer 矢野洋平, 立石裕樹, 後藤貴央, 川前隆一, 高橋菜生, 松浦徹, 宮津大輔, 渡邊裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 725-726, 2024. |
|---|
|
|
[P0073-2-PM]. Efforts of the pharmacist resident placement to an emergency visit in the second first aid-designated general hospital 沢田裕介, 林拓磨 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 726-727, 2024. |
|---|
|
|
[P0074-3-PM1]. Fact-finding about the means that the pharmacist who worked full time in an emergency visit used for the drug history grasp of the emergency patient 小倉理夏子, 宮田祐一, 澁谷侑季奈, 山口明奈, 高橋雪乃, 岩崎睦, 宮下栞, 大村史, 鬼村紀子, 中村雅敏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 727-727, 2024. |
|---|
|
|
[P0075-2-PM]. Investigation about the drug information offer that the pharmacist who worked full time in an emergency visit conducted 澁谷侑季奈, 宮田祐一, 小倉理夏子, 山口明奈, 高橋雪乃, 岩崎睦, 宮下栞, 大村史, 鬼村紀子, 中村雅敏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 727-728, 2024. |
|---|
|
|
[P0076-3-PM1]. Fact-finding about the corresponding clinical department of the pharmacist working full time in an emergency visit and the hospitalization ward 山口明奈, 宮田祐一, 小倉理夏子, 澁谷侑季奈, 高橋雪乃, 岩崎睦, 宮下栞, 大村史, 鬼村紀子, 中村雅敏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 728-728, 2024. |
|---|
|
|
[P0077-2-PM]. The current situation report of the osteoporotic liaison outpatient carried out by the multi-type of job 福田喬士, 梅原せいら, 野口祐介, 友金幹視 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 728-729, 2024. |
|---|
|
|
[P0078-3-PM1]. It is examined the unobservance factor of stopping medicine and health food cancellation instructions during preoperation in our hospital 神田康平1, 牛田浩司1, 中西大介1, 菱谷徳子2, 山口純子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 729-729, 2024. |
|---|
|
|
[P0079-2-PM]. Usefulness of by hospitalization front by the pharmacist and the future prospects 山崎彬史, 山内章嗣, 岸本亜矢子, 松岡勇作, 奥野昌宏, 森本茂文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 729-730, 2024. |
|---|
|
|
[P0080-3-PM1]. The thing which we saw from enforcement of ... outpatient department medication for securing of quality of the medical therapy in being at home 久岡清子, 増田博也, 澤口友紀, 大荒政志, 川村大輔, 間千晴, 小滝亜梨紗, 井上萌, 木原稔文, 坪田美風 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 730-730, 2024. |
|---|
|
|
[P0081-2-PM]. Shift support from self-assessment of the entry speed of the duties study first report drug history about the efficiency improvement of interpersonal duties and PC drug history software to iPad drug history software 堀雄史1,2, 曽布川洋平1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 731-731, 2024. |
|---|
|
|
[P0082-3-PM1]. Fact-finding about the remedy drug of the person with a disability in the Showa University dentistry hospital and the remedy method 太田品子1,2, 嘉手納未季3, 馬目瑶子3, 姜世野3, 佐藤ゆり絵3, 小野慎之介4, 徳増梨乃4, 原田努5, 龍家圭6,7, 肥田典子6,7,8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 731-732, 2024. |
|---|
|
|
[P0083-2-PM]. Enforcement situation investigation of the outpatient department in front of the pharmacist art for the surgery patients in the medical Topia Soka Hospital 太田隼樹, 長島真洋, 神谷徹也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 732-732, 2024. |
|---|
|
|
[P0084-3-PM1]. An evaluation and problem of the Epinephrine autoinjector pharmacist outpatient department for childhood adrenalin self injection patients 吉田真也, 安田茉緒, 木村美智男, 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 732-733, 2024. |
|---|
|
|
[P0085-2-PM]. Establishment of the pharmacist outpatient department (medicine confirmation before hospitalization) and investigation about report contents 花岡幸恵, 江原由里子, 齋藤友紀子, 岩佐李奈, 岸大輔, 實川東洋 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 733-733, 2024. |
|---|
|
|
[P0086-3-PM1]. Investigation (the third report) of the pharmaceutical management of the at-home self-injection instruction in the immune pharmacist outpatient 大場啓貴1,2,3, 平田一耕1,2, 井上将貴1,2, 小倉千亮1,2, 森健太郎1,2, 六反田諒4, 舟越亮寛1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 733-734, 2024. |
|---|
|
|
[P0087-2-PM]. The diarrhea management by medicine for intestinal disorders combination at Abemaciclib introduction and the medication counseling of the loperamide 野津薫乃1, 長尾由佳1, 石原泰子1, 有澤礼子1, 西村健二1, 山口和盛2, 上野彩子2, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 734-734, 2024. |
|---|
|
|
[P0088-3-PM1]. Efforts to improvement in calculation of the cooperation full addition in the Higashisapporo Hospital 千崎可奈子, 加藤遥平, 和泉早智子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 734-735, 2024. |
|---|
|
|
[P0089-2-PM]. Evaluation of the usefulness of the pharmacist outpatient department before the medical examination of the physician for foreign cancer chemotherapy patients 天野美穂, 佐々木順也, 千葉貴志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 735-735, 2024. |
|---|
|
|
[P0090-3-PM1]. Examination of the usefulness of the pharmacist interview before medical examination for the drug prescription patients for the medical care with the cancerous pain 小西千尋1,2, 上田武司1,2, 伊藤浩子1,2, 松浦暢子1, 阪井美緒2, 立本美紀2, 梶原絹代2, 石坂忠博1, 西澤昭彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 735-736, 2024. |
|---|
|
|
[P0091-2-PM]. Prescription suggestion of the pharmacist attending the palliative care outpatient department 村田朋美, 山崎彬史, 赤瀬博文, 松岡勇作, 奥野昌宏, 森本茂文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 736-736, 2024. |
|---|
|
|
[P0092-3-PM1]. Establishment of the pharmacist outpatient department in outpatient department anticancer medicine instruction duties and examination of the usefulness 眞弓健介, 藤本愛理, 宮下裕央, 佐藤朋佳, 高崎紘臣, 下村真代, 小山田純治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 736-737, 2024. |
|---|
|
|
[P0093-2-PM]. Introduction and usefulness evaluation of the inquiry simplification protocol for all prescriptions in the Fukuoka Tokushukai Hospital 宮津大輔, 立石裕樹, 矢野洋平, 高橋菜生, 川前隆一, 高木悠資, 松本貴行, 相江いずみ, 松浦徹, 山下大貴, 池田都, 重松由加, 秦晃二郎, 田中博和, 渡邊裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 737-737, 2024. |
|---|
|
|
[P0094-3-PM1]. Efficiency of the pharmacist duties by the task shift of compounding of medicines duties 河上卓弥, 石田真衣, 和田聡美, 馬場愛理, 崎山佳歩, 松本雄太, 松谷洋 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 737-738, 2024. |
|---|
|
|
[P0095-2-PM]. Enlarge the item of efforts ... representation correction of the representation correction of the prescription by the pharmacist; and ... 南利彩子, 吉田敏人, 寺沢匡史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 738-738, 2024. |
|---|
|
|
[P0096-3-PM1]. Effect of outside Parliament prescription inquiry simplification protocol and the in-hospital correspondence protocol on inquiry about the pharmaceutical products understock 植村太志1, 山下由貴1, 白崎真由子1, 石原佐織1, 鈴木一志2, 河井和子1, 浦崎圭太1, 久田純生1, 伊藤和幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 739-739, 2024. |
|---|
|
|
[P0097-2-PM]. Promote efficiency of anti-thing duties 別府博仁, 井後星哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 739-739, 2024. |
|---|
|
|
[P0098-3-PM1]. The task shift of the duties from a pharmacist to an office worker and the effect 寺沢匡史, 西田亜須佳, 福島綾, 一色かおり Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 740-740, 2024. |
|---|
|
|
[P0099-2-PM]. Examination about the usefulness of the representation prescription based on medical treatment management based on the protocol in the University of Occupational and Environmental Health Hospital thoracic surgery ward 井手健太, 寺松早紀, 友松明日香, 植木哲也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 740-740, 2024. |
|---|
|
|
[P0100-3-PM1]. Efforts to the task sharing of the pharmacist in the perioperative period using the periarticular multiple drug cocktail for the total hip replacement and the evaluation 栗崎貴啓1, 黒田安純1, 赤星璃1, 松窪恭子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 741-741, 2024. |
|---|
|
|
[P0101-2-PM]. The efforts of the task shift to the non-pharmacist of ward drug duties in the Aichi Medical University Hospital and the effect 佐久間晶基, 築山純代, 近藤あゆみ, 深谷さおり, 塩田有史, 手塚剛彦, 木下功, 竹内正幸, 大西正文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 741-742, 2024. |
|---|
|
|
[P0102-3-PM1]. Practice and usefulness evaluation of the prescription representation input based on PBPM 内野翔太1, 市川慶1, 中島美治1, 八木仁史1, 高田宏文1, 荒井宏人1, 河井良智2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 742-742, 2024. |
|---|
|
|
[P0103-2-PM]. It is a task shift and the effect from the nurse of Distribution of medicine duties to a pharmacist 吉田敏人1, 岩崎克也1, 真鍋由美子2, 寺沢匡史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 742-743, 2024. |
|---|
|
|
[P0104-3-PM1]. Evaluation of the usefulness that the temporary order input of the running out of bringing medicine spare plan by the ward pharmacist brings 幸野洋子, 永野桂子, 續政哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 743-743, 2024. |
|---|
|
|
[P0105-2-PM]. Activity of the pharmacist judging from contents of the prescription suggestion and adoption rate 山田直輝, 加藤奈帆, 川崎梨紗子, 竹村姫穂, 竹腰雄真, 吉澤典成, 濱田達志, 山本浩二郎, 山本倫数, 草薙みか, 大里恭章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 743-744, 2024. |
|---|
|
|
[P0106-3-PM1]. Effect of PBPM for medicine administration evasion contraindicated to the disease about the use drug at unrest 長谷川啓1, 石谷理紗1, 山根正也1, 千原里美1, 上田宏1, 三好崇文2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 744-744, 2024. |
|---|
|
|
[P0107-2-PM]. The effect that task shift/share by the representation prescription input using PBPM gives to the duties burden reduction of the physician 陶山泰治郎, 片桐将志, 中西順子, 篠永浩, 原田典和, 加地努 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 744-745, 2024. |
|---|
|
|
[P0108-3-PM1]. Usefulness and problem in the prescription support protocol of the ward pharmacist 中澤柊, 二神諒子, 前田翔子, 早瀬友和, 新井孝文, 午膓沙織, 稲垣正巳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 745-745, 2024. |
|---|
|
|
[P0109-2-PM]. Consciousness of patients satisfaction and the staff after duties improvement and the service training enforcement by the QC circle activity: Descriptive crossing study 美濃遥香1, 上江洲晴香1, 小岩井恵里香1, 山谷菜美1, 中村由美1, 宮脇沙祐美1, 麻田茄乃子1, 松木史2, 宮川英士3, 半田京子3, 松井優子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 745-746, 2024. |
|---|
|
|
[P0110-3-PM1]. Evaluation by the questionary survey for the efforts of perioperative drug duties in our hospital and the perioperative staff 奥津雄人1, 古波蔵未知2, 横山登英1, 西村康孝1, 諏訪潤子3, 鈴木道子2, 柄澤俊二3, 細谷治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 746-746, 2024. |
|---|
|
|
[P0111-2-PM]. About the reevaluation of the quantity of duties change after the drug progress management system operation 木津健一郎, 内田寿恵, 山本幸二郎, 井出和男, 小池博文, 佐橋幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 746-747, 2024. |
|---|
|
|
[P0112-3-PM1]. Research about the spread to a medical institution of electronic prescriptions 柴山良彦, 田中鈴菜, 青山海来, 猪苅優夏, 久保儀忠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 747-747, 2024. |
|---|
|
|
[P0113-2-PM]. About operation and the team activity of the list of patients in postoperative pain management team using CITA 宮原強1, 草葉一友1, 三浦大介2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 747-748, 2024. |
|---|
|
|
[P0114-3-PM1]. A problem in the standard master setting work for the electronic prescription introduction and future efforts 新田茜1, 村井宗正1, 篠崎聡1, 林由紀子1, 大沢幸嗣1, 嶋田美保子2, 五十嵐聰2, 並木路広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 748-748, 2024. |
|---|
|
|
[P0115-2-PM]. Analysis of prescription check results using the drug information database in the electronic medical chart 宮崎美香, 秋吉明子, 上田賢太郎, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 748-749, 2024. |
|---|
|
|
[P0116-3-PM1]. Problem in master maintenance and the operation for the introduction of the electronic prescription 遠藤達也, 穂積壮一, 菅野高弘, 藤本英明, 畠山綾子, 関川祐貴子, 成ヶ澤稔彦, 引地宗孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 749-749, 2024. |
|---|
|
|
[P0117-2-PM]. Inspection of the in-hospital digital signage introduction for patients in drugstore window duties 似内健人, 中嶋恵美, 大野奈子, 喜多力, 村上智香, 金住麻子, 田中悠季, 三本松泰孝, 鈴木千波, 田村広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 750-750, 2024. |
|---|
|
|
[P0118-3-PM1]. It is ... for duties shift and the reinforcement from duties improvement - object of injection drug formulations by construction, the operation of the injection drug collation system to an anti-person 岩尾恭寛 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 750-750, 2024. |
|---|
|
|
[P0119-2-PM]. Reporting to the multi-type of job for the purpose of the improvement of the medical security by the construction of the doubt inquiry database 堺香輔1, 神谷貴樹1,2, 市原菜美3, 松宮英美里1, 池田義人1, 森田真也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 751-751, 2024. |
|---|
|
|
[P0120-3-PM1]. Efforts of the drug information room in the reporting of the case collected in an in-hospital side effect report 大橋啓子, 阿達ひとみ, 嶋田紘也, 遠藤修司, 石久保義紀, 本多秀俊 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 751-752, 2024. |
|---|
|
|
[P0121-2-PM]. Examination of doubt inquiry in the Kushiro Red Cross hospital, the number grasp of questions and answers and the mention-style tool introduction effect 元木孝, 近江令司, 渡邊清人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 752-752, 2024. |
|---|
|
|
[P0122-3-PM1]. Maintenance, expansion of the drug information environment in the Osaka University faculty of medicine hospital and the evaluation 小門諒平, 吉田直樹, 小泉美希, 田井紀江, 嶺尾里奈, 山本智也, 奥田真弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 752-753, 2024. |
|---|
|
|
[P0123-2-PM]. The animal raw materials-containing drug database making in a critical care center and the intensive care unit and the utilization report 大森裕也, 加賀優妃, 田中宏樹, 西脇龍広, 岸大輔, 實川東洋 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 753-753, 2024. |
|---|
|
|
[P0124-3-PM1]. Efficiency of medicine manual making duties utilizing ChatGPT 佐澤卓哉, 吉田裕生, 上之将明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 753-754, 2024. |
|---|
|
|
[P0125-2-PM]. Construction https://ssdi.info of the injection drug incompatibility route choice system 芹澤健一, 杉本智恵子, 植松卓也, 菅尾高裕 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 754-754, 2024. |
|---|
|
|
[P0126-3-PM1]. The current situation investigation of the information about mention of the delirium to pharmaceutical products package insert 芳野雅巳, 岩崎雅弘, 新井克明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 754-755, 2024. |
|---|
|
|
[P0127-2-PM]. Consideration about Hallucination of ChatGPT in the drug information 松浦誠1, 長澤茉依1, 関本葵1, 豊田俊介2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 755-755, 2024. |
|---|
|
|
[P0128-3-PM1]. Inquiry analysis of the electrolyte preparation for the revision to be able to put in the past 10 years 掛水瑞芳, 五十嵐遼, 竹林佑花, 松田直子, 吉岡小都子, 佐々木美由紀, 福田まゆみ, 星泉, 河野裕則, 岩原良晴, 沢田憲彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 755-756, 2024. |
|---|
|
|
[P0129-2-PM]. The duties burden on pharmaceutical company person in charge by the complete computerization of the drug information medium and change of the consciousness 中田英夫, 金子健, 杉谷綾佳, 石川春樹, 袴田潤, 磯上一成, 津田壮一郎, 大谷壽一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 756-756, 2024. |
|---|
|
|
[P0130-3-PM1]. Examination of the evaluation about the use of JUS QA and problem point 片倉佐都子1, 定塚祐1, 寺西真凜1, 友寄旬1, 北川裕也1, 金子真弓1, 坂本和央1, 村中一大1, 中村裕一1, 岸田崚太郎2, 樋浦一哉3, 棚谷貢1, 船木映二1, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 757-757, 2024. |
|---|
|
|
[P0131-2-PM]. Fact-finding about the good use of material for items mentioned and patients of "the additional risk minimization activity" in pharmaceutical products risk management plan (RMP) 大幸淳1,5, 金井紀仁2,5, 高橋一栄3,5, 菅野浩1, 後藤伸之4,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 757-758, 2024. |
|---|
|
|
[P0132-3-PM1]. Contents investigation of the insurance application in our hospital out of the adaptation 川島悠吾, 下永吉弘樹, 村嶋彩加, 松本圭司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 758-758, 2024. |
|---|
|
|
[P0133-2-PM]. Evaluation of the quantity of prescription for the estimated renal function of the mirogabalin remedy patients 桐生寛一1, 島田美紀子2, 日下翔太3, 前田守4, 永野悠馬4, 市ノ渡真史4, 長谷川佳孝4, 月岡良太4, 大石美也4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 758-759, 2024. |
|---|
|
|
[P0134-3-PM1]. Formula redevelopment of the hypnogenesis medicine in 8 hospitals attached to Showa University 細川琴実1,2, 大島有貴2,3, 中山華2,3, 岡田貴裕2,3, 大城真理奈2,4, 中谷香織2,3, 戸村和希2,3, 鈴木絢子3, 若林仁美2,3, 内倉健2, 田中章久4, 柏原由佳2,4, 嶋村弘史2,3, 百賢二2,5, 高塩理6, 田中克巳2,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 759-759, 2024. |
|---|
|
|
[P0135-2-PM]. About medical information data base service "DATuM IDEA (R)" based on the next-generation medical base method 望月伸夫, 福田ゆき香, 奥田恭子, 田村智子, 松永智行, 小牧遼太, 市原大樹, 祖慶良巳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 759-760, 2024. |
|---|
|
|
[P0136-3-PM1]. Pharmaceutical products and search of the improvement medicine to cause the weight gain using the adverse drug reaction database 姫野ななか1, 渡邉智子1, 名倉京佑1, 岡崎優里1, 重信貴央1, 生野由佳1, 川村なな1, 渡邉剛士1, 郷原紗希2, 戸松侑那3, 宮崎大夢4, 相良英憲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 760-761, 2024. |
|---|
|
|
[P0137-2-PM]. One package about efficiency of the tablet sortation equipment operation 仲山拓努, 河端真以, 越野早紀, 蝦名勇樹, 津田雅大, 田中悠季, 三本松泰孝, 鈴木千波, 田村広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 761-761, 2024. |
|---|
|
|
[P0138-3-PM1]. Survey on the current status of sacubitril valsartan use at our hospital 伊藤弥紀, 東恵理 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 761-762, 2024. |
|---|
|
|
[P0139-2-PM]. The use situation and problem of the Lecanemab in our hospital 石橋真実1, 向井めぐみ1, 中島誠2, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 762-762, 2024. |
|---|
|
|
[P0140-3-PM1]. Development of the in-hospital operation about the proper use of the magnesium oxide preparation and the effect 守作美咲1, 伊藤佳織1,2,3, 加藤滉基1,3, 桑原宏貴1, 加藤さや香1,3, 山田成樹1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 762-763, 2024. |
|---|
|
|
[P0141-2-PM]. The use situation investigation of the morphine for the sufferings from breathing relaxation of the heart failure exacerbation in the Akashi medical center 山元優輝, 寺沢匡史, 岩崎克也, 吉田敏人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 763-763, 2024. |
|---|
|
|
[P0142-3-PM1]. National survey to a protector about Residual medicine and the reuse of the medicine for external application prescribed for preschool children 久知良礼美1,2, 守屋賀奈絵1,3, 小林麻美1,3, 田川菜緒1,3, 江畠麗1,2, 田中広紀1,4, 柏原由佳1,2, 嶋村弘史1,3, 阿部祥英5, 神谷太郎6, 今井孝成7, 百賢二1,8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 763-764, 2024. |
|---|
|
|
[P0143-2-PM]. The achievement situation of antimicrobial consumption and the AMR measures action plan in the outpatient department, future problem 高橋義弥1, 戸口拓弥1, 飯坂美香1, 谷田拓也1, 丸山俊夫1, 野々山由香理1, 吉田泉2, 櫻井正之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 764-764, 2024. |
|---|
|
|
[P0144-3-PM1]. Inquired fact-finding about the anti-doping in the general hospital 岡田拓朗1, 與儀早和子2, 大友謙太朗2, 阿部倉光伸1, 寺口徹1, 辻村舜1, 舟越亮寛1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 764-765, 2024. |
|---|
|
|
[P0145-2-PM]. A correlation of generic drug share and number of the epilepsy specialists of the antiepileptic drug every Japanese metropolis and districts: Description study using receipt data 松沼悟1, 須永茂樹2, 吉元公一1, 神保洋之2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 765-765, 2024. |
|---|
|
|
[P0146-3-PM1]. Graded approach for the local formula reintroduction 森良江, 前万紀子, 奥野昌宏, 森本茂文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 765-766, 2024. |
|---|
|
|
[P0147-2-PM]. The use situation investigation of the milk sugar as the additive for children with the cow's milk allergy using NDB opening data 小山乃々花, 渡邊徹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 766-766, 2024. |
|---|
|
|
[P0148-3-PM1]. Use situation of the dabigatran in the catheter ablation perioperative period and hemorrhagic complications investigation 木谷美月, 小野村直紀, 光野真弓, 江口善美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 767-767, 2024. |
|---|
|
|
[P0149-2-PM]. Investigation into hypokalemia associated with lasucfloxacin administration 草冨翔太, 前田太一, 安藤和也, 大森丈, 寺本敏清, 渋谷貞一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 767-768, 2024. |
|---|
|
|
[P0150-3-PM1]. Effect investigation to the occurrence of fall fall time with the remedy medicine 清水優依, 小泉真, 佐藤家恒, 小嶋雅人, 小川信二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 768-768, 2024. |
|---|
|
|
[P0151-2-PM]. The use situation investigation of the pre-medication in the daratumumab subcutaneous administration 徳武和馬1, 粂哲雄1, 原田翔平1, 及川和典1, 秋山加菜1, 吉嗣加奈子2, 深谷真史2, 式郁恵2, 榎並輝和2, 池田宇次2, 佐藤哲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 768-769, 2024. |
|---|
|
|
[P0152-3-PM1]. Introduction and the use situation of the Gee raster subcutaneous injection 3.6 mg body pod in our hospital 上林愛, 小野裕紀, 齋藤智美, 遠藤尚美, 樋口安耶, 芦野均 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 769-769, 2024. |
|---|
|
|
[P0153-2-PM]. The use actual situation of the prescription situation of the mirogabalin in the single institution and the effective dose 鈴木訓史1,4, 東敬太1,4, 小林美奈子1, 高橋紀子2,4, 櫻井睦美3,4, 田島つかさ3,4, 高橋通規3,4, 西村康人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 769-770, 2024. |
|---|
|
|
[P0154-3-PM1]. The medication situation investigation of the circulatory organ analogous drug for patients with end-stage cancer in the Anjo rebirth hospital palliative care unit 平野貴大1, 渡辺裕之1, 野々山陽子1, 小島礼菜1, 野本歩未1, 植松夏子1, 藤井友和2, 杉浦洋二3, 羽田勝彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 770-770, 2024. |
|---|
|
|
[P0155-2-PM]. The efforts to an evaluation and side effect measures of the analgesic effect for the medical drug first use patients in the NIHON CHOUZAI Kitasato drugstore. 坪井悠太, 伊熊恵美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 770-771, 2024. |
|---|
|
|
[P0156-3-PM1]. Fact-finding of a quantity of prescription of oral, the ad usum externum opioid and the prescription days change 深澤拓也1, 永瀬怜司1, 西悠吾1, 大道美保2, 戸田陽子3, 菅野浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 771-771, 2024. |
|---|
|
|
[P0157-2-PM]. Use fact-finding of the anamorelin of our hospital for the progress non-small cell lung cancer with the cachexia 平良奈々1, 花房伸幸1, 狩野裕久2, 別所昭宏3, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 771-772, 2024. |
|---|
|
|
[P0158-3-PM1]. ... that the right knowledge about research - medical drug about the proper use of the drug for the medical care is not associated with a thought for the impression and use 松本麻里1, 中野優孝1, 島袋倫1, 三浦快1, 飯塚康人1, 渡部智文2, 大平愼1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 772-773, 2024. |
|---|
|
|
[P0159-2-PM]. Use fact-finding of the antiinfluenza medicine in inpatients in the Nippon Life Insurance Co. Hospital 橋爪香, 内藤睦, 池田久雄, 平田貴宏, 神原弘和, 足立充司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 773-773, 2024. |
|---|
|
|
[P0160-3-PM1]. National survey to a protector about home Residual medicine and the reuse of the antimicrobial prescribed for non-school children 守屋賀奈絵1,2, 久知良礼美1,3, 小林麻美1,2, 田川菜緒1,2, 江畠麗1,3, 田中広紀1,4, 柏原由佳1,3, 嶋村弘史1,2, 阿部祥英5, 神谷太郎6, 今井孝成7, 百賢二1,8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 773-774, 2024. |
|---|
|
|
[P0161-2-PM]. Examination of the cost reduction effect after the tablet automatic assortment return device introduction 喜古康博, 宮澤正幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 774-774, 2024. |
|---|
|
|
[P0162-3-PM1]. Usefulness evaluation from the viewpoint of recognition, medical economy in the tablet assortment return device 秡川夏菜子, 町田幸枝, 古内容子, 後藤真明, 伊藤理咲, 須藤孝浩, 黒田純子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 774-775, 2024. |
|---|
|
|
[P0163-2-PM]. The signal detection investigation of the drug associated with the lower digestive tract perforation using the adverse drug reaction database 村上正樹, 石原慎之, 玉木宏樹, 矢野貴久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 775-775, 2024. |
|---|
|
|
[P0164-3-PM1]. Cost effectiveness analysis of the febrile neutropenia prevention by the proper use of Pegfilgrastim based on guidelines 伯野大樹, 税所篤行, 田村美穂, 佐々木孝彰, 岡田直人, 北原隆志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 776-776, 2024. |
|---|
|
|
[P0165-2-PM]. Examination of efforts for the generic name prescription spread and the effect 八倉巻真衣1, 小野尚志1, 寺川央一1, 武田怜1, 猪俣茉耶1, 太田麻美1, 山本香緒里1, 伊藤亜耶3, 木立康太2, 砂田貴志2, 橋場哲也3, 佐藤竜二2, 三辻史明2, 山本譲1, 中馬真幸1, 田崎嘉一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 776-777, 2024. |
|---|
|
|
[P0166-3-PM1]. Effect on inside the hospital, outside Parliament prescription by the in-hospital formula reintroduction 河野正憲, 伊藤俊和, 尾上雅英 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 777-777, 2024. |
|---|
|
|
[P0167-2-PM]. A scientific approach for the Biosimilar spread that it was driven by a pharmacist and conducted: Coquelin systematic review in the ophthalmology domain 須永登美子1,2, 前田真之3, Ng M Sueko4, 里美貴5, Mason Andrew6, 野間久史7, 大田えりか8, 長谷川毅9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 777-777, 2024. |
|---|
|
|
[P0168-3-PM1]. The local difference analysis of the Biosimilar substitution rate of the Darbepoetin Alfa preparation: Appropriate approach including bioSejm 玉山菜々夏, 田畑諒丞, 石橋郁佳, 太田実伶, 吉岡由宇, 中村暢彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 778-778, 2024. |
|---|
|
|
[P0169-2-PM]. Operational construction and effect for the calculation of the early period of biofollowing article introduction addition 藤田強記, 衛藤智章, 久松大祐, 高野豪, 後藤隆, 清水裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 778-779, 2024. |
|---|
|
|
[P0170-3-PM1]. About the use investigation of the peg filgrastim follower product in the Himeji medical center 竹松茂樹, 壇梨恵, 山本有紀, 岡陽子, 谷上知絵理, 永井聡子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 779-779, 2024. |
|---|
|
|
[P0171-2-PM]. Safety assessment in the case that we changed from precedent biomedicine of the bevacizumab to a biofollowing article during colon cancer treatment 吉川藍乃, 陶山登之, 長田大河, 渋江理恵, 石原慎之, 直良浩司, 玉木宏樹, 矢野貴久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 779-780, 2024. |
|---|
|
|
[P0172-3-PM1]. Inspection of the adverse event report after the rituximab Biosimilar preparation release 加藤滉基1,2, 水野智博1,2, 小木曽杏奈1,2, 戸邊隆夫1,2, 長谷川章1,2, 安藤洋介1,2, 中井剛1,2, 波多野正和1,2, 古関竹直1,2, 山田成樹1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 780-780, 2024. |
|---|
|
|
[P0173-2-PM]. A case which contributed to the early treatment that was addicted to opioid by the intervention of the pharmacist in the emergency visit 秋葉健太, 山崎彬史, 奥貞佳奈子, 松岡勇作, 奥野昌宏, 森本茂文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 780-781, 2024. |
|---|
|
|
[P0174-3-PM1]. Search of the factor to influence a renal function change of the early period of dapagliflozin start in patients with chronic cardiac insufficiency 緒方禮紗1, 田中こづえ1, 上瀧喬仁1, 石川智子1, 樋口恭子1, 福本義弘2, 古川恭治3, 熊野夏海3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 781-781, 2024. |
|---|
|
|
[P0175-2-PM]. 2 cases that presented serious hyperkalemia after the trimethoprim sulfamethoxazole internal use 片桐光, 武藤浩司, 小林竜司, 田中裕子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 781-782, 2024. |
|---|
|
|
[P0176-3-PM1]. One case of the patients who presented with the significant hyponatremia with thiazide system diuretics 原口ももな, 山田雅也, 梶原洋文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 782-782, 2024. |
|---|
|
|
[P0177-2-PM]. One case of the lymphoproliferative disorder improved after the methotrexate cancellation 赤星璃, 上田美咲, 栗碕貴啓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 783-783, 2024. |
|---|
|
|
[P0178-3-PM1]. One case with suspected drug-related thrombocytopenia with the dobutamine administration during heart failure medical treatment 笹野智子, 千葉貴志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 783-783, 2024. |
|---|
|
|
[P0179-2-PM]. Hypoglycemic one case with pentamidine which occurred during pneumocystis pneumonia treatment of the rheumatoid arthritis coexistence 星川果南1, 高田正弘1, 小谷智美1, 坂本靖之1, 小川喜通1, 中島理絵2, 荒木佑亮3, 久保田益亘4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 784-784, 2024. |
|---|
|
|
[P0180-3-PM1]. Is taking Abaco bread; 1 case of the ANCA-related vasculitis with suspected liver damage of starting late 緒方健二1,2, 山崎政虎2, 宮園素明2, 祖川倫太郎1, 鶴橋智子1, 島ノ江千里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 784-785, 2024. |
|---|
|
|
[P0181-2-PM]. 4 cases that took the orexin receptor blocker which the side effect of the nightmare developed 甲斐敬子1, 濱崎洋子1, 井上真2, 遠山泰崇2, 前原理佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 785-785, 2024. |
|---|
|
|
[P0182-3-PM1]. Analysis of the bevacizumab-induced gastrointestinal perforation using the adverse event spontaneous report database 杉下香菜1, 前澤美佳1, 広藤咲子1, 宮坂香海1, 野倉優華1, 市原奈々加1, 山下萌1, 山崎智文1, 田中秀幸1,2, 中尾智史1,3, 玉木啓文4, 井口和弘4, 中村光浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 785-786, 2024. |
|---|
|
|
[P0183-2-PM]. Unequal analysis of pharmaceutical products associated with the onset of proteinuria and the nephrotic syndrome using the Japanese adverse event report database 真砂聖1,2, 山岡健太2,3, 内田まやこ4, 植沢芳広5, 清水忠2, 依藤健之介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 786-786, 2024. |
|---|
|
|
[P0184-3-PM1]. Investigation of the Osimertinib-induced heart failure risk using receipt data 建部泰尚, 真鍋洋平, 東恩納司, 田中雄太, 濱野裕章, 村川公央, 座間味義人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 786-787, 2024. |
|---|
|
|
[P0185-2-PM]. Specialist in citizen of Osaka consecutive side effect Committee 2022 report summary 山本京1,6, 松本ミユキ2, 井上千紘3, 坂田勝美4, 清水順子5, 福田千佳6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 787-787, 2024. |
|---|
|
|
[P0186-3-PM1]. Efforts to herpes zoster therapeutic drug academic D tailing material development 杉山奈津子1, 出雲貴文2, 木村聡子3, 鈴木邦彦4, 頓宮美樹5, 長澤宏之6, 古野喬志7, 宗像千恵8, 森崎隆博2, 紺野奇重1, 辻稔1, 永井尚美9, 中谷善彦1, 平川聡史10, 岸達生11, 小茂田昌代2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 787-788, 2024. |
|---|
|
|
[P0188-3-PM1]. A nourishment evaluation in the combination therapy including the immune checkpoint inhibitor and platinum and examination about the association of duration of treatment and the side effect expression 岩田梨沙1, 橋野泰良3, 松下拓夢4, 松木美緒1, 片岡優太1, 後藤桂輔1, 星貴薫2, 若本あずさ1, 初山多恵1, 佐藤秀紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 788-788, 2024. |
|---|
|
|
[P0189-2-PM]. One case and literature review of the pilsicainide hydrochloride poisoning that a cause of the cardiogenic shock became clear by Residual medicine confirmation of the bringing medicine 木下照常1,2, 佐藤希帆1, 近藤悠希2, 酒井皓平3, 石塚洋一2, 滝本典夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 788-789, 2024. |
|---|
|
|
[P0190-3-PM1]. Evaluation of the effect on renal function by the RAS inhibitor in the use of orthopedics regional postoperative NSAIDs patients, the three-drug combination with diuretics and the two-drug combination with the RAS inhibitor 堀井一輝, 植松卓也, 芹澤健一, 風間耕介, 沖田英慎, 山崎悟志, 天海琢磨 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 789-789, 2024. |
|---|
|
|
[P0191-2-PM]. A case which a severe drug eruption developed after the nivolumab introduction, and became DLST-positive to a concomitant drug 星田唯史, 森本奈緒美, 藤原大一朗, 眞下惠次, 和田祥明, 野田明宏, 田辺和史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 790-790, 2024. |
|---|
|
|
[P0192-3-PM1]. Examination about the effect of the vancomycin administration plan method in the onset of acute renal failure at tazobactam/piperacillin and vancomycin combination 井上愛菜1,2, 橋本未雷1, 中川未菜1, 吉本辰暁1, 福山雄卯介1, 三角紳博1, 今泉芳孝2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 790-791, 2024. |
|---|
|
|
[P0193-2-PM]. The non-linear pharmacokinetic mathematics model analysis that pointed to the efficacy prediction of the DPP-4 inhibitor 佐久本莉那1, 中村亮1,2, 吉門崇1, 千葉康司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 791-791, 2024. |
|---|
|
|
[P0194-3-PM1]. Examination of the development of the assay using the HPLC of the new anticancer agent M-COPA relative and the internal change in the rat 野口直哉1, 斎藤樺乃2, 宮腰芹菜2, 前田絢子1,2, 筒井久澄3, 臼倉大輝3, 岡野宙輝3, 平田諒3, 金井大和3, 塩釜龍之介3, 村田貴嗣3, 椎名勇3, 真野泰成1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 791-792, 2024. |
|---|
|
|
[P0195-2-PM]. Construction of Risperidone using the dry filter paper blood and the Risperidone metabolite blood level assay 鈴木裕之1,2, 西城佳穂1, 西川陽介2,3, 金野太亮1,2, 大内竜介2,4, 渡邊卓嗣2,4,5, 薄井健介2,4, 中村仁1, 村井ユリ子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 792-793, 2024. |
|---|
|
|
[P0196-3-PM1]. The quantitative predictive model of tacrolimus drug interactions depending on CYP heredity seasonal polymorphism and blood CYP3A4 inhibitor levels: Case accumulation study 平井利典1,2, 青山隆彦3, 辻泰弘3, 伊野和子4, 池尻誠5, 俵功5, 岩本卓也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 793-793, 2024. |
|---|
|
|
[P0197-2-PM]. Predictive precision evaluation of blood Lenvatinib concentrations trough value by the non-linear mixed effect model 公文代將希1, 小川玲佳1, 林和未2, 前川正充1,2, 菊地正史1,2,3, 眞野成康1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 793-794, 2024. |
|---|
|
|
[P0198-3-PM1]. A case which gave information by a rise in blood level prediction of lapatinib based on PISCS 岩角祥子1, 早川晃央2, 菅裕亮3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 794-794, 2024. |
|---|
|
|
[P0199-2-PM]. Pharmaceutical intervention for the transluminal obstruction with levofloxacin in the simple suspension method 田中宏賢1, 山田衛2, 山中彩3, 三浦篤史1, 篠原徹4, 渡邉将隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 794-795, 2024. |
|---|
|
|
[P0200-3-PM1]. Examination of the interaction of a sleeping drug and the life-style related diseases therapeutic drug in drug-induced dementia of elderly people 向井淳治, 坂本竜平, 小竹優希, 堀口涼子, 山田佳菜子, 畠山亮, 奥田広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 795-795, 2024. |
|---|
|
|
[P0201-2-PM]. The case that the warfarin K was called off after the carbamazepine cancellation in children during warfarin K, valproic acid Na, carbamazepine combination 白山祐輝1, 高棹優1, 阿部真也1, 山口浩2, 野村和彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 795-796, 2024. |
|---|
|
|
[P0202-3-PM1]. About the search of the factor which acetaminophen combination using the machine learning gives to a change of PT-INR of the warfarin remedy patients 小林由佳1, 小松敏彰2, 増尾直亮1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 796-796, 2024. |
|---|
|
|
[P0203-2-PM]. Mechanism of decreased blood tacrolimus concentrations observed in patients receiving the enteral nutritional supplement Inolas(R) in combination with tacrolimus 斉藤佑治1, 水谷有希2, 灘井雅行3, 竹内正幸1, 大西正文1, 山本英督4, 築山郁人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 796-797, 2024. |
|---|
|
|
[P0204-3-PM1]. Pharmacokinetic interaction between tacrolimus and nilmatorevir/ritonavir in a kidney transplant patient with COVID-19 畑山昂大1, 藤田雄2, 中川潤一1, 石山雅大3, 村上礼一2, 富田泰史2,3, 新岡丈典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 797-797, 2024. |
|---|
|
|
[P0205-2-PM]. It is effect on analgesic effect after the operation by the combination of celecoxib and magnesium oxide 武藤虎甫1, 平山武司1,2, 齋藤雅俊1, 中村俊貴2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 797-798, 2024. |
|---|
|
|
[P0206-3-PM1]. Anticipatory comparison evaluation of two kinds of vancomycin TDM analysis software in children 糸谷茉友子, 櫻井紀宏, 中村安孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 798-798, 2024. |
|---|
|
|
[P0207-2-PM]. Making and evaluation of the vancomycin order set in the Hekinan Municipal Hospital 亀多健太, 天野哲史, 古畑理樹, 八並ゆかり, 石井彩子, 片山広美, 鈴木厚志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 799-799, 2024. |
|---|
|
|
[P0208-3-PM1]. Comparison between AUC24-48hr >= 600μgh/mL and early nephrotoxic expression risk between AUC24-48hr<600μgh/mL of vancomycin in the seriously ill domain 小林洋平1, 釜野健太郎1, 河津敏明1, 深津祥央1, 烏野隆博1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 799-799, 2024. |
|---|
|
|
[P0209-2-PM]. Examination of the early nephrotoxic risk factor of vancomycin in the seriously ill domain 釜野健太郎1, 小林洋平1, 深津祥央1, 烏野隆博2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 800-800, 2024. |
|---|
|
|
[P0210-3-PM1]. Does the endogenous blood 6-hydroxy melatonin/melatonin ratio become the index of the simple and easy new CYP1A2 activity evaluation? 横川彰朋, 秋山遥香, 深江桃花, 五十嵐俊二, 島崎隼人, 降幡知巳, 柴崎浩美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 800-801, 2024. |
|---|
|
|
[P0211-2-PM]. Examination of the blood vancomycin levels prediction based on serum creatinine level, cystatin C in the seriously disabled child (person) 山崎貴史1, 山本晃大1, 江崎由佳2, 林佳奈子1, 今田美里1, 齊田翌美1, 鶴崎泰史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 801-801, 2024. |
|---|
|
|
[P0212-3-PM1]. The effect that the change of the covariates using the renal-transplant recipients population analysis model in the Asian gives to a blood level change of tacrolimus 前原陸哉, 影山明, 原田大, 川久保孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 801-802, 2024. |
|---|
|
|
[P0213-2-PM]. Evaluation of renal failure frequencies before and after the AUC guide introduction of vancomycin for the elderly aged 75 or over and the early therapeutic range achievement quotient 宇都早希, 嶋本藍, 山内円, 中浴伸二, 平畠正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 802-802, 2024. |
|---|
|
|
[P0214-3-PM1]. Trough blood level prediction of vancomycin by the Bayesian estimate in consideration of a change of the serum creatinine 影山明1, 青山隆彦2, 前原陸哉1, 原田大1, 辻泰弘2, 川久保孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 802-803, 2024. |
|---|
|
|
[P0215-2-PM]. The development of the simultaneous assay of filgotinib out of the human plasma and active metabolite levels and the clinical application 新谷心苗1, 伊藤雄大1, 岩田彩伽1, 藤井隆夫2, 松原和夫1,3, 須野学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 803-803, 2024. |
|---|
|
|
[P0216-3-PM1]. 1 case that succeeded for blood level maintenance by the vancomycin supplementation of the nondialytic day in the patients who received intermittent haemodialysis with the spontaneous micturition 松崎裕紀, 吉川直樹, 南謙太朗, 田崎智也, 池田龍二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 803-804, 2024. |
|---|
|
|
[P0217-2-PM]. Examination of the vancomycin clearance change in patients with blood tumor of the decreased renal function case 五十嵐太一, 島田泉, 小林将文, 袖山健吾, 外山聡 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 804-804, 2024. |
|---|
|
|
[P0218-3-PM1]. The optimal drawing blood time for estimates of Area under the Blood Concentration Time Curve for vancomycin: Precision inspection of four Bayesian software 山本高成1, 川田敬1,2, 佐藤智恵美1, 田井達也3, 山口佳津騎3, 住吉健太3, 多田篤史3, 黒川直弘3, 元木貴大3, 田中裕章3, 小坂信二3, 阿部真治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 804-805, 2024. |
|---|
|
|
[P0219-2-PM]. One case that good blood level was obtained by the changes from oral tacrolimus to continuous infusions for interstitial pneumonia to be complicated with antiMDA5 antibody-positive dermatomyositis 竹上将史, 戎浦規文, 抱恵子, 藤田沙耶, 樽野麻依, 黒松誠, 梶田貴司, 奥野智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 805-806, 2024. |
|---|
|
|
[P0220-3-PM1]. One case of the pseudoaldosteronism that blood level was highly-concentrated, and was prolonged after the posaconazole cancellation 橋本直明1,2, 土岐浩介1, 井坂由佳1, 佐々木裕哉3, 坂田麻実子3, 本間真人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 806-806, 2024. |
|---|
|
|
[P0221-2-PM]. Revision method to improve AUC and the predictive precision of the trough value for vancomycin administration early 24 hours 堀田康弘1,2,3, 飯田萌子1,2, 早川智章1,2,3, 大橋一輝2,3, 朝岡みなみ1,2, 和知野千春1, 宮本武門1, 堀田祐志1,2, 中村敦3, 日比陽子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 806-807, 2024. |
|---|
|
|
[P0222-3-PM1]. One non-Asian case that required approval maximal dose or more during voriconazole (VRCZ) administration 齋藤貴之1, 長嶋真美1, 永尾侑平2, 森永正樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 807-807, 2024. |
|---|
|
|
[P0223-2-PM]. A case which evaluated blood level of the mycophenolate mofetil for the liver damage due to checkpoint inhibitor administration of immunity 漣航平1, 土手賢史1, 堀内望1, 塩飽英二1, 岩田敏之2, 西村尚志2, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 807-808, 2024. |
|---|
|
|
[P0224-3-PM1]. Comparison of the dose adjustment by one point of drawing blood in the vancomycin administration second day and two points of drawing blood 遠藤百華1, 丹羽隆1, 山田悠人1, 市橋菜月1, 原亘輝1, 宮下稜平1, 鷲見和之1, 藤林彩里1, 大坪愛実1, 鈴木昭夫1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 808-808, 2024. |
|---|
|
|
[P0225-2-PM]. Examination of the usefulness of the TDM based on the vancomycin one point drawing blood AUC 原田紗希, 陸丸幹男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 808-809, 2024. |
|---|
|
|
[P0226-3-PM1]. Effect by the injection prescription anticancer agent drug history printing system introduction 陸丸幹男1, 佐藤史織1, 辻村竜一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 809-809, 2024. |
|---|
|
|
[P0227-2-PM]. Mechanism construction of the Excel inflection in the omission of input confirmation of the injection anticancer agent continuation prescription and the evaluation 中村充希, 福井圭亮, 田中こずえ, 山村智代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 810-810, 2024. |
|---|
|
|
[P0228-3-PM1]. About efforts and the use situation for the introduction of the feh great (R) combination subcutaneous injection 前田直就, 廣瀬孝一, 鶴田和樹, 名嘉康平, 呉山友数, 山下剛史郎, 満田正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 810-811, 2024. |
|---|
|
|
[P0229-2-PM]. Examination of the usefulness about the internal use prescription input support of an antiemetic drug, the anticancer agent, pre-medication in the foreign chemotherapy regimen 高岡龍蔵, 桂川健司, 高取裕司, 遠山幸男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 811-811, 2024. |
|---|
|
|
[P0230-3-PM1]. The effect that steroid with the docetaxel therapy in the castration-resistant prostate cancer gives in the effectiveness and safety 高田遼1,2, 住井遥1, 藤原未稀1, 牧賢利1, 川口晃2, 河野晋太郎2, 藤田曙2, 増本弘史2, 高橋洋子1, 長谷川泰久2, 濱岡照隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 811-812, 2024. |
|---|
|
|
[P0231-2-PM]. About efforts for the calculation of the cancer medical therapy system full addition 鶴田和樹, 廣瀬孝一, 呉山友教, 名嘉康平, 前田直就, 金田典子, 北村瑞穂, 山下剛史郎, 満田正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 812-812, 2024. |
|---|
|
|
[P0232-3-PM1]. It is ... through the irAE measures task team irAE case which led to PMDA report of problem - our hospital which we saw after starting 四十物由香1, 小川竜徳1, 小川愛梨1, 松本玄紀1, 菊池早輝子2, 野島千恵2, 田地広明3, 大河原悠4, 遠藤剛5, 伊藤周作6, 品川篤司7, 堤雅一5, 田村明広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 812-813, 2024. |
|---|
|
|
[P0233-2-PM]. The current situation of the perioperative breast cancer chemotherapy in the municipal Kashiwabara Hospital 中市里実1, 佐野拓見1, 山下幸大1, 堀田佳世2, 谷口尚子2, 台野佳代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 813-813, 2024. |
|---|
|
|
[P0234-3-PM1]. It is the usefulness of the interview after the medical examination judging from the pharmaceutical intervention example of the foreign chemotherapy center - permanent residence pharmacist 古田祐美子, 土手賢史, 塩飽英二, 澤井麻記, 奧野雅樹, 冨士原あゆみ, 大川裕子, 岩根裕紀, 小林由佳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 813-814, 2024. |
|---|
|
|
[P0235-2-PM]. Efforts of University of Toyama Hospital for the smooth operation of the peg filgrastim automatic infusion type preparation 石川雄大, 高木昭佳, 加藤敦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 814-814, 2024. |
|---|
|
|
[P0236-3-PM1]. Usefulness evaluation - second report ... of PBPM about the examination for echocardiogram at the antiHER2 inhibitor administration 徳留章1,2, 佐藤彩伽1, 須賀明輝1, 樋浦一哉3, 山下美妃3, 木明貴幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 814-815, 2024. |
|---|
|
|
[P0237-2-PM]. Investigation of the annoyance by the job of foreign cancer chemotherapy patients obtained by the multi-type of job cooperation and the coexistence of the treatment 篠原義剛1, 細田悦子2, 原田有理沙3, 永田昌子3, 立石清一郎4, 植木哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 815-815, 2024. |
|---|
|
|
[P0238-3-PM1]. A case which we utilized an information appliance at a health insurance pharmacy from the treatment of patients with colon cancer to terminal phase and took medicine in cooperation with the multi-type of job and supported 金野泰1, 鮎川修2, 山門慎一郎2, 川島敏男3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 815-816, 2024. |
|---|
|
|
[P0239-2-PM]. Evaluation of the anticancer medicine mixture preparation robot introduction effect by the quantity of duties investigation 坂本健一, 片岡悦子, 佐伯千恵, 藤田真帆, 池亀芳野, 樫本考司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 816-816, 2024. |
|---|
|
|
[P0240-3-PM1]. Economical effect of a sterile preparation processing charges calculation turn of eventss and the number of the closed system anesthesia connection instrumentation decrease by the anticancer medicine mixed preparation robot introduction 赤木貴紀, 坂本健一, 片岡悦子, 池亀芳野, 藤田真帆, 佐伯千恵, 樫本考司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 817-817, 2024. |
|---|
|
|
[P0241-2-PM]. Effect of the preparation procedure change of the anticancer agent in the intravesical infusion therapy 川原和也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 817-818, 2024. |
|---|
|
|
[P0242-3-PM1]. The effect that closed system anesthesia drug transportation system (CSTD) gives to the preparation time for anticancer agent 築地可奈, 中島寿久, 久保晶子, 西垣玲奈, 浅野智央, 渡部大介, 齋藤義正, 赤木徹, 橋本浩伸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 818-818, 2024. |
|---|
|
|
[P0243-2-PM]. Effect of the negative pressure operation for the time to redissolve it for albumin suspension type paclitaxel parenteral injection 杉山昌秀, 米田亜希, 篠原佳祐, 宮田智陽, 吉池麻衣, 征矢あや乃, 柳澤沙織 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 818-819, 2024. |
|---|
|
|
[P0244-3-PM1]. Use fact-finding of the anticancer agent preparation robot in the International University of Health and Welfare Narita Hospital 長瀬友樹, 石岡美樹, 篠崎浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 819-819, 2024. |
|---|
|
|
[P0245-2-PM]. Anticancer medicine exposure measures using the hypochlorous acid water in our hospital and the evaluation 北川智大, 中西大介, 牛田浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 819-820, 2024. |
|---|
|
|
[P0246-3-PM1]. Change of the consciousness of the healthcare worker by the preparation process change of the epirubicin to use in hepatic artery chemoembolisation 長谷悠紀, 岸川春樹, 北島聖也, 平野真健, 藤堂朱香, 町田聖治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 820-820, 2024. |
|---|
|
|
[P0247-2-PM]. The case that was able to identify the cause of the side effect of patients with breast cancer by the patients follow-up in the family drugstore 島田淳史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 820-821, 2024. |
|---|
|
|
[P0248-3-PM1]. ... which thinks about warfarin and the way of drug interactions - medicine medicine cooperation of the internal use anticancer agent 池崎友明1, 松井雄一1, 田中真衣1, 河井比香里1, 堀川貴志1, 藤岡孝志1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 821-821, 2024. |
|---|
|
|
[P0249-2-PM]. Practice support of the hospital pharmacist for the oral antitumor agents prescription patients in the ambulatory practice 増田博也, 佐々木健志, 川村大輔, 間千晴, 木原稔文, 坪田美風, 久岡清子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 821-822, 2024. |
|---|
|
|
[P0250-3-PM1]. Satisfaction investigation of the reporting system for the patients of the pharmacist in the foreign cancer chemotherapy 渡瀬貴子1, 中尾友紀2, 井上裕貴1, 長岡宏一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 822-822, 2024. |
|---|
|
|
[P0251-2-PM]. Questionary survey to a health insurance pharmacy pharmacist about the construction of the medicine medicine cooperation system in the foreign cancer chemotherapy 中尾友紀1, 渡瀬貴子2, 井上裕貴2, 平野隆司3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 822-823, 2024. |
|---|
|
|
[P0252-3-PM1]. The example that a drugstore pharmacist contributed to exacerbation evasion of acute renal failure and anemia by the Abemaciclib 永井基瑛1, 市ノ渡真史2, 長谷川佳孝2, 月岡良太2, 大石美也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 823-823, 2024. |
|---|
|
|
[P0253-2-PM]. Appropriate renal function evaluation in consideration of the drug interactions in the oral anticancer agent remedy patients 林田大輝, 天方奉子, 牛浜直樹, 稲葉一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 824-824, 2024. |
|---|
|
|
[P0254-3-PM1]. Investigation about the duties time of the cancer pharmacist outpatient department 渡邊裕之1,2, 早坂大1, 入江紘加1, 村上賢次1, 宅和真由美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 824-824, 2024. |
|---|
|
|
[P0255-2-PM]. The use situation investigation of the fosnetupitant in the Shikoku cancer center 津郷佑規1,2, 松本拓真1, 生田智基2, 長谷部匡史1, 堀田修次1, 仙波靖士1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 825-825, 2024. |
|---|
|
|
[P0256-3-PM1]. The effectiveness and safe comparison between fosnetupitant and Fosaprepitant in the gynecologic cancer TC therapy 吉田悠, 松波奈緒美, 今多亮介, 宮下真美, 朝倉満直, 高川理来, 山田和司, 天間雅美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 825-825, 2024. |
|---|
|
|
[P0257-2-PM]. The effectiveness of aprepitant and the fosnetupitant in the gynecologic Carboplatin regimen and safe comparison 松尾圭祐, 西村沙也香, 中島文, 佐藤栄梨, 松元俊博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 826-826, 2024. |
|---|
|
|
[P0258-3-PM1]. Risk factors for nausea caused by trastuzumab deruxtecan 土屋直彦1,2,3, 浜善久2, 岡田敏宏2, 佐野史穂2, 池上悦子2, 小山茂1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 826-827, 2024. |
|---|
|
|
[P0259-2-PM]. The network meta analysis that compared the effectiveness of Dexamethasone-Sparing in the AC therapy between the generations of the 5-HT3 receptor blocker 渡邊大地1, 飯原大稔1,2, 小林亮1,3, 藤井宏典1, 森龍太郎4, 熊田恵介2, 清水雅仁2,5, 二村学4, 鈴木昭夫1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 827-827, 2024. |
|---|
|
|
[P0260-3-PM1]. Examination of the antiemesis therapy for the chemotherapy using azacitidine 若杉吉宣1, 池田義人1,2, 野田哲史2,3, 村田誠4, 森田真也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 827-828, 2024. |
|---|
|
|
[P0261-2-PM]. Investigation into appropriate antiemetic therapy for trastuzumab deruxtecan 吉村芙美1, 畑裕基2, 岡崎晴夏1, 青野由依1, 中橋麻友1, 楢本佳代1, 足立紗知1, 宮城和代1, 野田拓誠1, 長谷川英利1, 村津圭治1, 山下大輔1, 吉野宗宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 828-828, 2024. |
|---|
|
|
[P0262-3-PM1]. Investigation about the effectiveness, the safety of the fosnetupitant for the obstetrics and gynecology department domain PTX + CBDCA therapy 糸井直樹1, 西澤広介1, 中島萌1, 池田貴之1, 三橋未帆1, 仲岡佑季1, 杉野歩美1, 佐藤直子1, 石田洋昭2, 土井啓員1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 828-829, 2024. |
|---|
|
|
[P0263-2-PM]. Pharmaceutical intervention example count - by job evaluation - heart failure medical treatment instruction person of the ward pharmacist in the tumor circulatory organ domain for patients with blood cancer 石田有希, 荒川希美, 西田祥啓, 高橋喜統, 政氏藤玄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 829-829, 2024. |
|---|
|
|
[P0264-3-PM1]. Efforts of expression situation and PBPM of proteinuria due to the antiVEGF antibody in patients with colon cancer 福島ゆかり, 組橋由記 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 829-830, 2024. |
|---|
|
|
[P0265-2-PM]. The effect that the steroid of chemotherapy-induced vomiting measures gives for an immune-mediated adverse event 藤本愛理1,2,3,4,5,6,7,8, 高武嘉道2, 筒井佑紀3, 中原萌子2, 松尾圭祐4, 薮内百里香5, 上村豪6, 上原智博7, 川俣洋生8, 小山田純治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 830-831, 2024. |
|---|
|
|
[P0266-3-PM1]. Inhibitory effect of calmangafodipir in the paclitaxel-induced peripheral neuropathy rat model 川尻雄大1, 森皓平1, 石田晴多1, 上田真実1, 矢尾幸三2, 永濱文子2, 峯圭佑1, 森裕介1, 河良優介1, 藤田隼輔1, 島添隆雄1, 小林大介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 831-831, 2024. |
|---|
|
|
[P0267-2-PM]. A case which was able to be carried out by pacemaker implantation technique to autogenous graft for bradyarrhythmia with the diarsenic administration trioxide 諌見圭佑1, 鳥山陽子1, 大渡五月2, 杉尾由希子1, 片岡哲郎3, 大窪典子4, 大塚眞紀2, 山形真一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 831-832, 2024. |
|---|
|
|
[P0268-3-PM1]. Examination of the effect that medication method gives to onset of hypersensitivity of the doxorubicin 中村瑠里1, 古原優也1, 高橋正也2, 柏木伸一郎3, 中村安孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 832-832, 2024. |
|---|
|
|
[P0269-2-PM]. Examination using the meta-analysis about the usefulness of the magnesium prophylaxis for the cisplatin-induced renal failure 常風興平1, 西田基紀1, 森沢惇平1, 石田智滉1, 大平玲生2, 山崎智司2, 丸山拓実2, 深谷寛2, 浜田幸宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 832-833, 2024. |
|---|
|
|
[P0270-3-PM1]. About the use of levofolinate calcium situation and side effect expression in our hospital accompanied with folinate calcium supply restrictions 馬場結子, 平池美香子, 齋藤巨樹, 小園亜希, 湊本康則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 833-833, 2024. |
|---|
|
|
[P0271-2-PM]. Incidence of injection site reactions due to Phesgo administration and patient background factors 柳澤沙織, 杉山昌秀, 篠原佳祐, 宮田智陽, 吉池麻衣, 征矢あや乃, 渡邉将隆 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 833-834, 2024. |
|---|
|
|
[P0272-3-PM1]. One patient who presented with encephalopathy by mFOLFOX6 therapy in the cancer of the esophagus 鰐川有紗1, 水上拓郎2, 清水幸雄1, 田中昌代1, 内野慶太2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 834-834, 2024. |
|---|
|
|
[P0273-2-PM]. One case that a symptom was prolonged after the infliximab treatment for steroid refractoriness irAE enterocolitis 松田優斗, 延籐勇, 日野裕子, 山本浩史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 835-835, 2024. |
|---|
|
|
[P0274-3-PM1]. One case that helicobacter pylori sanitization was effective for the steroid-resistant immune thrombocytopenic purpura with the immune checkpoint inhibitor 田中耕太, 藤林遼, 山田将悟, 朝倉幹己, 齋藤公華, 橋本咲季, 山内萌生, 菊地亮朗, 山本翔太, 前川英輝, 高橋誠, 田中正臣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 835-836, 2024. |
|---|
|
|
[P0275-2-PM]. The expression situation of the adverse event of the immune checkpoint inhibitor in patients with lung cancer and association with duration of treatment and Geriatric Nutritional Risk Index 深澤美柚1, 三谷小春1, 清水敦也1, 後藤桂輔2, 若本あずさ2, 初山多恵2, 星貴薫3, 長谷川功1, 佐藤秀紀2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 836-836, 2024. |
|---|
|
|
[P0276-3-PM1]. Efforts to a rise in hepatitis B-related examination rate in patients receiving injectable anticancer agent 田中広大, 胎中博行, 山本桜絵, 西川真由, 中井梨都, 高岸良典, 藤澤康代, 高平豊, 公文登代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 836-837, 2024. |
|---|
|
|
[P0277-2-PM]. Report of a case of CRS caused by epcolitamab administration 西原夢乃1, 野口唯香1, 佐東慶一2, 木村雄太1, 明庭圭吾3, 森瀬修平3, 阿部結哉1, 高田慎也1, 山岸佳代1, 高橋承吾4, 江端浩4, 坂井俊哉4, 藤本勝也4, 橋下浩紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 837-837, 2024. |
|---|
|
|
[P0278-3-PM1]. The effect that a difference of the medication method of Cetuximab gives to the onset of low Mg blood symptom situation in patients with progress recurrence colon, rectal cancer 田中凌太1, 梁川稔規1, 片岡幸三2, 田中亜里菜1, 中村豪志1, 柳井美奈1, 田中邦佳1, 木村慶2, 伊藤一真2, 出町友子3, 平田真由美3, 池田正孝2, 木村健1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 837-838, 2024. |
|---|
|
|
[P0279-2-PM]. Look at the rear examining safety in the cancer of the esophagus FP therapy using the short hydration method; a mark observational study 小林明日香1, 近藤潤一1, 杉山菜穂1, 花谷直美1, 金澤温子1, 小杉三弥子1, 佐藤渉2, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 838-838, 2024. |
|---|
|
|
[P0280-3-PM1]. Efforts for an investigation and the improvement of the blood glucose level measurement situation of the use of immune checkpoint inhibitor patients in our hospital in measurement rate 山本桜絵, 田中広大, 中井梨郁, 門口直仁, 公文登代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 839-839, 2024. |
|---|
|
|
[P0281-2-PM]. One case of the follow-up that we performed for patients with colorectal cancer of progression recurrence that was impossible of curative resection with the BRAF mutation in the gene that we aggravated after the cancer chemotherapy 明比朋子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 839-839, 2024. |
|---|
|
|
[P0282-3-PM1]. Even the report system of a case ... associate panic values of the acute adrenal insufficiency by Nivolumab which saved by a telephone follow-up, an outside order examination can save patients; or ... 香取哲哉1, 河本怜史1, 都築竜太1, 青柳友彦1, 吉田裕紀1, 木村敦1, 星野睦美2, 村田圭祐2, 小茂田昌代1, 小林亮介3, 岡元るみ子4, 出雲貴文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 840-840, 2024. |
|---|
|
|
[P0283-2-PM]. Importance of an investigation and the follow-up of the use of drug for external use inappropriateness example in the onset of dermatopathy example of the oral anticancer agent 粟嶋敏, 片平将幸, 渡邉瑠依, 吉中愛莉, 徳岡安見 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 840-841, 2024. |
|---|
|
|
[P0284-3-PM1]. Investigation about the clinical features of the adrenal cortical insufficiency onset case in the use of immune checkpoint inhibitor patients 森岡友美1, 福永晟也1, 福永晃右1, 石田智之1, 鶴永大貴1, 堀内智裕1, 中村有莉恵1, 赤星真広1, 池増鮎美1, 佐多照正1, 細山田香2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 841-841, 2024. |
|---|
|
|
[P0285-2-PM]. Intervention of the drugstore pharmacist for the lacrimation of Tegafur gimeracil oteracil potassium combination tablets 小野恵美子, 鯨明美, 岩瀬裕治, 丹羽直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 841-842, 2024. |
|---|
|
|
[P0286-3-PM1]. Fact-finding (we look at the rear a mark observational study) of cancer medical treatment peripheral neuropathy measures to be able to put 牛膓沙織1, 野村翔1, 加藤幾1, 中澤柊1, 前田翔子1, 中野帆乃香2, 稲垣正巳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 842-842, 2024. |
|---|
|
|
[P0287-2-PM]. The case that the medication follow of the drugstore pharmacist contributed to regimen successful execution for a hand-and-foot syndrome of Grade2 by colon cancer postoperative CapeOX 伊津田知樹, 見越聖也, 大久保匡邦, 井ノ山綾香, 盛岡洋平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 843-843, 2024. |
|---|
|
|
[P0288-3-PM1]. A Case of Careful Pimitespib Administration Management - Administration Management Due to Decreased Renal Function After Administration - 樋口安耶1, 笹原由理子2, 小野裕紀1, 齋藤智美1, 遠藤尚美1, 上林愛1, 芦野均1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 843-843, 2024. |
|---|
|
|
[P0289-2-PM]. One case with suspected visual disturbances with oxaliplatin 宮本美咲1, 藏本裕信1, 藤木博2, 権藤直人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 844-844, 2024. |
|---|
|
|
[P0290-3-PM1]. Examination of risk factors for niraparib-induced nausea and vomiting 中井將人, 妹尾啓司, 阿部圭輔, 石田翔, 水上皓喜, 河村勇介, 西本早紀, 山根実里, 岡原夏実, 白木政博, 渡邊篤 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 844-844, 2024. |
|---|
|
|
[P0291-2-PM]. Two cases in which opioid switching was effective for preventing pain associated with dinutuximab 黒岩祐里香1, 歌野智之1, 高橋勇人1, 山田悠司2, 清谷知賀子2, 塩田曜子2, 寺島慶太2, 松本公一2, 赤羽三貴1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 845-845, 2024. |
|---|
|
|
[P0292-3-PM1]. Examination of the protein urine expression risk factor by the Lenvatinib 辻将成1, 小林一男2, 川上和宜2, 横川貴志2, 副島梓2, 清水久範2, 今井俊吾3, 吉田菜桜子3, 福田直樹4, 温泉川真由5, 笹平直樹6, 堀里子3, 山口正和2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 845-846, 2024. |
|---|
|
|
[P0293-2-PM]. In the cancer-related thromboembolism is examined usefulness and the safety of the type oral anticoagulant drug directly 青木楓佳, 川之辺淳, 渋谷悠真 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 846-846, 2024. |
|---|
|
|
[P0294-3-PM1]. A case of upper airway stenosis after blinatumomab administration in which treatment was continued and bridging therapy to hematopoietic stem cell transplantation was successfully completed 冨士原あゆみ1, 土手賢史1, 和田達也2, 菱澤方勝2, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 846-847, 2024. |
|---|
|
|
[P0295-2-PM]. Effect on oxaliplatin-induced peripheral neuropathy investigation of statin drugs 志賀有雅1, 藤井友和2, 森巧一3, 三浦崇則5, 杉浦洋二4, 羽田勝彦3, 間瀬悟1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 847-847, 2024. |
|---|
|
|
[P0296-3-PM1]. Use of foreign chemotherapy room patients questionary survey for the PRO-CTCAE introduction 鈴木弘文1, 千葉健史2,3, 柳生千代子4, 岩清水由希恵4, 佐藤真理4, 桜庭文子4, 高橋淑江4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 847-848, 2024. |
|---|
|
|
[P0297-2-PM]. Examination about the medicine for intestinal disorders prophylactic administration for the diarrhea of the Abemaciclib 生田智基1, 和田翼2, 榊原千夏2, 向井直子2, 松本拓真2, 堀田修次2, 森近俊之3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 848-848, 2024. |
|---|
|
|
[P0298-3-PM1]. Examination about the dose of an expression factor and the levothyroxine of the hypothyroidism by the Lenvatinib 白石ちひろ1,2, 加藤秀雄1,2, 朝居祐貴1,2, 岩本卓也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 849-849, 2024. |
|---|
|
|
[P0299-2-PM]. Examination of the usefulness in the pharmacist duties of the opioid conversion table, our hospital adoption medical drug list 鈴木博晃, 濱中悠賀, 栗原りか, 金井貴充 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 849-850, 2024. |
|---|
|
|
[P0300-3-PM1]. The effect that pharmacist placement gives on palliative care unit 野村祥子, 市江敏和, 大谷寧次郎, 鈴木大介, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 850-850, 2024. |
|---|
|
|
[P0301-2-PM]. Usefulness of the medical drug injection drug combination management tool based on the questionary survey for the mild medical therapy authorization pharmacist 近藤匡慶1, 宗像千恵2, 龍恵美3, 吉田真人1, 菅谷量俊1, 林太祐1, 国分秀也4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 850-851, 2024. |
|---|
|
|
[P0302-3-PM1]. The use situation investigation of the diclofenac sodium patch for the cancerous pain 小泉陽奈子, 間美和, 中原萌子, 高武嘉道, 大橋邦央, 藤瀬陽子, 橋本雅司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 851-851, 2024. |
|---|
|
|
[P0303-2-PM]. Fact-finding about the onset of diarrhea after the naldemedine tosyl acid salt introduction in the southern part of Saiseikai Yokohama-shi Hospital 南朱音, 小林奈緒, 高山直也, 矢野莉穂, 佐々木美理, 生田和之, 加藤一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 851-852, 2024. |
|---|
|
|
[P0304-3-PM1]. One case that the side effect of rise in blood level of methadone was suspected, and good pain control was obtained by switching to hydromorphone 高山浩太郎, 山口健也, 吉村真一朗, 進藤美船, 秋吉尚雄, 原田洸秀, 小倉秀美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 852-852, 2024. |
|---|
|
|
[P0305-2-PM]. It is one patient with suspected efficacy drop of hydromorphone by combination of hydromorphone hydrochloride tablets and Hangeshashinto 尾崎正和1, 山縣裕史2, 松井洋人3, 岡田直人1, 北原隆志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 852-853, 2024. |
|---|
|
|
[P0306-3-PM1]. One case that intervened in patients with left lower lobe lung cancer with suspected chemical coping by the multi-type of job 大内友季江1, 佐藤あづさ2, 曽我里紗1, 佐藤千穂1, 安達寛成1, 亀岡裕一3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 853-853, 2024. |
|---|
|
|
[P0307-2-PM]. The current situation and problem for "an opioid telephone follow-up" to see from the questionary survey to patients and a physician 田尻ユカリ1, 田渕祐輔2, 牧野洸太朗2, 内堀香里1, 天谷文昌3, 小阪直史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 853-854, 2024. |
|---|
|
|
[P0308-3-PM1]. Evaluation of the opioid explanation by the pharmacist using an original pamphlet about the cancer pain medical therapy 小藪恵里花, 神田友江, 大西利佳, 三岡麻千子, 郷真貴子, 木村美智男, 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 854-854, 2024. |
|---|
|
|
[P0309-2-PM]. It is a case using the steroid for the accessory symptom of the metastatic brain tumor 田紗永子1,2, 加美山遼1,2, 吉田佳織1, 大原泰斗1, 岡田颯太郎1, 笹本果穂1, 國安弘樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 855-855, 2024. |
|---|
|
|
[P0310-3-PM1]. The use of bisphosphonate within six months and denosumab extends the SRE onset than the use after six months after the metastases to bone diagnosis of patients with breast cancer 佐藤淳也1, 田中怜1, 東光久2, 室谷健太3, 柴田浩行4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 855-856, 2024. |
|---|
|
|
[P0311-2-PM]. Analysis and evaluation of the use drug for the supportive care reinforcement during craniocervical part cancer chemoradiotherapy in our hospital 佐藤彩佳1, 茂原圭佑1, 山田海帆1, 坂本理咲子1, 皆川卓也1, 島崎博士1, 平島徹1, 中川隼一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 856-856, 2024. |
|---|
|
|
[P0312-3-PM1]. Symptom grasp at the multiple myeloma initial induction therapy utilizing patients report type outcome ESAS-r and search of the pharmacist intervention point 江原純也1, 相良篤信2, 出川美沙子1, 奥津雄人1, 松本千明1, 加藤淳平1, 立田真也1, 吉見猛1, 石田耕太1, 高橋尚子3, 細谷治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 856-857, 2024. |
|---|
|
|
[P0313-2-PM]. We look at a retching improvement effect by opioid switching from oxycodone to fentanyl and the rear about the factor and examine a mark 高橋周平, 守田和憲, 徳永晃己, 柴田啓智, 田上治美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 857-857, 2024. |
|---|
|
|
[P0314-3-PM1]. Examination of the interruption risk factor of pregabalin for the cancer-related neuropathic pain 田島紳介1, 山口愛奈3, 正保智恵美2, 戸賀知香2, 鎮西美栄子2, 酒井良子3, 赤沢学3, 吉田正1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 857-858, 2024. |
|---|
|
|
[P0315-2-PM]. Investigation about the use situation of the antirheumatic drug at cancer chemotherapy enforcement of patients with rheumatoid arthritis 佐古夕芽, 深海広平, 馬島務, 龍神博之, 山下剛史郎, 満田正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 858-858, 2024. |
|---|
|
|
[P0316-3-PM1]. Satisfaction investigation of the member of pharmacy for PBPM to the HBV reactivation prevention in the cancer chemotherapy 黒部健太郎, 草葉一友 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 858-859, 2024. |
|---|
|
|
[P0317-2-PM]. The cancer medical therapy side effect detection from practice text data using the natural language processing and suggestion of the visualization technique 土屋雅美1, 嶋本公徳2, 河添悦昌2, 篠原恵美子2, 矢田竣太郎3, 若宮翔子3, 今井俊吾1, 木崎速人1, 堀里子1, 荒牧英治3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 859-859, 2024. |
|---|
|
|
[P0318-3-PM1]. Comparison of the characteristic of adverse event (irAE) of the immune checkpoint inhibitor 畠山亮, 向井淳治, 坂本竜平, 小竹優希, 奥田広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 860-860, 2024. |
|---|
|
|
[P0319-2-PM]. Annual change and cancer classification tendency of elderly people in the injectable anticancer agent initial administration 坂本靖宜1, 重村明香1, 長谷川拓也1, 宇山佳奈1, 小泉宏史1, 清水絢子1, 志村美沙子1, 中山知2,4, 長田智香3, 井出和男1, 畑千秋2, 小池博文1, 堀田信之4, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 860-860, 2024. |
|---|
|
|
[P0320-3-PM1]. Association of effect of treatment and the TTF-1 expression of the Carboplatin + pemetrexed + Pembrolizumab combination therapy as the initial treatment for the lung adenocarcinoma 水谷貴樹, 山本泰大, 林宏紀, 雨宮菜奈, 高木彩圭, 出口裕子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 861-861, 2024. |
|---|
|
|
[P0321-2-PM]. Examination about initial dosage and the side effect of the mFOLFOX6 therapy for patients with severe impaired renal function 高山良, 赤塚亜理沙, 田中りかえ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 861-862, 2024. |
|---|
|
|
[P0322-3-PM1]. A case in which treatment was continued even after the onset of severe renal impairment with encorafenib, binimetinib, and cetuximab 春名康裕1, 野口裕介2, 武田智子1, 友金幹視2, 長谷川晃司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 862-862, 2024. |
|---|
|
|
[P0323-2-PM]. A case of patients with advanced gastrointestinal stromal tumor which developed erythema multiforme by the regorafenib 松本玄紀1, 四十物由香1, 小川竜徳1, 小川愛梨1, 宇留島美佳1, 鈴木俊一1, 岩山竜大1, 八木澤昂大1, 曾睿夫2, 鴨志田敏郎2, 田村明広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 862-863, 2024. |
|---|
|
|
[P0324-3-PM1]. Relative inspection of the drug affecting the becoming severe and the gut flora of the interstitial pneumonia with the immune checkpoint inhibitor 野田拓誠1,2, 村津圭治1, 山下大輔1, 吉野宗宏1, 田中早織2, 幸田祐佳2, 加藤隆児2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 863-863, 2024. |
|---|
|
|
[P0325-2-PM]. 1 case that developed marrow variant characteristics syndrome during Olaparib administration for an ovarian cancer 松井駿亮, 森井悠介, 新居万莉, 田中亮, 森本智, 大河万顕, 瀬名波宏昌, 下村一徳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 864-864, 2024. |
|---|
|
|
[P0326-3-PM1]. Can the bone associated marker become the predictor for onset of low Ca blood symptom of the denosumab for the prostate cancer? 平井成和1, 有山智博2,3, 土井啓員1, 増田雅行2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 864-865, 2024. |
|---|
|
|
[P0327-2-PM]. Observational study of the backward viewpoint about the infusion reaction in daratumumab infusion preparation and the subcutaneous injection preparation 井上千菜美, 藤田行代志, 大橋崇志, 齊藤妙子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 865-865, 2024. |
|---|
|
|
[P0328-3-PM1]. Two cases that type I diabetes mellitus developed after the checkpoint inhibitor administration start of immunity and it was HbA1c high level at the onset of symptom, but was not able to discover early 本田弘1, 佐藤亜希1, 小野香菜2, 矢満田慎介2, 戸井之裕2, 中島繁美1, 大和一美3,4, 木村雄一郎1,2, 菅原俊一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 865-866, 2024. |
|---|
|
|
[P0329-2-PM]. We look at the rear and are investigated the temperature change of patients with colon cancer after the Panitumumab administration by the mark investigation 明野愛1, 伊藤紳人1, 田口玲実1, 壁谷めぐみ1,2, 古田竜一3, 城川優子4, 日比聡1, 戸川昭三5, 伊奈研二6, 湯浅周1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 866-866, 2024. |
|---|
|
|
[P0330-3-PM1]. Pharmaceutical intervention effect of the ward pharmacist in aminolevulinic acid hydrochloride treated patients 高井彩乃1, 田中和秀1, 舘知也1,2,3, 青山智1, 笠原千嗣2, 米田尚生4, 安田昌宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 866-867, 2024. |
|---|
|
|
[P0331-2-PM]. The Lymphocyte Albumin score predicts continuity of the treatment with liposomal irinotecan in patients with pancreatic cancer 伊藤雄大1, 新谷心苗1, 岩田彩伽1, 北野雅之2, 川井学3, 松原和夫1,4, 須野学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 867-867, 2024. |
|---|
|
|
[P0332-3-PM1]. Attempt of the validity evaluation of the S-1 weight loss in elderly patients 安藤基純1, 牛膓沙織2, 中村滉希1, 清家理子1, 前田翔子2, 冨田千颯2, 渡邊法男1, 稲垣正巳2, 河原昌美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 867-868, 2024. |
|---|
|
|
[P0333-2-PM]. Relation of the enforcement environmental maintenance and pharmacist of the aluminum Knox therapy 上之園咲1, 今村聖奈1, 鳥山陽子1, 杉尾由希子1, 大窪典子2, 桑原貴美子1, 山形真一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 868-868, 2024. |
|---|
|
|
[P0334-3-PM1]. A case which was given nivolumab and Pembrolizumab for the MSI-high excision inability small intestinal cancer which developed a liver damage as irAE in turn 廣瀬健一1, 大熊玲子1, 古林園子1, 市田泰彦1, 福冨聡2, 関口昌利1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 868-869, 2024. |
|---|
|
|
[P0335-2-PM]. One case that an anaphylactic symptom produced during Atezolizumab administration 梅津海王, 吉田真人, 近藤匡慶, 菅谷量俊, 林太祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 869-869, 2024. |
|---|
|
|
[P0336-3-PM1]. DVO drug choice ... aiming at coexistence of the single use of vial multiple times (DVO) - duties efficiency and medical expenses reduction utilizing the anticancer medicine preparation robot 守屋昭宏, 浅野裕紀, 木村美智男, 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 870-870, 2024. |
|---|
|
|
[P0337-2-PM]. Inspection of the modi operandi of the anticancer medicine mixture preparation robot in the municipal hospital and the effect contracted at preparation time 桂川健司, 高取裕司, 高岡龍蔵, 遠山幸男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 870-871, 2024. |
|---|
|
|
[P0338-3-PM1]. Quality of life evaluation of patients with foreign cancer 山下紗瑛奈1, 宮澤憲治1, 山本芽以2, 田代匠1, 山田桃子1, 西田涼馬1, 安達尚哉1, 網岡克雄2, 八田浩之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 871-871, 2024. |
|---|
|
|
[P0339-2-PM]. The best case of the lung cancer that gave the Pembrolizumab to patients with the rheumatoid arthritis during Upadacitinib remedy 東井優美1, 輿石徹1, 西岡菜々子1, 吉本公一1, 青木琢也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 871-872, 2024. |
|---|
|
|
[P0340-3-PM1]. CDDP weight loss reason in the pharyngeal carcinoma CCRT therapy, examination about the second treatment extraction rate including the recurrence 鳥山陽子, 諌見圭佑, 杉尾由希子, 上之園咲, 山形真一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 872-872, 2024. |
|---|
|
|
[P0341-2-PM]. The effectiveness, safe examination of the unresectable progress, Trifluridine/tipiracil + Bevacizumab therapy for recurrent colon cancer 三好孝法1, 深澤真実1, 和佐野英子1, 高武嘉道1, 筒井結子1, 藤瀬陽子1, 大橋邦央1, 田村真吾2, 橋本雅司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 872-873, 2024. |
|---|
|
|
[P0342-3-PM1]. The steroid refractoriness serious case myocarditis that occurred after durvalumab administration, 1 case of myasthenia gravis, the myositis 長谷川将1, 木本秀樹1, 吉田悦朗1, 山村真貴子1, 佐藤優希子1, 谷彩花1, 森本優鳥1, 田口みどり1, 林田翔太郎2, 三浦俊哉3, 中島洋4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 873-873, 2024. |
|---|
|
|
[P0343-2-PM]. A case of a kidney transplant patient receiving TC therapy and niraparib with dose adjustment for peritoneal cancer 高原悠子, 吉田弘樹, 鈴木雅人, 牧原明秀, 近藤舞子, 安田知弘, 三屋良太, 木全司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 873-874, 2024. |
|---|
|
|
[P0344-3-PM1]. Problems of the checkpoint inhibitor administration to patients with old cancer of immunity 阿部多一, 住谷達也, 染野澄, 井口恵美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 874-874, 2024. |
|---|
|
|
[P0345-2-PM]. Fact-finding of the adverse event in patients who received PV-R-CHP therapy 及川和典1, 粂哲雄1, 原田翔平1, 徳武和馬1, 秋山加菜1, 吉嗣加奈子2, 深谷真史2, 式郁恵2, 榎並輝和2, 池田宇次2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 874-875, 2024. |
|---|
|
|
[P0346-3-PM1]. We look at the rear about the effect that a serum albumin level gives in a trifluridine Tipiracil hydrochloride combination drug and the effectiveness of the bevacizumab combination therapy and study a mark 牧賢利1, 住井遥1, 藤原未稀1, 高田遼1, 高橋洋子1, 大塚眞哉2, 濱岡照隆1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 875-875, 2024. |
|---|
|
|
[P0347-2-PM]. About the use situation and hypothyroidism of the Durvalumab in our hospital 森本優鳥, 長谷川将, 木本秀樹, 山村真貴子, 田口みどり Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 876-876, 2024. |
|---|
|
|
[P0348-3-PM1]. The effect that the primary treatment gives for treatment continuation of the Pembrolizumab for patients with urothelium cancer 小栗良介1, 中尾優里2, 大野裕之1, 井上壽江1, 林高弘2, 平下智之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 876-877, 2024. |
|---|
|
|
[P0349-2-PM]. The fact-finding of the sequelae of new coronavirus infection and search of the risk factor 出来佑都1, 和知野千春2,3, 安部賀央里1, 小林紀香4, 宮崎ゆか5, 坪内希親5, 堀田祐志2,4, 近藤勝弘2,3, 日比陽子2,4, 頭金正博1, 服部友紀5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 877-877, 2024. |
|---|
|
|
[P0350-3-PM1]. Examination of 1,876 consultation examples that we had a medical examination in the consultation reception of the new corona vaccination that Yamaguchi pharmacist party supported and encouraged 山本武史1,2, 内田一成1,2, 古賀健太郎1,2, 有海秀人2,3, 山本晃之1,2,3, 吉田力久1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 877-878, 2024. |
|---|
|
|
[P0351-2-PM]. Survey on the use of molnupiravir in COVID-19 patients 平田ひとみ1, 山田楊太1, 宮崎元康1,2, 萩原知佳1, 中島章雄1,2, 小川新1, 雄谷希典3, 今給黎修1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 878-878, 2024. |
|---|
|
|
[P0352-3-PM1]. Functional neuropathic one case that was suspected after the new corona vaccination 武宮陽道, 奥美和, 玉置秀成 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 878-879, 2024. |
|---|
|
|
[P0353-2-PM]. Efforts and effect for the proper use of the oral antimicrobial in our hospital 佐多照正, 池増鮎美, 福永晟也, 石田智之, 鶴永大貴, 中村有莉恵, 堀内智裕, 赤星真広, 森岡友美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 879-879, 2024. |
|---|
|
|
[P0354-3-PM1]. Efforts for the duties reduction of the AST charge pharmacist by the cooperation with the ward pharmacist 金子泰也1,2, 木賀田亮介1,2, 神垣貴彦1,2, 丸山晴生1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 879-880, 2024. |
|---|
|
|
[P0355-2-PM]. A case which accepted hyperextension of PT-INR during cefmetazole administration 野田晃洋, 橋本未蕾, 福山雄卯介, 三角紳博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 880-880, 2024. |
|---|
|
|
[P0356-3-PM1]. Effect - that the intervention by proper use support - prescription reason of the third generation oral cephalosporin medicine in the foreign prescription results 松島菜々1, 紀戸綾香1, 西脇さおり1, 加賀谷隆彦1, 藤井奨2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 880-881, 2024. |
|---|
|
|
[P0357-2-PM]. Effect on oral third generation cephalosporin medicine for proton radiotherapy and transperineal prostate biopsy consumption by the pass change 水野知世1,2,3,4, 長水正也1, 伊藤真早代4, 久田宜範1, 朝倉宏紀1, 角田祥1, 菊地基雄2, 森下修行1, 秋田憲志3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 881-881, 2024. |
|---|
|
|
[P0358-3-PM1]. The rate of recurrence investigation in Clostridioides difficile infection treatment based on a disease severity classification 長山優介1, 東加奈子1, 井幡圭佑1, 村田久枝1, 細見光一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 881-882, 2024. |
|---|
|
|
[P0359-2-PM]. Association between low K blood symptom index (Hypokalemia index level) based on the serum potassium characteristic curve area with the amphotericin B liposome preparation and acute renal failure 植田貴史1,2, 中嶋一彦1,2, 一木薫1, 石川かおり1, 田久保慎吾3, 木村健3, 竹末芳生2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 882-882, 2024. |
|---|
|
|
[P0360-3-PM1]. Fact-finding of the creatine kinase rise in daptomycin treated patients 石田茂伸, 眞野裕, 多胡友絵, 星育子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 882-883, 2024. |
|---|
|
|
[P0361-2-PM]. One case of cholangitis to have nephropathic possibilities with the beta lactamase inhibitor 青柿和樹, 大荒政志, 合田さやか, 久岡清子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 883-884, 2024. |
|---|
|
|
[P0362-3-PM1]. A case which caused a drug-related high Ca blood symptom of the eldecalcitol for acute renal failure by the sulfamethoxazole trimethoprim medical mixture remedy 川崎日向子, 田村安希, 花房伸幸, 森英樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 884-884, 2024. |
|---|
|
|
[P0363-2-PM]. Investigation of the hepatic dysfunction frequencies in the dose of micafungin 天本雄大1, 山下泰子1, 唐川聖司1, 酒井義朗1, 樋口恭子1, 渡邊浩2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 884-885, 2024. |
|---|
|
|
[P0364-3-PM1]. About the relations of dose and the AST, ALT rise of TAZ/PIPC in patients of Ccr10-40mL/min 佐々木裕太, 井上雅義, 尼崎正路 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 885-885, 2024. |
|---|
|
|
[P0365-2-PM]. Individual optimization dosage law based on the PK/PD analysis according to the age group of the cefoperazone-sulbactam combination drug in children 佐野由衣1, 大仁田哲修1, 猪川和朗2, 石原慎之1, 直良浩司1, 玉木宏樹1, 矢野貴久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 885-886, 2024. |
|---|
|
|
[P0366-3-PM1]. Efforts for the antimicrobial proper use support in our hospital 松村真裕1,2, 長谷川和恵1,2, 西野多江子1,3, 甲斐幸代1,4, 福盛達也1,5, 服部英喜1,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 886-886, 2024. |
|---|
|
|
[P0367-2-PM]. Comparison of blood micafungin levels for patients with liver transplant in the perioperative period and lung transplantation 平井真智子1,2, 片田佳希1,2, 中川俊作1, 梅村圭祐1, 小島悠輔1,2, 勝部友理恵1, 石村裕樹1, 松村勝之1, 奥村晋也3, 中島大輔4, 長尾美紀2,5, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 886-887, 2024. |
|---|
|
|
[P0368-3-PM1]. We look at the rear about the effect that the Teicoplanin administration plan by the pharmacist gives to achievement of aim blood level and evaluate a mark 渡邊崇平1, 大池恵生2, 高岡龍蔵1, 杉村聡1, 吉見冬威1, 遠山幸男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 887-887, 2024. |
|---|
|
|
[P0369-2-PM]. The enforcement situation investigation of the vancomycin administration plan that assumed AUC an index 古川誠之, 渡邊太朗, 甲斐崇文, 名和田幸介, 有間幹人, 手嶋ひさ子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 887-888, 2024. |
|---|
|
|
[P0370-3-PM1]. Comparison of the ACTIONs Bundle compliance in the prognosis of candidemia-treated patients 横山靖法, 森田幸男, 吉澤典成, 前田晃佑, 山本浩二郎, 大里恭章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 888-888, 2024. |
|---|
|
|
[P0371-2-PM]. The sepsis case that was able to start antibiotic exposure early by an infection control authorization pharmacist working in an emergency visit 古川大樹1, 伊藤嘉英1, 大橋武司1, 伊藤優子1, 林房枝2, 菱田志乃3, 小林都仁夫4, 中尾彰宏5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 888-889, 2024. |
|---|
|
|
[P0372-3-PM1]. Use turn of eventss of the antiMRSA medicine for the staphylococcus aureus bacteremia after the dimethoxyphenyl penicillin resistance gene (mecA) quickness PCR testing introduction 塩原悠貴1,2, 坂井孝行1,2, 藤田裕美1,3, 安藤諒1,3, 影向晃1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 889-889, 2024. |
|---|
|
|
[P0373-2-PM]. Consideration for a case that a fosfomycin IV infusion was effective for MRSA UTIs 佐古久美子1, 海老根卓也2, 高橋信1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 889-890, 2024. |
|---|
|
|
[P0374-3-PM1]. The prescription situation and analysis of the Access antimicrobial in the outpatient department 小木篤仁, 岡田瑠佳, 高理絵, 昆野智大, 浅子由衣, 山口菜摘, 上原みどり, 柏木真祐, 吉住和敏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 890-891, 2024. |
|---|
|
|
[P0375-2-PM]. Effect on use pulse-taking - antimicrobial by use restrictions of the carbapenem-based antimicrobial-sensitive rate and number of resistant bacteria detection ... 知念沙綾1, 玉城哲子1, 城間盛彦1, 黒澤雅資1, 宮城凛1, 浦崎清美2, 島袋朝太郎1, 安座間照子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 891-891, 2024. |
|---|
|
|
[P0376-3-PM1]. Importance ... of the checking prescription by relation ... pharmacist to proper use of vaccine, toxoid 鵜澤秀章1, 丸山樹1, 小林正太郎1, 桝田浩司2, 篠崎浩司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 891-892, 2024. |
|---|
|
|
[P0377-2-PM]. Bacteria pollution investigation inside and outside the spray can of the ethanol for disinfection 中川博雄1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 892-892, 2024. |
|---|
|
|
[P0378-3-PM1]. Efforts of the pharmacy in the clinical introduction of vaccine LC16 "KMB" where dried cell culture pox complies with 大橋養賢1, 大橋裕丈1, 有山真由美1, 吉野景子1, 瀬戸恵介1, 百武宏志1, 下川亨明2, 高橋梢3, 氏家無限3, 大曲貴夫3, 西村富啓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 892-893, 2024. |
|---|
|
|
[P0379-2-PM]. Understock of the antimicrobial is ... about the inspection results for effect on use of antimicrobial trend and infection treatment - two years of our hospital giving it 植田徹1,6, 高田尚子1,6, 庄司智香2,6, 山内衛2,6, 大谷祐介3,6, 櫻本稔4,6, 北澤文章1, 高田泰次5,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 893-893, 2024. |
|---|
|
|
[P0380-3-PM1]. To promote antimicrobial proper use; future relation ... authorization pharmacist ... 中野聡, 織田雄一郎, 副島將司, 山本大策, 大場久美, 海瀬有沙, 上野遥香, 小川遼, 長澤真利絵 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 893-894, 2024. |
|---|
|
|
[P0381-2-PM]. An evaluation of the pharmacist-led antimicrobial proper use intervention in the middle scale hospital: a pragmatic quasi-experimental study 中野祐樹1, 平井利典2, 安河内寿成1, 浦和也3, 末安禎子4, 蓮輪博嗣1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 894-894, 2024. |
|---|
|
|
[P0382-3-PM1]. Evaluation of the task shift share between physician - pharmacists in antimicrobial proper use support team (AST) 長崎皓光1, 内田守次1, 沖中友秀2, 長谷川雄一2, 梅田勇一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 894-895, 2024. |
|---|
|
|
[P0383-2-PM]. Prescribed establishment about bacteria pollution investigation and the use of the repeated shading cover which we used of shading cover at the injection drug administration 鶴岡翔太1, 宮崎絵美1, 信清眞千子1, 本濱諭1, 中西貴裕2, 神野雅史2, 濃沼政美3, 楠見彰宏1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 895-895, 2024. |
|---|
|
|
[P0384-3-PM1]. It is the use situation investigation of the clinical path antimicrobial for the use of antimicrobial adequacy in the infection prophylaxis after the operation 多田聡子, 西田綾子, 慶元箕, 伊東俊雅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 896-896, 2024. |
|---|
|
|
[P0385-2-PM]. The effect that the number of the drugs adjustment in patients with aspiration pneumonia of elderly people gives to the rate of recurrence 納富智基, 奥苑朱加, 杉本智哉, 遠山幸男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 896-896, 2024. |
|---|
|
|
[P0386-3-PM1]. Efforts for the improvement in hand hygiene in the drug department 西井美香, 林唯香, 中辻貴雄, 山田由佳, 松川晏利, 関口彩, 小松加奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 897-897, 2024. |
|---|
|
|
[P0387-2-PM]. The correlation of modified antibiotic heterogeneity index and carbapenem of Pseudomonas aeruginosa-sensitive rate: Multicenter observational study for 15 institutions 沢田佳祐1,2, 村木優一2, 豕瀬諒2, 河野修治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 897-898, 2024. |
|---|
|
|
[P0388-3-PM1]. An attitude survey in the in-hospital training that we repeated in the antimicrobial proper use of the acute respiratory tract infection and study on held pattern 綺田尚久1, 橋本拓郎1, 西野広将2, 北野裕司3, 中村忠之3, 原田吉将4, 吉田紀子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 898-898, 2024. |
|---|
|
|
[P0389-2-PM]. Examination of the usefulness of the urinalysis views in the Proteus mirabilis estimate using the Gram stain 木村順平1,2,3,4, 門野健二1, 武田龍馬2, 山田和範2, 山澤裕司2, 岡亨治3, 中村博彦4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 898-899, 2024. |
|---|
|
|
[P0390-3-PM1]. Verification of the cause and clinical significance of abnormally high (1→3)-β-D-glucan levels 山科卓也1,2, 高橋政成2, 中野貴文1, 内山将伸1, 松尾宏一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 899-899, 2024. |
|---|
|
|
[P0391-2-PM]. Comparison, evaluation with DASC which is a new index of the use of antimicrobial and the existing index 清水智也1, 中野美香2, 諸星総一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 900-900, 2024. |
|---|
|
|
[P0392-3-PM1]. Result of the AST intervention by the estimated bacteria early report system 加藤一雲1, 吉村昌紘1, 坂野昌志1, 杉浦茂樹1, 竹内章2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 900-900, 2024. |
|---|
|
|
[P0393-2-PM]. Investigation of the use of fluoroquinolone antibacterial situation in the Fukuoka Municipal Hospital ambulatory practice 柳原有希1, 堀内寿志2, 槇恭佑2, 保坂洸喜2, 山添知加子3, 近藤聡子3, 原田由紀子4, 倉田賢生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 901-901, 2024. |
|---|
|
|
[P0394-3-PM1]. Effect on aspiration pneumonia treatment in the adoption standard change of ampicillin sulbactam 森井悠介, 瀬名波宏昌, 高橋勝史, 新居万莉, 下村一徳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 901-902, 2024. |
|---|
|
|
[P0395-2-PM]. Cross sectional study about the association between depression and cardiovascular disease onset risk factor in the Japanese HIV infected person 築地茉莉子1, 山崎伸吾1, 矢幅美鈴2, 谷口俊文2, 猪狩英俊2, 石井伊都子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 902-902, 2024. |
|---|
|
|
[P0396-3-PM1]. One case that supported a change to sustained-release parenteral injection for the HIV patients of the poor adherence 屋地慶子, 高濱和弘, 寺薗英之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 902-903, 2024. |
|---|
|
|
[P0397-2-PM]. Survey of the antipsychotics administration situation in our hospital delirium treatment 田口諒, 元木孝, 近江令司, 渡邊清人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 903-903, 2024. |
|---|
|
|
[P0398-3-PM1]. Evaluation of the examination order support using the support sheet in the psychiatry outpatient department 進健司, 森高啓太, 梅田勇一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 903-904, 2024. |
|---|
|
|
[P0399-2-PM]. Evaluation of the benzodiazepine receptor agonist decrease medicine recommended stamp pasting to an electronic medical record 森高啓太, 進健司, 梅田勇一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 904-904, 2024. |
|---|
|
|
[P0400-3-PM1]. The effect that a supply stop of the amoxapine preparation gives to prescribed medicine and patients 福山雄卯介1, 倉田青弥2, 蓬莱彰士2, 三角紳博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 904-905, 2024. |
|---|
|
|
[P0401-2-PM]. What kind of effect does the nurse effect - psychiatry that the pasting act of the schizophrenia treatment patch in the nurse at psychiatry gives feel? 五味和彦1,5, 宮浦淳一2, 成田芳昭3, 松本早苗1, 山本和幸1, 埴原秋児4, 亀井浩行5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 905-905, 2024. |
|---|
|
|
[P0402-3-PM1]. Toward the establishment of effective and safe medication reduction and dosage reduction for inpatients with schizophrenia: a survey of prescription practices at Nagoya University Hospital 加藤朱莉1, 中村真理子1, 吉見陽1,2,3, 吉原希1, 小西郁代2, 加納正暉1, 池田匡志3, 尾崎紀夫3, 野田幸裕1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 905-906, 2024. |
|---|
|
|
[P0403-2-PM]. About a lights out change and a change of the number of sleeping drug draughts of medicine 小倉弥生1, 望月温子2, 上原香織3, 石山真3, 大木孝夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 906-906, 2024. |
|---|
|
|
[P0404-3-PM1]. It is ... for the pregnancy, the seamless medical therapy that can be relieved from efforts - prescription choice of our hospital for the list of lactational psychotropic drug evaluations making 三上有希1, 岸田有希子1, 宮城崇史2, 芦原隆仁3, 澤田眞智子4, 小林由佳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 906-907, 2024. |
|---|
|
|
[P0405-2-PM]. Role of a pregnant woman, the nursing mother authorization pharmacist in the postoperative pain management team 仲村聡美1, 岡田雄介1, 光永義治1, 渡部多真紀1,2, 長瀬幸恵1,2, 片岡明香3, 杉本真理子4, 長阪一憲5, 安野伸浩1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 907-908, 2024. |
|---|
|
|
[P0406-3-PM1]. An effect and problem by the information tool making about the use drug in a pregnant woman, the nursing mother 奥野真里絵, 藤谷美佐, 富山徹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 908-908, 2024. |
|---|
|
|
[P0408-3-PM1]. Examination of the application of main medical database possibility to perinatal pharmacoepidemiology in this country 畠山史朗1, 酒井隆全2, 土屋雅美3, 菊池大輔4, 近藤悠希5, 佐藤ユリ6, 佐藤泉美7, 岡田裕子8, 小原拓9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 908-909, 2024. |
|---|
|
|
[P0409-2-PM]. The effectiveness and safety assessment of the preparation for the dinoprostone intravaginal custody in the induced labour 日野光記枝, 木村美智男, 大橋健吾, 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 909-909, 2024. |
|---|
|
|
[P0410-3-PM1]. An onset of neonatal drug withdrawal syndrome risk accompanied with the cross-placental transfer: Analysis using the large-scale database 岡田章1,2, 竹田晃輝2,3, 世良庄司1,2, 永井尚美1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 909-910, 2024. |
|---|
|
|
[P0411-2-PM]. A case that the choice of the insulin device by the pharmacist affected the diabetes medical treatment life after the discharge 中島理絵1, 西田朋洋2, 小谷智美2, 坂本靖之2, 小川喜通2, 白石泰尚3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 910-910, 2024. |
|---|
|
|
[P0412-3-PM1]. Change of HbA1c accompanied with the drug change from Dulaglutide 中島隆良 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 910-911, 2024. |
|---|
|
|
[P0413-2-PM]. Understanding degree investigation of the diabetes therapeutic drug in patients on dialysis 勝山みなみ, 田仲祐子, 府川祥子, 阿部多嘉浩, 長濱藍, 喜友名侑舞, 玉城亜寿香, 伊藤千夏, 喜多洋嗣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 911-911, 2024. |
|---|
|
|
[P0414-3-PM1]. Examination of the efficacy of tirzepatide in patients switched from dulaglutide to tirzepatide 山岸三恵, 和田祐一郎, 後藤匠, 坂井裕美, 加藤香奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 911-912, 2024. |
|---|
|
|
[P0415-2-PM]. Efficacy and safety of tirzepatide in GLP-1-naive patients 後藤匠, 和田祐一郎, 山岸三恵, 坂井裕美, 寺西ゆかり, 加藤香奈 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 912-912, 2024. |
|---|
|
|
[P0416-3-PM1]. Fact-finding of the in-hospital operation about the perioperative SGLT2 inhibitor discontinuation 石橋幸子, 江本晶子, 本岡千佳, 島ノ江千里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 912-913, 2024. |
|---|
|
|
[P0417-2-PM]. Investigation about the impression for patients with diabetes that the pharmacist has 山田佳菜子, 向井淳治, 奥田広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 913-913, 2024. |
|---|
|
|
[P0418-3-PM1]. The effect that drug instruction gives to improvement in understanding degree for the subsequent renal function at the discharge utilizing the kidney seal 伊藤璃音1, 藤吉里紗2, 大野裕之2, 井上壽江2, 平下智之2, 林高弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 913-914, 2024. |
|---|
|
|
[P0419-2-PM]. About the current situation in the CKD seal pasting and future subjects examination 皆木優門, 設楽愛美, 渡邊健太郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 914-914, 2024. |
|---|
|
|
[P0420-3-PM1]. Fact-finding of the dapagliflozin administration cancellation in patients in CKD 増田章秀, 大林巧志, 山本美智, 中ノ内唯可, 中山朋美, 山添晶子, 舩越真理, 土谷有美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 914-915, 2024. |
|---|
|
|
[P0421-2-PM]. Examination about mechanism of Everolimus-induced proteinuria and measures 平田憲史郎, 金行七海, 坂口諒, 佐藤拓爾, 樋口彩弥香, 宮村重幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 915-915, 2024. |
|---|
|
|
[P0422-3-PM1]. Examination of risk factors affecting the occurrence of diarrhea and loose stools after tenapanor 高橋優聡, 中村雄亮, 北川瑚姫, 助畑歩, 小森均 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 915-916, 2024. |
|---|
|
|
[P0423-2-PM]. Evaluation second report about the difference between the measuring equipment of blood level measurements of mycophenolic acid for renal-transplant recipients 星茜1,2, 二村哲未1,2, 内倉健1,2, 金正興1, 杉山恵理花4, 田島正教4, 加藤容二郎5, 吉武理5, 百賢二2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 916-916, 2024. |
|---|
|
|
[P0424-3-PM1]. One case of haemodialysis patients with suspected encephalopathy associated with the ceftriaxone administration 山口京香1,2, 岩田聡1, 市川舞1, 濱田眞里亜1, 野尻文香1, 金子智慈1, 鰐田芽未1, 伊藤さおり1, 太田達也1, 田中章郎1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 917-917, 2024. |
|---|
|
|
[P0425-2-PM]. The approach of the bone fracture liaison service that we reviewed with a secondary bone fracture prevention follow-up charges new establishment and the effect 森崎崇文1, 清田克彦2, 高井聖子2, 杉山留美子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 917-918, 2024. |
|---|
|
|
[P0426-3-PM1]. Relation of the pharmacist in the bone fracture liaison service 高橋弘季, 橋詰宏美, 瀬戸口由, 増田成美, 藤原純平, 平川理紗, 横山晋一郎, 田路章博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 918-918, 2024. |
|---|
|
|
[P0427-2-PM]. The use of drug situation investigation of the oral maintenance addition calculation residents in the care health center for the elderly 浅野志津1, 甲元大樹1, 出宮千聖1, 笠原なつみ2, 森英樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 918-919, 2024. |
|---|
|
|
[P0428-3-PM1]. Search of the risk factor of the proximal thighbone bone fracture onset in women after the fracture of the distal radius 60 years or older 長谷奈那子1,2, 高木明1, 中谷英仁1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 919-919, 2024. |
|---|
|
|
[P0429-2-PM]. Than a quantity of prescription change of effect - sleeping drug, antipsychotics of elderly people delirium measures by the collaboration of a pharmacist and the nurse ... 山下弘毅1, 青柳和代2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 920-920, 2024. |
|---|
|
|
[P0430-3-PM1]. Effect on wound treatment for the inpatient accompanied with the supply stop of the zinc oxide combination ointment 眞野裕1, 山名映己子2, 石田茂伸1, 多胡友絵1, 小泉祐一3, 星育子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 920-921, 2024. |
|---|
|
|
[P0431-2-PM]. 4 fantastic introduction to the heart failure that decreased of the left ventricular ejection fraction: Use fact-finding and examination of effective/safety 大橋隼人1, 花井雄貴2, 小川隆之1, 文挾美咲1, 松本高広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 921-921, 2024. |
|---|
|
|
[P0432-3-PM1]. Role of the enforcement situation and the pharmacist of osteoporosis treatment for patients with proximal thighbone bone fracture in the acute phase hospital 宮下諒1, 野間将太1, 吉田憲司1, 清水裕1, 米本直史2, 高梨緑3, 矢吹直寛1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 921-922, 2024. |
|---|
|
|
[P0433-2-PM]. For intractable pemphigus vulgaris and fallen leaves form pemphigus, it is a 2 case receiving rituximab 松岡里枝1, 高橋愛未1, 的場美香1, 友井理恵子1, 木村貴1, 木澤成美1, 金銅葉子1, 片岡葉子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 922-922, 2024. |
|---|
|
|
[P0434-3-PM1]. Activities of the exclusive duty pharmacist in the operating room 竹内恵, 宮原強, 草葉一友 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 922-923, 2024. |
|---|
|
|
[P0435-2-PM]. Sleeping drug proper use by the list of sleeplessness instructions recommendation medicine development and the effect 麻生美佐子, 高木日菜, 杉森祐一朗, 高橋知里, 吉川英里, 坂林加奈子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 923-923, 2024. |
|---|
|
|
[P0436-3-PM1]. The investigation of the Fantastic Four introduction rate in heart failure treatment of our hospital and future problem 武田知佳, 近藤智幸, 斉藤芳敬, 増渕幸二, 荻野健吾 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 923-924, 2024. |
|---|
|
|
[P0437-2-PM]. One case that was able to contribute to an up tight military ration of GDMT from a pharmacist in our hospital heart failure outpatient department 大舘祐佳1, 鹿間沙生1, 小野剛2, 小林俊介1, 竹場和代1, 小倉敬史1, 北岡晃1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 924-924, 2024. |
|---|
|
|
[P0438-3-PM1]. Examination about the effectiveness of the SGLT2 inhibitor in the initial heart failure inpatient 洲山佳寛1, 菅原隆文1, 宮嵜純治1, 布施菜々子1, 山近葵2, 成宮彩加1, 薮田理子1, 渡邊篤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 924-925, 2024. |
|---|
|
|
[P0439-2-PM]. The use situation investigation of the Budesonide enteric extended-release for under 20 years old in our center 小谷七子, 寺岡知香, 進藤清則, 安達嘉織, 藤原康浩, 前原大輔, 本間久美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 925-925, 2024. |
|---|
|
|
[P0440-3-PM1]. Efforts of our hospital for the in-hospital formula reoperational start 秋田一樹, 高嶋祥匡, 市江敏和, 鈴木大介, 三浦毅 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 925-926, 2024. |
|---|
|
|
[P0441-2-PM]. Examination of the clinical effect by the bringing medicine change on L-form calcium-channel blocker from T N type calcium-channel blocker 鈴木祐太, 西村沙也香, 佐藤栄梨, 松元俊博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 926-926, 2024. |
|---|
|
|
[P0442-3-PM1]. Efforts of the bone density measurement and the improvement for the steroid long-term use patients in rate of use of osteoporosis treatment 上原智博1, 東盛裕里1, 荒木志乃1, 池上幸恵1, 石新あおい1, 黒原健1, 木下晶惠6, 宮里征武2, 徳元翼3, 山本泉美4, 渡嘉敷崇5, 津曲恭一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 926-927, 2024. |
|---|
|
|
[P0443-2-PM]. It is examined the usefulness in being administered daily the small quantity of ST combination tablets 田畑裕介1, 松波潤1, 柴田悠平2, 谷村瞬2, 中川育磨2, 清水昌人2, 小池隆夫2, 谷村一秀2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 927-927, 2024. |
|---|
|
|
[P0444-3-PM1]. Does the thickness water affect the pharmacokinetics of the ciprofloxacin? Pharmacokinetic controlled trial ... of the ciprofloxacin for ... health men 滝伊織1,2, 山崎太義1,2, 高橋伸幸3, 山本明和2, 當重明子2, 池浦温子1, 井上永介4, 三邉武彦2,4, 水上拓也5, 内田直樹5, 原田努6, 肥田典子1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 927-928, 2024. |
|---|
|
|
[P0445-2-PM]. Look at the rear to examine it about the reactive prediction of the tolvaptan in patients with congestive heart failure; a mark investigation 中井慎一1, 鈴木康崇1, 武田元樹1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 928-928, 2024. |
|---|
|
|
[P0446-3-PM1]. A case which succeeded in the medication introduction support of children with autism spectrum symptom by the cooperation with the child life specialist 桜木優太1,2, 臼井拓也1, 佐藤裕1, 細野萌子1, 前川麻央1, 佐藤祐司1, 渡辺悠2, 片山紗乙莉2, 前川正充1, 眞野成康1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 928-929, 2024. |
|---|
|
|
[P0448-3-PM1]. Effect examination of the cellulitis treatment using the alternative agent accompanied with cefazolin supply restrictions 金田碧1, 澤海健作1, 佐久間将之1, 岩田潤一2, 藤本忠行1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 930-930, 2024. |
|---|
|
|
[P0449-2-PM]. A case that cytomegalovirus enterocolitis recurred by Upadacitinib administration for the ulcerative colitis 神農麻里奈1, 辻中海斗1,2, 小川敦1,2, 坂東貴司1,2, 新田綾香1,2, 運天紘人1,2, 中村真悠1, 里和也1,2, 川田敬2,3, 櫻田巧1,2, 桐野靖1,2, 合田光寛1,2, 石澤啓介1,2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 930-930, 2024. |
|---|
|
|
[P0450-3-PM1]. Efficacy of lemborexant in patients receiving long-term benzodiazepines 長田日菜子1, 堀田彰悟1,2, 吉見陽1,2,3, 野田幸裕1,2,3, 溝口博之1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 931-931, 2024. |
|---|
|
|
[P0451-2-PM]. Effect of sacubitril valsartan on glycemic control in patients with renal impairment 河村泰男, 町支優和, 白井景 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 931-931, 2024. |
|---|
|
|
[P0452-3-PM1]. The case that presented pseudo dysfibrinogenemia by administration of argatroban 上田彩加1, 渡部真志2, 玉井宏一1, 烏谷政和1, 倉田知久1, 大坪治喜2, 白岡朗2, 京樂格2, 岡本憲省2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 932-932, 2024. |
|---|
|
|
[P0453-2-PM]. Examination of the drug global assessment adjustment intervention effect by the pharmacist in the local inclusion care ward 林誠1, 東拓馬1,2, 伊勢拓之3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 932-933, 2024. |
|---|
|
|
[P0454-3-PM1]. Visualization of assessment contents based on the symptom hearing of the drugstore drug history utilizing the natural language processing technology 柳澤友希1, 渡部哲1, 横山さくら1, 木崎速人1, 今井俊吾1, 染谷光洋2, 谷口亮央2, 矢田竣太郎3, 荒牧英治3, 堀里子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 933-933, 2024. |
|---|
|
|
[P0455-2-PM]. Examination of the specialized support that a pharmacist is demanded from by an institution visit in the bowel movement management and the use of the care office staff of laxative 奥田衣理1,3, 宮坂善之1, 義岡友子2, 染川裕乃2, 平野剛3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 933-934, 2024. |
|---|
|
|
[P0456-3-PM1]. Investigation about the enforcement degree of the family pharmacist duties that we compared in presence or absence of family pharmacist instruction charges calculation in Kochi 加藤友唯1, 今西孝至1, 石崎宏人2, 阿部恭宜2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 934-934, 2024. |
|---|
|
|
[P0457-2-PM]. Attitude survey for the proper use actual situation and the pharmacist by the drug review in the no drugstore area 高橋恵美利1,2, 野村直矢1, 高橋雄太2, 長嶺歩2, 大林恭子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 934-935, 2024. |
|---|
|
|
[P0458-3-PM1]. Problem search about the recognition of a pharmacist and the pharmacy student for a remote island, the remote place and the local unevenly distributed 宮坂善之, 奥田衣理 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 935-935, 2024. |
|---|
|
|
[P0459-2-PM]. Case report of the medication counseling to the patients who are hard to talk 高木正信1,2, 加納美知子1,2, 田中祥子1,2, 赤嶺有希子2, 赤嶺美奈1,2, 松尾律子1,2, 姜恵元1,2, 高安美南1, 吉原澄吉3, 谷田弘3, 澤井一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 935-936, 2024. |
|---|
|
|
[P0460-3-PM1]. 1 case of patients with chronic cardiac insufficiency that aimed at the home care using a morphine sustained injection, a dobutamine sustained injection 岩永崇志1,2, 後藤祐子1, 平田恭洋3, 寺尾正子2, 藤井秀一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 936-936, 2024. |
|---|
|
|
[P0461-2-PM]. Use in the at-home medical care at the end of life of midazolam injection and role of the drugstore 山口峻平 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 937-937, 2024. |
|---|
|
|
[P0462-3-PM1]. The case that came by an at-home shift smoothly as the relaxation medical therapy authorization pharmacist of the health insurance pharmacy intervened for at-home medicine with a little experience of the at-home relaxation 山中幸典 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 937-938, 2024. |
|---|
|
|
[P0464-3-PM1]. Efforts about field of activities and the visualization of the medical participation of the pharmacist in treatment at home needs 岡崎優里1, 山本晃之2,3, 内田一成3, 大坪泰昭3, 神谷浩貴3, 渡邊智子1, 吉田力久3, 相良英憲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 938-938, 2024. |
|---|
|
|
[P0465-2-PM]. Attitude survey of the pharmacist about the wearable device introduction in the treatment at home 小林一男1, 長谷川佳孝2, 清水久範1, 月岡良太2, 辻将成3, 鈴木賢一4, 市村丈典5,6, 中野泰寛1, 山口俊司2, 大山実7, 山口正和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 938-939, 2024. |
|---|
|
|
[P0466-3-PM1]. Change of the antimicrobial prescription in pharyngitis treatment after physician - pharmacist discussion 宗像宏友1, 高橋渉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 939-939, 2024. |
|---|
|
|
[P0467-2-PM]. Evaluation after the doubt inquiry simplification protocol introduction in the door front drugstore 古嶋美桜子1, 八木仁史1, 高田宏文1, 河井良智2, 荒井宏人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 939-940, 2024. |
|---|
|
|
[P0468-3-PM1]. The effect that the understock of pharmaceutical products gives for the inquiry-response duties from the health insurance pharmacy 安井琢来, 高瀬友貴, 尾山将樹, 久米学, 室井延之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 940-940, 2024. |
|---|
|
|
[P0469-2-PM]. Report second about the communalization of the doubt inquiry contents of hospital pharmacist and the drugstore pharmacist 中川義浩1, 黒木拓也2, 桑村恒夫2, 梅崎りさ3, 清原珠美4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 941-941, 2024. |
|---|
|
|
[P0470-3-PM1]. Efforts of the discharge drug control summary computerization 石垣俊樹, 本田貴朗, 佐藤智也, 眞木秀子, 羽太光範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 941-941, 2024. |
|---|
|
|
[P0471-2-PM]. Medicine medicine cooperation ... by cord - drug control summary to connect from a hospital to the health insurance pharmacy 海家亜希子, 堀由布子, 楢本佳代, 清水彩加, 足立紗知, 上野由貴, 池田絢, 村津圭治, 山下大輔, 吉野宗宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 942-942, 2024. |
|---|
|
|
[P0472-3-PM1]. One ... that medicine medicine cooperation succeeded by drug reporting about the follow after the discharge of the prescribed medicine excessive quantity internal use patients at a ... discharge 井上雄太1, 高橋伸子2, 杉山哲大1, 前山博輝3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 942-943, 2024. |
|---|
|
|
[P0473-2-PM]. Examination of the current situation investigation of the cancer medicine medicine cooperation using the questionary survey and the future problem 和佐野英子, 三好孝法, 深澤真実, 高武嘉道, 菊地憂衣, 大橋邦央, 藤瀬陽子, 橋本雅司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 943-943, 2024. |
|---|
|
|
[P0474-3-PM1]. The holding of the cooperation enhancement addition web workshop for outside Parliament drugstore pharmacists and future problem (the second report) 越智啓介1, 末廣拓1, 十亀將輝1, 宇都本孝夫1, 新居田能章1, 明下佳祐1, 村井望1, 松岡葉子1, 西畑友尋1, 玉井宏一1, 烏谷政和1, 倉田知久1, 渡部早苗2, 中野友寛2, 山下広恵3, 武田千津3, 井上考司4, 中西徳彦4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 943-944, 2024. |
|---|
|
|
[P0475-2-PM]. Correspondence of offer charges 3 such as the medication information, and the like in the foreign interview before operation by the hospitalization and release support charge pharmacist and future problem 赤松柚有, 小間貴洋, 金森有佑, 矢野茜, 池田奈々 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 944-944, 2024. |
|---|
|
|
[P0476-3-PM1]. Introduction of the inquiry simplification protocol about the outside Parliament prescription in the Nagoya University Hospital and the fact-finding 宮崎雅之, 阪井祐介, 丹羽洋介, 倉地茜, 太田小織, 木下沙織, 松永安未, 小西郁代, 加藤奈波, 溝口博之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 944-945, 2024. |
|---|
|
|
[P0477-2-PM]. Construction of the medicine medicine cooperation utilizing the ICT infrastructure and the prospects 堤克成, 本田勝亮, 古橋草平, 矢部勝茂 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 945-945, 2024. |
|---|
|
|
[P0478-3-PM1]. The situation of the medicine medicine cooperation with the health insurance pharmacy by the drug control summary introduction and future problem 上村拓生, 新町圭央, 在間優衣, 上泰大, 藤高浩輝, 中村豪志, 石井一也, 大塚識稔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 945-946, 2024. |
|---|
|
|
[P0479-2-PM]. Understanding and attitude survey of the chronic cardiac insufficiency in the neighborhood drugstore pharmacist 文挾美咲1, 大橋隼人1, 小川隆之1, 花井雄貴2, 松本高広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 946-946, 2024. |
|---|
|
|
[P0480-3-PM1]. Use fact-finding of the medication reporting book in all Yokohama municipal institutions and the Red Cross hospital 鈴木利周, 男全昭紀, 阿部多一, 井口恵美子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 946-947, 2024. |
|---|
|
|
[P0481-2-PM]. Inventory survey for the health insurance pharmacy pharmacist for the purpose of the stocktaking of the doubt inquiry simplification protocol to affect outside Parliament prescription and the operational improvement 寺本忠弘, 近藤沙菜, 相馬侑加, 都村勇樹, 宇都宮真理, 河合麻里, 藤原愛美, 松原千明, 野口賀代, 大川幾代, 河西貴絵, 小林聡子, 大原京子, 森譲二, 白石貴寿 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 947-947, 2024. |
|---|
|
|
[P0482-3-PM1]. Questionary survey for the irAE evaluation tool which we made jointly by Takamatsu-shi pharmacist society and Kagawa Prefectural Central Hospital pharmacy 立道貴清1,2, 越野優希1,2,4, 中山順子3, 永井綾彦3, 細谷亮裕2, 原丈晴2, 林哉江2, 安部浩美3, 中筋美保3, 元木泰史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 947-948, 2024. |
|---|
|
|
[P0483-2-PM]. Efforts to medicine medicine cooperation by the cooperation full addition calculation start in our hospital 徳永ありさ1, 桑原貴美子2, 東島幸道1, 鈴田浩孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 948-948, 2024. |
|---|
|
|
[P0484-3-PM1]. Comparison about the patients satisfaction of non-elderly people for the efforts and elderly people with illness medicine cooperation in the foreign cancer medical therapy 井上竜一1, 角康隆1, 長郷あかね1,2, 内山将伸3, 柿本秀樹4, 大倉野将広1, 武田佳子1, 五十嵐保陽1, 井上貴文1, 真島宏太1, 川田哲史1, 江越菜月1, 塩入真衣1, 池内忠宏1, 兼重晋1, 緒方憲太郎1,2, 神村英利1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 948-949, 2024. |
|---|
|
|
[P0485-2-PM]. Efforts to cooperation full addition calculation in the Ehime Prefectural center Hospital and future problem (the second report) 村井望1, 末廣拓1, 中野友寛2, 宇都本孝夫1, 新居田能章1, 十亀將輝1, 越智啓介1, 松岡葉子1, 西畑友尋1, 玉井宏一1, 烏谷政和1, 倉田知久1, 渡部早苗2, 山下広恵3, 武田千津3, 井上考司4, 中西徳彦4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 949-949, 2024. |
|---|
|
|
[P0486-3-PM1]. Efforts and problem in the cooperation full addition calculation in our hospital 久松大祐1,2, 樋口文子2, 筒井佑紀3, 高野豪2, 後藤隆2, 清水裕彰2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 949-950, 2024. |
|---|
|
|
[P0487-2-PM]. Efforts of the drugstore to utilize immune checkpoint inhibitor (ICI) management tool 柴山はる子1,2,3, 畑智恵子2, 寺田弘毅1, 大坪恵子1, 三浦英子1, 松原有紀1, 相田真梨子1, 犬丸未来1, 家里夏子1, 天野萌子1, 瀧川歩美1, 神吉麻美1, 奥田菜由子1, 西原雅美2, 芦田明2, 宮田広樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 950-950, 2024. |
|---|
|
|
[P0488-3-PM1]. Role of a member of DMAT duties adjustment in the Wajima medical care welfare adjustment headquarters and the pharmacist 石橋廉司, 遠山幸男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 951-951, 2024. |
|---|
|
|
[P0489-2-PM]. A disaster relief dispatch pharmacist is ... through investigation - Noto Peninsula earthquake about the information to ask for 坂本千明, 岡林瑞希, 谷大輔, 山瀬大雄, 森田直, 仲里泰太朗, 山地優依子, 向井雄治, 有江宏樹, 塚田加奈子, 山岸実結, 湯井政志, 城塚早也圭, 安富暉浩, 辻井佳代, 小林政彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 951-952, 2024. |
|---|
|
|
[P0490-3-PM1]. A role and practice of the pharmacist utilized the viewpoint of the community medical care at disaster 坂啓子, 島崎亮司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 952-952, 2024. |
|---|
|
|
[P0491-2-PM]. Experimental search of the area (the no drugstore municipalities, and the like) where pharmacist support demand becomes higher at the disaster that we assumed from the support situation by the Noto Peninsula earthquake 服部れいあ1, 外山和弥1, 玉木啓文1, 長内理大1, 伊野陽子2, 山下修司3, 林秀樹3, 中村光浩4, 井口和弘1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 952-953, 2024. |
|---|
|
|
[P0492-3-PM1]. Inspection of the education effect by the disaster simulation using "a pharmacy version disaster-response game" 森川祥彦1, 加藤秀雄1, 庄司雅紀2, 岸和田昌之3,4, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 953-953, 2024. |
|---|
|
|
[P0493-2-PM]. An activity report and opinion collection by the questionnaire to a pharmacist dispatched for the Noto Peninsula earthquake by Sendai Red Cross hospital relief squad in 2024 中村隆志, 坂田摩耶, 黒川咲子, 森田航平, 小林拓未, 小野寺裕二, 大棒雄大 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 953-954, 2024. |
|---|
|
|
[P0494-3-PM1]. The support of the disaster pharmacist in the disaster correspondence of the 2024 Noto Peninsula earthquake and problem of the hospital pharmacy 田井達也1, 渡邊政博4, 山下紗矢佳2, 元木貴大2, 山口佳津騎3, 田中裕章2, 小坂信二2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 954-954, 2024. |
|---|
|
|
[P0495-2-PM]. The differentiation of the tablet body and an investigation and analysis of the universal design which is effective in identification 生野由佳1, 中川文馨2, 山本ひとみ2, 笠谷早千巴2, 小川憲一2, 相良英憲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 954-955, 2024. |
|---|
|
|
[P0496-3-PM1]. It is ... from the viewpoint of differentiation of the tablet body and investigation of the universal design which is effective in identification and text mining using analysis - KH Coder 重信貴央1, 生野由佳1, 中川文馨2, 山本ひとみ2, 笠谷早千巴2, 小川憲一2, 相良英憲1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 955-956, 2024. |
|---|
|
|
[P0497-2-PM]. Construction of the cooperation system with the medical safe section utilizing the doubt inquiry risk classification 松宮英美里1, 神谷貴樹1,2, 池田義人1, 清水智治2, 森田真也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 956-956, 2024. |
|---|
|
|
[P0498-3-PM1]. The countermeasure accompanied with the heparin Na lock syringe supply stop and the evaluation 垣内祥宏1, 渥美弘美1, 緑川拓也1, 池澤和人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 956-957, 2024. |
|---|
|
|
[P0499-2-PM]. Analysis of pre-avoidance reports related to acetaminophen injections for the creation of a clinical pathway at our hospital 茂原圭佑1, 中川隼一2, 藤下頌子1, 島崎博士1, 平島徹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 957-957, 2024. |
|---|
|
|
[P0500-3-PM1]. The effect of switching from suvorexant to lemborexant as a ward medication on falls 小池彩子1, 高尾水緒1, 出宮千聖1, 花房伸幸1, 石田裕久2, 藤岡香代子3, 歳森淳一4, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 957-958, 2024. |
|---|
|
|
[P0501-2-PM]. Prescription suggestion and an exhibition to inside the hospital of doubt inquiry contents and the evaluation 田中伽歩, 奥野昌宏, 原田卓弥, 山崎彬史, 西村亮, 中西真也, 松岡勇作, 森本茂文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 958-958, 2024. |
|---|
|
|
[P0502-3-PM1]. The establishment of the Andexanet alpha operation procedure in the local government Hospital and the inspection 西山祐美1, 吉岡睦展1, 高橋直浩1, 中川史絵1, 長尾彰太1, 新康憲1, 森田聡子1, 美山真崇2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 958-959, 2024. |
|---|
|
|
[P0503-2-PM]. About the efforts of the drug history management operational start in the electronic medical chart in our hospital 中島瑞貴, 大久保嘉則, 東島幸道, 鈴田浩孝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 959-959, 2024. |
|---|
|
|
[P0504-3-PM1]. Usefulness evaluation of contraindicated medicine false administration prevention system IRIS with the drug information according to the ingredient unit 橋詰淳1, 里加代子2, 伊藤直子1, 兒玉幸修1, 大山要1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 959-960, 2024. |
|---|
|
|
[P0505-2-PM]. PPT activity in our hospital for 6 years 手塚博文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 960-960, 2024. |
|---|
|
|
[P0506-3-PM1]. Relation to patients with efforts and the drug allergy of the operating room pharmacist in the perioperative medical care 鬼原亜紀, 高橋信矢, 中川慧, 室岡邦彦, 高瀬久光 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 960-961, 2024. |
|---|
|
|
[P0507-2-PM]. Questionary survey for use situation grasp of the tool for a new face pharmacist education material of the person in charge of JA Aichi public welfare consecutive pharmacy education meeting making and the evaluation 高橋弘泰1, 大野愛2, 内山耕作3, 粟田浩文4, 澤柳直樹5, 更谷彩伽1, 中村和行6, 塩崎沙耶6, 古田美里6, 成瀬加代7, 加藤洋介2, 大平勇二8, 齋藤宏明8 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 961-961, 2024. |
|---|
|
|
[P0508-3-PM1]. Practice and effect of the academic D tailing education for pharmacy school business trainees 近江一太1, 大矢智則1, 田中怜2, 吉田智浩1, 栃木恵里1, 佐藤淳也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 961-962, 2024. |
|---|
|
|
[P0509-2-PM]. Satisfaction investigation of the business trainee using the questionary survey after the DI training in the Okayama University hospital pharmacy 田中雄太, 槇田崇志, 佐田光, 濱野裕章, 村川公央, 座間味義人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 962-962, 2024. |
|---|
|
|
[P0510-3-PM1]. Inspection of the effect that the case study of patients with breast cancer gave to a young pharmacist for a gestation period 野嶋芳紀1, 大橋寛子1, 齋藤聡夫1, 松尾宗一郎1, 邑瀬誠1, 深津英人2, 松井洸2, 山口浩2, 野村和彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 962-963, 2024. |
|---|
|
|
[P0511-2-PM]. About consciousness about the antimicrobial of the pharmacy school new pupil 小森由美子, 植田康次 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 963-963, 2024. |
|---|
|
|
[P0512-3-PM1]. It is ... for psychiatric practice training more satisfying than cooperation extension ... of the hospital pharmacy business training 柴田博子1, 赤松規子1, 高井英里1, 西海一生1, 南野希1, 下雅意彩2, 元持富見代3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 964-964, 2024. |
|---|
|
|
[P0513-2-PM]. Qualitative interview about the factor to affect the carrier continuation of the pharmacist in the child care period 永田実沙 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 964-965, 2024. |
|---|
|
|
[P0514-3-PM1]. Fact-finding of the training about the cancer medical treatment for other drugstore pharmacists whom a specialized medical institution cooperation drugstore performs in 本田雅志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 965-965, 2024. |
|---|
|
|
[P0515-2-PM]. Construction of "the online educational program to learn antimicrobial proper use support" for pharmacists 池垣美奈子1,2, 町田尚子4, 日馬由貴2,3, 松尾裕央2,3, 山本剛1,2, 佐田竜一1,2, 忽那賢志2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 965-966, 2024. |
|---|
|
|
[P0516-3-PM1]. Study support for clinical pharmacists by the clinical studies adviser 肥田典子1,2, 龍家圭1,3, 水上拓也1,4, 諸星北人1,5, 井上永介6, 小林真一1,3, 三邉武彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 966-966, 2024. |
|---|
|
|
[P0517-2-PM]. It is reported the temporary transfer situation to a hospital other than hospital pharmacist 新井亘1, 増田裕一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 966-967, 2024. |
|---|
|
|
[P0518-3-PM1]. Problem in the education of the hospital pharmacist to examine from the questionnaire of the person of resident program completion 榎本貴一1, 枦秀樹2, 瀬戸弘和3, 関翔太3, 近藤崇雄4, 谷口聡5, 鈴木慶介6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 967-967, 2024. |
|---|
|
|
[P0519-2-PM]. Effect of the new training lecture introduction for new face pharmacists 野々宮悠真, 中村匡志, 山口正和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 967-968, 2024. |
|---|
|
|
[P0520-3-PM1]. It is analyzed the annual change of questionnaire results after the recurrent lecture attendance for local pharmacists 野村由貴1,2, 井口和弘1,3, 玉木啓文3, 野口義紘4, 長内理大3, 佐口弥1,2, 吉村知哲1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 968-968, 2024. |
|---|
|
|
[P0521-2-PM]. The Effects of Post-Graduate Clinical Training for Pharmacists - Single-Institution Report - 吉野秀紀1, 上野沙恵子1, 小松絵美1, 上田実佳2, 前山瑞希3, 安富暉浩1, 塚田加奈子1, 木下里紗1, 瀬名波暢子1, 辻井佳代1, 小林政彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 968-969, 2024. |
|---|
|
|
[P0522-3-PM1]. Development and evaluation of the drugstore pharmacist educational program 遠藤友理恵1, 松本麻里2, 大平愼2, 安島力1, 松本司2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 969-969, 2024. |
|---|
|
|
[P0523-2-PM]. Having learned through the visit of clinical pharmacist duties of the Torrance memorial medical center 坂田摩耶, 大棒雄大 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 970-970, 2024. |
|---|
|
|
[P0524-3-PM1]. Result report of "the ten years plan" to get a pharmacist 花香淳一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 970-970, 2024. |
|---|
|
|
[P0525-3-PM2]. Effect second report by the operation of representation correction/doubt inquiry PBPM in the in-house prescription 井後彩加, 吉田三矢, 植田裕美, 櫛田宏幸, 庄野裕志, 佐光留美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 971-971, 2024. |
|---|
|
|
[P0526-4-PM]. Investigation of the output, good use of assist sheet situation associated with the renal function 奥山沙弥, 杉山菜穂, 藤田彩花, 宇野洋司, 小杉三弥子, 佐橋幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 971-972, 2024. |
|---|
|
|
[P0527-3-PM2]. Pharmaceutical intervention in the foreign chemotherapy 西阪宏彰1, 山田健人1, 吉田貴大2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 972-972, 2024. |
|---|
|
|
[P0528-4-PM]. It is tested the inspection precision of the tablet inspection support system one package under the true clinical practice in the Fukuoka Tokushukai Hospital 池田都, 重松由加, 高松瞳, 川前隆一, 秋吉正貴, 山下大貴, 奧野美和, 矢野洋平, 佐々木文野, 立石裕樹, 秦晃二郎, 宮津大輔, 田中博和, 渡邊裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 972-973, 2024. |
|---|
|
|
[P0529-3-PM2]. Examination of the effect that automatic drug picking device introduction gives to the education of the new face pharmacist 小島庸子, 桂川健司, 遠山幸男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 973-973, 2024. |
|---|
|
|
[P0530-4-PM]. Survey about the PT-INR measurement situation of the warfarin internal use patients in our hospital outpatient department 北郁弥, 田口諒, 元木孝, 近江令司, 渡邊清人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 973-974, 2024. |
|---|
|
|
[P0531-3-PM2]. Outcome evaluation of our hospital checking prescription system by the analysis of the doubt inquiry record 橋本里々佳, 稲垣晃熙, 粟田浩文, 奥平正美, 羽田勝彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 974-974, 2024. |
|---|
|
|
[P0532-4-PM]. Efforts to the efficiency of pharmacist duties by the injection automatic withdrawal system update and medical security 竹野智彦, 下澤那津, 平田ゆり, 大石裕樹, 川野昭, 藤永理恵子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 974-975, 2024. |
|---|
|
|
[P0533-3-PM2]. The safe drug supply that the introduction of the inspection support system results in one package 和泉早智子, 加藤遥平, 千崎可奈子, 伊与絵里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 975-975, 2024. |
|---|
|
|
[P0534-4-PM]. Fact-finding of doubt inquiry for the injection prescription in the Iizuka Hospital 構木結花, 長崎皓光, 内田啓太, 森高啓太, 進健司, 梅田勇一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 975-975, 2024. |
|---|
|
|
[P0535-3-PM2]. Introduction of the simple suspension method in our hospital 今福浩輝1, 舟橋梨華子1, 坂本華穂1, 鶴谷茉里恵1, 高木奏1, 宿谷光則1, 池川貴和子1, 辻野裕紀2, 林啓吾3, 神谷友理子1, 前田幹広1, 濱野公俊1, 坂上逸孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 976-976, 2024. |
|---|
|
|
[P0536-4-PM]. By a change and the prescription indication of the drug placement place misunderstand it and is evaluated preventive measures 内田啓太, 進健司, 梅田勇一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 976-977, 2024. |
|---|
|
|
[P0537-3-PM2]. Duties efficiency by inspection system update, the operational change 火口裕弥, 有松利惠, 佐々木緑, 辻卓矢 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 977-977, 2024. |
|---|
|
|
[P0538-4-PM]. The current situation investigation of the polypharmacy in the star mound respect and affection garden 植村隆, 内田優香, 牧野幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 977-978, 2024. |
|---|
|
|
[P0539-3-PM2]. Correspondence and problem of the pediatric special hospital by the shipment stop of the growth hormone preparation 荒木麻里奈, 上條早奈美, 鈴木英二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 978-978, 2024. |
|---|
|
|
[P0540-4-PM]. Efforts to the pharmaceutical products disposal amount of money inhibition in the Fukuoka Tokushukai Hospital 高橋菜生, 立石裕樹, 古川桂子, 大塚志穂, 相江いずみ, 秦晃二郎, 田中博和, 宮津大輔, 渡邊裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 978-979, 2024. |
|---|
|
|
[P0541-3-PM2]. Introduction effect of cubic in the hospital management 新美雅規, 榊原洋一, 吉川直利, 横田学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 979-979, 2024. |
|---|
|
|
[P0542-4-PM]. Introduction of an automatic tablet sorting and return device for efficient medication return and its effects 高橋直浩, 新康憲, 森田聡子, 西山祐美, 正置耕一, 吉岡睦展 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 979-980, 2024. |
|---|
|
|
[P0543-3-PM2]. Association with properties of matter of a characteristic and the medication adjuvant jelly of pharmaceutical products in the taste bitter masking 太田美鈴1, 渡辺恵理香2, 栗原里佳子2, 柴崎一輝2, 富田隆1, 小幡誉子2, 池内由里2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 980-980, 2024. |
|---|
|
|
[P0544-4-PM]. Efforts to the unification of adoption pharmaceutical products for the business integration and reduction 横田学1,2, 平野貴志1, 木原大輔1, 河合健1, 外山昌伸2, 澤田昌司2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 980-981, 2024. |
|---|
|
|
[P0545-3-PM2]. The type of job crossing-like efforts about the adequacy of a ward, the foreign fixed number drug for household delivery 森直樹, 横山千紘, 若杉正, 小池博文, 佐橋幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 981-981, 2024. |
|---|
|
|
[P0546-4-PM]. The current situation and problem of the handling of nonrecognition, the pharmaceutical products of the infection domain in the national international medical research center hospital out of the adaptation 大橋裕丈1, 大橋養賢1, 木村涼那1, 鈴木恭彦1, 鈴木梨紗1, 原量平1, 瀬戸恵介1, 百武宏志1, 増田純一1, 亀谷航平2, 秋山裕太郎2, 山元佳2, 森岡慎一郎2, 氏家無限2, 大曲貴夫2, 西村富啓1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 981-982, 2024. |
|---|
|
|
[P0547-3-PM2]. Response of the pharmacist for the pharmaceutical products supply shortage 吉野有香子, 油屋恵, 赤瀬博文, 松岡勇作, 奥野昌宏, 森本茂文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 982-982, 2024. |
|---|
|
|
[P0548-4-PM]. Efforts of the pharmacy for the calculation method shift of the hospitalization medical fee by the DPC/PDPS method 尾崎誠一1, 西阪英恵2, 米田麗奈2, 原田有希2, 槇恒雄2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 982-983, 2024. |
|---|
|
|
[P0549-3-PM2]. Preparation of the lanthanum carbonate jelly agent which assumed starch/gellan gum mixture system a basis 下山哲哉, 渡邊春果, 池田初音, 伊藤邦彦, 小林道也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 983-983, 2024. |
|---|
|
|
[P0550-4-PM]. Preparation and taking calcium acetate-containing orally disintegrating tablet aiming at improvement in medication adherence, mini-tablet and silverberry preparation-related evaluation 河本小百合1, 岡村悠真1, 山崎柚香1, 三浦基靖1, 柏倉康治1, 鈴木寛1,2, 山内克哉1,2, 並木徳之3, 内田信也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 983-984, 2024. |
|---|
|
|
[P0551-3-PM2]. Examination of the usefulness of the myocardial protection liquid to use for childhood open heart surgery (del Nido Chikamori Modification) 坪田吉宏1, 古屋順一1, 菊池真美1, 栗山武宜1, 大林万利子1, 和田直樹2, 桑原優大2, 田辺克也3, 石丸博雅1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 984-984, 2024. |
|---|
|
|
[P0552-4-PM]. Efforts to in-hospital formulation of the potassium preparation for the highly-concentrated revision and medical security 浦田修平, 大野梨絵, 岩田円夏, 是枝秀彦, 土生陵太, 平原康寿, 池田龍二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 984-985, 2024. |
|---|
|
|
[P0553-3-PM2]. The introduction example that was useful when it adopted it as hospital preparation that the correspondence to the item which became the wall at use of Mohs paste was considered enough 塚野優介, 米田仁保, 徳永楓果, 後藤若菜, 北園幸大, 屋敷大輔, 長ヶ原琢磨, 荻尾夕起子, 岸本真 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 985-986, 2024. |
|---|
|
|
[P0554-4-PM]. Comparison about the hospital preparation Lidocain eardrum anesthesia liquid 福井美奈子, 原伸輔, 米村俊哉, 松井浩子, 前田真一郎, 奥田真弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 986-986, 2024. |
|---|
|
|
[P0555-3-PM2]. Activity report of the urination care team 河村茉衣1, 川上隆弘1, 松岡梨奈1, 長崎幸恵2, 藤岡英子2, 末永綾香2, 遠部佳寿美3, 森滉平4, 竹中皇4, 森英樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 986-987, 2024. |
|---|
|
|
[P0556-4-PM]. Examination of the background factor of the patients who were able to complete α 1 blocking agent after the urethral catheters withdrawal in the convalescent rehabilitation ward 大屋和福1, 磯野礼果1, 細野真吾1, 永谷魅香2, 桃瀬尚子2, 平田愛美3, 早野達也3, 堀浩子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 987-987, 2024. |
|---|
|
|
[P0557-3-PM2]. Examination of the usefulness of the multi-type of job collaboration polypharmacy measures in the cranial nerve internal medicine 山田翔也1, 西田承平1, 林祐一2,4, 淺井奈央1, 山田未知1, 渡邊大地1, 志水真也1, 藤井宏典1, 丹羽隆1, 飯原大稔1, 國枝顕二郎3, 吉倉延亮3, 小林亮1,4, 下畑享良3, 鈴木昭夫1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 987-988, 2024. |
|---|
|
|
[P0558-4-PM]. Analysis of the pharmaceutical intervention by the operating room working full time pharmacist 西健太郎1, 柴田啓智1, 加藤清彦2, 原武義和2, 田上治美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 988-988, 2024. |
|---|
|
|
[P0559-3-PM2]. Efforts and result of the inhalational instruction to patients with respiratory illness in the Fukuoka Tokushukai Hospital 高木悠資, 河村莉奈, 松本貴行, 大塚志穂, 田原裕希乃, 重松由加, 渡邊裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 988-989, 2024. |
|---|
|
|
[P0560-4-PM]. A case of refractory idiopathic thrombocytopenic purpura treated with fostamatinib after splenectomy 依田真由子, 清水悠太, 遠藤愛樹, 松本香織 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 989-989, 2024. |
|---|
|
|
[P0561-3-PM2]. An effect and the usefulness that were obtained than use of 10% of immunoglobulin preparation for patients with Kawasaki's disease 1 year or older 伊藤優子1, 藤原真希1, 辻和代1, 柏木春菜1, 関昭吾1, 村上佳愛1, 中谷健一1, 谷口嘉宏1, 長谷川豊1, 猪野彩2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 989-990, 2024. |
|---|
|
|
[P0562-4-PM]. Evaluation of efforts and the osteoporosis therapeutic drug rate of use in the bone fracture liaison service of the Konan public welfare hospital 梶田直博, 小玉幸与, 永井孝正, 今井麻未, 城山晴佳, 田中弓貴, 冨田敦和, 今西忠宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 990-990, 2024. |
|---|
|
|
[P0563-3-PM2]. Examination about the participation of the pharmacist in the proper use of the osteoporosis therapeutic drug after the FSL team establishment 山川美月1, 佐々木貴之1, 大野航輝1, 佐々木香織1, 山川智一1, 加藤恵一1, 服部徹也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 990-991, 2024. |
|---|
|
|
[P0564-4-PM]. The Fantastic4 introduction situation investigation using Simple GDMTscore 奥迫彩華, 秋山留里, 菅加奈子, 関戸美咲, 下村周嗣, 高江洲夢子, 有銘千賀子, 阿部多嘉浩, 森智子, 喜多洋嗣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 991-991, 2024. |
|---|
|
|
[P0565-3-PM2]. Efforts of the drug global assessment adjustment addition in the kidney medical service 松木克仁1, 堀沢知世1, 平野淳2, 田淵克則1, 薄雅人1, 平野隆司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 991-992, 2024. |
|---|
|
|
[P0566-4-PM]. Examination about the operational situation of the medication self-care judgment table for the inpatient 川井杏樹, 清水忠洋, 福本祐以, 島田雅彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 992-992, 2024. |
|---|
|
|
[P0567-3-PM2]. Examination of the pharmacist intervention effect in the OLS activity 中嶋丈晴1, 齊藤有花1, 小笠原綾子1, 佐藤真衣1, 星野裕太1, 千崎康司2, 伊藤功治2, 外岡久和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 992-993, 2024. |
|---|
|
|
[P0568-4-PM]. Questionary survey to the pharmacy service under health insurance drugstore for the improvement of medicine medicine cooperation for patients with diabetes 伊木亮司, 馬島務, 龍神博之, 山下剛史郎, 満田正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 993-993, 2024. |
|---|
|
|
[P0569-3-PM2]. The analysis of the doubt inquiry contents in the orthopedics ward and future problem 南里本, 草葉一友 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 994-994, 2024. |
|---|
|
|
[P0570-4-PM]. It is evaluated the ward duties after the change a ward from the central duties hierarchy system to the duties cross-sectional system 山田菫, 真志田絵美子, 佐藤智人, 柴田ゆうか, 松尾裕彰 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 994-994, 2024. |
|---|
|
|
[P0571-3-PM2]. The questionary survey that is targeted for the nurse for the Edaravone private business suspension change from an Edaravone injection 木村修徳1, 近藤讓2, 田中誠1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 995-995, 2024. |
|---|
|
|
[P0572-4-PM]. Construction of the system with item confirmation and the instruction record making function corresponding to the clinical path of a circulatory organ, the urologic domain utilizing the VBA function of Excel 内川実咲1, 小松敏彰1, 尾鳥勝也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 995-996, 2024. |
|---|
|
|
[P0573-3-PM2]. Efforts aiming at medication counseling system reinforcement by the system introduction resident on Friday in the local inclusion care ward in the ward drug duties non-enforcement institution 岸本真1,2, 徳丸章佳1, 石渡美樹1, 後藤若菜1, 中村杏果1, 北園幸大1, 屋敷大輔1, 長ヶ原琢磨1, 荻尾夕起子1, 徳永仁2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 996-996, 2024. |
|---|
|
|
[P0574-4-PM]. Efforts to drug global assessment adjustment addition calculation promotion in the Kasugai Municipal Hospital 有馬亮輔, 坂田洋, 中村敏史, 服部芳明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 996-997, 2024. |
|---|
|
|
[P0575-3-PM2]. Analysis of the factor associated with the postoperative pain in the gynecologic surgery patients and retching, the vomiting onset 柏渕弓佳1,2, 杉沢諭1,2, 森田くる美3, 内藤結花1,2, 井上裕美子1,2, 平出美紀1,2, 森中遥香1,2, 尾頭希代子4, 大江克憲4, 和田紀子1, 嶋村弘史1,2, 田中克巳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 997-997, 2024. |
|---|
|
|
[P0576-4-PM]. Construction of the system with an evaluation and the instruction record making function of the lung cancer medical therapy regimen utilizing the VBA function of Excel 太田彩美1, 小松敏彰1, 尾鳥勝也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 997-998, 2024. |
|---|
|
|
[P0577-3-PM2]. One patient who a ward pharmacist cooperated with an urination care team, and introduced an urination disorder therapeutic drug, and discovered a side effect early 林剛史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 998-998, 2024. |
|---|
|
|
[P0578-4-PM]. Introduction of the treatment with safe sirolimus in the neonatal intensive care unit which an exclusive duty pharmacist led 山崎琢真1, 本田勝亮1, 長浦宏之1, 長岡翔1, 今坂悦子2, 安藤静香2, 山本将太2, 土手友梨3, 菊池新3, 杉浦弘3, 矢部勝茂1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 999-999, 2024. |
|---|
|
|
[P0579-3-PM2]. Inspection of the introduction effect of the management system for the improvement in calculation rate of drug control instruction charges 荒木良介, 長谷康史, 山田英紀, 菱沼隆一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 999-1000, 2024. |
|---|
|
|
[P0580-4-PM]. About a relationship of side effect expression and the combination antimicrobial of the QT prolonged accompanied with the use of clofazimine 地田凌1, 鈴木亮平2, 平野淳1, 滝久司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1000-1000, 2024. |
|---|
|
|
[P0581-3-PM2]. Fact-finding of the renal function evaluation in the on admission 松下佳奈, 徳永晃己, 守田和憲, 柴田啓智, 田上治美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1000-1001, 2024. |
|---|
|
|
[P0582-4-PM]. Than need - critical care center admission data of the acute drug intoxication medical care education for non-exclusive duty pharmacists ... 渡辺圭1, 近藤匡慶1, 源平麻衣1, 長野槙彦1, 矢島領2, 久野将宗3, 菅谷量俊1, 林太祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1001-1001, 2024. |
|---|
|
|
[P0583-3-PM2]. One patient who responded to multiple haemodialysis for lithium poisoning 前田晃佑, 山本浩二郎, 栗野大輔, 福村真須美, 北井佑樹, 吉澤典成, 竹腰雄真, 草薙みか, 大里恭章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1001-1002, 2024. |
|---|
|
|
[P0584-4-PM]. One patient who took metformin in large quantities, and presented with lactic acidosis 宿谷光則1, 高木奏1, 坂本華穂1, 前田幹広1, 安武夫2, 坂上逸孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1002-1002, 2024. |
|---|
|
|
[P0585-3-PM2]. One case that combination of ST medical mixture and levofloxacin was effective for bacteremia by Stenotrophomonas maltophilia in patients with extensive burns 門口直仁, 伊東愛理, 濱田一成, 公文登代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1002-1003, 2024. |
|---|
|
|
[P0586-4-PM]. One case that presented coagulation disorder after the cefmetazole administration for urinary tract infection that developed in an undernourished patient after the chemotherapy 鳥海未奈1, 吉元公一1, 蒲原英伸2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1003-1003, 2024. |
|---|
|
|
[P0587-3-PM2]. Comparison of the Over The Counter medicine excessive quantity medication number of cases before and after the COVID-19 pandemic 瓦比呂子, 門野めぐみ, 松本圭司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1004-1004, 2024. |
|---|
|
|
[P0588-4-PM]. Precision inspection by the comparison affiliated at time of two kinds of excessive renal clearance prediction score 三上龍生1,2, 早川峰司3, 今井俊吾4, 佐藤夕紀5, 柏木仁5, 梨本俊亮5, 菅原満1,5, 武隈洋1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1004-1005, 2024. |
|---|
|
|
[P0589-3-PM2]. 2 cases that was able to provide safe surgery to patients who held rare blood type 平川大輔, 相澤賢人, 山根侑子, 片山真育, 大西晴, 藤田祐規, 吉田健太郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1005-1005, 2024. |
|---|
|
|
[P0590-4-PM]. The activity in the postoperative pain management team and future problem 山原慶子1, 長谷川和恵1, 青木ひとみ2, 西脇小百合2, 山下春美3, 乾大資4, 西岡達也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1005-1006, 2024. |
|---|
|
|
[P0591-3-PM2]. Effect on use of pain-killer by activities and the intervention of the postoperative pain management team 日江井和英1, 土本暁斗1, 安田翔1, 中村英嗣1, 高澤圭輔1, 松由幸司1, 若尾留美2, 山崎潤二3, 宇佐美英績4, 宮部芳之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1006-1006, 2024. |
|---|
|
|
[P0592-4-PM]. Attitude survey about the decision making at the emergency in the medical care for citizens 山崎亜里紗, 佐藤真由子, 竹平理恵子, 正村優子, 有田悦子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1006-1007, 2024. |
|---|
|
|
[P0593-3-PM2]. It is ... from the viewpoint in an allergy, the side effect career using perioperative drug control by the cooperation of surgery center pharmacist and the ward pharmacist and usefulness - joint ownership seat 松野咲紀1, 島村奈緒美1, 中島梓1, 島本百合子1, 早川智久1, 村松博1, 大谷壽一1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1007-1007, 2024. |
|---|
|
|
[P0594-4-PM]. Evaluation of the operating room pharmacist duties in the Mie University faculty of medicine hospital using the customer satisfaction analysis 田坂健1, 森川祥彦1, 杉野友紀1, 北畠朱莉1, 田川佳於里1, 川瀬亮介1, 朝居祐貴1, 岡本明大1, 向原里佳1, 深谷みゆき2, 賀来隆治3, 岩本卓也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1007-1008, 2024. |
|---|
|
|
[P0595-3-PM2]. Efforts of the pharmacist in the diabetes dialysis prevention outpatient department 徳丸翔大, 小原衣未里, 田杭直哉, 近藤匡慶, 菅谷量俊, 林太祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1008-1008, 2024. |
|---|
|
|
[P0596-4-PM]. The relation of the pharmacist using the video in the kidney disease outpatient department of our hospital and the future prospects 内海紗良1, 田川慎二1, 藤岡睦1, 小笹佑輔1, 横川亜希代2, 山田公美2, 木村廣志3, 高津宏典1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1008-1009, 2024. |
|---|
|
|
[P0597-3-PM2]. Examination of the usefulness of the inhalational maneuver evaluation with the practical skill instruction using the remote inhalational instruction system 佐川怜香1, 朝倉佳代子1, 原宏恵1, 喜多知子1,3, 岡村みや子1, 田中沙弥1, 平大樹1, 永易敦子1, 志田あゆみ1, 川上恵1, 白井克子1, 田辺直也2, 砂留広伸2, 重面雄紀1, 宗可奈子3, 中川俊作1, 津田真弘1, 佐藤篤靖2, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1009-1009, 2024. |
|---|
|
|
[P0598-4-PM]. Efforts to Provide Effective Inhalation Instruction for Patients Continuing on Respimat - The Benefits of Short-Term Instruction - 阿部晃太, 畠山敬寿, 佐々木稜太, 眞山遼太, 川口翔平, 山下友輝, 岩堀真弓, 後藤悠, 東修司, 田畑裕和, 今井隆人, 小林龍 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1009-1010, 2024. |
|---|
|
|
[P0599-3-PM2]. An investigation about the medication of children and making of the medication support material 山内梨緒, 遠藤可奈子, 山下敦史, 矢田山瑞稀, 島津智行, 福島麻里乃, 石田陽美, 田中悠季, 三本松泰孝, 鈴木千波, 田村広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1010-1010, 2024. |
|---|
|
|
[P0600-4-PM]. During the preoperation by the pharmacist in the outpatient department in front of the art about stopping medicine confirmation and an effect of the medicine medicine cooperation 八島有彌, 安達真紀子, 涌嶋伴之助, 栢木啓介, 松本徳人, 藤吉正哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1011-1011, 2024. |
|---|
|
|
[P0601-3-PM2]. Examination about a relation and the usefulness to support before hospitalization by the pharmacist 相澤聡子1, 新家恵子2, 大江彰彦1, 竹中智子1, 小野祐志1, 宇佐美順子1, 児玉雅美2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1011-1012, 2024. |
|---|
|
|
[P0602-4-PM]. Tie it speedily; is the medical therapy that continued in the outpatient department medication 川村大輔, 久岡清子, 増田博也, 澤口友紀, 大荒政志, 間千晴, 木原稔文, 小滝亜梨紗, 坪田美風 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1012-1012, 2024. |
|---|
|
|
[P0603-3-PM2]. Efforts and evaluation of the perioperative pharmacy management in the orthopedics special hospital 石倉久美子, 河原有紀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1012-1013, 2024. |
|---|
|
|
[P0604-4-PM]. Report of efforts and the activity results of the on admission drug history interview duties by the pharmacist 川村真実子, 坂井克也, 本田壯一郎, 山中規明, 大島有美子, 堀田敏之, 桜田宏明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1013-1013, 2024. |
|---|
|
|
[P0605-3-PM2]. About the usefulness of the hospitalization support task by the pharmacist in our hospital 藤原聖美, 武部友梨香, 丸川華穂, 藤原麻衣, 井上敬之, 長谷川真美, 辻川正彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1013-1014, 2024. |
|---|
|
|
[P0606-4-PM]. Zero of the postponement of surgery by evaluation (the second report) - discontinuation lapse of memory of the risk factor of the patients discontinuation in the admitting department for becoming it - 山本弓子, 遠藤愛樹, 中根優, 佐久間大樹, 松本香織 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1014-1014, 2024. |
|---|
|
|
[P0607-3-PM2]. Examination of the usefulness in the construction of the qualitative evaluation system of drugstore pharmacist duties and the application to a new face pharmacist 桶野友恵, 石野晃浩, 本間絵里子, 岩崎正宏, 灘本夏子, 高嶋健太, 徳永佳代, 宮本雄大, 谷口亮央, 早川達, 中島史雄 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1014-1015, 2024. |
|---|
|
|
[P0608-4-PM]. Efforts to a problem solution in the pharmacist outpatient department in front of the art 今田剛志, 鐘司光貴, 中山大明, 大西莉子, 富永樹範, 関井将太, 三浦遥, 佐藤凛子, 篠崎浩司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1015-1016, 2024. |
|---|
|
|
[P0609-3-PM2]. The effect on surgery planned inpatient investigation that an operational change about the bringing medicine's confirmation gives 石井照樹1, 森黒唯1, 大嶋成奈優1, 沖廣絵里子1, 高橋公子1, 石原瑛太郎1, 中西順子1, 篠永浩1, 加地努1, 石山晃子2, 中津守人3, 矢野禎浩4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1016-1016, 2024. |
|---|
|
|
[P0611-3-PM2]. Evaluation of the acting discontinuation input protocol before operation for the general anesthesia surgery patients in the Fukuoka Tokushukai Hospital 松本貴行, 阿部由起子, 山本貴一, 相江いずみ, 関根彩乃, 永田理佳, 立石裕樹, 後藤貴央, 宮津大輔, 渡邊裕之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1016-1017, 2024. |
|---|
|
|
[P0612-4-PM]. Improvement and result of the compounding of medicines duties by visualization and the task shift of duties 安部絵里, 木村美智男, 吉田真也, 郷真貴子, 伊藤加代, 安田茉緒, 篠田梨恵, 山田志緒里, 浅野泉, 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1017-1017, 2024. |
|---|
|
|
[P0613-3-PM2]. Investigation of the problems that it showed after the pharmacist intervention in the oral pediatric food endurance test patients 岩熊里沙, 佐古有紀, 脇本友絵, 安永顕子, 河瀬志保 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1017-1018, 2024. |
|---|
|
|
[P0614-4-PM]. PBPM introduction and evaluation of the hepatitis B screening for patients receiving chemotherapeutic drug and immunosuppressive drug 外山未来1, 宮本康敬1, 平野公美1, 八木貴彦1, 大和千穂1, 野木村藍1, 中村拓哉1, 影山富士人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1018-1018, 2024. |
|---|
|
|
[P0615-3-PM2]. The current situation and problem of PBPM which we performed from 2019 津曲恭一1, 上原智博1, 荒木志乃1, 東盛裕里1, 池上幸恵1, 石新あおい1, 黒原健1, 木下晶惠2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1019-1019, 2024. |
|---|
|
|
[P0616-4-PM]. The inflection situation of the protocol of the hypercalcemia prevention of the use of vitamin D3 preparation patients in the Buddha of Healing Hospital 矢野涼子1, 長岡宏一2, 竹川祐以1, 伊藤朱里1, 渡邉幸雄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1019-1019, 2024. |
|---|
|
|
[P0617-3-PM2]. Efforts and the current situation for the hepatitis B reactivation prevention in infliximab treated patients 福江悠香1, 柿本秀樹1, 吹上勇真1, 萩原知佳1, 藤木将勝1, 福山安里彩1, 中島章雄1,2, 眞崎晃3, 金子朋博3, 加治杏奈4, 宮崎元康1,2, 今給黎修1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1019-1020, 2024. |
|---|
|
|
[P0618-4-PM]. Examination for blood drug concentration order input support by the pharmacist evades vancomycin-induced renal failure 宮田千秋, 吉川直樹, 是枝秀彦, 仲原周一, 松崎裕紀, 池田龍二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1020-1021, 2024. |
|---|
|
|
[P0619-3-PM2]. About efforts and an evaluation of the duties support protocol about the vancomycin TDM 大野裕之, 田中佳子, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1021-1021, 2024. |
|---|
|
|
[P0620-4-PM]. Questionary survey about the representation order by the pharmacist for the practice of PBPM 石坂麻衣1, 新倉匠1, 市川慶1, 栗山明子1, 八木仁史1, 高田宏文1, 河井良智2, 荒井宏人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1021-1022, 2024. |
|---|
|
|
[P0621-3-PM2]. The number of inquiries about Residual medicine adjustment and the use postscript decreases when we introduce outside Parliament prescription inquiry simplification protocol 川上あゆみ1, 中根茂喜1, 鈴木一志1, 小川裕美1, 高井理恵1, 武馬優也1, 新田雄司1, 渡辺裕介1, 前田芳樹1, 山下智穂2, 兼松哲史3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1022-1022, 2024. |
|---|
|
|
[P0622-4-PM]. Effect on consciousness of the physician whom the task shift in HBV reactivation measures brings 家村恵, 中西真也, 松岡勇作, 奥野昌宏, 森本茂文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1022-1023, 2024. |
|---|
|
|
[P0623-3-PM2]. Operation and evaluation of the ward pharmacist commuter pass prescription support protocol in our hospital 山嵜久未, 高橋怜史, 増尾昌則, 清水実, 仲鉢英夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1023-1023, 2024. |
|---|
|
|
[P0624-4-PM]. It is introduced tablet sortation equipment "TABSORT+" task shift/share and one package of our hospital 駒田典伽, 満武亜弥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1023-1024, 2024. |
|---|
|
|
[P0625-3-PM2]. Effect by a task having shifted part of drug information room duties to an office worker 森崎真理子1, 市江敏和1, 加藤里帆2, 高嶋祥匡1, 荒川泰代1, 曽根綾太1, 大谷寧次郎1, 三浦毅1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1024-1024, 2024. |
|---|
|
|
[P0626-4-PM]. IP, Ca for haemodialysis patients, usefulness of the Mg monitoring 濱田達志, 山本倫数, 加藤奈帆, 川崎梨紗子, 竹村姫穂, 竹腰雄真, 吉澤典成, 山田直輝, 山本浩二郎, 草薙みか, 大里恭章 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1024-1025, 2024. |
|---|
|
|
[P0627-3-PM2]. An effect of the efforts for the prescription correction rate improvement after the outside Parliament prescription inquiry simplification protocol (inside the hospital-adaptive) introduction and future problem 山内章嗣1, 西村亮1, 磯部佳歩2, 原田卓弥1, 松岡勇作1, 奥野昌宏1, 森本茂文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1025-1025, 2024. |
|---|
|
|
[P0628-4-PM]. Efforts to perioperative drug control duties of our hospital 山口成美, 山田政典, 黒川雄太, 宮崎智史, 齋藤巨樹, 小園亜希, 湊本康則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1025-1026, 2024. |
|---|
|
|
[P0629-3-PM2]. Recommendation for task shifting in dispensing rooms 小島一晃, 松本弘誠, 松本明子, 安達美里, 山村裕佳子, 中西輝, 濱武清範, 徳田悦美, 山地祥恵, 竹内邦子, 中元真紀子, 美和孝之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1026-1026, 2024. |
|---|
|
|
[P0630-4-PM]. Effect by the intervention of the postoperative pain management team 苗村彰浩1, 吉田三矢1, 櫛田宏幸1, 庄野裕志1, 佐光留美1, 山西香織2, 松本奈緒美3, 笠井智美4, 林英明4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1027-1027, 2024. |
|---|
|
|
[P0631-3-PM2]. About the expansion of a change and the pharmacist duties of the formulations error by the formulations support system introduction 山口知紀1,2, 岡野芳彦1, 豊田真史1, 山崎智世1, 田久保碧1, 深野光司2, 城田幹生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1027-1027, 2024. |
|---|
|
|
[P0632-4-PM]. Frequency analysis of the haemorrhagic cerebral infarction in alteplase using JADER and anticoagulant/antithrombocytic agent combination 中井剛1, 中尾公香2, 加藤滉基1, 高橋和男2, 山田成樹1, 松本省二3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1028-1028, 2024. |
|---|
|
|
[P0633-3-PM2]. Study on effect on GI tract disturbance of the JAK inhibitor using JADER 土川拓也, 小寺聖, 田中佳子, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1028-1029, 2024. |
|---|
|
|
[P0634-4-PM]. The medication adherence of antihypertensive medications combination tablets and allied analysis with the brain cardiovascular events onset period 松村光紗2, 中村敏明1, 角山香織1, 矢野良一1, 岩永一範1, 交久瀬綾香2, 今西嘉生里2, 坂本麻衣2, 中野一也2, 山西香織2, 中蔵伊知郎2, 畝佳子2, 中村任1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1029-1029, 2024. |
|---|
|
|
[P0635-3-PM2]. Analysis about the safety of Sulfamethoxazole and Trimethoprim using adverse drug reaction database (JADER) 佐川喬也1, 石田智滉1, 常風興平1, 森沢惇平1, 赤垣恵太1,2, 柳澤成佳1, 岡崎萌水1, 八木祐助1, 浜田幸宏1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1029-1030, 2024. |
|---|
|
|
[P0636-4-PM]. Analysis of the factor influencing side effect expression of Lacosamide 大磯茂1,2, 大久保伸哉1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1030-1030, 2024. |
|---|
|
|
[P0637-3-PM2]. Screening method for drug proper use utilizing the pharmaceutical care support tool 加川美由紀, 後藤純一, 岡田美桜, 松田圭一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1030-1031, 2024. |
|---|
|
|
[P0638-4-PM]. Examination about the low blood pressure during an adverse drug reaction spontaneous report database and the operation by the use of agent 5-aminolevulinic acid for the rays dynamic diagnosis using the meta analysis 森沢惇平, 石田智滉, 常風興平, 浜田幸宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1031-1031, 2024. |
|---|
|
|
[P0639-3-PM2]. Examination about the association of JAK inhibitor and myocardial infarction using adverse drug reaction database (JADER) 久保利樹, 祖川倫太郎, 島ノ江千里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1031-1032, 2024. |
|---|
|
|
[P0640-4-PM]. Adverse event expression of naldemedine risk analysis using adverse drug reaction database (JADER) 藤村一紗1, 柴田富美子2, 杉山太一3, 百合野佐和子4, 前田守5, 伊藤将5, 市ノ渡真史5, 長谷川佳孝5, 月岡良太5, 大石美也5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1032-1033, 2024. |
|---|
|
|
[P0641-3-PM2]. About effect on number of reports by the education system and the internal regulations revision of the young pharmacist about the pharmaceutical products safety information report 金沢優1, 向井優太朗1, 坂倉広大1, 北場秋恵1, 永田理香子1, 波部彩乃1, 佐々木京子1, 今西嘉生里1, 坂本麻衣1, 中藏伊知郎1, 山西香織1, 中野一也1, 川端一功2, 畝佳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1033-1033, 2024. |
|---|
|
|
[P0642-4-PM]. Exhaustive analysis of the onset of endocrinopathy risk with the immune checkpoint inhibitor using adverse drug reaction database (JADER) 松本礼1, 永野悠馬2, 前田守2, 市ノ渡真史2, 長谷川佳孝2, 月岡良太2, 大石美也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1033-1034, 2024. |
|---|
|
|
[P0643-3-PM2]. Analysis of the onset of disseminated intravascular coagulation syndrome by the docetaxel using adverse drug reaction database (JADER) and haemorrhage symptom risk 村上紘世1, 前田守2, 伊藤将2, 市ノ渡真史2, 長谷川佳孝2, 月岡良太2, 大石美也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1034-1034, 2024. |
|---|
|
|
[P0644-4-PM]. Unequal analysis of stomatitis with the anticancer medicine using adverse event report database (JADER) 細中孝輔1,2, 山岡健太2,3, 池田奈央恵2, 内田まやこ4, 植沢芳広5, 清水忠2, 高橋一栄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1034-1035, 2024. |
|---|
|
|
[P0645-3-PM2]. Effect by the computerization of the drug over Dors case report 桑原悠里, 土本大輔, 大西克浩, 出口裕子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1035-1035, 2024. |
|---|
|
|
[P0646-4-PM]. Efforts of the reporting that the nursing and a drug are new 中島研1, 香西祥子2, 植松和子3, 山根律子4, 刈込博5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1035-1036, 2024. |
|---|
|
|
[P0647-3-PM2]. We make a fool of a herpes zoster therapeutic drug candy and are tried the objective evaluation of the building 魚住春歌1, 深澤佑樹1, 池澤直樹1, 森崎隆博1, 間宮桐子1, 鈴木邦彦2, 中村建3, 櫻井正太郎4, 出雲貴文1, 小茂田昌代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1036-1036, 2024. |
|---|
|
|
[P0648-4-PM]. Investigation about the recognition of pharmaceutical products inquiry contents and the drug information room in our hospital 中井優作, 原田悠佑, 盛谷翔太, 泉川博子, 八代哲也, 小牟田豊 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1036-1037, 2024. |
|---|
|
|
[P0649-3-PM2]. About the mention situation of the package insert about the attention of the food allergy in the ethical drug 佐田光, 槇田崇志, 田中雄太, 西原茂樹, 村川公央, 濱野裕章, 座間味義人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1037-1037, 2024. |
|---|
|
|
[P0650-4-PM]. Examination of the passage-related evaluation by the difference of the maneuver between the staff concerned with the drug transluminal administration to neonates 小林悠, 小森智也, 岡野真澄美, 小池博文, 佐橋幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1037-1038, 2024. |
|---|
|
|
[P0651-3-PM2]. Examination, inspection (followup) about the making of a database, the offer site of the taste information of pharmaceutical products including the information about RMP 尾島稔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1038-1038, 2024. |
|---|
|
|
[P0652-4-PM]. The use situation investigation of the antimicrobial using Days of Antibiotic Spectrum Coverage (DASC) 福山博務, 大塚健太, 深野光司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1038-1039, 2024. |
|---|
|
|
[P0653-3-PM2]. HBV reactivation prophylactic efforts and evaluation of the pharmacist intervention 田中美安1, 小栗良介2, 大野裕之2, 田中佳子2, 井上壽江2, 平下智之2, 林高弘1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1039-1039, 2024. |
|---|
|
|
[P0654-4-PM]. Attitude survey of hepatitis B reactivation measures 梅本啓史1, 大重彰彦2, 谷口潤1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1039-1040, 2024. |
|---|
|
|
[P0655-3-PM2]. Valacyclovir proper use investigation in the Ashikaga Red Cross hospital outside Parliament prescription 矢部雅子, 前原梨恵, 邉見光利 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1040-1040, 2024. |
|---|
|
|
[P0656-4-PM]. The wall to the polypharmacy measures in the university hospital: From the comparison between the types of job of the questionary survey 西川はる1, 安藤崇之2, 清宮啓介3, 西木美優1, 石川春樹1, 百武美沙2, 河野佐代子4, 藤澤大介2, 佐々木駿一1, 池田理紗1, 大谷壽一1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1041-1041, 2024. |
|---|
|
|
[P0657-3-PM2]. Fact-finding about the laxative prescription in the outpatient department of patients with chronic cardiac insufficiency in our hospital 寺島純一1, 纐纈理紗子1, 河村隆登1, 山田哲也1, 坂口輝洋2, 神原貴博2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1041-1041, 2024. |
|---|
|
|
[P0658-4-PM]. Investigation about the use actual situation and the polypharmacy of fantastic four for patients with heart failure that a left ventricular ejection fraction decreased 森本雅生, 高尾水緒, 田村安希, 花房伸幸, 森英樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1042-1042, 2024. |
|---|
|
|
[P0659-3-PM2]. Use fact-finding of the morphine preparation for a feeling of dyspnea of patients with terminal heart failure in the best Red Cross hospital in Kyoto 伏見久美子1, 山添晶子1, 中山朋美1, 太田垣未央1, 小森桂子1, 富井真一1, 舩越真理1, 谷口彩乃2, 土谷有美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1042-1043, 2024. |
|---|
|
|
[P0660-4-PM]. Fact-finding about the instruction of the antibacterial eye drops of the health insurance pharmacy pharmacist for the patients before cataract surgery 小見暁子, 土井信幸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1043-1043, 2024. |
|---|
|
|
[P0661-3-PM2]. The introduction situation of Fantastic Four in patients with hospitalization chronic cardiac insufficiency of the Handa City solder hospital 渡辺彩里華, 野崎達也, 古田麻衣子, 横田学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1043-1044, 2024. |
|---|
|
|
[P0662-4-PM]. Investigation into further appropriate use of daprodustat in patients with renal anemia 下村萌絵, 橋本みさき, 今井雄介, 勢力育美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1044-1044, 2024. |
|---|
|
|
[P0663-3-PM2]. Japanese edition The perceived service quality scale (pSQS) development based on the patients experience value 鈴木渉太1, 西川佳孝2, 中山健夫2, 岡田浩1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1044-1045, 2024. |
|---|
|
|
[P0664-4-PM]. Analysis of pharmacists' responses when polypharmacy patients bring their "medication information" documents to the pharmacy and factors that lead to medication reduction 高橋寛1,3, 鈴木秀実2, 相磯友哉2, 新井学2, 熊谷明知3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1045-1045, 2024. |
|---|
|
|
[P0665-3-PM2]. Correspondence to interaction and generic medicine of the antiepileptic attack medicine at the health insurance pharmacy: Multicenter questionary survey 吉川博1,2, 音成秀一郎2,3, 香川幸太2,4, 里章平1,2, 西垣内亮1,2, 藤井健司1, 飯田幸治2, 松尾裕彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1045-1046, 2024. |
|---|
|
|
[P0666-4-PM]. About the continuous inhalational instruction cooperation system to think about from COVID-19 season 北原和花子1, 水谷妙子1, 田中文1, 榊間絢子1, 横山征史1, 前澤優圭1, 百瀬貴史1, 登内盛治1, 蜂谷勤2, 市川椋2, 矢崎達也2,3, 濱峰幸3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1046-1046, 2024. |
|---|
|
|
[P0667-3-PM2]. Alteration of consciousness of holding and the participant of the civic lecture about the disaster for inhabitants of the TambaSasayama area 字廻祐輔1, 橋本佳奈1,2, 渡邉暁洋3, 志方敏幸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1047-1047, 2024. |
|---|
|
|
[P0668-4-PM]. Future problem to regard as the allergy to beta lactam antimicrobial registration situation by the interview in our hospital from an antimicrobial choice at the readministration 只佐宣子, 浅田一樹, 古閑恵梨奈, 梶谷真也, 徳本和哉, 要田芳代, 川上恵子, 竹増まゆみ, 只佐正嗣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1047-1048, 2024. |
|---|
|
|
[P0669-3-PM2]. Questionnaire findings after the set prescription beginning to use of the Andexanet alpha 相川実穂1, 松尾待池1, 大津貴寛1, 橋本未雷1, 福山雄卯介1, 里吉拓海2, 木場みちよ2, 辻村美希代2, 宮本瑠美2, 権志成3, 中道親昭3, 三角紳博3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1048-1048, 2024. |
|---|
|
|
[P0670-4-PM]. Study on association of the harassment actual situation and sleep, quitting a job in the pharmacist 菊岡正芳1, 豊島久雄1, 赤瀬朋秀1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1048-1049, 2024. |
|---|
|
|
[P0671-3-PM2]. Attitude survey for the clinical studies for members of Ibaraki hospital pharmacist society 中村隆二1, 大神正宏1, 高嶋泰之1, 櫻井靖1, 四十物由香1, 松本晃一2, 本間真人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1049-1049, 2024. |
|---|
|
|
[P0672-4-PM]. Prescription change of the insomnia therapeutic drug in the Sado General Hospital 霍間尚樹, 池田考介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1049-1050, 2024. |
|---|
|
|
[P0673-3-PM2]. Around the source of the satisfaction of the person who experienced Manager of ethno graphic research - drug section about Well-Being of the hospital pharmacist - 赤瀬朋秀 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1050-1050, 2024. |
|---|
|
|
[P0674-4-PM]. Effect by the Dors rounding of the trastuzumab preparation in patients with breast cancer 楢原由生未1, 門野愛美1, 益本周治1, 山口和盛2, 高柳和伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1050-1051, 2024. |
|---|
|
|
[P0675-3-PM2]. Cost effectiveness analysis of the anamorelin treatment for the cancer cachexia 西川達也1, 柏宗伸2, 崔吉道1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1051-1051, 2024. |
|---|
|
|
[P0676-4-PM]. Effect on patients whom a supply drop of the Dulaglutide brought 大槻愛, 春名康裕, 山中知恵子, 長谷川晃司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1051-1052, 2024. |
|---|
|
|
[P0677-3-PM2]. It is cost effect analysis of tamoxifen and anastrozole in the endocrine therapy after the operation for the postmenopausal hormone receptor-positive breast cancer 千葉遊太, 村上琉海, 中川直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1052-1052, 2024. |
|---|
|
|
[P0678-4-PM]. Comparison - of cost effect analysis - allopurinol about the uric acid synthase inhibitor and the febuxostat 大沼正尭, 中川直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1052-1053, 2024. |
|---|
|
|
[P0679-3-PM2]. Cost effect analysis of valproic acid and the levetiracetam in the general and unclassifiable epileptic seizure diagnosed newly 大崎琴美, 中川直人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1053-1053, 2024. |
|---|
|
|
[P0680-4-PM]. The examination about the drug remedy rate in local inhabitants of Yamagata and the factor affecting it: Yamagata cohort study 金子基子1, 小倉次郎1,2, 山口浩明1,2, 今田恒夫3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1054-1054, 2024. |
|---|
|
|
[P0681-3-PM2]. Making of the balun strike scorecard in the hospital pharmacy attached to Yokohama City Univ. 志村美沙子, 長井絵里奈, 小森智也, 小池博文, 佐橋幸子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1054-1054, 2024. |
|---|
|
|
[P0682-4-PM]. Polypharmacy investigation for polypharmacy measures in the Secomedic Hospital 山崎梨夏, 山内たきよ, 渡辺孔明, 長澤宏之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1055-1055, 2024. |
|---|
|
|
[P0683-3-PM2]. Effect on ward pharmacist duties by the bringing medicine differentiation in the hospitalization support center 齋藤恵美1, 白石俊介1, 中島美治1, 八木仁史1, 高田宏文1, 河井良智2, 荒井宏人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1055-1056, 2024. |
|---|
|
|
[P0684-4-PM]. Proper use investigation of the on admission bringing medicine in the decreased renal function patients 河北和馬, 中村俊之, 大岡千寿子, 野洌孝二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1056-1056, 2024. |
|---|
|
|
[P0685-3-PM2]. An example report of the hospitalization support by the pharmacist intervention in our hospital and future problem 川村竜矢 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1056-1057, 2024. |
|---|
|
|
[P0686-4-PM]. Evaluation about bringing medicine differentiation 滝澤康志, 矢野均, 久保田令枝, 西澤さとみ Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1057-1057, 2024. |
|---|
|
|
[P0687-3-PM2]. The current situation and problem of the discontinuation before operation in the perioperative pharmacy administrative work of our hospital 高澤美月1, 小島香織1, 金子健一1, 鈴木正論2, 濃沼政美2, 宮里裕子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1057-1058, 2024. |
|---|
|
|
[P0688-4-PM]. It is analyzed the drug information for the purpose of the proper use of OTC eye drops with the indication for "an eyestrain" 秋山滋男1, 近藤ひかる1, 宮本悦子2, 石田志朗3, 堀祐輔1, 土井信幸4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1058-1058, 2024. |
|---|
|
|
[P0689-3-PM2]. The use fact-finding of the commercial drug for the preoperation patients and construction of the search system 松原花乃1, 野戸大和1, 坂東香織1, 若松遼介1, 久保茜1, 石塚仁保1, 伊藤悠里子1, 須藤大雄1, 桂川みき1, 樋浦一哉2, 棚谷貢1, 船木映二1, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1058-1059, 2024. |
|---|
|
|
[P0690-4-PM]. We evaluate it after the changes from Budesonide/formoterol inhalant innovator drug to a generic drug 福永晃右1, 福永晟也1, 石田智之1, 福迫美保菜1, 鶴永大貴1, 中村有莉恵1, 堀内智裕1, 赤星真広1, 森岡友美1, 池増鮎美1, 佐多照正1, 副島賢忠2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1059-1059, 2024. |
|---|
|
|
[P0691-3-PM2]. One case that the interstitial pneumonia that occurred during temozolomide internal use discontinuation became the death outcome 小原衣未里1, 山崎道生2, 吉田真人1, 近藤匡慶1, 菅谷量俊1, 林太祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1059-1060, 2024. |
|---|
|
|
[P0692-4-PM]. Examination of frequencies investigation of the drug allergy in the foreign chemotherapy center and the correspondence 水野貴仁1, 瀬戸口里奈2, 金子智美2, 東川万里子1, 勝野晋也1, 木村智樹3, 梶口智弘4, 山田哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1060-1060, 2024. |
|---|
|
|
[P0693-3-PM2]. Analysis of the clinical features of the patients who needed direct hospital admission of emergency by immune-mediated adverse event (irAE) 池田樹生1, 二瓶哲1,2, 齋藤一樹1, 朝賀純一1,2, 工藤賢三1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1060-1061, 2024. |
|---|
|
|
[P0694-4-PM]. The administration situation and side effect investigation of the Pembrolizumab + Lenvatinib therapy for the cancer of endometrium in the Toyohashi Municipal Hospital 戸崎友梨, 町支優和, 原田哲彦, 坂野博紀, 村上仁志, 白井景 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1061-1061, 2024. |
|---|
|
|
[P0695-3-PM2]. Risk factors for cytokine release syndrome induced by blinatumomab 計良貴之, 吉冨加奈子, 丸本かおり, 荒井園枝, 小林加寿夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1062-1062, 2024. |
|---|
|
|
[P0696-4-PM]. One case that a dexamethasone massive dose therapy was effective for immune thrombocytopenic purpura by the Pembrolizumab 東川万里子1, 油谷綾夏1, 水野貴仁1, 高木えり奈2, 梶口智弘2, 武田宗万3, 勝野晋哉1, 山田哲也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1062-1062, 2024. |
|---|
|
|
[P0697-3-PM2]. It is one patient of adjuvant chemotherapy patients after the breast cancer technique regarded as anaphylaxis to come from the taxane structure body 加藤遥平1, 小池奈穂1, 嘉代愛弓1, 和泉早智子1, 三原大佳2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1063-1063, 2024. |
|---|
|
|
[P0698-4-PM]. It is one patient with suspected serositis by the Pembrolizumab from pleural effusion retention, edema 本間崇正1, 藤島亮太2, 堀和美3, 武田直也3, 吉田憲生3, 榊原隆志1, 滝本典夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1063-1063, 2024. |
|---|
|
|
[P0699-3-PM2]. Real world data about the drug-related necrosis of the jaw bone onset of patients with denosumab treatment metastases to bone in our hospital 橋本光弘1, 兼平暖1, 田沼道也1, 清水幸雄1, 山城正司2, 田中昌代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1064-1064, 2024. |
|---|
|
|
[P0700-4-PM]. One case that presented severe diarrhea and interstitial pneumonia by Abemaciclib administration 角陽子1, 伊藤佳織2,3, 長谷川真美1, 辻川正彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1064-1064, 2024. |
|---|
|
|
[P0701-3-PM2]. Search of the immune-mediated adverse event onset predictor of the Pembrolizumab for the triple negative breast cancer 寺澤美智代, 藤川史子, 木崎秀和, 打谷和記 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1065-1065, 2024. |
|---|
|
|
[P0702-4-PM]. Rise in dose-dependent serum creatinine level by the ST medical mixture which is unrelated to renal function 鵜野竜馬, 辻本高志, 東亮佑, 高橋諒多, 山本明日香, 加納宏樹, 川本由加里, 後藤仁和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1065-1066, 2024. |
|---|
|
|
[P0703-3-PM2]. 1 case that showed a significant rise of CRP by daptomycin used for a wound part infection after the artificial joint replacement, and obtained improvement after the cancellation 川崎奈美江1, 大埜理絵2, 富士谷昌典1, 木村初1, 南義人3, 梁尚志4, 小泉祐一1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1066-1066, 2024. |
|---|
|
|
[P0704-4-PM]. A case of advanced age non-diabetes that caused seriously ill hypoglycemia by levofloxacin administration and diet intake defectiveness 八島一史1, 佐藤伸輔2, 櫻井淳二1, 岡田優1, 佐々木美織1, 高橋識至3, 宮内康夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1066-1067, 2024. |
|---|
|
|
[P0705-3-PM2]. Effect of the Albumin Bilirubin score to give it to the onset of cefepime-induced liver damage risk: The study that is targeted for a single institution case 勝弘毅1, 朝居祐貴2, 平野隆司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1067-1067, 2024. |
|---|
|
|
[P0706-4-PM]. Retrospective survey of the incidence of side effect of difference in dose including the gastrointestinal disorder of the insulin Degludec liraglutide combination note 汐月りか1, 平田一耕2,3, 舟越亮寛2,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1067-1068, 2024. |
|---|
|
|
[P0707-3-PM2]. Effects of vadadustat and daprodustat on thyroid function 杉木壮吉1,2, 宇野英理子1, 川澄紀代1, 野々垣知行2, 大西正文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1068-1068, 2024. |
|---|
|
|
[P0708-4-PM]. One patient whom blood gentamicin levels increased in intra-Soft tissue antibiotics perfusion (iSAP), and renal failure developed in 馬淵将吾, 篠田康孝, 木村美智男, 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1068-1069, 2024. |
|---|
|
|
[P0709-3-PM2]. The fact-finding of feces-related ileus and the use drug: Look at the single institution rear; a mark observational study 大野凜太郎, 石井幹世, 渡部義和, 斎藤和悦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1069-1069, 2024. |
|---|
|
|
[P0710-4-PM]. Onset of hypermagnesemia risk factor analysis during magnesium oxide remedy 三好貴之1, 小田真司1, 武智研志2, 大塚尚1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1069-1070, 2024. |
|---|
|
|
[P0711-3-PM2]. One case of the photo-allergy that occurred during hydrochlorothiazide chronic administration 森脇健太郎1,2, 鈴村雅之1, 山口英人1, 豊田景子1, 矢田里奈2, 岡本絵蒔2, 脇田大暉2, 窪田知仁2, 水谷日花里2, 大矢知立城2, 北本千晴2, 高橋千裕2, 加藤公人2, 西川嘉広2, 今西義紀2, 小出哲朗2, 伊藤久美子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1070-1070, 2024. |
|---|
|
|
[P0712-4-PM]. 2 cases that the hyposensitization for the onset of eruption patients with the sulfamethoxazole trimethoprim combination drug was useful 安原涼子, 金田典子, 馬島務, 龍神博之, 山下剛史郎, 満田正樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1070-1071, 2024. |
|---|
|
|
[P0713-3-PM2]. Fact-finding for the drug eruption practice in the dermatologist absence hospital 漢那迪華, 島袋優花, 又吉やよい, 浜元善仁 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1071-1071, 2024. |
|---|
|
|
[P0714-4-PM]. About the effect that the combination of the antiemetic drug gives in acceptability of the constipation therapeutic drug agate Pross ton 丸田佐知子1, 河原有希1, 仁木富美子1, 高橋侑子1, 猿渡康宏1, 伊藤由希1, 水本智子1, 平井裕子1, 高野正太2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1072-1072, 2024. |
|---|
|
|
[P0715-3-PM2]. Investigation of the incidence of a continuance rate of tocilizumab and the Sarilumab of the IL-6 inhibitor and the side effect 平田一耕1,2, 大場啓貴1,2,3, 舟越亮寛1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1072-1073, 2024. |
|---|
|
|
[P0716-4-PM]. Problem of cover suspicion medicine identification, treatment and the adverse drug reaction relief system of Stevens-Johnson syndrome 沢仁美1,3, 西井奈央子1, 岡村政道2, 中村暢彦4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1073-1073, 2024. |
|---|
|
|
[P0717-3-PM2]. Examination of the background factor of the case that we developed bradycardia at use of bisoprolol patch in the elderly aged 75 or over and canceled 的場麻知子, 西牟田昇吾, 三木彩楓, 佐古守人, 黒沢秀夫, 野村剛久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1073-1074, 2024. |
|---|
|
|
[P0718-4-PM]. The case that led to blistering and necrosis of tissue by extravasation of the noradrenaline 早坂美希, 千葉貴志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1074-1074, 2024. |
|---|
|
|
[P0719-3-PM2]. The current situation of the adverse event report in our hospital 前浩史, 外賀裕次郎, 福田夏稀, 渡部美緒, 柏瀬しのぶ, 塩川満 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1074-1075, 2024. |
|---|
|
|
[P0720-4-PM]. Medical drug excessive intake example in the opioid-free person 高橋晴音, 宮澤正幸, 見目英継, 喜古康博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1075-1075, 2024. |
|---|
|
|
[P0721-3-PM2]. Examination of the intake to become the N-acetylcysteine administration index in the acetaminophen overdose patients 新田滉基, 森光輝, 木村美智男, 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1076-1076, 2024. |
|---|
|
|
[P0722-4-PM]. The effect that Elraglusib of the GSK3β inhibitor gives to UGT1A1 and expression of UGT1A6 加藤美紀, 小島綾華, 灘井雅行 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1076-1076, 2024. |
|---|
|
|
[P0723-3-PM2]. Examination of the xanthine oxidoreductase activity in the stroke easy onset hypertensive spontaneous rat liver, serum 田山剛崇, 藤井千穂, 前田志津子, 杉原数美, 三宅勝志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1077-1077, 2024. |
|---|
|
|
[P0724-4-PM]. One case that was able to control blood level of immunosuppressive drug (po) by the intervention of the formulations method in the kidney transplantation case with tablet dysphagia well 北川瑚姫, 中村雄亮, 高橋優聡, 小森均 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1077-1078, 2024. |
|---|
|
|
[P0725-3-PM2]. Search of the new biomarker reflecting cytochrome P450 2D6 activity using the non-target metabolic syndrome loam analysis 小田絢子1, 鈴木陽介1, 神尾奈月1, 飯野滉大1, 鈴木さくら1, 山岸尚1, 小山晃英2, 大野恵子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1078-1078, 2024. |
|---|
|
|
[P0726-4-PM]. Pulmonary aspergillosis after the living body lung transplantation that tried the change of the antifungal agent during immunosuppressive therapy 塩田亮介1, 矢部勝茂1, 本田勝亮1, 柏原道志1, 長岡翔1, 河野雅人2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1078-1079, 2024. |
|---|
|
|
[P0727-3-PM2]. A case of the stomach cancer with suspected drug interactions of fosnetupitant and the fentanyl 北出紘規, 宮永和美, 西野正義 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1079-1079, 2024. |
|---|
|
|
[P0728-4-PM]. Concomitant use of commonly used medications during administration of nilmatrervir/ritonavir and a case report of concomitant use of sacubitril and valsartan 桝本彩季1, 高瀬友貴1, 久米学1, 黒田浩一2, 室井延之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1079-1080, 2024. |
|---|
|
|
[P0729-3-PM2]. Safe H. in the tacrolimus remedy patients after the kidney transplantation Examination of the pylori sanitization regimen 重松知沙1, 安田知弘1, 木全司1, 姫野智紀2, 島本侑樹2, 長谷川雄基2, 児玉卓也2, 西川涼馬2, 青木太郎2, 二村健太2, 岡田学2, 平光高久2, 鳴海俊治2, 渡井至彦2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1080-1080, 2024. |
|---|
|
|
[P0730-4-PM]. Examination for the association between vancomycin renal failure and AUC at tazobactam piperacillin combination 松井統哉1,2, 川口博資1,2, 山下佑麻1, 北井葉月1, 森畑直也1, 糸谷茉友子1, 櫻井紀宏1,2, 掛屋弘2, 中村安孝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1080-1081, 2024. |
|---|
|
|
[P0731-3-PM2]. Directly about effect of the polypharmacy on blood level of the oral anticoagulant drug 向井優太朗1, 宮本康二2, 坂本麻衣1, 中野一也1, 山西香織1, 中藏伊知郎1, 和田恭一3, 中村任3, 畝佳子1, 草野研吾2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1081-1081, 2024. |
|---|
|
|
[P0732-4-PM]. Study on effect that posaconazole in the allogeneic hematopoietic stem cell transplantation patients gives to blood level of tacrolimus 清水悠太1, 依田真由子1, 南貴之1, 遠藤愛樹1, 飯野昌樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1082-1082, 2024. |
|---|
|
|
[P0733-3-PM2]. Examination of the VCM administration plan method in consideration of nephrotoxic frequencies 松木祥彦1,2, 小島雄太郎2, 石倉裕美2, 平井莉菜2, 本田ゆめ2, 渡邉理央2, 石坂優太2, 大竹千夏2, 長沼沙也花2, 松山絢音2, 上原良太2, 佐古兼一3, 渡部多真紀4,5, 安野伸浩4,5, 渡辺茂和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1082-1083, 2024. |
|---|
|
|
[P0734-4-PM]. About predictive precision of the vancomycin administration plan using TDM software PAT for patients with severe impaired renal function 田杭直哉1, 小鹿海里1, 黒田香織1, 近藤匡慶1, 菅谷量俊1, 丸山弘2, 林太祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1083-1083, 2024. |
|---|
|
|
[P0735-3-PM2]. Did the administration plan in AUC guides of VCM reduce renal failure? 加藤渓1, 久保健児2, 奥村麻佐子1, 田邊和史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1083-1084, 2024. |
|---|
|
|
[P0736-4-PM]. Examination about the usefulness of the medical treatment management based on a protocol in the administration plan of vancomycin 佐々木貴之1,2, 加藤裕利華1,2, 井田夢華1,2, 大野航輝1,2, 森尚義3, 前川真己4, 加藤恵一1, 白木克哉2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1084-1084, 2024. |
|---|
|
|
[P0737-3-PM2]. Promotion of the voriconazole proper use in the municipal hospital: Initial evaluation of the pharmacist-led TDM introduction using LM1010 久保田健1,6, 森川剛2, 宮澤衣鶴1,6, 小池恵理1,6, 栗林優太1,6, 岡澤香津子1, 芳賀右京5,6, 副島将史5,6, 酒井健司3,6, 島庸介4,6, 千秋智重5,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1084-1085, 2024. |
|---|
|
|
[P0738-4-PM]. Reevaluation of the vancomycin initial administration plan system by the pharmacist 川崎祥平, 小林義和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1085-1085, 2024. |
|---|
|
|
[P0739-3-PM2]. For the higher quality TDM duties of the vancomycin note 合田さやか, 青柿和樹, 増田博也, 久岡清子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1085-1086, 2024. |
|---|
|
|
[P0740-4-PM]. Effect of the ADL metrics in the prediction of vancomycin levels of patients with low creatinine blood symptom 松屋翔太, 川端俊介, 竹田克明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1086-1086, 2024. |
|---|
|
|
[P0741-3-PM2]. Search of patient factors having an influence on the aim achievement quotient of the AUC in the vancomycin first time 篠田真歩, 成田久美, 野津祐貴, 田代結女, 戸田純司, 室岡邦彦, 高瀬久光 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1086-1087, 2024. |
|---|
|
|
[P0742-4-PM]. Relationship of First 24h AUC and the clinical course of vancomycin 東美佳, 中野貴文, 佐藤啓介, 江口幸臣, 森脇典弘, 釜田充浩, 池内忠宏, 兼重晋, 緒方憲太郎, 神村英利 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1087-1087, 2024. |
|---|
|
|
[P0743-3-PM2]. Factor associated with the aim trough value maintenance by the Teicoplanin maintenance administration plan in antimicrobial TDM clinical practice guidelines 2022 森山哲志, 日笠真一, 徳谷晃, 坂本淳一, 中村豪志, 田中邦佳, 木村健 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1087-1088, 2024. |
|---|
|
|
[P0744-4-PM]. Introduction effect of the vancomycin TDM manual based on guidelines 栗林優太1, 久保田健1,6, 森川剛5, 宮澤衣鶴1,6, 小池恵理1,6, 岡澤香津子1, 酒井健司2,6, 島庸介3,6, 千秋智重4,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1088-1088, 2024. |
|---|
|
|
[P0745-3-PM2]. Precaution in the vancomycin administration using Practical AUC-guided TDM for vancomycin for leptosome patients 川端俊介, 松屋翔太, 山口智江, 竹田克明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1088-1089, 2024. |
|---|
|
|
[P0746-4-PM]. Comparison of the AKI frequencies by an AUC evaluation and the trough evaluation by the trough value one point drawing blood in vancomycin 上田拓, 今井清隆, 小川結, 中嶋正博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1089-1090, 2024. |
|---|
|
|
[P0747-3-PM2]. The Teicoplanin blood level in patients with hypoalbuminemia and safe examination 杉田裕貴, 長谷香織, 小林奈央, 楠本真子, 中村有理, 小田怜, 瀬戸崇光, 松村友和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1090-1090, 2024. |
|---|
|
|
[P0748-4-PM]. Relations with an adverse event and the drug plasma concentration to develop early in the administration in voriconazole normal oral administration patients 浅野岳人1, 粟田浩文1, 杉山惠亮1, 羽田勝彦1, 柿本実咲2, 長谷川洋一2, 三浦崇則3, 澤正史4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1090-1091, 2024. |
|---|
|
|
[P0749-3-PM2]. The establishment of the tofacitinib blood level assay and the clinical application 須野学1, 伊藤雄大1, 高尾政輝2, 新谷心苗1, 岩田彩伽1, 北野雅之2, 松原和夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1091-1091, 2024. |
|---|
|
|
[P0750-4-PM]. Examination - case report - about the association of Donepezil blood level and the arrhythmia onset 松田翔平1, 竹田凌1, 森信博2, 横大路智治3, 小田啓祐2, 高倉英樹2, 村上照夫2, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1091-1092, 2024. |
|---|
|
|
[P0751-3-PM2]. Construction of the blood level simultaneous analytical procedure of the new antiepileptic drug using LC-MS 加治侑樹1, 土谷祐一2, 岩下昂太1, 金城奏乃1, 川尻雄大1, 藤田隼輔1, 峯昌敏2, 廣田豪2, 小林大介1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1092-1092, 2024. |
|---|
|
|
[P0752-4-PM]. One case of the VKORC1-1639G allele carriers that a change of the dietary intake due to eating disorders affected the warfarin sensitivity 齊藤伸, 木元健寛, 瀬戸亘, 吹谷真紀子, 鈴木ひとみ, 仙葉悠紀, 齋藤香織, 篠田和人, 山崎恵葉, 佐藤圭, 金美紀, 一関美江子, 八代佳子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1092-1093, 2024. |
|---|
|
|
[P0753-3-PM2]. Basic examination for the usefulness evaluation of the CYP2D6 activity prediction biomarker candidate 林和未1, 公文代將希2, 前川正充1,2, 眞野成康1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1093-1093, 2024. |
|---|
|
|
[P0754-4-PM]. Recurrence, 2 cases that was treated with DCEP therapy for intractable multiple myeloma 小山加奈世1, 小倉圭史2, 民西葉子2, 阿部史誉1, 中尾光成2, 早川太朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1093-1094, 2024. |
|---|
|
|
[P0755-3-PM2]. The effectiveness of the Lenvatinib Pembrolizumab therapy in patients with endometrial cancer and safe investigation 門田陵平, 渡邊梓, 池村健治, 山本智也, 奥田真弘 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1094-1094, 2024. |
|---|
|
|
[P0756-4-PM]. Investigation into the occurrence of infusion reactions in combination with 90-minute rituximab infusion and polatuzumab vedotin 水岡大策1, 山口佳津騎2, 元木貴大1, 田中裕章1, 小坂信二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1094-1095, 2024. |
|---|
|
|
[P0757-3-PM2]. Efforts of the safety management about the cancer chemotherapy 小竹優希, 向井淳治, 坂本竜平, 堀口涼子, 奥田広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1095-1095, 2024. |
|---|
|
|
[P0758-4-PM]. The oral adverse event "correlation in patients who received foreign cancer medical therapy of usefulness of the medical person intervention and Pro-CTCAE and CTCAE" 坂井由紀1, 勝良剛詞2, 小竹正晃1, 外山聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1095-1096, 2024. |
|---|
|
|
[P0759-3-PM2]. Multidisciplinary collaboration to introduce blinatumomab into outpatient treatment using a portable precision infusion pump and a case report 小林美奈子1, 鈴木訓史1, 唐芳浩太1, 永澤佑佳1, 東敬太1, 吉田美貴子2, 及川恵2, 長谷のりこ2, 窪田佳奈子2, 勝岡優奈3, 内藤義博1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1096-1097, 2024. |
|---|
|
|
[P0760-4-PM]. Fact-finding and problem search of the patients who received foreign cancer chemotherapy follow-up 島田斗茂美1, 清水孝祐1, 林和可1, 及川紀子1, 亀山涼子1, 佐野加代子1, 高橋佳奈1, 小出知嘉子2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1097-1097, 2024. |
|---|
|
|
[P0761-3-PM2]. A case which utilized PRO-CTCAE at a health insurance pharmacy, and conducted patients with cancer follow-up 高見陽一郎1, 金本拓始1, 松元享平1, 岡泰子1, 平田まゆら1, 松尾陽子1, 高岡純也1, 田坂友紀2, 大倉裕祐2, 田坂祐一3, 安倉央1, 高橋正志1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1097-1098, 2024. |
|---|
|
|
[P0762-4-PM]. Intensity of treatment investigation before and after the cancer chemotherapy tracing report acceptance in our hospital 佐藤家恒, 小泉真, 清水優依, 小嶋雅人, 小川信二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1098-1098, 2024. |
|---|
|
|
[P0763-3-PM2]. Evaluation after the telephone follow introduction in the Lenvatinib + Pembrolizumab combination therapy in our hospital 井上智敦, 平池美香子, 齋藤巨樹, 小園亜希, 湊本康則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1098-1098, 2024. |
|---|
|
|
[P0764-4-PM]. Effect inspection ... of the workshop holding targeted for activity report - healthcare worker of the cancer medical therapy support team in the large Hannan medical center 植田裕美1, 佐々木祐太1, 庄野裕志1, 櫛田宏幸1, 佐光留美1, 工藤慶太2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1099-1099, 2024. |
|---|
|
|
[P0765-3-PM2]. The effectiveness of the chemical resolution of the antitumor agents in the short time response with the dilution sodium hypochlorite 濱宏仁, くわ原晶子, 大川恭子, 田内義彦, 辻本勉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1099-1099, 2024. |
|---|
|
|
[P0766-4-PM]. Competitive review about the anticancer medicine exposure before and after the CSTD change 矢野琢也, 松本大輝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1100-1100, 2024. |
|---|
|
|
[P0767-3-PM2]. Inspection about exposure measures and the effect for 5FU which exposure investigation after the closed system anesthesia drug transportation system full-scale introduction showed [the second report] 齋藤順, 延川正雄, 杉本拓哉, 松田圭一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1100-1100, 2024. |
|---|
|
|
[P0769-3-PM2]. Examination (the third report) of the effect that altitude gives for vial internal pressure in the anticancer medicine preparation 高野秀仁1, 渡邉航平2, 安室修3, 渡邉浩志1, 舟越亮寛3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1101-1101, 2024. |
|---|
|
|
[P0770-4-PM]. Exposure investigation about the gemcitabine paclitaxel by the alcohol sterilization at germfree preparation room import 松本拓真, 津郷佑規, 和田翼, 長谷部匡史, 堀田修次, 仙波靖士 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1101-1102, 2024. |
|---|
|
|
[P0771-3-PM2]. Examination of simplifying it of the environmental research of cyclophosphamide using the qualitative analysis kit 増渕敬久1, 傅恵美1, 井野川徹1, 榎本英明1, 景秀典1, 辻健作1, 石丸博雅2, 津田泰正1, 後藤一美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1102-1102, 2024. |
|---|
|
|
[P0772-4-PM]. Efforts to duties efficiency by the construction of the anticancer agent preparation remote inspection system 藤原純平, 瀬戸口由, 橋詰宏美, 増田成美, 高橋弘季, 平川理紗, 横山晋一郎, 田路章博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1102-1103, 2024. |
|---|
|
|
[P0773-3-PM2]. The calculation situation of the cooperation full addition in our hospital and future problem 木本秀樹, 長谷川将, 山村真貴子, 佐藤優希子, 田口みどり Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1103-1103, 2024. |
|---|
|
|
[P0774-4-PM]. One case that the intervention of the drugstore pharmacist contributed to treatment continuation for patients with S-1 therapy started pancreatic cancer 河端明子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1103-1104, 2024. |
|---|
|
|
[P0775-3-PM2]. The actual situation comparison of doubt inquiry about the cancer medical therapy before and after the specialized medical institution cooperation drugstore authorization 西垣貴司1, 田辺憲人1, 島貫英二2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1104-1104, 2024. |
|---|
|
|
[P0776-4-PM]. One case of the BRCA mutation in the gene-positive ovarian cancer which long-term nothing recurrent survival was able to maintain by medication of the Olaparib by the continuous intervention of the pharmacist 野口裕介1, 加藤良隆1, 大坪達弥1, 加藤聖子2, 豕瀬諒3, 村木優一3, 友金幹視1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1104-1105, 2024. |
|---|
|
|
[P0777-3-PM2]. One patient who responded to nivolumab for patients with stomach cancer during haemodialysis treatment 山村真貴子, 森本優鳥, 木本秀樹, 長谷川将, 田口みどり Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1105-1106, 2024. |
|---|
|
|
[P0778-4-PM]. Efforts to the tracing report report number and the improvement of the cancer domain in quality 中村久美, 鬼窪利英 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1106-1106, 2024. |
|---|
|
|
[P0779-3-PM2]. Evaluation of the calculation method of the seamless cooperation full addition when we switch over from hospitalization to an outpatient 池上幸恵1, 津曲恭一1, 上原智博1, 荒木志乃1, 東盛裕里1, 石新あおい1, 黒原健1, 木下晶惠2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1106-1107, 2024. |
|---|
|
|
[P0780-4-PM]. Medication follow-up-adaptive tool "Followcare (LINE cooperation) One case of the patients with cancer follow-up utilizing " 木村貴徳 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1107-1107, 2024. |
|---|
|
|
[P0781-3-PM2]. 1 case that the night telephone correspondence by the health insurance pharmacy pharmacist was connected for the side effect of foreign cancer-treated patients and uneasy reduction, and was useful in improvement in quality of life 中村俊貴1,2, 爲我井一統1, 坂本岳志1, 境美智順1, 木村雅彦1, 平山武司2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1107-1108, 2024. |
|---|
|
|
[P0782-4-PM]. Use fact-finding of the NK1 receptor blocker for the moderate emetic risk regimen containing oxaliplatin of patients with colon cancer and stomach cancer 葛原寛子1, 眞貝萌1, 猪熊容子1, 幾田慧子1, 今吉菜月1, 池見泰明1, 野村久祥1, 津田真弘1,2, 中川俊作1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1108-1108, 2024. |
|---|
|
|
[P0783-3-PM2]. Investigation of the use situation of the fosnetupitant and the effectiveness 又吉嘉寿人, 喜多洋嗣, 駒井勇太, 人見百合子, 水野康平, 宇根良祐, 水摩ひかり, 知念ほのか, 高橋利佳子, 行武由美子, 横山夏季, 徳城雄大 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1109-1109, 2024. |
|---|
|
|
[P0784-4-PM]. Investigation about the effect on retching that changes from aprepitant to fosnetupitant result in 芦崎雅之1, 小野寺馨2, 奥田博介2, 平田力1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1109-1110, 2024. |
|---|
|
|
[P0785-3-PM2]. Comparison of the antiemetic effects of first-generation and second-generation 5-HT3 receptor antagonists in combination with an NK1 receptor antagonist on nausea and vomiting during initial administration of R±CHOP therapy 西村巧1, 岩本大紀2, 小沼大祐1, 寶福誠1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1110-1110, 2024. |
|---|
|
|
[P0786-4-PM]. Prophylactic antiemesis effect of olanzapine on antiemesis situation and poor antiemesis case in the doxorubicin + ifosfamide combination chemotherapy of malignant soft part tumor 山田友奈美1, 星野良1, 藤井宏典1, 飯原大稔1, 原亘輝1, 小林亮2, 永野昭仁3, 次田雅典3, 秋山治彦3, 鈴木昭夫1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1110-1111, 2024. |
|---|
|
|
[P0787-3-PM2]. Observational, prospective study (JASCC-CINV2001) about the emetic risk of trifluridine/Tipiracil for patients with colon cancer 陳美樹1, 藤井宏典2, 飯原大稔2, 土屋雅美3, 平手大輔4, 高橋克之5, 郷真貴子6, 工藤敏啓7, 下村一景8, 安藤洋介9, 谷伸也10, 渡邊大地2, 林克剛3, 大塚亮1, 松波奈緒美4, 高橋正也5, 長谷川晶子7, 内田敬3, 久保晶子1, 高橋孝夫11, 松橋延壽11, 鈴木昭夫2, 西村潤一12, 乾直輝13, 橋本浩伸1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1111-1111, 2024. |
|---|
|
|
[P0788-4-PM]. Effective comparison by the diabetes history presence or absence of three-drug antiemesis therapy in patients with fluorouracil + cisplatin therapy enforcement cancer of the esophagus 木村俊哉1, 羽鳥正浩1, 福岡聖大2, 川上和宜1, 橋本幸輝1, 小林一男1, 山口研成2, 山口正和1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1111-1112, 2024. |
|---|
|
|
[P0789-3-PM2]. The effect that changes from aprepitant to fosnetupitant give to retching, vomiting in dose dense-EC of the breast cancer chemotherapy and the EC 松井頌明1, 寄高美奈子1, 原田未紗1, 岩村高弘1, 神原史織1, 森光保武1, 岡田直人2, 池田雅彦3, 藤井秀一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1112-1113, 2024. |
|---|
|
|
[P0790-4-PM]. Satisfaction investigation of patients who received foreign chemotherapy in the pharmaceutical intervention before practice 西場弘美, 千吉良幸子, 小材直人, 蟻川勝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1113-1113, 2024. |
|---|
|
|
[P0791-3-PM2]. A case of the hypoadrenalism that was careless for the early detection of the thing which detected clinical manifestations during nivolumab administration 高橋杏奈, 木元慎一郎, 遠藤大介 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1113-1114, 2024. |
|---|
|
|
[P0792-4-PM]. A case that a nutrient for intestinal administration was useful for hypomagnesemia by the panitumumab 吉川英里, 坂林加奈子, 城口将太, 杉森祐一朗, 高木日菜, 麻生美佐子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1114-1114, 2024. |
|---|
|
|
[P0793-3-PM2]. Fact-finding of the initial examination situation at use of immune checkpoint inhibitor 斉藤匡昭, 佐藤匠, 平泉達哉 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1114-1115, 2024. |
|---|
|
|
[P0794-4-PM]. Analysis of the risk factor to be involved in onset of low Mg blood symptom with cetuximab 廣上典和, 舟瀬和美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1115-1115, 2024. |
|---|
|
|
[P0795-3-PM2]. The case that drug-induced aortitis by the peg filgrastim developed, and pain was prolonged after the views improvement by steroid administration 遠藤美央, 玉木慎也 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1115-1116, 2024. |
|---|
|
|
[P0796-4-PM]. Investigation of the protective efficacy of the Bilastine for the infusion response at the daratumumab subcutaneous administration 磯知輝, 南雲昭人 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1116-1116, 2024. |
|---|
|
|
[P0797-3-PM2]. One case that was improved by the active intervention of the pharmacist for frequent diarrhea by the Atezolizumab for the breast cancer 嘉村基樹, 地下隆介, 玉置祐輔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1117-1117, 2024. |
|---|
|
|
[P0798-4-PM]. Efforts ... to safety management by cardiac activity disorder management ... multi-type of job collaboration of anthracyclines 樋口文子1, 吉田ミナ2,3, 河野美穂子2,4, 衛藤智章1, 後藤隆1, 清水裕彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1117-1117, 2024. |
|---|
|
|
[P0799-3-PM2]. A case of intervention for thrombocytopenia side effect in a patient receiving niraparib as maintenance therapy after initial chemotherapy for ovarian cancer 松本浩次 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1118-1118, 2024. |
|---|
|
|
[P0800-4-PM]. Fact-finding of the ICI treatment in the non-small cell lung cancer 山田桃子, 田代匠, 宮澤憲治, 山下紗瑛奈, 西田涼馬, 安達尚哉, 八田浩之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1118-1118, 2024. |
|---|
|
|
[P0801-3-PM2]. Survey of cancer treatment-related cardiac dysfunction in patients receiving trastuzumab deruxtecan 井川実穂1, 猪熊容子1, 渡邉愛未1, 幾田慧子1, 今吉菜月1, 野村久祥1, 津田真弘1,2, 中川俊作1, 寺田智祐1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1119-1119, 2024. |
|---|
|
|
[P0802-4-PM]. One case of the lung cancer that resulted in serious nervous system disorder after the entrectinib remedy 西岡菜々子1, 中村太陽2, 今井健太郎2, 吉元公一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1119-1120, 2024. |
|---|
|
|
[P0803-3-PM2]. We look at the first generation, the rear of the allergic expression situation by the use of second generation antihistamine to an oxaliplatin hypersensitivity reaction and examine a mark 倉橋真弓, 植田有希, 山東真寿美, 新井花緒, 堀友紀, 木村美甫, 口分田章典, 中野寛之, 藤田敬子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1120-1120, 2024. |
|---|
|
|
[P0804-4-PM]. Use evaluation of the azulene Xylocaine tranexamic acid gargle in the cisplatin combination radiotherapy for patients with head and neck cancer 小出博義1, 野田哲史1,2, 大脇成広3, 清水猛史3, 森田真也1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1120-1121, 2024. |
|---|
|
|
[P0805-3-PM2]. One case that we prescribed different Chinese medicine of the mechanism of action, and a drugstore pharmacist suggested it to the hot flash of hormonal therapies after the breast cancer technique and improved 佐藤友美1, 武石美奈子1, 佃拓也2, 小川国大2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1121-1121, 2024. |
|---|
|
|
[P0806-4-PM]. Examination of the factor indicated for "Gee raster subcutaneous injection 3.6 mg body pod" 加藤幾1, 牛膓沙織1, 野村翔1, 中澤柊1, 柴田雅央2, 稲垣正巳1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1121-1122, 2024. |
|---|
|
|
[P0807-3-PM2]. A case which we followed up by cooperation with an application and the hospital pharmacist of the nonprescription drug as a family pharmacist for an eye manifestation during S1 treatment 東中川雅史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1122-1122, 2024. |
|---|
|
|
[P0808-4-PM]. The case that we followed up without using rasburicase for recurrent DLBCL patients of the tumor lysis syndrome high risk 近藤有結季, 輿石徹, 寺澤路子, 吉元公一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1122-1123, 2024. |
|---|
|
|
[P0809-3-PM2]. Fact-finding of the onset of eruption in the GEM+nab-PTX therapy of our hospital 貝阿彌杏由, 伴具也, 長谷川広樹, 櫻井登代子, 大津山裕美子, 三浦誠 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1123-1124, 2024. |
|---|
|
|
[P0810-4-PM]. About the effectiveness of the supportive care medicine for the dermatopathy during use of docetaxel for the breast cancer perioperative period 高取裕司, 桂川健司, 高岡龍蔵, 遠山幸男 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1124-1124, 2024. |
|---|
|
|
[P0811-3-PM2]. The effect that the administration method and renal function give to onset of serious neutropenia with trifluridine Tipiracil hydrochloride combination tablets in colon cancer 折戸花帆1, 安藤洋介2, 水野智博2, 松岡宏3, 堀口明彦4, 林高弘1,2, 山田成樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1124-1125, 2024. |
|---|
|
|
[P0812-4-PM]. One case of renal cell carcinoma that the dosage of the tocilizumab + dexamethasone was effective for irAE- cytokine release syndrome 合原嘉伸1, 竹内耕治1, 古野龍也1, 猪口雅章1, 久保利樹1, 柿木寛明2, 永瀬圭3, 山口優香子2, 中村和樹2, 野口満2, 島ノ江千里1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1125-1125, 2024. |
|---|
|
|
[P0813-3-PM2]. Examination of the effect of the surgical glove for the purpose of the development of peripheral neuropathy prevention in the albumin suspension type paclitaxel administration 島田泉1, 中川裕介1, 外山聡1, 渡部聡2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1125-1126, 2024. |
|---|
|
|
[P0814-4-PM]. There is a well-known CK rise after administration G-SOX + Nivo, irAE dysfunction thyroid and a case which became clear 冨井隆弘1, 輿石徹1, 吉元公一1, 中村洋典2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1126-1126, 2024. |
|---|
|
|
[P0815-3-PM2]. Effect on subsequent systolic blood pressure and treatment with difference in antihypertensive agent introduction blood pressure continuation for the ramucirumab-induced high blood pressure 吉見彩香, 吉田弘樹, 笠井翼, 牧原明秀, 近藤舞子, 渡邊ちひろ, 安藤武志, 三屋良太, 高原悠子, 鈴木雅人, 木全司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1126-1127, 2024. |
|---|
|
|
[P0816-4-PM]. Examination about the oxaliplatin-induced hypersensitivity reaction risk aversion effect with 6.6 mg of dexamethasone and 13.2 mg of administration 名和田幸介1, 相良英憲2, 古川誠之1, 内田航1, 渡邊太朗1, 手嶋ひさ子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1127-1127, 2024. |
|---|
|
|
[P0817-3-PM2]. The case that resulted in a cytokine-releasing syndrome by Atezolizumab and bevacizumab combination therapy for patients with multiple hepatocellular carcinoma 神原諒1, 小山加奈世1, 大林隼一1, 大井舜也2, 早川太朗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1128-1128, 2024. |
|---|
|
|
[P0818-4-PM]. One patient who underwent dermatopathy measures in the thiotepa administration for the adult malignant lymphoma 浅賀香里1, 森本隼多1, 小谷野実香2, 吉澤成一郎3, 鮎原秀明1, 後藤明彦3, 竹内裕紀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1128-1129, 2024. |
|---|
|
|
[P0819-3-PM2]. Tolerability evaluation about the short hydration method at the cisplatin administration in the slight moderate decreased renal function patients 得能正裕1, 牛島智子1, 原一正2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1129-1129, 2024. |
|---|
|
|
[P0820-4-PM]. Study on usefulness of the Chinese medicine prescribed medicine in the chemotherapy adjuvant in pancreatic cancer preoperation 西本亜沙美, 花岡幸恵, 廣永和也, 木村覚, 片山皓希, 實川東洋 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1129-1130, 2024. |
|---|
|
|
[P0821-3-PM2]. One case that steroid and an IVIG did not succeed for autoimmune encephalitis by Nivolumab 山本佳苗1, 鳥海未奈1, 松沼悟1, 輿石徹1, 秋田泰之輔2, 吉元公一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1130-1130, 2024. |
|---|
|
|
[P0822-4-PM]. Efforts of the confirmation by the pharmacist of drawing blood data before anticancer agent administration in the inpatient 原口智彦, 藤田靖之, 原田周平, 入江貞治, 井上知哉, 馬場麗名, 荒木正義, 池上沙織, 丸山真理子, 隈部法子, 池田能利子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1130-1131, 2024. |
|---|
|
|
[P0823-3-PM2]. Effect with the chronic administration of micafungin in our hospital 田代結女, 戸田純司, 篠田真歩, 野津祐貴, 成田久美, 室岡邦彦, 高瀬久光 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1131-1131, 2024. |
|---|
|
|
[P0824-4-PM]. Examination of the short hydration method to patients with biliary cancer with the decreased renal function 大岡千寿子, 中村俊之, 河北和馬, 野洌孝二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1131-1132, 2024. |
|---|
|
|
[P0825-3-PM2]. Examination about the effectiveness, the safety of the naldemedine prophylaxis for the opioid-induced constipation 水谷彰史1, 山下友輝2, 須藤美穂子1, 佐藤愛莉3, 先名健太1, 坂本和央1, 小原秀治1, 前田久恵4, 館野亜紀子4, 桂川みき1, 樋浦一哉3, 棚谷貢1, 船木映二1, 柴波明男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1132-1132, 2024. |
|---|
|
|
[P0826-4-PM]. One patient who relieved dyspnea in the self-care of the drug injection in Anjo rebirth hospital palliative care unit 渡辺裕之1, 野本歩未1, 小島礼菜1, 中村里英奈1, 高津章恵1, 植松夏子1, 鈴木千晴1, 藤井友和2, 米山英二1, 沖哲3, 足立康則3, 羽田勝彦1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1132-1133, 2024. |
|---|
|
|
[P0827-3-PM2]. School education about the preparation procedure of the drug parenteral injection, the actual situation of the workplace education attendance 外山智章1,2, 相田和希2, 大野凜太郎2, 藤村昭太2, 板垣鈴香2, 加納亜由子2, 佐藤淳也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1133-1133, 2024. |
|---|
|
|
[P0828-4-PM]. Search of the alleviation of fever effect of the diclofenac sodium percutaneous absorption type preparation on patients with cancer 秋吉尚雄1, 山口健也2, 吉村真一郎2, 小林郁夫2, 高山浩太郎1, 原田洸秀1, 進藤美舟3, 西尾拓海1, 居塚しのぶ1, 小倉秀美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1134-1134, 2024. |
|---|
|
|
[P0829-3-PM2]. 1 case that persisted, and injected a medical drug hypodermically using a portable PCA pump, and became the home discharge 小川実華, 奥田和貴, 高橋里沙, 大久保麻依, 安見塁, 山田智子, 河野正和, 中尾耕治, 河井良智 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1134-1135, 2024. |
|---|
|
|
[P0830-4-PM]. A case that dose adjustment of tramadol in patients with old cancer with the decreased renal function succeeded 白石童子1, 木村純子1, 大平サラ1, 石井友也1, 酒井敏直1, 相坂爽月1, 早乙女彩子2, 早乙女浩之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1135-1135, 2024. |
|---|
|
|
[P0831-3-PM2]. A case that ketamine continuous intravenous infusion combination was effective in addition to opioid for the clear cells sarcoma which had poor pain control 小山雅敏, 世古口拓也, 三宅知宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1135-1136, 2024. |
|---|
|
|
[P0832-4-PM]. Is codeine useful for sufferings from breathing symptom of patients with cancer? 丸山紗緒里1, 中村和代1, 林崎修也1, 岸本寛史2, 櫻井和子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1136-1136, 2024. |
|---|
|
|
[P0833-3-PM2]. The current situation of the polypharmacy measures in palliative care rounds 岩田一史, 西上依里, 土屋惠菜, 小山勢納, 合澤啓二, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1136-1137, 2024. |
|---|
|
|
[P0834-4-PM]. Naldemedine administration continuance rate in the cancer terminally ill patients with a few opioid doses 覚前有希子1, 水野智博1, 蟹江孝樹1, 古関竹直1, 花本彩2, 富田雅子3, 林高弘1,3, 松岡宏4, 山田成樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1137-1137, 2024. |
|---|
|
|
[P0835-3-PM2]. Research about the current situation of the regional alliances drugstore about the at-home mild medical acceptance and the consciousness 長谷圭悟1, 下菊早紀2, 中原麻佑3, 面谷幸子3, 名徳倫明3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1137-1138, 2024. |
|---|
|
|
[P0836-4-PM]. Use fact-finding of the drug parenteral injection in the at-home terminally ill patients 中川友之1, 高橋広将1, 丸一泰雄2, 草場大作2, 折戸真澄3, 荒川太一4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1138-1138, 2024. |
|---|
|
|
[P0837-3-PM2]. Fact-finding (followup) after the opioid rounds operational change 中原萌子, 高武嘉道, 大橋邦央, 藤瀬陽子, 橋本雅司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1138-1139, 2024. |
|---|
|
|
[P0838-4-PM]. Examination of the making of the medical drug self-care manual by the multi-type of job collaboration and the operational problem 畝本由貴1,2, 小田原めぐみ2, 比良大輔1,2, 世良真愛子1,2, 中上小百合2, 別所千枝1,2, 則行敏生2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1139-1139, 2024. |
|---|
|
|
[P0839-3-PM2]. Make weak point attitude survey - competency about the mild domain in the pharmacy of the national international medical research center hospital; and ... 渡邊一史, 工藤浩史, 大橋養賢, 増田純一, 西村富啓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1139-1140, 2024. |
|---|
|
|
[P0840-4-PM]. Questionary survey for the medical person about the drug self-care for the medical care 仲田浩成1,2, 樋口文子2, 久松大祐1,2, 泊由布子3, 小崎千尋3, 安永浩子3, 嶋本正弥4, 江崎泰斗1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1140-1140, 2024. |
|---|
|
|
[P0841-3-PM2]. Examination about the effect that dietary intake gives to the effectiveness of the naldemedine 中谷健一, 村上佳愛, 金子昌平, 長谷川豊 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1140-1141, 2024. |
|---|
|
|
[P0842-4-PM]. The example report that we connected with measures reinforcement through serious immune-mediated adverse event (irAE) 石崎文子, 芳山健太郎, 北爪教貴, 寺島里枝, 相原敏彦, 仲鉢英夫 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1141-1141, 2024. |
|---|
|
|
[P0843-3-PM2]. Report of the study implementation situation using PBPM for the HBV reactivation in the cancer chemotherapy 井上海容, 小中健, 斎藤辰彦, 森剛志, 都築大輔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1141-1142, 2024. |
|---|
|
|
[P0844-4-PM]. Examination about optimum doses in the gemcitabine + nab paclitaxel combination therapy 小中健1,2, 井上海容1, 斉藤辰彦1,2, 森剛志1,2, 森本美由樹2,3, 松村圭一郎4, 都築大輔1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1142-1143, 2024. |
|---|
|
|
[P0845-3-PM2]. 3 cases that HBV reactivation had after working on HBV reactivation measures by PBPM, and starting 中嶋紘文, 村永諒, 神佳祐, 吉田壘, 山本いずみ, 櫻田穣, 坂田幸雄, 長浜谷耕司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1143-1143, 2024. |
|---|
|
|
[P0846-4-PM]. Specific ... of the D-Dimer level of phlebothrombus of lower extremities embolism monitoring - sonography enforcement of patients with ramucirumab administration stomach cancer 竹中翔也, 岩井美奈, 木村美智男, 宇佐美英績 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1143-1144, 2024. |
|---|
|
|
[P0847-3-PM2]. Examination about myelosuppression of the Pola-BR therapy in the decreased renal function patients 坂本竜平, 向井淳治, 小竹優希, 内海百桃, 奥田広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1144-1144, 2024. |
|---|
|
|
[P0848-4-PM]. Investigation about the pulmonary disorder of non-small cell lung cancer Durvalumab treated patients 久保田真生, 合津貴志, 田崎政則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1144-1145, 2024. |
|---|
|
|
[P0849-3-PM2]. Interim report of patients support and the pharmacist intervention utilizing ePRO in the treatment with anticancer agent 木内貴章1, 河原陽介1, 水野奈穂子1, 上杉章紀1, 工藤陽一1, 上田重人2, 加藤良治1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1145-1145, 2024. |
|---|
|
|
[P0850-4-PM]. Examination about the methotrexate levofolinate relief therapy at a large quantity of methotrexate therapy enforcement 野口直子, 西村典子, 延島勇 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1145-1146, 2024. |
|---|
|
|
[P0851-3-PM2]. For the hepatocellular carcinoma in the friendship medical center about Tremelimumab and Durvalumab combination therapy 東恩納寛悟, 譜久原朝也, 上里芽衣子, 平塚真弘, 小杉卓弘, 國分千代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1146-1146, 2024. |
|---|
|
|
[P0852-4-PM]. A case which started Pembrolizumab+FP therapy for cancer of the esophagus, and developed serious irAE approximately four months after administration in the pembrolizumab last 岩村高弘, 藤井秀一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1146-1147, 2024. |
|---|
|
|
[P0853-3-PM2]. The search of the factor associated with the administration continuation of the anamorelin in the cancer cachexia patients: Single institution retrospective study 江川優香1, 内山将伸1,2, 江越菜月1, 五十嵐保陽1, 安高勇気1,3, 山科卓也1,2, 中野貴文1,2, 松尾宏一1,2, 兼重晋1, 神村英利1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1147-1147, 2024. |
|---|
|
|
[P0854-4-PM]. 1 case that completed ST medical mixture after bendamustine + obinutuzumab maintenance therapy successful execution in half a year, and developed pneumocystis pneumonia one year later 成田綾香1, 曽根崇2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1147-1148, 2024. |
|---|
|
|
[P0855-3-PM2]. Comparison ... of an effect - cancer case and the non-cancer case for the renal function of Triple Whammy in the cancer case 滝澤苑美1, 吉野真樹1, 中村美沙季1, 渡辺なつみ1, 関崎和美1, 粉川直明2, 大沼明子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1148-1148, 2024. |
|---|
|
|
[P0856-4-PM]. Examination of the factor predicting continuity of the checkpoint inhibitor, Axitinib combination therapy for patients with progress renal carcinoma of immunity 岩田彩伽1, 伊藤雄大1, 新谷心苗1, 山下真平2, 松原和夫1,3, 須野学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1148-1149, 2024. |
|---|
|
|
[P0857-3-PM2]. Histories of treatment of the Pola-R-miniCHP therapy for super elderly patients in our hospital 80 years or older 助畑歩, 中村雄亮, 高橋優聡, 北川瑚姫, 小川綾香, 大聖遥香, 小森均 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1149-1149, 2024. |
|---|
|
|
[P0858-4-PM]. Examination of the effectiveness of CARG score for patients with our hospital colon cancer 上杉章紀, 善本亜由美, 木内貴章, 工藤陽一, 加藤良治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1149-1150, 2024. |
|---|
|
|
[P0859-3-PM2]. Examination of the effectiveness of the biomarker in the effect of treatment prediction by the daratumumab 藤井元1, 岡村篤夫2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1150-1150, 2024. |
|---|
|
|
[P0860-4-PM]. One case that produced a dangerously ill low Na blood symptom by Nab-PTX+Ramucirumab combination therapy 高取俊和1, 柴田亜実子1, 沖田健太郎1, 宇野太2, 船越幸代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1150-1151, 2024. |
|---|
|
|
[P0861-3-PM2]. A case of multiple myeloma patient receiving tube-administered pomalidomide using a simple suspension method 牧原明秀1, 安藤武志1, 三屋良太1, 近藤舞子1, 高原悠子1, 鈴木雅人1, 吉田弘樹1, 小林美希2, 内田俊樹2, 木全司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1151-1151, 2024. |
|---|
|
|
[P0862-4-PM]. We look at the rear about the successful execution factor of the Durvalumab maintenance therapy for the local advanced non-small cell lung cancer and analyze a mark 小竹正晃1, 坂井由紀1, 渡部聡2, 外山聡1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1152-1152, 2024. |
|---|
|
|
[P0863-3-PM2]. Investigation about the onset of hepatic dysfunction situation by the anamorelin 江越菜月1, 内山将伸1,2, 江川優香1, 安高勇気1,3, 五十嵐保陽1, 井上竜一1, 中野貴文1,2, 松尾宏一1,2, 兼重晋1, 神村英利1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1152-1153, 2024. |
|---|
|
|
[P0864-4-PM]. Use fact-finding of the anamorelin for the cancer cachexia 住吉恵, 前田七海, 高武嘉道, 藤瀬陽子, 大橋邦央, 橋本雅司 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1153-1153, 2024. |
|---|
|
|
[P0865-3-PM2]. The effect that Nivolumab administration in progress, recurrent gastric cancer first treatment gives for the second treatment 大山翔子1, 松岡宏2, 安藤洋介3, 水野智博3, 林高弘1,3, 山田成樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1153-1154, 2024. |
|---|
|
|
[P0866-4-PM]. Therapy with chemotherapy gemcitabine + nab - paclitaxel (as follows: GnP) for the progress pancreatic cancer and thermotherapy (hyperthermia) 和田祐一郎1, 栗本拓也2, 小林亜里紗1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1154-1154, 2024. |
|---|
|
|
[P0867-3-PM2]. A case which performed desensitization for Carboplatin drug allergy, and was able to continue long-term treatment 村瀬実希, 菊千香子, 飛永あゆみ, 青山佳代, 佐治侑理奈, 堤田由布, 冨田敦和, 今西忠宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1154-1155, 2024. |
|---|
|
|
[P0868-4-PM]. A case that readministration was useful for early relapse after the caplacizumab chronic administration of the acquired thrombotic thrombocytopenic purpura 須田冴香, 三浦知美, 出口真人, 冨田敦和, 今西忠宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1155-1155, 2024. |
|---|
|
|
[P0869-3-PM2]. Investigation about the domestic clinical study information in Foundation one CDx/Liquid CDx cancer genome profile analysis results report and the C-CAT findings 藤原大一朗, 大野智里, 永宮もえ, 星田唯史, 宮本幸一, 堂本佳加, 野田明宏, 田辺和史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1155-1156, 2024. |
|---|
|
|
[P0870-4-PM]. An anticancer medicine follow-up sheet and effect (the second report) that the cooperation full addition gives for patients follow-up 加藤良隆, 渡邉愛梨, 井上渉, 山田春香, 須藤ほおみ, 藤本彩花, 大坪彩子, 小林大祐, 大坪達弥, 友金幹視 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1156-1157, 2024. |
|---|
|
|
[P0871-3-PM2]. It is the 2 case of the central nerve recurrence malignant lymphoma receiving the Tirabrutinib by the simple suspension method 大野峻, 森下怜美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1157-1157, 2024. |
|---|
|
|
[P0872-4-PM]. About the training effect of the pharmacist (cancer) specialized in local pharmacy care 佐村頼寿1, 小山光2, 浦松敬宏2, 清水大生2, 田渕祐輔2, 小阪直史2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1157-1158, 2024. |
|---|
|
|
[P0873-3-PM2]. Evaluation of the effect to give to bacterial growth of the killer cells-related anticancer medicine for in-hospital bacteria 菊池健1, 佐藤秀紀2, 前田伸司3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1158-1158, 2024. |
|---|
|
|
[P0874-4-PM]. Efforts for the hepatitis B reactivation prevention by our hospital pharmacist 六田湧紀, 財間富士子, 前畠一友, 岡崎直樹, 高橋真理 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1158-1159, 2024. |
|---|
|
|
[P0875-3-PM2]. A case of the premenopausal hormone acceptor-positive HER2-negative recurrent breast cancer which gave Abemaciclib from gastric fistula by the simple suspension method 平木祥子1, 宮東利恵1, 西川美香子1, 北川奈津子1, 真舘育子1, 井口雅史2, 政氏藤玄1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1159-1159, 2024. |
|---|
|
|
[P0876-4-PM]. Oxaliplatin-induced peripheral neuropathy is inhibited by nafamostat mesilate 鈴木景子1,2, 鈴木昭夫3,4, 小林亮3,4, 渡辺大地4, 伊野陽子5, 野口義紘6, 吉村知哲1,6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1159-1160, 2024. |
|---|
|
|
[P0877-3-PM2]. The current situation of the inhalation therapy in patients with bronchial asthma by the corona evil in the community pharmacy: For appropriate inhalational instruction in the infection expansion situation 加納正暉1, 中村真理子1, 松本憲昭2, 榊原幹夫2, 金井俊樹3, 倉地晃良4, 平松正行1, 野田幸裕1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1160-1160, 2024. |
|---|
|
|
[P0878-4-PM]. Pharmacist support for prescription of Nilmatrervir tablets/Ritonavir tablets 長田和士1, 久保泰裕1, 嶋田奈奈恵2, 田中俊憲3, 瀧澤好廣3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1160-1161, 2024. |
|---|
|
|
[P0879-3-PM2]. Intervention of the pharmacist for the new coronavirus infection therapeutic drug in the chronic phase hospital 竹山千晶, 新枦義之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1161-1161, 2024. |
|---|
|
|
[P0880-4-PM]. Than the interview investigation to qualitative examination - citizen about the psychology for an infection and the vaccine ... 古谷理紗, 浅井美穂, 竹平理恵子, 正村優子, 有田悦子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1162-1162, 2024. |
|---|
|
|
[P0881-3-PM2]. Research about the intervention effect on vancomycin of the antimicrobial proper use support team in haemodialysis patients 林健太郎, 大平敦子, 小川大輝, 森内敬二, 井上智博 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1162-1163, 2024. |
|---|
|
|
[P0882-4-PM]. Effect of the review of the antimicrobial proper use support activity by the cooperation with the infection measures improvement addition cooperation institution working full time pharmacist 中野克哉1, 村澤寛美1, 佐々木康弘2, 常松健一郎3, 上蓑義典4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1163-1163, 2024. |
|---|
|
|
[P0883-3-PM2]. Investigation about the change of the number of the foreign oral antimicrobial of prescription and the bacterial drug-resistant rate 井上貴惠, 福重友理, 赤松隼人, 森塚暁裕, 今村政信, 中川博雄, 兒玉幸修, 大山要 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1163-1164, 2024. |
|---|
|
|
[P0884-4-PM]. The effect that introduction of a check gives to a sensitivity rate of the use situation of the antimicrobial and the gram-negative bacteria in the early period of treatment with AST 後藤拓也1,2, 梅橋梨永1,2, 相澤佑佳1,2, 堀沢知世1,2, 平野隆司1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1164-1164, 2024. |
|---|
|
|
[P0885-3-PM2]. Use trend of the foreign oral antimicrobial in from 2020 to 2023 of our hospital 佐藤智功 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1164-1165, 2024. |
|---|
|
|
[P0886-4-PM]. Investigation of the prescription situation of the meropenem preparation in our hospital 林靖久, 山口健太郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1165-1165, 2024. |
|---|
|
|
[P0887-3-PM2]. Use fact-finding of the antimicrobial in the treatment of the pelvic inflammatory disease 川勝優, 海野明子, 木原星衣, 奥村梨央, 矢野莉穂, 青木旦未, 鹿島弥生, 小林奈緒, 松本勝城, 長澤彩華, 加藤一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1165-1166, 2024. |
|---|
|
|
[P0888-4-PM]. The prescription situation investigation of the antimicrobial for patients with acute respiratory tract infection in the outpatient department 小山実央1, 鈴木智代1,2, 井出和男1, 渡邉直優1,2, 佐野加代子2, 友山瑛人2, 田中克志2, 藤井裕明2, 加藤英明2, 小池博文1, 佐橋幸子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1166-1166, 2024. |
|---|
|
|
[P0889-3-PM2]. Efforts to antimicrobial proper use by the pharmacist participation of the conference before urologic operation 高原みずほ1, 柴田拓実1, 渡邉雄斗1, 佐藤聡一郎1, 保田彩花2, 松本吉隆2, 大森洋平2, 厨川謙2, 友部光朗2, 佐藤健3, 長沢法子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1166-1167, 2024. |
|---|
|
|
[P0890-4-PM]. The use situation investigation of the antimicrobial of patients with aspiration pneumonia in our hospital 後藤義之, 仲村恵理子, 谷本百恵, 梅下翔, 青木理恵, 島崎沙織, 茶野下貴恵, 松岡未紗, 古本真由美, 岡田久美, 清水翔子, 角紀一郎, 森戸敏志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1167-1167, 2024. |
|---|
|
|
[P0891-3-PM2]. Gram-negative bacilli bacteremia derived from the UTIs in the Fukuyama Municipal Hospital urology department, sensitivity investigation of the origin bacteria 池田敦, 荻野裕介, 岡本直樹, 森光保武, 藤井秀一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1167-1168, 2024. |
|---|
|
|
[P0892-4-PM]. Effect - multicenter rearward observational study of the meropenem supply stop 西裕美1, 高武嘉道2, 平田亮介2, 副島啓司3, 塚田寛子4, 濱崎翔平5, 長崎洋司6, 橋本雅司2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1168-1168, 2024. |
|---|
|
|
[P0893-3-PM2]. The analysis of the factor associated with ampicillin/sulbactam tolerance of Escherichia coli: Retrospective cohort study 松本栞1, 樫村拓也1, 渋田成二1, 塩谷龍斗1, 大和田真輝1, 阿部朱里1, 齋藤祥子2, 鈴木貴弘3, 橋本英樹4, 田村明広1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1168-1169, 2024. |
|---|
|
|
[P0894-4-PM]. A case of bacteremia and pyelonephritis caused by NDM-producing Klebsiella pneumoniae successfully treated with cefiderocol 山本将司1, 森岡悠2, 西尾美津留3, 宮川佐和子1, 土本大輔1, 桑原悠里1, 大西克浩1, 水野彩花1, 出口裕子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1169-1169, 2024. |
|---|
|
|
[P0895-3-PM2]. The prescription situation and drug resistance investigation of the oral antimicrobial in the outpatient 冨山育朗, 工藤晋, 丹代恭太, 鈴木弘文 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1170-1170, 2024. |
|---|
|
|
[P0896-4-PM]. Comparison of the time to alleviation of fever of the cefmetazole administrated group and the meropenem group in the non-severe ESBL-producing Escherichia coli bacteremia 宮崎公爾1, 星貴薫2, 渡邉恵生1, 福村悠太1, 高橋まどか1, 谷口栄1, 木村慎吾1, 斎藤亜利紗1, 和田直樹3, 西條正二4, 板谷眞理恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1170-1170, 2024. |
|---|
|
|
[P0897-3-PM2]. The current situation investigation of the anti-therapeutic drug change suggestion after examining it, and diagnosing a request and endophthalmitis to the outside Parliament ophthalmology of patients with candidemia in the AST activity 佐古守人, 川戸美帆, 山本侑弥, 林春乃, 伊倉堅多, 豊島茂大, 黒沢秀夫, 野村剛久 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1171-1171, 2024. |
|---|
|
|
[P0898-4-PM]. Examination about the effect on renal failure by the difference between tacrolimus and azole-based antifungal agent to use together 吉田三矢, 井後彩加, 仲野真実, 櫛田宏幸, 庄野裕志, 佐光留美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1171-1172, 2024. |
|---|
|
|
[P0899-3-PM2]. 1 case of the Nocardia brain abscess that became clear during the close inspection of the intracranial lesion 出口奈緒美1, 佐々木暢琢1, 堀部緑1, 葛西樹里1, 市川尚己2, 荒木朋浩2, 木村匡男1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1172-1172, 2024. |
|---|
|
|
[P0900-4-PM]. Examination of the usefulness about de-escalation to cefmetazole in the substrate specific expansion type β - lactamase (ESBL)-producing bacteria bacteremia of elderly people 笹野央1, 宗村盛2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1172-1173, 2024. |
|---|
|
|
[P0901-3-PM2]. The current situation of the antimicrobial choice for pneumonia in our hospital 壇梨恵, 濱本将成, 山本有紀, 竹松茂樹, 永井聡子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1173-1173, 2024. |
|---|
|
|
[P0902-4-PM]. Examination of the factor to decrease promotion and SSI development of the antimicrobial proper use for perioperative infection prophylaxis in the surgery 小関崇文1,2, 篠田莉奈1,2, 大貫敏明1,2, 足立智子2, 大場雄一2, 奥村正樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1173-1174, 2024. |
|---|
|
|
[P0903-3-PM2]. A case that AST was associated with the gonococcal infection that presented pyogenic arthritis 吉岡祐貴, 小林義和 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1174-1174, 2024. |
|---|
|
|
[P0904-4-PM]. Investigation of the effect that meropenem supply restrictions gave for emergency care of our hospital 坂口美也子, 山田政典, 吉原涼子, 宮田拓周, 松下馨介, 稲田夏実, 齋藤巨樹, 小園亜希, 湊本康則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1174-1175, 2024. |
|---|
|
|
[P0905-3-PM2]. Advisability investigation - medical treatment case ... of the successful execution between therapeutic stages of the antimicrobial which we chose as target treatment for the infective endocarditis with streptococcus 坂倉広大1, 中蔵伊知郎1, 若林智仁1,2, 永田理香子1, 今西嘉生里1, 大西由華1, 廣瀬優冴1, 坂本麻衣1, 中野一也1, 山西香織1, 高橋彩子2, 佐田誠2, 畝佳子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1175-1175, 2024. |
|---|
|
|
[P0906-4-PM]. Examination of measures and the effect on Bacillus bacteremia in the beef lead (R) infusion use patients 佐々木優衣, 森章典, 白井景 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1175-1176, 2024. |
|---|
|
|
[P0907-3-PM2]. Efforts to use of the third generation oral cephalosporin medicine reduction in the Kiyoe society Hospital 河野敦志1, 上地沙也佳1, 野口裕之1, 小川一恵2, 藤田一彦2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1176-1176, 2024. |
|---|
|
|
[P0908-4-PM]. Efforts for the antimicrobial proper use of the AST working full time pharmacist using prescription monitoring system 本田貴朗, 石山晶子, 佐藤智也, 羽太光範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1177-1177, 2024. |
|---|
|
|
[P0909-3-PM2]. Change of the activity of our hospital AST which took advantage of meropenem supply restrictions 辻未希子1, 東慶之介2, 浦田孝之3, 狩野惠彦2, 船本哲生1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1177-1177, 2024. |
|---|
|
|
[P0910-4-PM]. Proper use of the antimicrobial in the urethroplasty 南真進1, 相澤雄介1, 鈴木剛史1, 堀口明男2, 井上博章1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1178-1178, 2024. |
|---|
|
|
[P0911-3-PM2]. A case that Film array PCR testing and the early intervention of the pharmacist were useful in cryptococcal meningitis treatment 中川喬統1, 山本諭1, 馬島務1, 日下駿1, 山下剛史郎1, 太田基博2, 野見洋基3, 川村尚久4, 満田正樹1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1178-1179, 2024. |
|---|
|
|
[P0912-4-PM]. The effect that a dose and age of clarithromycin give to the sanitization success rate in Vonoprazan combination Helicobacter pylori first sanitization therapy 藤林遼, 前川英輝, 山田将悟, 齋藤公華, 山内萌生, 橋本咲季, 菊地亮朗, 朝倉幹己, 田中耕太, 山本翔太, 高橋誠, 田中正臣 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1179-1179, 2024. |
|---|
|
|
[P0913-3-PM2]. The global point prevalence rate investigation (G-PPS) results and problem about the use situation and the tolerance of the antimicrobial in the Osaka mother and the child medical center 飯野香菜子1, 浅原章裕1, 長瀧谷美樹1, 運天奈緒美1, 谷口公啓2, 野崎昌俊2,3, 望月千枝1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1179-1180, 2024. |
|---|
|
|
[P0914-4-PM]. An evaluation and remedy in our hospital of the "improvement in improvement in exogenous infection measures addition and infection measures addition" that became the addition by medical service fees revision in 2024 institution standard 松永智子1,2,3, 安田暢子1, 丸田果鈴1, 馬場親紀1, 福井良枝2, 本田章子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1180-1180, 2024. |
|---|
|
|
[P0915-3-PM2]. Risk assessment of the CDI recurrence by DASC 永岡大輝1,2, 守田侑真3, 大矢智則1,6, 佐藤淳也4, 荒井悠太1, 岩下沙織1, 木内駿太郎1, 高橋和郎5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1180-1181, 2024. |
|---|
|
|
[P0916-4-PM]. Study on biomarker inflection for the early detection of the candidemia style infection 末廣陽子1,2, 塚本仁1,2, 東高士1,2, 上谷幸男1, 岩崎博道2, 酒巻一平3, 後藤伸之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1181-1181, 2024. |
|---|
|
|
[P0917-3-PM2]. Fact-finding about the use of the prophylactic antimicrobial in the surgery patients using medical big data 森翔一1,2, 詫間章俊1,2, 百賢二1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1181-1182, 2024. |
|---|
|
|
[P0918-4-PM]. About a use of own institution antimicrobial situation evaluation using the J-SIPHE and DASC method 葛間慎介1,2, 佐藤正幸1, 上野哲史1,2, 岩井中里香2, 卸川紘光2, 松浦しほみ2, 平林鑑2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1182-1182, 2024. |
|---|
|
|
[P0919-3-PM2]. Evaluation of the protocol introduction for the improvement in vaccination rate for the splenectomy patients 堀田奈央1, 大橋健吾1, 篠田康孝1, 新井かおり1, 松岡知子1, 吉村知哲2, 宇佐美英績1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1182-1183, 2024. |
|---|
|
|
[P0920-4-PM]. Investigation of the number of the development and the hand hygiene situation of the healthcare-associated infection in our hospital 池永啓介1, 田沼道也1,2, 渡邊愛子2, 黒田潤子2, 櫻井隆之2,3, 田中昌代1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1183-1183, 2024. |
|---|
|
|
[P0921-3-PM2]. A clinical course in the trace element hospital preparation administration that it non-contains iron for the iron excess of the long-term central venous hyperalimentation case and the evaluation 池西政幸1, 川上祥代1,2, 西川彩菜1,2, 畠中英理子1,2, 石井康世3, 角田すみ代2, 福原真美2, 辻井悟2,4, 待本貴文5, 奥野智之1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1183-1184, 2024. |
|---|
|
|
[P0922-4-PM]. One case of the anorexia nervosa given nourishment management intervention through ward pharmacist duties 大窪しおり, 近藤匡慶, 田杭直哉, 菅谷量俊, 林太祐 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1184-1184, 2024. |
|---|
|
|
[P0923-3-PM2]. About the administration of fat preparation situation in hyperalimentation treated patients 丸山昌広, 門井実, 定盛理純 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1185-1185, 2024. |
|---|
|
|
[P0924-4-PM]. Combined effect of the amino acid addition peripheral venous nutrition infusion for patients with infection 相馬直記 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1185-1185, 2024. |
|---|
|
|
[P0925-3-PM2]. The current situation investigation of "the healthy support business" by the pharmacist 近藤宏樹1,2, 篠永浩1,2, 加地努1,2, 矢野禎浩2, 和泉和子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1186-1186, 2024. |
|---|
|
|
[P0926-4-PM]. Investigation about the association of a sleeping drug and the respiratory depression using the adverse event database 秀島早紀, 祖川倫太郎, 島ノ江千里 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1186-1187, 2024. |
|---|
|
|
[P0927-3-PM2]. A retrospective study on the introduction of lemborexant to elderly and non-elderly people using sleep medications 大藪康平1,2, 安高勇気1,3, 舌間清晃1, 今任拓也2, 右田啓介2, 岩崎克典4, 神村英利1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1187-1187, 2024. |
|---|
|
|
[P0928-4-PM]. Analysis of risk factors for lemborexant-induced nightmares 保田和哉, 池田龍二 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1187-1188, 2024. |
|---|
|
|
[P0929-3-PM2]. The effect that delirium high risk medicine gives to delirium after the cardiovascular surgery surgery 廣田志由子1,4, 上田明穂1,4, 内藤喜隆2,4, 姫野麻菜美2,4, 清水一紀3,4, 奥村佳史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1188-1188, 2024. |
|---|
|
|
[P0930-4-PM]. About the efforts of the change of the sleeplessness by the dementia care team, restless time instructions 上野沙恵子, 辻井佳代, 玉木範子, 奥薗文代, 水田弘人, 宮原淳一, 枌祐二, 井上学, 小林政彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1188-1189, 2024. |
|---|
|
|
[P0931-3-PM2]. Effect to give to mother's milk transitivity of atorvastatin and control-related T-cell differentiation 田口和貴1,5, 田中祥子1, 町田晃一2, 袴田秀樹2, 池袋真3,4, 田中未央里4, 神谷太郎3, 水野克己3, 立沢正臣5, 下泰司5, 恩田健二1, 杉山健太郎1, 鈴木賢一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1189-1189, 2024. |
|---|
|
|
[P0932-4-PM]. One patient who received chemotherapy for patients with breast cancer for a gestation period who had the vein of lower extremity thrombosis 後藤裕美子1, 岩澤瞳1, 宇野英理子1, 黒瀬優輔1, 水野翼1, 中野正吾2, 大西正文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1189-1190, 2024. |
|---|
|
|
[P0933-3-PM2]. A case which the pregnancy was found out during nilotinib internal use for the chronic myelogenous leukemia, and led to delivery 中川友恵1,2,3, 長水正也1, 佐藤由美子1, 森下修行1, 濱嶋直樹2, 田尻佐和子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1190-1190, 2024. |
|---|
|
|
[P0934-4-PM]. Use fact-finding of the sleep inducing drug in the early puerperium 手島慶子1, 野元玲奈2, 瀬川侑里香1, 上田真美1, 小西麗子2, 向井啓2, 小森浩二2, 木村真策1, 河田興2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1190-1191, 2024. |
|---|
|
|
[P0935-3-PM2]. Problem search for the foundation and improvement of the pregnant woman nursing mother medical therapy workshop in the Tokushukai drug sectional meeting in correspondence ability to a pregnant woman nursing mother 三好文子1, 山村智代2, 松下貴英3, 福井幸4, 岩崎睦5, 宮坂善之6, 小茂田昌代1,7, 出雲貴文1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1191-1191, 2024. |
|---|
|
|
[P0936-4-PM]. Fact-finding in "the nursing and medicine outpatient department" of our hospital 岩澤春奈1, 一瀬ひろみ1, 篠原尚樹1, 山口佳津騎2, 元木貴大1, 田中裕章1, 小坂信二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1191-1192, 2024. |
|---|
|
|
[P0938-4-PM]. Investigation of the predictor about the adverse event of the oral semaglutide lock 山崎雄平1, 多胡友絵1, 星育子1, 小泉祐一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1192-1192, 2024. |
|---|
|
|
[P0939-3-PM2]. Investigation about the hypoglycemic experience in the drugstore store 藤山裕児1, 邑瀬誠2, 深津英人3, 松井洸3, 山口浩3, 野村和彦3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1192-1193, 2024. |
|---|
|
|
[P0940-4-PM]. The statin drugs inhibit the onset of diabetic peripheral neuropathy: Retrospective cohort study 岩根剛志1, 岩根詩織2, 田中雅幸1,2, 西山徳人1, 打谷和記1, 谷川昇1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1193-1193, 2024. |
|---|
|
|
[P0941-3-PM2]. Rearward observation of the hemoglobin hematopoiesis modifying factor of the SGLT2 inhibitor in patients with type 2 diabetes 吉田雄貴1,2, 山田治美2, 佐藤淳也3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1193-1194, 2024. |
|---|
|
|
[P0942-4-PM]. Association between prescription and digestion ductal carcinoma and precancerous lesion of the oral antidiabetic drug in patients with type 2 diabetes 山口知紗1, 村松泰地1, 五十嵐千都1, 神山奈子1, 五藤由奈1, 酒井良子1, 赤沢学1, 山室大介1, 菊池貴子2, 櫛山暁史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1194-1194, 2024. |
|---|
|
|
[P0943-3-PM2]. Examination of the factor to give it to the effectiveness, safety of the oral GLP-1 receptor agonist semaglutide (reBartha's) in patients with type 2 diabetes and effect of treatment 佐藤孝穂1, 早川伸樹1,2, 津川透1,3, 桑原宏貴3, 戸邊隆夫4, 伊藤佳織1,4, 平塚いづみ2, 吉野寧維2, 鈴木敦詞2, 山田成樹3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1195-1195, 2024. |
|---|
|
|
[P0944-4-PM]. Efforts to the diabetes education hospitalization using the tablet terminal 白髪恵美1, 扇喜真紀2, 五十野桃子2, 三木千春3, 木下亜美4, 浅川隆重1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1195-1196, 2024. |
|---|
|
|
[P0945-3-PM2]. Examination of the anemia improvement effect in the presence or absence of protein urine of the Empagliflozin on patients in diabetes non-merger CKD 川野智美1, 小野寺慶太1, 塚田寛子1, 堀南奈子1, 平山愛理1, 森島恵理佳1, 黒川真佑花1, 関瞭1, 下村真代1, 小山田純治1, 平木洋一2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1196-1196, 2024. |
|---|
|
|
[P0946-4-PM]. Association between HIF-PH inhibitor and heart failure 宮尾舞1, 石郷友之1, 相神智宏1, 野々山雅俊1, 山下智久2, 小山雅之3,4, 藤居賢1, 矢野俊之3, 古橋眞人3, 福土将秀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1196-1197, 2024. |
|---|
|
|
[P0947-3-PM2]. Research of the bleeding risk factor that weight loss administration is recommended of the edoxaban 佐藤真維 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1197-1197, 2024. |
|---|
|
|
[P0948-4-PM]. Pulse-taking after the drug suggestion of the bone fracture liaison service (FLS) intervention patients in consideration of renal function 瀬古高裕, 伊田厚輝 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1197-1197, 2024. |
|---|
|
|
[P0949-3-PM2]. Evaluation of safety and efficacy in patients who continued treatment for secondary hyperparathyroidism by switching from etelcalcetide to upacicalcet 大久麻里, 播磨里美, 饗庭孝一, 岡平将志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1198-1198, 2024. |
|---|
|
|
[P0950-4-PM]. Effect on iron index and hemoglobin by the iron medicine remedy at the HIF-PH inhibitor start 相神智宏1, 石郷友之1, 宮尾舞1, 野々山雅俊1, 山下智久2, 小山雅之3,4, 藤居賢1, 矢野俊之3, 古橋眞人3, 福土将秀1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1198-1199, 2024. |
|---|
|
|
[P0951-3-PM2]. Investigation about the estrangement of eGFRcys and eGFRcre in advanced age, low weight and the hypoalbuminemia 上坊健太, 藤原大一朗, 加藤渓, 星田唯史, 野田明宏, 田辺和史 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1199-1199, 2024. |
|---|
|
|
[P0952-4-PM]. Analysis of the intervention effect of the polypharmacy measures team mainly composed of pharmacists in the circulatory organ medical service 大石綾香, 村上礼隆, 上田百合菜, 井上清美, 植竹宣江, 北本真一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1199-1200, 2024. |
|---|
|
|
[P0953-3-PM2]. Change of the use of osteoporosis therapeutic drug situation for patients with fragile bone fracture by the activity of the osteoporotic working group 水口真利江1, 久賀谷幸昌1, 竹田凌1, 山崎真里2, 内田聡3, 和田直人3, 岩見憲司3, 外裏貴子4, 濱崎貴彦1,5, 西園寺真二1, 面田恵1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1200-1200, 2024. |
|---|
|
|
[P0954-4-PM]. Intervention significance of the medication actual situation and the drugstore pharmacist in the elderly people institution 寺田大輝1, 山口奈々1, 関下禅美2, 山本健3, 廣原正宜3, 串田一樹3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1201-1201, 2024. |
|---|
|
|
[P0955-3-PM2]. 2 cases using a heart failure follow-up sheet: Problem of the current situation and the drugstore follow-up of the home medical treatment 松本由加里, 杉村真也子, 白川奈津実, 野村悠, 藤井貴子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1201-1201, 2024. |
|---|
|
|
[P0956-4-PM]. Investigation about a change and the BMI of the serum cholinesterase level with the rivastigmine percutaneous absorption type preparation 足岡秀樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1202-1202, 2024. |
|---|
|
|
[P0957-3-PM2]. A case in which prescription medication for chronic pain was reduced through patient education and collaboration with external medical institutions 野村隼人1, 三村睦美1, 深谷寛1, 柏瀬しのぶ1, 吉永健太郎2, 塩川満1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1202-1202, 2024. |
|---|
|
|
[P0958-4-PM]. A case of the Werner syndrome that almost got over by the combined modality therapy to the ulcer which occurred in a heel, and reached the independence walk possibility 西村博之1, 吉田陽1, 塩山由紀1, 高田雅文1, 坂田美咲1, 石塚洋一2, 近藤悠希2, 稗島州雄3, 栗並昇3, 鈴木知子3, 梶原敬三3, 杉山正悟3, 陣内克紀3, 陣内冨男3, 陣内秀昭3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1203-1203, 2024. |
|---|
|
|
[P0959-3-PM2]. A challenge to pharmacist-led Cochrane Systematic Review: Primary treatment protocol of the extensive-stage small cell lung cancer 市村丈典1,2,3, 杉田栄樹1,2,3, Toyoda Shunsuke4, 野間久史5, 大田えりか6, 長谷川毅3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1203-1204, 2024. |
|---|
|
|
[P0960-4-PM]. A challenge to pharmacist-led Cochrane Systematic Review: Usefulness (protocol) of Telepharmacy for the chronic disease outpatient 杉田栄樹1,2,3, 里美貴4, 野間久史5, 大田えりか6, Toyoda Shunsuke7, 長谷川毅3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1204-1204, 2024. |
|---|
|
|
[P0961-3-PM2]. Difference in skin fluid volume after various skin drug for external use application 吉川慧1, 小関莉留1, 渡邊歩加1, 渡部智文2, 山中光3, 鈴木崚介3, 岩淵良3, 吉川真一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1204-1205, 2024. |
|---|
|
|
[P0962-4-PM]. Effect of the antimicrobial on epileptic seizure in patients with glioma 田中雅彬, 炭本隆宏, 龍田涼佑, 田中遼大, 伊東弘樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1205-1205, 2024. |
|---|
|
|
[P0963-3-PM2]. Examination of the factor giving it to the treatment cancellation of the biological drug of patients with moderate disease and severe ulcerative colitis 中島章雄1,2, 福山安里彩1, 宮崎元康1,2, 藤木将勝1, 柿本秀樹1, 久部高司3, 今給黎修1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1205-1206, 2024. |
|---|
|
|
[P0964-4-PM]. Investigation about the postoperative pain by the intervention of the postoperative pain management team 濱本裕太, 牧田亮, 古谷一平, 井上壽江, 平下智之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1206-1206, 2024. |
|---|
|
|
[P0965-3-PM2]. Sustained MRSE bacteremia in the extremely-low-birth-weight infants who tried treatment in Daptomycin 長岡翔1, 本田勝亮1, 柏原道志1, 塩田亮介1, 織辺圭太2, 赤羽洋佑2, 菊池新2, 杉浦弘2, 矢部勝茂1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1206-1207, 2024. |
|---|
|
|
[P0966-4-PM]. Effect of the new therapeutic drug candidate copper complex on cytochrome c oxidase activity in the brain tissue of the Menkes disease model mouse 平野茉優1, 米澤拓都1, 倉方雛1, 森田夏鈴1, 嶋田愛子1, 小川康子1, 鈴木亮2, 児玉浩子3, 高橋秀依4, 山岸喜彰1,5, 工藤敏之1,5, 伊藤清美1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1207-1207, 2024. |
|---|
|
|
[P0967-3-PM2]. Examination of the analgesic effect that COX-2 inhibition of the iguratimod gives to patients with rheumatoid arthritis 松井澄直, 菊地佑太, 田本光莉, 須賀萌美, 金澤沙衣, 渕上俊介, 田中悠季, 三本松泰孝, 鈴木千波, 田村広志 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1207-1208, 2024. |
|---|
|
|
[P0968-4-PM]. One patient who introduced a heart failure standard therapeutic drug into the HFrEF patients, and showed the improvement of the left ventricular ejection fraction 今川知香, 加耒由彩, 佐々木洋平, 久保和彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1208-1208, 2024. |
|---|
|
|
[P0969-3-PM2]. The introduction situation of the fantastic four 近藤和宏, 尾形美絵, 長澤欣弘, 中村槙一郎, 羽生智宏, 新関みどり, 田村和彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1209-1209, 2024. |
|---|
|
|
[P0970-4-PM]. Effect of treatment of the Pemafibrate for the high TG blood symptom merger Alcoholic liver disease 大谷綾1, 玉井嘉乃1, 並村澄子1, 中尾啓子1, 笹瀬典子1, 金啓二1, 金守良2, 金秀基2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1209-1210, 2024. |
|---|
|
|
[P0971-3-PM2]. One case that good pain control was obtained using tramadol for the neuropathic pain that occurred after the thoracic spinal cord tumorectomy enforcement 大崎綾華1, 大内竜介1,2, 薄井健介1,2, 渡邊卓嗣1,2, 児山香3, 長尾宗紀3, 鈴木清寿3, 山方俊弘3, 佐々木達也4, 遠藤俊毅4, 高橋義晴4, 西澤威人4, 岡田浩司1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1210-1210, 2024. |
|---|
|
|
[P0972-4-PM]. The current situation of the drug instruction at osteoporosis therapeutic drug start by the pharmacist in our hospital 下川千賀子1, 古河静香1, 米澤嘉朗2, 米澤幸平2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1210-1211, 2024. |
|---|
|
|
[P0973-3-PM2]. The use situation of the opioid for the palliation of a feeling of dyspnea of patients with heart failure in the Naha Municipal Hospital 中村沙希, 祖堅由伎, 上原葵, 永井賢作, 金城雄一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1211-1211, 2024. |
|---|
|
|
[P0974-4-PM]. 2 cases that removed the necrotic tissue using gel for the pineapple stem juice refinement outside of this mundane world for a severe burn from head to foot 古賀春香, 山田政典, 小園亜希, 齋藤巨樹, 湊本康則 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1211-1212, 2024. |
|---|
|
|
[P0975-3-PM2]. Safe evaluation of the sustained washing therapy using the aminoglycoside derivative antimicrobial in the orthopedics domain 西嶋友里乃1, 山田政典1, 小園亜希1, 齋藤巨樹1, 湊本康則1, 福元哲也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1212-1212, 2024. |
|---|
|
|
[P0976-4-PM]. A role and problem of prescription support, the hospital pharmacist in the examination suggestion whom we saw in the practice succession of a business of the social welfare corporation 村上秀治1, 半田直也2, 吉浦史明3, 藤井悦美4, 尾畑昇悟5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1213-1213, 2024. |
|---|
|
|
[P0977-3-PM2]. Based on the effect on collect rate drop that silicone oil at simple suspension method enforcement gives and the effect by relations - pH change of the physicochemical nature - 長崎裕也1, 友田吉則1,2, 宮坂優人1, 春日井公美1,2, 小松敏彰1, 尾鳥勝也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1213-1214, 2024. |
|---|
|
|
[P0978-4-PM]. About the efforts of the clinical studies support room in Rousaibyoin, Yokohama 横山雅子, 中島明日香, 屋城由樹, 角田誠一 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1214-1214, 2024. |
|---|
|
|
[P0979-3-PM2]. Relation of the pharmacist in Clinical Tumor Board after the examination for oncogene panel 大野梨絵1,2, 浦田修平1,2, 岩井美奈代3, 山口昌俊3, 佐藤勇一郎4, 細川歩5, 池田龍二1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1214-1215, 2024. |
|---|
|
|
[P0980-4-PM]. Invention to expand the trial training period of pharmacy school and the faculty of medicine trainee 日野隼人1,2, 川上英治1,2, 三浦太郎1,2, 斎藤まど香1,2, 奥田浩人1,2, 早川美紀1,2, 大月理恵子1,2, 難波志穂子2, 槇枝大貴1,2, 黒田智1,2, 濱野裕章1, 櫻井淳2, 座間味義人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1215-1215, 2024. |
|---|
|
|
[P0981-3-PM2]. 1 case that Goreisan supplementation was effective for oedema lower limb of the chronic cardiac insufficiency with the decreased renal function 中谷祐樹 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1215-1216, 2024. |
|---|
|
|
[P0982-4-PM]. Information sharing and problem in the illness medicine cooperation system which we built for unionization of the inhalational instruction in the area 三浦佳江1, 田中崇2, 高橋由1, 石原慎之1, 玉木宏樹1, 景山修介3, 園山智宏3, 横手克樹3, 堀田尚誠4, 濱口俊一5, 天野芳宏6, 直良浩司1, 礒部威6, 矢野貴久1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1216-1216, 2024. |
|---|
|
|
[P0983-3-PM2]. Research about the effect that the medical cooperation with the heart failure seal gives for heart failure management 長谷川浩三1, 森山健一1, 岡本茂洋2, 羽山悦子3, 玉飼博之4, 鬼木健太郎5, 猿渡淳二5, 門脇大介6 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1216-1217, 2024. |
|---|
|
|
[P0984-4-PM]. Medication support of the drugstore pharmacist sought after the discharge of the home care patient intervening before hospitalization 浅野陽子1, 日高良昌1, 藤田美佐子1, 小田川周平1, 森川則文2, 臼井晶真2, 小林瞭友2, 猪川和朗2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1217-1217, 2024. |
|---|
|
|
[P0985-3-PM2]. The duties actual situation of 24 hours and the drugstore of the pharmaceutical products offer 西田翔1, 小島良介1, 山本健2, 廣原正宣2, 串田一樹2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1218-1218, 2024. |
|---|
|
|
[P0986-4-PM]. Inventory survey about a doubt inquiry simplification protocol for the purpose of the duties burden reduction of the physician and the improvement of the community medical care and the tracing report 近藤沙菜, 松成菜穂子, 岡田卓也, 相馬侑加, 福田心, 田中真理, 河合麻里, 高橋佳祐, 野口賀代, 大川幾代, 小林聡子, 寺本忠弘, 佐藤竜馬, 森譲二, 白石貴寿 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1218-1218, 2024. |
|---|
|
|
[P0987-3-PM2]. Questionnaire findings - for problem - drugstore pharmacist in the enforcement of the home care patient online medication counseling 野田清花1, 近藤優歩1,2, 玉木啓文1, 長内理大1, 伊野陽子3, 野々村和哉1,4, 高島英滋5, 甲斐絢子2, 林秀樹2,6, 井口和弘1,2,7 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1219-1219, 2024. |
|---|
|
|
[P0988-4-PM]. Effect of the pharmacist temporary transfer from the university hospital which we saw by securing of Hiroshima hospital pharmacist model business to the community hospital 石井聡一郎1, 柴田ゆうか1, 村上秀治2, 岡田史恵3, 松尾裕彰1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1219-1219, 2024. |
|---|
|
|
[P0989-3-PM2]. Surge - of the interest in eating habits by efforts (the first report) - AGEs measurement of the periodical healthy conference for housing complex residence elderly people 梶原光1, 江下樹七1, 小野和彦2, 甲斐麻美子1, 勢島英3, 園木遥3, 渡邉邦宏4, 三井所尊正4, 冨永宏冶2, 江川孝1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1220-1220, 2024. |
|---|
|
|
[P0990-4-PM]. About the situation of hospital pharmacist duties seven years after the drugstore opening of an office in the site and a future problem 郷原学, 坪内こあ, 河野祥之, 齋藤理伽, 栗山万里子, 橋本香緒梨, 河野将大, 安木早紀, 望月優里, 脇浦勇樹, 大谷崇仁, 大霜玲子, 宅江孝修, 吉田勝好, 田原明子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1220-1220, 2024. |
|---|
|
|
[P0991-3-PM2]. Mukogawa Women's University-Style Drug Education Research - Development of Hygienic Handwashing Educational Materials for Young Children - 吉田都1,2, 林紗希1, 堀江美都里1, 桑原晶子1, 吉井美奈子3, 原口珠実1,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1221-1221, 2024. |
|---|
|
|
[P0992-4-PM]. Good use of postvaccinal follow-up sheet of the HPV vaccine reporting in the community medical care 渡辺香織1,2, 保坂昌彦1,2, 薬袋貴美1,2, 中村由喜1,2, 内藤貴夫1, 宮原富士子3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1221-1222, 2024. |
|---|
|
|
[P0993-3-PM2]. Consideration about collapse and the elution in the medication with medication jelly and the thickness agent 盛本修司, 川崎浩延, 澤田拓磨, ジェイコブ アダム Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1222-1222, 2024. |
|---|
|
|
[P0994-4-PM]. We look at the rear about hospital pharmacist temporary transfer, the system maintenance support project of Miyagi and research a mark 千葉僚, 五十嵐敏明, 前川正充, 松浦正樹, 佐藤真由美, 赤坂和俊, 眞野成康 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1222-1223, 2024. |
|---|
|
|
[P0995-3-PM2]. Efforts to medicine medicine cooperation of the Tokyo west Tokushukai Hospital and the future prospects 堀越俊彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1223-1223, 2024. |
|---|
|
|
[P0996-4-PM]. The current situation for the CKD aggravation prophylactic efforts and future problem 竹場光笛, 元茂拓法, 佐久間緑菜子, 菊地実, 川口啓之 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1223-1224, 2024. |
|---|
|
|
[P0997-3-PM2]. Efforts of the CKD seal in our hospital 近藤萌花, 古田麻衣子, 吉川直利, 榊原洋一, 鰐部紗矢香, 横井沙也加, 横田学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1224-1224, 2024. |
|---|
|
|
[P0998-4-PM]. Effect on decreased renal function patients measures of the health insurance pharmacy pharmacist whom CKD seal operation gives 井上瑞基1, 古田麻衣子1, 吉川直利1, 榊原洋一1, 新谷美帆1, 深谷恵里1, 服部聡2, 高本善己2, 横田学1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1224-1225, 2024. |
|---|
|
|
[P0999-3-PM2]. The task which we saw from the actual situation of the heart failure management in the health insurance pharmacy and questionary survey of the information that we required 菅直恵, 鈴木啓一郎, 仁熊宏樹, 宮地南帆, 西江美智子, 亀井健人, 徳田衡紀, 高柳和伸 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1225-1225, 2024. |
|---|
|
|
[P1000-4-PM]. Questionary survey about the current situation of the drug control instruction at the health insurance pharmacy in rheumatism, the collagenosis therapeutic drug 岩本里味1, 山根隆志2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1225-1226, 2024. |
|---|
|
|
[P1001-3-PM2]. Fact-finding of the inhalational instruction using the inhalational instruction check seat in our hospital outpatient after the inhalant instruction addition development 奥野葵, 岩本里味 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1226-1226, 2024. |
|---|
|
|
[P1002-4-PM]. Fact-finding of the current situation of the inhalant prescription in the Kasugai Municipal Hospital and the inhalational instruction at the health insurance pharmacy 松尾有美, 中村敏史, 坂田洋, 服部芳明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1226-1227, 2024. |
|---|
|
|
[P1003-3-PM2]. The tracing report use situation investigation in our hospital 星野光紀, 篠原奈々, 宮崎晶, 原田桂作 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1227-1227, 2024. |
|---|
|
|
[P1004-4-PM]. It is ... for introduction - seamless medical therapy of the drug control summary in the convalescent rehabilitation hospital 大滝智陽, 永島紗耶, 森園芹奈, 渡邉美耶子, 山川加奈子, 宮本裕斗, 浅見楓, 瀧澤幸三 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1227-1228, 2024. |
|---|
|
|
[P1005-3-PM2]. A case that intelligence and the multi-type of job cooperation become important for the disadvantageous evasion of patients with ketogenic diet therapy enforcement West syndrome: Case report 岩井里奈子, 松木史, 滝口知顕, 炭井志穂, 藤本正典, 松井優子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1228-1228, 2024. |
|---|
|
|
[P1006-4-PM]. Attitude survey in the patients with heart failure follow-up at the health insurance pharmacy 石川夕起1, 中山七海1, 八木仁史1, 高田宏文1, 河井良智2, 荒井宏人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1229-1229, 2024. |
|---|
|
|
[P1007-3-PM2]. Fact-finding of special functioning hospital, the information cooperation tool published in the website of the local support hospital 鈴木亮平1, 神保美紗子2, 水野智博3, 島崎良知4, 藤原久登5, 眞中章弘6, 小島太郎7, 竹屋泰8, 亀井美和子9, 溝神文博10,11 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1229-1230, 2024. |
|---|
|
|
[P1008-4-PM]. We correspond to pharmacist regional alliances after the cooperation full addition calculation start in our hospital 大澤万智子, 出水睦子, 中尾夕美, 千原里美, 上田宏 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1230-1230, 2024. |
|---|
|
|
[P1009-3-PM2]. Effect by development of the Shinagawa-ku regional alliances inquiry simplification protocol and the introduction 中澤昂平1, 兼平暖1, 阿部誠治2,3, 市橋孟1,5, 服部はるか2,3, 和田紀子3,4, 加藤肇5, 田中広紀3,6, 峰松清7, 嶋村弘史2,3, 田中昌代1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1230-1231, 2024. |
|---|
|
|
[P1010-4-PM]. Inventory survey for the purpose of the inflection of the tracing report in the cancer chemotherapy for health insurance pharmacy pharmacists and the improvement of the quality 森譲二, 岡田卓也, 近藤沙菜, 松成菜穂子, 福田心, 都村勇樹, 田中真理, 宇都宮真理, 高橋佳祐, 藤原愛美, 松原千明, 河西貴絵, 寺本忠弘, 佐藤竜馬, 大原京子, 白石貴寿 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1231-1231, 2024. |
|---|
|
|
[P1011-3-PM2]. The inflection situation of the tracing report in our hospital 菅野隆太朗1, 奥村俊一1, 大石一彦1, 河内大和2, 石井紀子1, 廣井順子1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1231-1232, 2024. |
|---|
|
|
[P1012-4-PM]. Fact-finding of the tracing report utilization situation in the pediatric hospital 萱場麻紀子, 濱町友里恵, 清野泰史, 勝治みなみ, 戸羽香織, 西川真璃絵, 嶋田昌枝, 穂積裕香子, 中井啓 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1232-1232, 2024. |
|---|
|
|
[P1013-3-PM2]. Report contents investigation of doubt inquiry depending on the registration of patient situation of the medical information cooperation network 高村優太1, 平井利幸1, 秋山裕史1, 小橋川祥2, 関利一1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1232-1233, 2024. |
|---|
|
|
[P1014-4-PM]. Report about the current situation of the refill prescription in the drugstore 松下隼士1, 片山莉乃1, 八木沙耶香1, 尾崎加代子1, 金松里奈1, 篠崎奈保子1, 新地聖子1, 堀内祐里2, 三浦誠3, 小川愛4, 永渕学5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1233-1233, 2024. |
|---|
|
|
[P1015-3-PM2]. Development ... in medicine medicine cooperation - hospitalization and release support center in the discontinuation management before operation 井上亜紗美1, 田渕知佳1, 佐藤啓介1, 山廣胤之1, 兼重晋1, 神村英利1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1233-1234, 2024. |
|---|
|
|
[P1016-4-PM]. Efforts of "the discharge drug information summary" to expand medicine medicine cooperation in Face to Face 板垣有紀, 石垣俊樹, 羽太光範 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1234-1234, 2024. |
|---|
|
|
[P1017-3-PM2]. Correspondence by the outside Parliament prescription inquiry simplification protocol (antitussive substitute protocol) for the antitussive understock 三浦篤史1, 堀内賢一2,4, 渡邉将隆1,2, 関戸大司3, 今牧健之5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1235-1235, 2024. |
|---|
|
|
[P1018-4-PM]. The use situation investigation of the sleep inducer associated with the fall fall in the Kasugai Municipal Hospital 沼田奈央子, 鈴木大吾, 中村敏史, 坂田洋, 服部芳明 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1235-1235, 2024. |
|---|
|
|
[P1019-3-PM2]. Evaluation of the Sleep Medicine Formulary at Yuai Medical Center - With a View to Regional Medical Collaboration - 上里芽衣子, 安丸史織, 小杉卓大, 國分千代 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1236-1236, 2024. |
|---|
|
|
[P1020-4-PM]. Efforts to the excess reduction of the potassium level accompanied with the change to KCL note 20mEq preparation by alerting it utilizing the medicine master of the electronic medical chart 淺井裕司, 横田学 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1236-1237, 2024. |
|---|
|
|
[P1021-3-PM2]. Fact-finding of the prescription drug in a fall, the patients who fell 中村舞美1, 嶋田沙織1,2, 土岐浩介1,3, 細野智美1, 和田哲郎2,4, 本間真人1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1237-1237, 2024. |
|---|
|
|
[P1022-4-PM]. About the fall risk reduction effect of the inpatient by the clinical path review of the sleeping drug 高橋真一, 伊東充, 新井由希, 佐藤香織, 加藤潤一郎 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1237-1238, 2024. |
|---|
|
|
[P1023-3-PM2]. The careful selection of the sleeping drug decreases a fall after the administration in predominance 岩切智美1, 奥村学2, 吉川直樹1, 保田和哉1, 長友隆雄1, 神田久美子2, 甲斐由紀子2, 恒吉勇男2,3, 綾部貴典2, 池田龍二1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1238-1238, 2024. |
|---|
|
|
[P1024-4-PM]. Investigation about an allergy to iodine system contrast media and the relationship with the COVID-19 season 細川拓海1, 外間翔平1, 渡邊裕之1, 勝呂涼2, 濱田淳也2, 宅和真由美1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1238-1239, 2024. |
|---|
|
|
[P1025-3-PM2]. Analysis of a tendency to development and the factor of the incident associated with the TDM in our hospital 山口佳津騎1, 酒井佳代1, 近藤恵1, 柏木麻衣子1, 田中裕章2, 元木貴大2, 田井達也3, 松浦奈都美1, 村上和司1, 小坂信二2, 杉元幹史1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1239-1239, 2024. |
|---|
|
|
[P1026-4-PM]. Examination of the drug continuation injection self withdrawal risk factor in patients not to deceive 末永亘1,2, 五十嵐隆志1, 山形真一2, 川崎敏克1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1240-1240, 2024. |
|---|
|
|
[P1027-3-PM2]. About the construction of the system using the dispatch situation and the manual to the in-hospital outside of the doubt inquiry example 福泉聡子, 嘉村有紗, 小野寺慶太, 眞弓健介, 藤本愛理, 下村真代, 小山田純治 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1240-1241, 2024. |
|---|
|
|
[P1028-4-PM]. Included examination ... patients of the regional alliances means that a pharmacist in the perioperative drug control sent it to; and type of job mutual understanding and motivation ... 井上稚枝子1,2, 前川綾子2,3, 平松洋子2,4, 岡野泰子2,5, 竹増真也2,3, 近藤真志2,6, 安倉央2,7, 小川大介2,8, 市川大介2,9, 二宮洋子2,10, 安本和善2,11, 赤木晋介2,12 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1241-1241, 2024. |
|---|
|
|
[P1029-3-PM2]. Influence ... of the medicine medicine cooperation tool which we turned to examination - other types of job of the regional alliances means that a pharmacist in the perioperative drug control sent it to 前川綾子1,2, 井上稚枝子2,3, 平松洋子2,4, 岡野泰子2,5, 二宮洋子2,6, 出石英治2,7, 安本和善2,8, 赤木晋介2,9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1241-1242, 2024. |
|---|
|
|
[P1030-4-PM]. Evaluation of efforts for the perioperative care addition calculation and one-year operating room duties 上田賢太郎, 馬場貴子, 富島喜朗, 下石和樹, 合澤啓二, 陣上祥子 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1242-1242, 2024. |
|---|
|
|
[P1031-3-PM2]. Review of application, the examination system about specialist in nonrecognition newcomer medicines, and the like 荒井幸子1,2, 若杉正1,2, 齊藤薫苗2,3,4, 伊東香里2,3, 島田朋子4, 小池博文1, 佐橋幸子1,2, 田村功一5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1242-1243, 2024. |
|---|
|
|
[P1032-4-PM]. We investigate human error from a drug-related incident report 田中敏, 我妻雄太 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1243-1243, 2024. |
|---|
|
|
[P1033-3-PM2]. The disaster training enforcement to the business trainee by the disaster dispatch experience pharmacist and investigation of the alteration of consciousness 安富暉浩, 谷大輔, 木下里紗, 吉野秀紀, 辻井佳代, 小林政彦 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1243-1244, 2024. |
|---|
|
|
[P1034-4-PM]. Effect to give the confidence of the drugstore pharmacist: Questionary survey of the self-efficacy 丸一泰雅1,3, 中川友之2, 本間利通4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1244-1244, 2024. |
|---|
|
|
[P1035-3-PM2]. Construction of the learning strategy of the pharmacy business training that intended the acquisition of the ability to provide patients-centered medical treatment 三村佳久1,2, 杉山洋介1,2, 木村理恵2, 真川明将1,2, 堀田康弘1,2, 堀田祐志1,2, 日比陽子1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1244-1245, 2024. |
|---|
|
|
[P1036-4-PM]. The current situation of the case conference in the hospital pharmacy gate of this country 長谷川裕矢1,9, 宮脇未来2,9, 板井進悟3,9, 荒木隆一4,9, 上塚朋子5,9, 間瀬広樹6,9, 矢吹拓7,9, 矢野良一8,9 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1245-1245, 2024. |
|---|
|
|
[P1037-3-PM2]. Evaluation - by the analysis of consciousness and impression - training diary of the trainee in a ward, the team approach in medical care training 野々宮菜彌1, 石川春樹1, 早川智久1, 小林聡太1, 金沢和幸1, 金子健1, 津田壮一郎1, 村松博1, 大谷壽一1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1246-1246, 2024. |
|---|
|
|
[P1038-4-PM]. Analysis - by effect - RIAS that a glance gives to communication at online medication counseling 森綾子1, 加藤いづみ1, 鳴海克哉1,2, 武隈洋3, 柏木仁4, 佐藤夕紀4, 菅原満3,4, 小林正紀1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1246-1247, 2024. |
|---|
|
|
[P1039-3-PM2]. Making and education effect of "pharmacy karuta" conducting the study Osamu support of the field of basic pharmacy of the pharmacy student 大坪和弘1,2, 西山空輝1,2, 笠間結斗1,2, 田中怜1, 尾関あゆみ1, 国分秀也1, 佐藤淳也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1247-1247, 2024. |
|---|
|
|
[P1040-4-PM]. Job hunting fact-finding in the pharmacy student graduating in March, 2025 鶏内遥 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1247-1248, 2024. |
|---|
|
|
[P1041-3-PM2]. The role that the drug section managerial class and the businessman teacher in the cooperation with a public hospital and the single department college of pharmacy fulfil 城田幹生1, 安武夫2,3,4, 寺山義泰3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1248-1248, 2024. |
|---|
|
|
[P1042-4-PM]. Attitude survey of the desired motive and job hunting for the hospital pharmacist until the new college graduate third year when we found work in Tottori 冨岡謙二1,4, 清水浩幸2,4, 金田達也3,4 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1248-1249, 2024. |
|---|
|
|
[P1043-3-PM2]. Problem - after the construction (the fifth report) - clinical ladder interview start of the hospital pharmacist staff education system 長崎郁美1, 稲野寛2, 婦川貴博1, 山本悠樹1, 坂倉智子2, 尾鳥勝也1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1249-1249, 2024. |
|---|
|
|
[P1044-4-PM]. The current situation analysis and problem grasp of the pharmacist resident program in Juntendo Clinic attached to the Juntendo University faculty of medicine 池田朱里1, 宿利美香1, 青嶋瑞樹1, 水山和紀1, 亀山典子1, 中島梢1, 畦地拓哉1,2, 中鏡暁子1, 佐藤邦義1, 木村利美1,2,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1249-1250, 2024. |
|---|
|
|
[P1045-3-PM2]. Efforts to the research activities promotion in the staff of public hospital practice Engineering Department of the depopulated area 鶴居勝也1, 荒木遼太1, 小川紗知1, 讓原千広1, 波多晶子1, 中澤美樹子1, 橋爪和恵1, 窪田真弓1, 栗原祥吾2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1250-1251, 2024. |
|---|
|
|
[P1046-4-PM]. Inflection of the R2C2 model aiming at effective feedback in the upbringing (the 23rd report) new face training of the pharmacist who carried the next generation 猪田宏美1, 村尾卓哉1, 三好智子2, 西原茂樹1, 濱野裕章1, 座間味義人1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1251-1251, 2024. |
|---|
|
|
[P1047-3-PM2]. 2024 Koto hospital pharmacy growth strategy using the balun strike scorecard 黒田健吾, 岡田侑子, 寺島清文, 霞流千佳子, 佐藤大輔 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1251-1252, 2024. |
|---|
|
|
[P1048-4-PM]. The drugstore pharmacist training in the hospital to show extensive pharmacy management function 勝呂美香1,2, 近藤留美子1,2, 厚田幸一郎1,2, 尾鳥勝也2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1252-1252, 2024. |
|---|
|
|
[P1049-3-PM2]. Having been able to see it from making and evaluation results of the Shinnyu staff educational program centering on specialty and member of society basic skills 三木郁帆, 村上賢次, 渡邊裕之, 宅和真由美 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1252-1253, 2024. |
|---|
|
|
[IP-01]. Luteolin protects against neuronal cell death in cellular model of Parkinson' s disease via an upregulation of HRD1 and SEL1L Hiroki Nishiguchi1, Tomohiro Omura1, Ayaka Sato2, Yumi Kitahiro1, Kazuhiro Yamamoto1,3, Kotaro Itohara1, Junichi Kunimasa2, Ikuko Yano1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1254-1254, 2024. |
|---|
|
|
[IP-02]. Usefulness of Leucine-rich α2 glycoprotein as a biomarker in Cerebral Infarction Patients Ai Kanzaki1,2, Takafumi Nakano1,2, Keiichi Irie1, Soichiro Ushio1,2, Toshinobu Hayashi1,2, Yoshihiko Nakamura3, Hidetoshi Kamimura1,2, Kenichi Mishima1, Takashi Egawa1,2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1254-1255, 2024. |
|---|
|
|
[IP-03]. Characterization of pharmacokinetics and pharmacodynamics of remimazolam in Japanese patients undergoing general anesthesia Satoshi Ueshima1, Serina Nagahara1, Kenta Nakaya1, Mayu Kawamura1, Daiki Hira1,2, Yu Matsuura3, Kaneyuki Kawamae3,4, Mikio Kakumoto1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1255-1256, 2024. |
|---|
|
|
[IP-04]. A case of colon cancer with disorders of consciousness due to hyperammonemia during mFOLFOX6 therapy and suspected high dihydropyrimidine dehydrogenase activity Shun-ichi Hiramatsu, Ritsuki Onishi, Noriko Sekoguchi, Yuki Asai, Hideo Kato, Takuya Iwamoto Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1256-1257, 2024. |
|---|
|
|
[IP-05]. Risk evaluation of bleeding after atrial fibrillation ablation under uninterrupted anticoagulant therapy using dabigatran etexilate Yasuyuki Takashima1,2, Kosuke Doki1,3, Masato Homma1,3 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1257-1257, 2024. |
|---|
|
|
[IP-06]. The usefulness of urine protein to creatinine ratio for older patients receiving angiogenesis inhibitors Akihiro Sonoda1, Yoshitaka Iwashita1, Yukina Shibata1, Ryu Hamazono1, Masahiro Kambori1, Momoka Kawahara1, Sachi Matsuyama1, Misaki Taguchi1, Sho Shibata1, Chisa Morinaga1, Mayo Kodama1, Kazuhisa Ishida1, Masayuki Yanagi2 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1258-1258, 2024. |
|---|
|
|
[IP-07]. Assessment of Reye's syndrome profile with data from the FDA Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases using the disproportionality analysis Kazuhiro Iguchi1, Kiyoka Matsumoto1, Shiori Hasegawa1, Satoshi Nakao1, Kazuyo Shimada1, Ririka Mukai1, Mizuki Tanaka1, Riko Satake1, Yu Yoshida1, Fumiya Goto1, Misaki Inoue1, Hiroaki Ikesue2, Tohru Hashida2, Mitsuhiro Nakamura1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1258-1259, 2024. |
|---|
|
|
[IP-08]. Trends associated with hemorrhoids in Japan : Data mining of medical information datasets and the National Database of Health Insurance Claims and Specific Health Checkups of Japan Open Data Japan Mitsuhiro Nakamura1, Ririka Mukai1, Kazuyo Shimada1, Takaaki Suzuki1, Satoshi Nakao1, Mizuki Tanaka1, Kiyoka Matsumoto1, Yu Yoshida1, Fumiya Goto1, Misaki Inoue1, Riko Satake1, Yuri Nishibata2, Honami Sugihara1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1259-1260, 2024. |
|---|
|
|
[IP-09]. Drug Use Evaluation of Atezolizumab at a single institution Mee Ae Jang, Kyong Nam Ye, Jung Tae Kim Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1260-1261, 2024. |
|---|
|
|
[IP-10]. Algorithm for COVID-19 Recommendations Based on a Survey of OTC Drug Use Trends in Accommodation Care Facilities Mao Tsuji1, Nao Yoshida1, Kikuno Matsukuma1, Soyoka Yamamura1, Yoshino Sugihara1, Rina Hirai1, Megumi Katsuta1,2, Ai Kanzaki1, Soichiro Ushio1, Toshinobu Hayashi1, Takashi Egawa1 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1261-1261, 2024. |
|---|
|
|
[IP-11]. Activities by Community Pharmacy Pharmacists in Health Counseling Sessions for the Elderly Based on Regional Medical Cooperation Juna Eshita1, Akari Kajiwara1, Ei Sejima2, Ryosuke Yamaguchi3, Kunihiro Watanabe4, Takamasa Miisho4, Kazuhiko Ono5, Mamiko Kai1, Koji Tominaga5, Takashi Egawa1,5 Abstracts of Annual Meeting of Japanese Society of Pharmaceutical Health Care and Sciences (suppl.1): 1261-1262, 2024. |
|---|
